Pharmaceutical composition for treating Alzheimer&#39;s disease

ABSTRACT

A pharmaceutical composition for treating Alzheimer&#39;s disease containing a compound represented by the general formula (I); 
                         
wherein ring A is an optionally substituted carbocyclic group or an optionally substituted heterocyclic group;
     E is lower alkylene, etc.;   X is S, O, or NR 1 ;   R 1  is a hydrogen atom or lower alkyl;   R 2a , R 2b , R 3a , R 3b , R 4a  and R 4b  are each independently a hydrogen atom, halogen, hydroxy, etc.;   n and m are each independently an integer of 0 to 3;   n+m is an integer of 1 to 3; and   R 5  is a hydrogen atom, optionally substituted lower alkyl, etc.;   its pharmaceutically acceptable salt, or a solvate thereof as an active ingredient.

TECHNICAL FIELD

The present invention relates to a pharmaceutical composition which hasreducing effect to produce amyloid β protein and is useful as an agentfor treating disease induced by production, secretion and/or depositionof amyloid β protein, especially Alzheimer's disease.

BACKGROUND ART

In the brain of Alzheimer's patient, the peptide composed of about 40amino acids residue as is called amyloid β protein, that accumulates toform insoluble specks (senile specks) outside nerve cells is widelyobserved. It is concerned that this senile specks kill nerve cells tocause Alzheimer's disease. The therapeutic agents for Alzheimer'sdisease, such as decomposition agents of amyloid β protein and amyloid βvaccine, are under investigation.

Secretase is an enzyme which cleaves amyloid βprecursor protein (APP) incell and produce amyloid β protein. The enzyme which controls theproduction of N terminus of amyloid β protein is called as BACE 1(beta-site APP-cleaving enzyme 1, β-secretase). It is thought thatinhibition of this enzyme leads to reduction of producing amyloid βprotein and that the therapeutic agent for Alzheimer's disease will becreated by the inhibition.

Patent Literature 1 describes the compounds which are similar to thoseof the compounds contained in the pharmaceutical composition of thepresent invention, and the compounds have NO synthase enzyme inhibitoryactivity and are useful for dementia.

Patent. Literature 2 to 10 describes the compounds which are known asBACE 1 inhibitor, however, have different structures from the compoundscontained in the pharmaceutical composition of the present invention.

-   [Patent Literature 1] International Patent Application Publication    WO96/014842-   [Patent Literature 2] International Patent Application Publication    WO02/96897-   [Patent Literature 3] International Patent Application Publication    WO04/043916-   [Patent Literature 4] International Patent Application Publication    WO2005/058311-   [Patent Literature 5] international Patent Application Publication    WO2005/097767-   [Patent Literature 6] International Patent Application Publication    WO2006/041404-   [Patent Literature 7] International Patent Application Publication    WO2006/041405-   [Patent Literature 8] US Patent Application Publication    US2007/0004786-   [Patent Literature 9] US Patent Application Publication    US2007/0004730-   [Patent Literature 10] US Patent Application Publication    US2007/27199-   [Patent Literature 11] International Patent Application Publication    WO2007/049532

DISCLOSURE OF INVENTION Problems to be Solved by the Invention

The present invention provides pharmaceutical compositions which havereducing effects to produce amyloid β protein, especially BACE 1inhibitory activity, and which are useful as an agent for treatingdisease induced by production, secretion and/or deposition of amyloid βprotein.

Means to Solve the Problems

The present invention provides:

-   (a) a pharmaceutical composition for treating Alzheimer's disease    containing a compound represented by the general formula (I):

-   wherein ring A is an optionally substituted carbocyclic group or an    optionally substituted heterocyclic group;

-   wherein Alk¹ is lower alkylene or lower alkenylene;-   R⁰ is a hydrogen atom, lower alkyl or acyl;-   X is S, O, or NR¹;-   R¹ is a hydrogen atom or lower alkyl;-   R^(2a) and R^(2b) are each independently a hydrogen atom, hydroxy,    optionally substituted lower alkyl, optionally substituted lower    alkenyl, optionally substituted amino, optionally substituted    amidino, optionally substituted acyl, optionally substituted    carbamoyl, optionally substituted carbamoylcarbonyl, optionally    substituted lower alkylsulfonyl, optionally substituted    arylsulfonyl, an optionally substituted carbocyclic group or an    optionally substituted heterocyclic group;-   R^(3a), R^(4a) and R^(4b) are each independently a hydrogen atom,    halogen, hydroxy, optionally substituted lower alkyl, optionally    substituted lower alkenyl, optionally substituted acyl, carboxy,    optionally substituted lower alkoxycarbonyl, optionally substituted    amino, optionally substituted carbamoyl, an optionally substituted    carbocyclic group or an optionally substituted heterocyclic group;-   n and m are each independently an integer of 0 to 3;-   n+m is an integer of 1 to 3;-   each R^(3a), each R^(3b), each R^(4a), and each R^(4b) may be    independently different;-   R⁵ is a hydrogen atom, optionally substituted lower alkyl,    optionally substituted lower alkenyl, optionally substituted lower    alkynyl, an optionally substituted carbocyclic group or an    optionally substituted heterocyclic group;

-   R⁵ and ring A can be taken together to form

wherein R^(5a) and R^(5b) are each independently a hydrogen atom orlower alkyl;

-   s is an integer of 1 to 4;-   each R^(5a) and each R^(5b) may be different;-   with the proviso that the compound wherein n+m is 2; R⁵ is a    hydrogen atom; and-   ring A is non-substituted phenyl is excluded,-   its pharmaceutically acceptable salt, or a solvate thereof as an    active ingredient,-   (a1) a pharmaceutical composition for treating Alzheimer's disease    containing a compound represented by the general formula (I):

-   wherein ring A is an optionally substituted carbocyclic group or an    optionally substituted heterocyclic group;

-   wherein Alk¹ is lower alkylene;-   R⁰ is a hydrogen atom, lower alkyl or acyl;-   X is S, O, or NR¹;-   R¹ is a hydrogen atom or lower alkyl;-   R^(2a) and R^(2b) are each independently a hydrogen atom, hydroxy,    optionally substituted lower alkyl, optionally substituted lower    alkenyl, optionally substituted amino, optionally substituted    amidino, optionally substituted acyl, optionally substituted    carbamoyl, optionally substituted lower alkylsulfonyl, optionally    substituted arylsulfonyl, an optionally substituted carbocyclic    group or an optionally substituted heterocyclic group;-   R^(3a), R^(3b), R^(4a), and R^(4b) are each independently a hydrogen    atom, halogen, hydroxy, optionally substituted lower alkyl,    optionally substituted lower alkenyl, optionally substituted acyl,    carboxy, optionally substituted lower alkoxycarbonyl, optionally    substituted amino, optionally substituted carbamoyl, an optionally    substituted carbocyclic group or an optionally substituted    heterocyclic group;-   n and m are each independently an integer of 0 to 3;-   n+m is an integer of 1 to 3;-   each R^(3a), each R^(3b), each R^(4a), and each R^(4b) may be    independently different;-   R⁵ is a hydrogen atom, optionally substituted lower alkyl,    optionally substituted lower alkenyl, optionally substituted lower    alkynyl, an optionally substituted carbocyclic group or an    optionally substituted heterocyclic group;

-   R⁵ and ring A can be taken together to form

wherein R^(5a) and R^(5b) are each independently a hydrogen atom orlower alkyl;

-   s is an integer of 1 to 4;-   each R^(5a) and each R^(5b) may be different;-   with the proviso that the compound wherein n+m is 2; R³ is a    hydrogen atom; and-   ring A is non-substituted phenyl is excluded,-   its pharmaceutically acceptable salt, or a solvate thereof as an    active ingredient,-   (b) the pharmaceutical composition for treating Alzheimer's disease    according to (a), wherein X is S,-   (c) the pharmaceutical composition for treating Alzheimer's disease    according to (a), wherein n is 2, and m is 0,-   (d) the pharmaceutical composition for treating Alzheimer's disease    according to (a), wherein E is a bond,-   (e) a pharmaceutical composition for treating Alzheimer's disease    containing a compound represented by the general formula (I):

-   wherein each symbols are the same as described in (a), with the    proviso that the compounds as shown below;-   i) wherein n+m is 2, R³ is a hydrogen atom, and ring A is    non-substituted phenyl;-   ii) wherein n is 2, m is 0, R^(2a) is a hydrogen atom, R^(2b) is a    hydrogen atom or acetyl, R⁵ is methyl, and ring A is phenyl or    4-methoxyphenyl;-   iii) wherein n is 2, m is 0, R^(2a) is a hydrogen atom, R^(2b) is a    hydrogen atom or acetyl,-   R⁵ is ethyl, and ring A is 3,4-dimethoxyphenyl;-   iv) wherein n is 2, in is 0, R^(2a) is a hydrogen atom, R^(2b) is a    hydrogen atom or acetyl, and R⁵ and ring A is phenyl;-   v) wherein n is 2, m is 0, R^(2a) and R^(2b) is a hydrogen atom, R⁵    and ring A are taken together to form

wherein Me is methyl, and each symbols are the same as described above;and

-   vi) wherein n+m is 2,-   R⁵ is a hydrogen atom, and-   ring A is phenyl substituted with one or two substituent(s) selected    from the group of hydroxy, halogen, lower alkyl, lower alkoxy,    nitro, amino, lower alkylcarbonylamino, mercapto, lower alkylthio,    and carbamoyl, non-substituted phenyl,-   or non-substituted naphthyl; are excluded,-   its pharmaceutically acceptable salt, or a solvate thereof as an    active ingredient,-   (f) the pharmaceutical composition for treating Alzheimer's disease    according to (e), wherein X is S,-   (g) the pharmaceutical composition for treating Alzheimer's disease    according to (e) or (f), wherein n is 2, and m is 0,-   (h) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (g), wherein R⁵ is optionally    substituted lower alkyl, optionally substituted lower alkenyl,    optionally substituted lower alkynyl, an optionally substituted    carbocyclic group or an optionally substituted heterocyclic group,-   (i) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (h), wherein R^(1a) is a hydrogen    atom; R^(2b) is a hydrogen atom, optionally substituted lower alkyl,    optionally substituted acyl, optionally substituted lower    alkylsulfonyl, or optionally substituted amidino,-   (j) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (h), wherein NR^(2a)R^(2b) is    represented by the formula:

wherein R⁶, R⁷, and R⁸ are each independently a hydrogen atom, loweralkyl or acyl, Y is optionally substituted lower alkylene, optionallysubstituted lower alkenylene or optionally substituted lower alkynylene;

-   Z is O or S;-   (k) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (j), wherein ring A is substituted    phenyl,-   (l) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (j), wherein ring A is represented by    the formula:

wherein R⁹, R¹⁰ and R¹¹ are hydrogen atom or G;

-   G is halogen, hydroxy, cyano, nitro, mercapto, optionally    substituted lower alkyl, optionally substituted lower alkoxy,    optionally substituted lower alkenyl, optionally substituted lower    alkynyl, optionally substituted acyl, optionally substituted    acyloxy, carboxy, optionally substituted lower alkoxycarbonyl,    optionally substituted lower alkoxycarbonyloxy, optionally    substituted aryloxycarbonyloxy, optionally substituted amino,    optionally substituted carbamoyl, optionally substituted    carbamoyloxy, optionally substituted lower alkylthio, optionally    substituted arylthio, optionally substituted lower alkylsulfonyl,    optionally substituted arylsulfonyl, optionally substituted lower    alkylsulfinyl, optionally substituted arylsulfinyl, optionally    substituted lower alkylsulfonyloxy, optionally substituted    arylsulfonyloxy, an optionally substituted carbocyclic group,    optionally substituted carbocyclicoxy, an optionally substituted    heterocyclic group or optionally substituted heterocyclicoxy;-   each G may be independently different,-   (m) the pharmaceutical composition for treating Alzheimer's disease    according to (l),-   wherein G is represented by the formula:

wherein Q¹, Q², and Q³ are each independently a bond, optionallysubstituted lower alkylene, or optionally substituted lower alkenylene;

-   Q⁴ is optionally substituted lower alkylene or optionally    substituted lower alkenylene;-   W¹ and W² are each independently O or S;-   W³ is O, S or NR¹²;-   R¹² is a hydrogen atom, lower alkyl, hydroxy lower alkyl, lower    alkoxy lower alkyl, lower alkoxycarbonyl lower alkyl, carbocyclic    lower alkyl or acyl;-   R¹⁴ is a hydrogen atom or lower alkyl;-   ring B is an optionally substituted carbocyclic group or an    optionally substituted heterocyclic group;-   Alk² is optionally substituted lower alkyl;-   p is 1 or 2;-   if there are multiple W¹, multiple W³, and multiple R¹², each may be    independently different;-   in (xii), the position of an oxygen atom may be cis or trans to a    substituent R¹⁴,-   (n) the pharmaceutical composition for treating Alzheimer's disease    according to (m), wherein ring B is aryl optionally substituted with    one or more substituents selected from the group of halogen,    hydroxy, optionally substituted lower alkyl, optionally substituted    lower alkoxy, optionally substituted acyl, optionally substituted    amino, cyano, optionally substituted carbamoyl, an optionally    substituted carbocyclic group, optionally substituted carbocyclicoxy    and an optionally substituted heterocyclic group, or-   heteroaryl optionally substituted with one or more substituents    selected from the group of halogen, hydroxy, optionally substituted    lower alkyl, optionally substituted lower alkoxy, optionally    substituted acyl, optionally substituted amino, cyano, optionally    substituted carbamoyl, an optionally substituted carbocyclic group,    optionally substituted carbocyclicoxy and an optionally substituted    heterocyclic group,-   (o) the pharmaceutical composition for treating Alzheimer's disease    according to (m), wherein G is represented by the formula:

wherein, each symbols are the same as described above,

-   (p) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (o), wherein R⁵ is C1 to C3 alkyl,-   (q) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (o), wherein R⁵ is methyl,-   (r) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (q), wherein-   R^(3a) and R^(3b) are each independently a hydrogen atom, halogen,    hydroxy, optionally substituted lower a optionally substituted lower    alkoxy or optionally substituted aryl,-   (s) the pharmaceutical composition for treating Alzheimer's disease    according to any one of (e) to (q), wherein-   R^(3a) and R^(3b) are both hydrogen atoms,-   (t) the pharmaceutical composition according to any one of (a)    to (d) which is the composition for reducing amyloid β production,-   its pharmaceutically acceptable salt, or a solvate thereof as an    active ingredient,-   (u) the pharmaceutical composition according to any one of (a)    to (d) or (d) which is the composition for treating disease induced    by production, secretion and/or deposition of amyloid β protein,-   (v) a method for treating disease induced by production, secretion    and/or deposition of amyloid β protein (for example, Alzheimer's    disease) comprising administering the compound as defined in any one    of formula (I) in above (a),-   its pharmaceutically acceptable salt, or a solvate thereof,-   (w) use of the compound as defined in any one of formula (I) in    above (a), its pharmaceutically acceptable salt, or a solvate    thereof, in the manufacture of a medicament for the treatment of    disease induced by production, secretion and/or deposition of    amyloid β protein (for example, Alzheimer's disease),-   (x) a method for treating Alzheimer's disease characterizing in    administering the compound as defined in any one of formula (I) in    above (a),-   its pharmaceutically acceptable salt, or a solvate thereof,-   (y) use of the compound as defined in any one of formula (I) in    above (a),-   its pharmaceutically acceptable salt, or a solvate thereof, in the    manufacture of a medicament for the treatment of Alzheimer's    disease.

Effect of the Invention

The composition of the present invention is useful as an agent fortreating disease such as Alzheimer's disease induced by production,secretion and/or deposition of amyloid β protein.

Additionally, because the pharmaceutical composition of the presentinvention comprises the compound which has the characteristics: it hashigh inhibitory activity against BACE-1, it has high selectivity againstother enzymes, and the like; as an active ingredient, it can be amedicament whose side effects are reduced. The pharmaceuticalcomposition of the present invention can be a medicament which possess agreat safety margin in side effect by comprising an optical activecompound which has a suitable conformation as an active ingredient. Thepharmaceutical composition of the present invention can be an excellentmedicament because it comprises the compound which has the followingcharacteristics as an active ingredient: high metabolic stability, highdissolubility, high oral absorbability, high bioavailability, preferableclearance, high transfer to brain, long half-life, high protein-unboundfraction, low inhibitory activity to hERG channel, low inhibitoryactivity to CYPs, and/or negative activity in Ames assay.

BEST MODE FOR CARRYING OUT THE INVENTION

As used herein, the “halogen” includes fluorine, chlorine, bromine, andiodine. A halogeno part of the “halogeno lower alkyl”, the “halogenolower alkoxy”, the “halogeno acyl”, the “halogeno lower alkylthio” andthe “halogeno lower alkoxycarbonyl” is the same.

The “lower alkyl” includes a straight or branched alkyl of a carbonnumber of 1 to 15, preferably a carbon number of 1 to 10, furtherpreferably a carbon number of 1 to 6, and more further preferably acarbon number of 1 to 3, and examples include methyl, ethyl, n-propyl,isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl,isooctyl, n-nonyl, and n-decyl.

A lower alkyl part of the “carbocyclic lower alkyl”, the “lower alkoxy”,the “halogeno lower alkyl”, the “halogeno lower alkoxy”, the “halogenolower alkylthio”, the “hydroxy lower alkyl”, the “lower alkoxycarbonyl”,the “halogeno lower alkoxycarbonyl”, the “lower alkoxycarbonyl loweralkyl”, the “lower alkoxycarbonyloxy”, the “lower alkylamino”, the“lower alkylcarbonylamino”, the “lower alkoxycarbonylamino”, the “loweralkoxy lower alkyl”, the “lower alkylcarbamoyl”, the “hydroxy loweralkylcarbamoyl”, the “amino lower alkyl”, the “hydroxy imino loweralkyl”, the “lower alkoxy imino lower alkyl”, the “lower alkylthio”, the“lower alkylsulfonyl”, the “lower alkyl sulfamoyl”, the “loweralkylsulfinyl”, the “lower alkylsulfonyloxy”, the “lower alkoxycarbonyllower alkynyl”, the “lower alkylthio lower alkyl”, the “aryl loweralkyl”, the “aryl lower alkylamino”, the “aryl lower alkoxycarbonyl”,the “aryl lower alkylcarbamoyl”, the “heterocyclic group loweralkylamino” and the “heterocyclic group lower alkylcarbamoyl” is thesame as that of the aforementioned “lower alkyl”.

The example of the “optionally substituted lower alkyl” as a substituentof ring A is lower alkyl optionally substituted with one or moresubstituents selected from the “substituent group α”, “hydroxyimino” and“lower alkoxyimino”; the group defined as above (i), (iv), (vi), (x)(wherein each Q¹ is optionally substituted lower alkylene); the groupdefined as (v), (vii), (ix) (wherein Q² is optionally substituted loweralkylene); and the group (xii).

In other “optionally substituted lower alkyl” is optionally substitutedwith one or more substituents selected from the “substituent group α”.

The “substituent group α” is selected from the group of halogen,hydroxy, lower alkoxy, hydroxy lower alkoxy, lower alkoxy lower alkoxy,acyl, acyloxy, carboxy, lower alkoxycarbonyl, amino, acylamino, loweralkylamino, lower alkylthio, carbamoyl, lower alkylcarbamoyl, hydroxylower alkylcarbamoyl, sulfamoyl, lower alkylsulfamoyl, loweralkylsulfinyl, cyano, nitro, aryl, and heterocyclic group.

Especially as a substituent of the “optionally substituted lower alkyl”in Alk², halogen, hydroxy, lower alkoxy, lower alkoxy lower alkoxy,lower alkoxycarbonyl, amino, acylamino, lower alkylamino and/or loweralkylthio are preferable.

The example of the “optionally substituted lower alkoxy” as asubstituent of ring A is lower alkoxy optionally substituted with one ormore substituents selected from the above “substituent group α”; above(iii) wherein Q¹ is optionally substituted lower alkylene. Q² is a bond,W² is O; above (v) wherein Q¹ is optionally substituted lower alkylene,Q² is a bond. W³ is O; above (vi) wherein Q¹ is a bond, Q² is optionallysubstituted lower alkylene, W² is O; or above (xi) wherein Q⁴ isoptionally substituted lower alkylene, W² is O.

In other case, the substituents of the “optionally substituted loweralkoxy”, the “optionally substituted lower alkoxycarbonyl”, the“optionally substituted lower alkoxycarbonyloxy”, the “optionallysubstituted lower alkylsulfonyl”, the “optionally substituted loweralkylsulfinyl”, the “optionally substituted lower alkylsulfonyloxy” andthe “optionally substituted lower alkylthio” are one or moresubstituents selected from the “substituent group α”.

The “lower alkenyl” includes a straight or branched alkenyl of a carbonnumber of 2 to 15, preferably a carbon number of 2 to 10, furtherpreferably a carbon number of 2 to 6 and more further preferably acarbon number of 2 to 4 having one or more double bonds at an arbitraryposition. Specifically examples include vinyl, allyl, propenyl,isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl,isopentenyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl,nonenyl, decenyl, undecenyl, dodenyl, tridecenyl, tetradecenyl, andpentadecenyl.

The “lower alkynyl” includes a straight or branched alkynyl of a carbonnumber of 2 to 10, preferably a carbon number of 2 to 8, furtherpreferably a carbon number of 3 to 6, having one or more triple bonds atan arbitrary position. Specifically, examples include ethynyl, propenyl,butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, and decynyl.These may further have a double bond at an arbitrary position.

A lower alkynyl part of the “lower alkoxycarbonyl lower alkynyl” is thesame as that of above “lower alkynyl”.

The example of the “optionally substituted lower alkenyl” as asubstituent of ring A is lower alkenyl optionally substituted with oneor more substituents selected from the above “substituent group α”;above (i), (ii), (iv), (vi), (viii) or (x), wherein Q¹ is optionallysubstituted lower alkenylene; (v), (vii) or (ix), wherein Q²isoptionally substituted lower alkenylene.

In other case, the substituents of the “optionally substituted loweralkenyl” and the “optionally substituted lower alkynyl” are one or moresubstituents selected from the “substituent group α”.

The example of the “optionally substituted lower amino” as a substituentof ring A is amino optionally substituted with one or more substituentsselected from the group of lower alkyl, acyl, hydroxy, lower alkoxy,lower alkoxyl carbonyl, a carbocyclic group and a heterocyclic group;(ii), wherein Q¹ is a bond; (iv), wherein Q¹ is a bond; (v), wherein Q²is a bond, W³ is NR¹²; (ix), wherein Q²is a bond; (xiii); or (xiv).

The example of the “optionally substituted carbamoyl” as a substituentof ring A is carbamoyl optionally substituted with one or moresubstituents selected from the group of lower alkyl, acyl, hydroxy,lower alkoxy, lower alkoxycarbonyl, a carbocyclic group and aheterocyclic group; (i), (viii), wherein each Q¹ is bond; or (xv).

In other case, the substituents of the “optionally substituted amino”,the “optionally substituted amidino”, the “optionally substitutedcarbamoyl”, the “optionally substituted carbamoylcarbonyl”, and the“optionally substituted carbamoyloxy” are one or two substituentsselected from the group of lower alkyl, acyl, hydroxy, lower alkoxy,lower alkoxycarbonyl, a carbocyclic group and a heterocyclic group, andthe like.

The “acyl” includes aliphatic acyl of a carbon number of 1 to 10,carbocyclic carbonyl and heterocyclic carbonyl. Specifically, formyl,acetyl, propyonyl, butylyl, isobutylyl, valeryl, pivaloyl, hexanoyl,acryloyl, propioloyl, methacryloyl, crotonoyl, benzoyl,cyclohexanecarbonyl, pyridinecarbonyl, furancarbonyl, thiophenecarbonyl,benzothiazolcarbonyl, pyradinecarbonyl, piperidinecarbonyl,thiomorpholinocarbonyl, and the like.

The part of the acyl of the “halogenoacyl”, the “acylamino” and the“acyloxy” is the same as the aforementioned “acyl”.

The substituent of the “optionally substituted acyl” and “optionallysubstituted acyloxyl” is one or more substituents selected from thegroup of the “substituent group α”. The ring part of the “carbocycliccarbonyl” and the “heterocyclic carbonyl” is optionally substituted withone or more substituents selected from the group of “lower alkyl”; the“substituent group α”; and “lower alkyl substituted with one or moresubstituents selected from the group of the substituent α”.

The “carbocyclic group” includes cycloalkyl, cycloalkenyl, aryl andnon-aromatic fused carbocyclic group.

The “cycloalkyl” includes a carbocyclic group of a carbon number of 3 to10, preferably a carbon number of 3 to 8, further preferably a carbonnumber of 4 to 8, and examples include, cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, andcyclodecyl, and the like.

The “cycloalkenyl” includes cycloalkenyl having one or more double bondsat an arbitrary position in a ring of the aforementioned cycloalkyl, andexamples include cyclopropenyl, cyclobutenyl, cyclopentenyl,cyclohexenyl, cycloheptynyl, cyclooctynyl, and cyclohexadienyl, and thelike.

The “aryl” includes phenyl, naphthyl, anthryl, and phenanthryl, and thelike, and phenyl is particularly preferable.

The “non-aromatic fused a carbocyclic group” includes group fused withtwo or more ring groups selected from the group of the above“cycloalkyl”, the “cycloalkenyl” and the “aryl”. Specifically, examplesinclude indanyl, indenyl, tetrahydronaphthyl, and fluorenyl, and thelike.

The carbocyclic part of the “carbocyclicoxy”, and the “carbocyclic loweralkyl” is the same as the aforementioned “carbocyclic group”.

The aryl part of the “aryl lower alkyl”, the “aryloxy”, the“aryloxycarbonyl”, the “aryloxycarbonyloxy”, the “aryl loweralkoxycarbonyl”, the “arylthio”, the “arylamino”, the “aryl loweralkylamino”, the “arylsulfonyl”, the “arylsulfonyloxy”, the“arylsulfinyl”, the “arylsulfamoyl”, the “arylcarbamoyl” and the “aryllower alkylcarbamoyl” is the same as the aforementioned “aryl”.

The “heterocyclic group” includes a heterocyclic group having one ormore heteroatoms arbitrary selected from O, S, and N in a ring,specifically includes a 5- to 6-membered heteroaryl such as pyrrolyl,imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl,isothiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furyl and thienyl;a bicyclic fused heterocyclic group such as indolyl, isoindolyl,indazolyl, indolidinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl,cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, purinyl,pteridinyl, benzopyranyl, benzimidazolyl, benzioxazolyl, benzoxazolyl,benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl,benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl,pyrazolopyridyl, triazolopyridyl, itnidazothiazolyl,pyrazinopyridazinyl, quinazolinyl, quinolyl, isoquinolyl,naphthyridinyl, dihydrobenzofuryl, tetrahydroquinolyl,tetrahydroisoquinolyl, dihydrobenzoxazine, tetrahydrobenzothienyl; atricyclic fused heterocyclic group such as carbazolyl, acridinyl,xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, dibenzofuryl,and imidazoquinolyl; a non-aromatic heterocyclic group such as dioxanyl,thiiranyl, oxyranyl, oxathioranyl, azethidinyl, thianyl, pyrrolidinyl,pyrrolinyi, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl,piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl,thiomorpholino, dihydropyridyl, dihydrobenzoimidazolyl,tetrahydropyridyl, tetrahydrofuryl, tetrahydropyranyl,tetrahydrothiazolyl, tetrahydroisothiazolyl, dihydroxadinyl,hexahydroazepinyl, tetrahydroazepyinyl. Preferable is a 5- to 6-memberedheteroaryl, or a non-aromatic heterocyclic group.

The heterocyclic part of the “heterocyclicoxy”, the “heterocyclic thio”,the “heterocyclic carbonyl”, the “heterocyclic amino”, the “heterocycliccarbonylamino”, the “heterocyclic sulfamoyl”, the “heterocyclicsulfonyl”, the “heterocyclic carbamoyl”, the “heterocyclicoxycarbonyl”,the “heterocyclic lower alkylamino” and the “heterocyclic lower alkylcarbamoyl” is the same as the aforementioned “heterocyclic group”.

The example of the substituent of the “optionally substitutedcarbocyclic group” and the “optionally substituted heterocyclic group”in ring A is;

-   the substituent α, wherein preferable is for example, halogen,    hydroxy, acyl, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl,    amino, lower alkylamino, lower alkylthio; lower alkyl optionally    substituted with one or more substituents selected from the group of    substituent α, wherein preferable is halogen, hydroxy, lower alkoxy,    lower alkoxycarbonyl, and the like;-   amino lower alkyl substituted with one or more substituents selected    from the group of substituent α, wherein preferable is acyl, lower    alkyl and for lower alkoxy, and the like; hydroxyimino lower alkyl;    lower alkoxyimino lower alkyl;-   lower alkenyl optionally substituted with one or more substituents    selected from the group of substituent α, wherein preferable is    lower alkoxycarbonyl, halogen and /or halogeno lower alkoxycarbonyl,    and the like;-   lower alkynyl optionally substituted with one or more substituents    selected from the group of substituent α, wherein preferable is for    example, lower alkoxycarbonyl,-   lower alkoxy optionally substituted with one or more substituents    selected from the group of substituent α, wherein preferable is for    example, lower alkyl carbamoyl and for hydroxy lower alkyl    carbamoyl,-   lower alkylthio optionally substituted with one or more substituents    selected from the group of substituent α,-   lower alkylamino substituted with one or more substituents selected    from the group of substituent α,-   lower alkylsulfonyl optionally substituted with one or more    substituents selected from the group of substituent α,-   aryl lower alkoxycarbonyl optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl,-   acyl substituted with one or more substituents selected from the    group of substituent α,-   cycloalkyl optionally substituted with one or more substituents    selected from the group of substituent α, azido, and lower alkyl,-   lower alkylsulfinyl optionally substituted with one or more    substituents selected from the group of substituent α, sulfamoyl,-   aryl optionally substituted with one or more substituents selected    from the group of substituent α, azido, and lower alkyl,-   heterocyclic optionally group substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl,-   aryloxy optionally substituted with one or more substituents    selected from the group of substituent α, azido, and lower alkyl,-   heterocyclicoxy optionally substituted with one or more substituents    selected from the group of substituent α, azido, and lower alkyl,-   arylthio optionally substituted with one or more substituents    selected from the group of substituent α, azido, and lower alkyl,-   heterocyclicthio optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl, arylamino optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl,-   heterocyclicamino optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl, aryl lower alkylamino optionally substituted with one    or more substituents selected from the group of substituent α,    azido, and lower alkyl,-   heterocyclic lower alkylamino optionally substituted with one or    more substituents selected from the group of substituent α, azido,    and lower alkyl,-   lower alkyl sulfamoyl optionally substituted with one or more    substituents selected from the group of substituent α,-   aryl sulfamoyl optionally substituted with one or more substituents    selected from the group of substituent α, azido, and lower alkyl,-   heterocyclic sulfamoyl optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl,-   arylsulfonyl optionally substituted with one or more substituents    selected from the group of substituent α, azido, and lower alkyl,-   heterocyclic sulfomyl optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl,-   aryl carbamoyl optionally substituted with one or more substituents    selected from the group of substituent α, azido, and lower alkyl,-   heterocyclic carbamoyl optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl,-   aryl lower alkylcarbamoyl optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl,-   heterocyclic lower alkylcarbamoyl optionally substituted with one or    more substituents selected from the group of substituent α, azido,    and lower alkyl,-   aryloxycarbonyl optionally substituted with one or more substituents    selected from the group of substituent α, azido, and lower alkyl,-   heterocyclicoxycarbonyl optionally substituted with one or more    substituents selected from the group of substituent α, azido, and    lower alkyl,-   lower alkylenedioxy optionally substituted with halogen; oxo; azido;

-   wherein Q¹, Q² and Q³ are each independently a bond, optionally    substituted lower alkylene or optionally substituted lower    alkenylene;-   Q⁴ is optionally substituted lower alkylene or optionally    substituted lower alkenylene;-   W¹ and W² are each independently O or S;-   W³ is O, S or NR¹²;-   R¹² is a hydrogen atom, lower alkyl, hydroxy lower alkyl, lower    alkoxy lower alkyl, lower alkoxycarbonyl lower alkyl, carbocyclic    group lower alkyl or acyl;-   R¹⁴ is a hydrogen atom or lower alkyl;-   ring B is an optionally substituted carbocyclic group or an    optionally substituted heterocyclic group;-   Alk² is optionally substituted lower alkyl;-   and the ring A is optionally substituted with one or more    substituents selected from these groups.-   If there are multiple W¹, multiple W³, and multiple R¹², each may be    independently different.-   In addition, an oxygen atom in (xii) may be cis or trans position to    the substituent R¹⁴.-   The substituent of the “substituted phenyl” is, in the same way,    phenyl substituted with one or two substituents selected preferably    from the group of the substituent α or (i) to (xv).

The substituent of the “optionally substituted carbocyclic group” or the“optionally substituted heterocyclic group” in ring B is optionallysubstituted with one or more substituents selected from the followinggroup of, for example;

-   the substituent α, wherein preferable is halogen, hydroxy, lower    alkoxy, carboxy, lower alkoxycarbonyl, acyl, amino, lower    alkylamino, acylamino, carbamoyl, lower alkylcarbamoyl, cyano, and    nitro, and the like;-   lower alkyl optionally substituted with one or more substituents    selected from the group of the substituent α, wherein preferable is    halogen, hydroxy, and lower alkoxy, and the like; amino lower alkyl    substituted with one or more substituents selected from the group of    substituent α,-   hydroxyimino lower alkyl;-   lower alkoxyimino lower alkyl;-   lower alkenyl optionally substituted with one or more substituents    selected from the group of substituent α;-   lower alkynyl optionally substituted with one or more substituents    selected from the group of substituent α;-   lower alkoxy optionally substituted with one or more substutuents    selected from the group of substituent α, wherein preferable is    halogen, hydroxy, and the like;-   lower alkylthio optionally substituted with one or more substituents    selected from the group of substituent α, wherein preferable is    halogen;-   lower alkylamino substituted with one or more substituents selected    from the group of substituent α, wherein preferable is amino;-   lower alkylsulfonyl optionally substituted with one or more    substituents selected from the group of substituent α;-   aryl lower alkoxycarbonyl optionally substituted with one or more    substituents selected from the group of substituent α and lower    alkyl;-   acyl substituted with one or more substituents selected from the    group of substituent α, wherein preferable is halogen;-   lower alkylsulfonyl optionally substituted with one or more    substituents selected from the group of substituent α;-   sulfamoyl;-   lower alkyl sulfamoyl optionally substituted with one or more    substituents selected from the group of substituent α;-   cycloalkyl optionally substituted with one or more substituents    selected from the group of substituent α, azido and lower alkyl;-   aryl optionally substituted with one or more substituents selected    from the group of substituent αazido and lower alkyl;-   heterocyclic group optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl, wherein preferable is halogen, lower alkyl, and the    like; aryloxy optionally substituted with one or more substituents    selected from the group of substituent α, azido and lower alkyl;-   heterocyclicoxy optionally substituted with one or more substituents    selected from the group of substituent α, azido and lower alkyl;-   arylthio optionally substituted with one or more substituents    selected from the group of substituent α, azido and lower alkyl,    wherein preferable is halogen, hydroxy, lower alkoxy, acyl, and the    like;-   heterocyclic thio optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl;-   arylamino optionally substituted with one or more substituents    selected from the group of substituent α, azido and lower alkyl,    wherein preferable is halogen, hydroxy, lower alkoxy, acyl;-   heterocyclic amino optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl;-   aryl lower alkylamino optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl, wherein preferable is halogen, hydroxy, lower alkoxy,    acyl;-   heterocyclic lower alkylamino optionally substituted with one or    more substituents selected from the group of substituent α, azido    and lower alkyl;-   arylsulfamoyl optionally substituted with one or more substituents    selected from the group of substituent αazido and lower alkyl;-   heterocyclic sulfamoyl optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl;-   arylsulfonyl optionally substituted with one or more substituents    selected from the group of substituent α, azido and lower alkyl;-   heterocyclic sulfonyl optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl;-   arylcarbamoyl optionally substituted with one or more substituents    selected from the group of substituent α, azido and lower alkyl;-   heterocyclic carbamoyl optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl;-   aryl lower alkylcarbamoyl optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl;-   heterocyclic lower alkylcarbamoyl optionally substituted with one or    more substituents selected from the group of substituent α, azido    and lower alkyl;-   aryloxy carbonyl optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl;-   heterocyclicoxycarbonyl optionally substituted with one or more    substituents selected from the group of substituent α, azido and    lower alkyl;-   lower alkylenedioxy optionally substituted with halogen; oxo; and    the like.

In other case, the substituent of the “optionally substitutedcarbocyclic group”, the “optionally substituted heterocyclic group”, the“optionally substituted carbocyclicoxy”, the “optionally substitutedarylsulfonyl”, the “optionally substituted aryloxycarbonyloxy”, the“optionally substituted heterocyclicoxy”, the “optionally substitutedarylsulfinyl”, the “optionally substituted arylsulfonyloxy”, the“optionally substituted arylthio” is one or more substituents selectedfrom the group of “lower alkyl” and the “substituent α”.

-   “heteroaryl” include aromatic ring group in the aforementioned    “heterocyclic group”.

The substituent of the “optionally substituted 5- to 6-memberedheteroaryl” is the same as the substituent of the “optionallysubstituted heterocyclic group” in the aforementioned “ring B”.Preferable is one or more substituent selected from lower alkyl and asubstituent α.

The “lower alkylene” includes a straight or branched bivalent carbonchain of a carbon number of 1 to 10, preferably a carbon number of 1 to6, further preferably a carbon number of 1 to 3, Specifically, examplesinclude methylene, dimethylene, trimethylene, tetramethylene, andmethyltrimethylene, and the like.

The part of lower alkylene of the “lower alkylenedioxy” is the same asthe aforementioned “lower alkylene”.

The “lower alkenylene” includes a straight or branched bivalent carbonchain of a carbon number of 2 to 10, preferably a carbon number of 2 to6, further preferably a carbon number of 2 to 4 having double bond at anarbitrary position. Specifically, examples include vinylene,propenylene, butenylene, butadienylene, methylpropenylene, pentenylene,and hexenylene, and the like.

The “lower alkynylene” includes a straight or branched bivalent carbonchain of a carbon number of 2 to 10, preferably a carbon number of 2 to6, further preferably a carbon number of 2 to 4 having triple bond at anarbitrary position. Specifically, examples include ethynylene,propynylene, butynylene, pentynylene, and hexynylene, and the like.

The substituent of the “optionally substituted lower alkylene”, the“optionally substituted lower alkenylene”, the “optionally substitutedlower alkynylene” is the substituent α, preferable is halogen, hydroxyand the like.

The “each R^(3a), each R^(3b), each R^(4a), and each R^(4b) may beindependently different” means when n is 2 or 3, two or three R^(3a) maybe independently different, and two or three R^(3b) may be independentlydifferent. In the same way, when in is 2 or 3, two or three R^(4a) maybe independently different, and two or three R^(4b) may be independentlydifferent.

-   R⁵ and ring A can be taken together to form

-   means for example, include the following structures.

-   wherein each symbols are the same as described above;-   preferably, R^(5a) and R^(5b) are all hydrogen atoms.

In this description, “solvate” includes, for example, a solvate with anorganic solvent and a hydrate, and the like. When hydrate is formed,arbitrary number of water molecules may be coordinated.

The compound (I) includes a pharmaceutically acceptable salt. Examplesinclude salts with alkali metals (lithium, sodium or potassium, and thelike), alkaline earth metals (magnesium or calcium, and the like),ammonium, organic bases or amino acids, and salts with inorganic acids(hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid,phosphoric acid or hydroiodic acid, and the like), and organic acid(acetic acid, trifluoroacetic acid, citric acid, lactic acid, tartaricacid, oxalic acid, maleic acid, fumaric acid, manderic acid, glutaricacid, malic acid, benzoic acid, phthalic acid, benzenesulfonic acid,p-toluenesulfonic acid, methanesulfonic acid, or ethanesulfonic acid,and the like). Particularly, hydrochloric acid, phosphoric acid,tartaric acid, or methanesulfonic acid is preferable. These salts can beformed by a conventional method.

In addition, the compound (I) is not limited to a specific isomer, butincludes all possible isomers (keto-enol isomer, imine-enamine isomer,diastereo isomer, optical isomer, and rotational isomer, and the like)and racemates. For example, the compound (I), wherein R^(2a) is ahydrogen atom, includes following tautomer.

The compound (I) in this invention can be prepared by the processdescribed in, for example Non-patent Document 1 or following process.

The synthesis of aminodihydrothiazine ring; Method A

In formula, at least either R^(2b) or R^(2c) is a hydrogen atom, eitherR^(3c) or R^(3d) is each independently a hydrogen atom, halogen,hydroxy, optionally substituted lower alkyl, optionally substitutedlower alkenyl, optionally substituted acyl, carboxy, optionallysubstituted lower alkoxycarbonyl, optionally substituted amino,optionally substituted carbamoyl, an optionally substituted carbocyclicgroup or an optionally substituted heterocyclic group. Other symbols arethe same as described above.

(Step 1)

To a solution of compound (a), which is commercially available orprepared by known method, in appropriate solvent or mixture of solvents,such as ether, tetrahydrofuran, and the like is added the Grignardreagent having substituent corresponds to the target compound; forexample vinylmagnesium chloride, vinylmagnesium bromide, orpropenylmagnesium bromide, and the like; at −100° C. to 50° C.,preferably −80° C. to 0° C. The mixture is reacted for 0.2 to 24 hours,preferably 0.5 to 5 hours, to obtain compound (b).

(Step 2)

The compound (b) in solvent, such as toluene or absence of solvent istreated with thiourea derivatives having substituent corresponds to thetarget compound, such as thiourea, N-methylthiourea,N,N′-dimethylthiourea, and the like in the presence of an acid ormixture of acids, such as acetic acid, trifluoroacetic acid,hydrochloric acid, or sulfuric acid, and the like. The mixture isreacted at −20° C. to 100° C., preferably 0° C. to 50° C. for 0.5 to 120hours, preferably 1 to 72 hours, to obtain the compound (c).

(Step 3)

The compound (c) in solvent, such as toluene or absence of solvent istreated with an acid or mixture of acids, such as trifluoroacetic acid,methanesulfonic acid, trifluoromethanesulfonic acid, and the like. Themixture is reacted at −20° C. to 100° C., preferably 0° C. to 50° C. for0.5 to 120 hours, preferably 1 to 72 hours, to obtain the compound(I-2), wherein R^(2b) is a hydrogen atom, or the compound (I-1), whereinR^(2c) is a hydrogen atom.

The synthesis of aminodihydrothiazine ring; Method B

In formula, L is leaving group such as halogen or sulfonyloxy, and thelike. Other symbols are the same as described above.

(Step 1)

The compound (d) which is commercially available or prepared by knownmethod is reacted with thiocyanic acid; for example, sodium thiocyanicacid, ammonium thiocyanic acid, and the like; in solvent; for example,toluene, chloroform, tetrahydrofuran, and the like; in the presence ofacid; for example, water, hydrochloric acid, sulfuric acid, and thelike; at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 to 24hours, preferably 1 to 12 hours, to obtain the compound (e),

(Step 2)

To the compound (e) in solvent or mixture of solvents; for example,tetrahydrofuran, methanol, ethanol, water, and the like; in the presenceor the absence of buffer like sodium dihydorgen phosphate, and the like;reducing agent; for example sodium borohydride, and the like; is addedand the mixture is reacted at −80° C. to 50° C., preferably −20° C. to20° C. for 0.1 to 24 hours, preferably 0.5 to 12 hours, to obtain thecompound (f).

(Step 3)

The compound (f) in the presence or the absence of solvent; for example,toluene, dichloromethane, and the like; is reacted with halogenatingagent; for example thionyl chloride, phosphorus oxychloride, carbontetrabromide-triphenylphosphine, and the like; at −80° C. to 50° C.,preferably −20° C. to 20° C. for 0.1 to 24 hours, preferably 0.5 to 12hours, to obtain the compound (g). Alternatively, the compound (f) inthe presence or the absence of solvent; for example, toluene,dichloromethane, and the like; under base; for example triethylamine,and the like; is reacted with sulfonating agent; for example,methanesulfonyl chloride, p-toluenesulfonylchloride, and the like; at−80° C. to 50° C., preferably −20° C. to 20° C. for 0.1 to 24 hours,preferably 0.5 to 12 hours, to obtain the compound (g).

(Step 4)

To the compound (g) in solvent or mixture of solvents, for examplemethanol, ethanol, water, and the like; is reacted with primary amine;for example, ammonia or methylamine, and the like; at −20° C. to 80° C.,preferably 0° C. to 40° C. for 0.5 to 48 hours, preferably 1 to 24hours, to obtain the compound (I-3).

The synthesis of aminodihydrothiazine ring; Method C

In formula, R is a hydrogen atom or protective groups of carboxyl group.Other symbols are the same as described above.

(Step 1)

The compound (h) which is commercially available or prepared by knownmethod is reacted with reducing agent; for example, lithium aluminiumhydride, diisobutyl aluminium hydride, and the like; in solvent; forexample tetrahydrofuran, ether, and the like; at −80° C. to 150° C.,preferably 25° C. to 100° C. for 0.1 to 24 hours, preferably 0.5 to 12hours, to obtain the compound (i).

(Step 2)

The compound (i) in solvent; for example, toluene, chloroform,tetrahydrofuran, and the like; in the presence or the absence of base;for example, diisopropylethylamine, triethylamine, pyridine, sodiumhydroxide, and the like; is reacted with corresponding isothiocyanate;for example, 4-methoxybenzylisothiocyanate, t-butylisothiocyanate, andthe like; or corresponding thiocarbamoylhalide; for example,N,N-dimethylthiocarbamoylchloride, N,N-diethylthiocarbamoylchloride, andthe like; at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 to120 hours, preferably 1 to 72 hours, to obtain the compound (j).

(Step 3)

The compound (j) in solvent; for example, acetonitrile, toluene,dichloromethane, and the like; is reacted with halogenating agent; forexample thionyl chloride, phosphorus oxychloride, carbontetrabromide-triphenylphosphine, and the like; at −80° C. to 50° C.,preferably −20° C. to 20° C. for 0.1 to 24 hours, preferably 0.5 to 12hours, or alternatively, the compound (j) in solvent; for example,toluene, dichloromethane, and the like; in the presence of base; forexample triethylamine, and the like; is reacted with sulfonating agent;for example, methanesulfonyl chloride, p-toluenesulfonylchloride, andthe like; at −80° C. to 50° C., preferably −20° C. to 20° C. for 0.1 to24 hours, preferably 0.5 to 12 hours. The obtained halogenated compoundor sulfonylated compound is reacted with base; for example,diisopropylamine, potassium carbonate, sodium hydrogencarbonate, sodiumhydride, sodium hydroxide, and the like; at 0° C. to 150° C., preferably20° C. to 100° C. for 0.5 to 120 hours, preferably 1 to 72 hours, toobtain the compound (I-4).

The synthesis of aminodihydrothiazine ring; Method D

The synthesis of aminothiazoline ring; Method A

The synthesis of tetrahydrothiazepine ring; Method A

In formula, L is leaving group such as halogen or sulfonyloxy, and thelike; m is an integer of 1 to 3; and the other symbols are the same asdescribed above.

(Step 1)

The compound (k) which is commercially available or prepared by knownmethod is reacted with azide reagent; for example, sodium azide, and,the like; in solvent; for example N,N-dimethylformamide,tetrahydrofuran, and the like; at 0° C. to 200° C., preferably 40° C. to150° C. for 0.5 to 24 hours, preferably 1 to 12 hours, to obtain thecompound (l).

(Step 2)

The compound 0) is reacted with reducing agent; for example, lithiumaluminium hydride, diisobutyl aluminium hydride, and the like; insolvent; for example tetrahydrofuran, ether, and the like; at −80° C. to150° C., preferably 25° C. to 100° C. for 0.1 to 24 hours, preferably0.5 to 12 hours, to obtain the compound (m).

(Step 3)

The compound (m) in solvent; for example, toluene, chloroform,tetrahydrofuran, and the like; is reacted with correspondingisothiocyanate; for example, methylisothiocyanate, ethylisothiocyanate,and the like; or corresponding thiocarbamoylhalide; for example,N,N-dimethylthiocarbamoylchloride, N,N-diethylthiocarbamoylchloride, andthe like; at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 to120 hours, preferably 1 to 72 hours, to obtain the compound (n).

(Step 4)

The compound (n) in solvent; for example, acetonitrile, toluene,dichloromethane and the like; is reacted with halogenating agent; forexample thionyl chloride, phosphorus oxychloride, carbontetrabromide-triphenylphosphine, and the like; at −80° C. to 50° C.,preferably −20° C. to 20° C. for 0,1 to 24 hours, preferably 0.5 to 12hours, or alternatively, the compound (n) in solvent; for example,toluene, dichloromethane, and the like; in the presence of base; forexample diisopropylethylamine, triethylamine, and the like; is reactedwith sulfonating agent; for example, methanesulfonyl chloride,p-toluenesulfonylchloride, and the like; at −80° C. to 50° C.,preferably -20° C. to 20° C. for 0,1 to 24 hours, preferably 0.5 to 12hours. The obtained halogenated compound or sulfonylated compound isreacted with base; for example, diisopropylamine, potassium carbonate,sodium hydrogencarbonate, sodium hydride, sodium hydroxide, and thelike; at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 to 120hours, preferably 1 to 72 hours, to obtain the compound (I-5).

The synthesis of aminodihydrothiazine ring; Method E

The synthesis of aminothiazoline ring; Method B

The synthesis of tetrahydrothiazepine ring; Method B

In formula, at lease one of R^(2b)) and R^(2c) is a hydrogen atom, n isan integer of 1 to 3, and the other symbols are the same as describedabove.

(Step 1)

The compound (o) which is commercially available or prepared by knownmethod is reacted with substituted thiourea; for example, thiourea,N-methylthiourea, N,N,-dimethylthiourea, N,N′-dimethylthiourea, and thelike; in solvent; for example, ethanol, methanol, tetrahydrofuran,toluene, and the like; at −20° C. to 200° C., preferably 0° C. to 150°C. for 0.5 to 200 hours, preferably 1 to 120 hours, to obtain thecompound (p).

(Step 2)

To the compound (p) in solvent or mixture of solvents; for example,ether, tetrahydrofuran, and the like; the Grignard reagent havingsubstituent corresponding to target compound; for examplemethylmagnesium chloride, ethylmagnesium bromide, or benzylmagnesiumbromide, and the like; is added at −100° C. to 50° C., preferably −80°C. to 30° C., and the mixture is reacted for 0.2 to 24 hours, preferably0.5 to 5 hours, to obtain the compound (q).

(Step 3)

To the compound (q) in the presence or the absence of solvent; forexample, toluene, and the like; acid or mixture of acids, such astrifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonicacid, and the Like; is added and the mixture is reacted at −20° C. to100° C., preferably 0° C. to 50° C. for 0.5 to 200 hours, preferably 1to 150 hours, to obtain the compound (I-6)(wherein R^(2c) is H), or thecompound (I-7)(wherein R^(2b) is H).

The synthesis of aminodihydrothiazine ring; Method F

In formula, each symbols are the same as described above.

(Step 1)

The compound (r) which is commercially available or prepared by knownmethod is reacted with ammonium chloride in solvent; for example, aceticacid, and the like; at 0° C. to 200° C., preferably 10° C. to 100° C.for 0.1 to 100 hours, preferably 0.5 to 24 hours, to obtain the compound(s).

(Step 2)

The compound (s) is reacted with reducing agent; for example, lithiumaluminium hydride, diisobutyl aluminium hydride, and the like; insolvent; for example tetrahydrofuran, ether, and the like; at −80° C. to150° C., preferably 0° C. to 100° C. for 0.1 to 24 hours, preferably 0.5to 12 hours, to obtain the compound (t).

(Step 3)

The compound (t) in solvent; for example, toluene, chloroform,tetrahydrofuran, and the like; in the presence or the absence of base;for example, diisopropylethylamine, triethylamine, pyridine, sodiumhydroxide, and the like; is reacted with corresponding isothiocyanate;for example, 4-methoxybenzylisothiocyanate, t-butylisothiocyanate, andthe like; or corresponding carbamoylhalide; for example,N,N-dimethylthiocarbamoylchloride, N,N-diethylthiocarbamoylchloride, andthe like; at 0° C. to 150° C., preferably 20° C. to 100° C. for 0.5 to120 hours, preferably 1 to 72 hours, to obtain the compound (u).

(Step 4)

The compound (u) in solvent; for example, acetonitrile, toluene,dichloromethane, and the like; is reacted with halogenating agent; forexample thionyl chloride, phosphorus oxychloride, carbontetrabromide-triphenylphosphine, and the like; at −80° C. to 50° C.,preferably −20° C. to 20° C. for 0.1 to 24 hour preferably 0.5 to 12hours, or alternatively, the compound (u) in solvent; for example,toluene, dichloromethane, and the like; in the presence of base; forexample triethylamine, and the like; is reacted with sulfonating agent;for example, methanesulfonyl chloride, p-toluenesulfonylchloride, andthe like; at −80° C. to 50° C. preferably −20° C. to 20° C. for 0.1 to24 hours, preferably 0.5 to 12 hours. The obtained halogenated compoundor sulfonylated compound is reacted with base; for example,diisopropylamine, potassium carbonate, sodium hydrogencarbonate, sodiumhydride, sodium hydroxide, and the like; at 0° C. to 150° C., preferably20° C. to 100° C. for 0.5 to 120 hours, preferably 1 to 72 hours, toobtain the compound (I-8).

The synthesis of aminodihydrooxazine ring; Method A

The synthesis of aminotetrahydrooxazepine ring; Method A

In formula, each symbols are the same as described above.

(Step 1)

The compound (n) which is obtained by Step 3(the compound (m) to thecompound (n)) of “The synthesis of aminodihydrothiazine ring; Method D”,in solvent; for example, methanol, ethanol, N,N-dimethylformamide,tetrahydrofuran, and the like; in the presence or the absence of base;for example, diisopropylethylamine, triethylamine, pyridine, sodiumhydroxide, and the like; is reacted with alkylating agent; for example,methyl iodide, dimethyl sulfate, benzyl bromide, and the like; at 0° C.to 200° C., preferably 40° C. to 150° C. for 0.1 to 48 hours, preferably0.5 to 24 hours, to obtain the compound (v).

(Step 2)

The compound (v) in solvent; for example, N,N-dimethylformamide,tetrahydrofuran, dichloromethane, and the like; in the presence or theabsence of base; for example, diisopropylethylamine, triethylamine,pyridine, sodium hydroxide, and the like; is reacted with metallicoxide; for example, silver oxide, mercury oxide, manganese dioxide, andthe like; at 0° C. to 200° C., preferably 10° C. to 150° C. for 1 to 120hours, preferably 0.5 to 100 hours, to obtain the compound (I-9).

The synthesis of aminodihydrooxazine ring; Method B

The synthesis of aminoxazoline ring

The synthesis of aminotetrahydrooxazepine ring; Method B

In formula, R¹⁵ is optionally substituted lower alkyl; for example,t-butyl, benzyl, and the like; R¹⁶ is hydrogen atom or lower alkyl; n isan integer of 1 to 3, and the other symbols are the same as describedabove.

(Step 1)

The compound (w) which is commercially available or prepared by knownmethod in solvent; for example, toluene, t-butylalcohol,tetrahydrofuran, and the like; in the presence of base; for example,diisopropylethylamine, triethylamine, pyridine, and the like; is reactedwith azide reagent; for example, diphenyl phosphoryl azide, and thelike; at 0° C. to 200° C., preferably 40° C. to 150° C. for 1 to 48hours, preferably 0.5 to 24 hours, to obtain the compound (x).

(Step 2)

The compound (x) in solvent; for example, toluene, xylene,N,N-dimethylformamide, tetrahydrofuran, and the like; is reacted withalcohol; for example, t-butylalcohol, 3,4-dimethoxybenzylalcohol,4-methoxybenzylalcohol, and the like; at 0° C. to 300° C., preferably50° C. to 200° C. for 1 to 800 hours, preferably 5 to 500 hours, toobtain the compound (y).

(Step 3)

The compound (y) in the presence or the absence of solvent; for example,water, toluene, dichloromethane, methanol, 1,4-dioxane, acetic acid,ethyl acetate, and the like; in the presence of acid; for example,hydrochloric acid, sulfuric acid, hydrobromic acid, trifluoroaceticacid, and the like; at 0° C. to 200° C., preferably 25° C. to 150° C.for 0.1 to 48 hours, preferably 0.5 to 24 hours, to obtain the compound(z).

(Step 4)

The compound (z) in solvent; for example, toluene, chloroform,tetrahydrofuran, and the like; in the presence of base; for example,diisopropylethylamine, triethylamine, pyridine, and the like; is reactedwith corresponding isothiocyanate, or thiocarbamoylhalide correspondingto target compound; for example, N,N-dimethylthiocarbamoylchloride,N,N-diethylthiocarbamoylchloride, and the like; at 0° C. to 150° C.,preferably 20° C. to 100° C. for 0.5 to 120 hours, preferably 1 to 72hours, to obtain the compound (aa).

(Step 5)

The compound (aa) in solvent; for example, methanol, ethanol,N,N-dimethylformamide, tetrahydrofuran, and the like; in the presence orthe absence of base; for example, diisopropylethylamine, triethylamine,pyridine, sodium hydroxide, and the like; is reacted with alkylatingagent; for example, methyl iodide, dimethyl sulfate, benzyl bromide, andthe like; at 0° C. to 200° C., preferably 40° C. to 150° C. for 1 to 48hours, preferably 0.5 to 24 hours, to obtain the compound (ab).

(Step 6)

The compound (ab) in solvent; for example, N,N-dimethylformamide,tetrahydrofuran, dichloromethane, and the like; in the presence of base;for example, diisopropylethylamine, triethylamine, pyridine, sodiumhydroxide, and the like; is reacted with metallic oxide; for example,silver oxide, mercury oxide, manganese dioxide, and the like; at 0° C.to 200° C., preferably 10° C. to 150° C. for 1 to 120 hours, preferably0.5 to 100 hours, to obtain the compound (O-10).

The synthesis of aminotetrahydropyrimidine ring

In formula, each symbols are the same as described above.

(Step 1)

To the compound (ac) prepared by known method in solvent; for example,N,N-dimethylformamide, methanol, and the like; is reacted with azidereagent; for example, sodium azide, lithium azide, and the like; at 20°C. to 150° C., preferably 50° C. to 100° C. for 0.5 to 120 hours,preferably 1 to 72 hours, to obtain the compound (ad).

(Step 2)

To the suspension of lithium aluminium hydride in solvent; for example,tetrahydrofuran, or ether, and the like; the compound (ad) dissolved insolvent; for example, tetrahydrofuran, or diethyl ether, and the like;is added under nitrogen atmosphere, at −80° C. to 20° C., preferably−30° C. to 0° C., and the mixture is reacted for 1 minute to 10 hours,preferably 10 minutes to 1 hour, or alternatively to the compound (ad)in solvent; for example, ethanol, isopropanol, or n-butanol, and thelike; Raney-Nickel is added at 10° C. to 110° C., preferably 50° C. to80° C., and reacted for 1 minute to 10 hours, preferably 10 minutes to 1hour, to obtain the compound (ae).

(Step 3)

The compound (ae) in solvent; for example, tetrahydrofuran,dichloromethane, and the like; in the presence of acid; for example,acetic acid, or propionic acid, and the like; is reacted with reducingagent; for example, sodium cyanoborohydride, sodiumtriacetoxyborohydride, and the like; at −50° C. to 100° C., preferably0° C. to 50° C., for 0.1 to 48 hours, preferably 0.5 to 24 hours, or thecompound (ae) in solvent; for example, tetrahydrofuran,N,N-dimethylformamide, and the like; in the presence of dehydratingagent; for example,1-ehthyl-3-(3-dimethylaminopropyl)carbodiimide-N-hydroxybenzotriazole,carbonyldiimidazole, and the like; or in the presence of base; forexample, triethylamine, potassium carbonate, and the like; is reactedwith carboxylic acid; for example, formic acid, acetic acid, and thelike; at −50° C. to 100° C., preferably 0° C. to 50° C. for 0.1 to 48hours, preferably 0.5 to 16 hours, to obtain the compound (af). Andnext, to the suspension of lithium aluminium hydride in solvent; forexample, tetrahydrofuran, or diethyl ether, and the like; theaforementioned amide compound dissolved in solvent; for example,tetrahydrofuran, or ether, and the like; is added at −50° C. to 60° C.,preferably 0° C. to 50° C., and the mixture is reacted for 1 minute to48 hours, preferably 10 minutes to 10 hours, to obtain the compound(af).

(Step 4)

The compound (ae) or the compound (af) in solvent; for example,acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and the like; isreacted with 3,5-dimethylpyrazole-1-carboxyamidine or S-methylthioureaat 0° C. to 150° C., preferably 20° C. to 100° C., and the mixture isreacted for 0.5 to 120 hours, preferably 1 to 24 hours, to obtain thecompound (ag).

(Step 5)

To the compound (ag) (wherein at least either R^(2b) or R^(2c) is ahydrogen atom) in the presence or the absence of solvent; for example,toluene, and the like; acid; for example, trifluoroacetic acid,methanesulfonic acid, trifluoromethanesulfonic acid, and the like, orthe mixture thereof; is added and the mixture is reacted at −20° C. to100° C., preferably 0° C. to 50° C., and the mixture is reacted for 0.5to 120 hours, preferably 1 to 72 hours, to obtain the compound (I-2)(wherein R^(2b) is a hydrogen atom) or the compound (I-1) (whereinR^(2c) is a hydrogen atom) respectively, Proviso, if R^(2a), R^(2b), andR^(2c) have fragile structure under acidic condition; for example,t-butyloxycarbonyl, and the like; R^(2a), R^(2b), and R^(2c) in thecompound (I-1) or the compound (I-2) may be transformed into a hydrogenatom.

The synthesis of aminothiazoline ring; Method C

In formula, Hal is halogen, and other symbols are the same as describedabove.

(Step 1)

The compound (ah) which is commercially available or prepared by knownmethod in solvent; for example, toluene, chloroform, tetrahydrofuran,and the like; or in mixed-solvent; for example, chloroform-water, andthe like; is reacted with halogen; for example, including iodine,bromine, chorine; phase transfer catalyst; for example, sodiumthiocyanic acid, ammonium thiocyanic acid, and the like; at 0° C. to150° C., preferably 20° C. to 100° C., for 0.5 to 48 hours, preferably 1to 24 hours, to obtain the compound (ai).

(Step 2)

The compound (ai) in solvent; for example, toluene, chloroform,tetrahydrofuran, and the like; is reacted with amine having substituentcorresponding to target compound; for example ammonia, methylamine,diethylamine, and the like; at 0° C. to 150° C., preferably 20° C. to100° C., for 0.5 to 48 hours, preferably 1 to 24 hours, to obtain thecompound (I-11).

The aminoacyl derivative-1

In formula, R¹⁷ is optionally substituted lower alkyl, an optionallysubstituted carbocyclic group or an optionally substituted heterocyclicgroup, and the other symbols are the same as described above.

The compound (I-12) wherein R^(2b) is a hydrogen atom in the presence orthe absence of solvent; for example, tetrahydrofuran, dichloromethane,and the like; in the presence of base; for example, pyridine,triethylamine, and the like; is reacted with acylating agent havingsubstituent corresponding to target compound; for example, benzoylchloride, 2-furoyl chloride, acetic anhydride, and the like; at −80° C.to 100° C., preferably −20° C. to 40° C., for 0.1 to 24 hours,preferably 1 to 12 hours, or alternatively, the compound (I-12) insolvent; for example, N,N-dimethylformamide, tetrahydrofuran,dichloromethane, and the like; in the presence of dehydrating agent; forexample, dicyclohexylcarbodiimide, carbonyldiimidazole, and the like; isreacted with carboxylic acid having substituent corresponding to targetcompound; for example, amino acid, glycolic acid, and the like; at −80°C. to 100° C., preferably −20° C. to 40° C., for 0.1 to 24 hours,preferably 1 to 12 hours, to obtain the compound (I-13) and/or thecompound (I-14) (wherein R^(2a) is a hydrogen atom).

The guanidino derivatives

In formula, each symbols are the same as described above,

The compound (I-12) wherein R^(2b) is a hydrogen atom in solvent; forexample, acetonitrile, tetrahydrofuran. N,N-dimethylformamide, and thelike; in the presence or the absence of base; for example,triethylamine, sodium hydrogencarbonate, and the like; is reacted with3,5-dimethylpyrazole-1-carboxyamidine, or S-methylisothiourea etc. at 0°C. to 150° C., preferably 20° C. to 100° C., for 0.5 to 120 hours,preferably 1 to 24 hours, to obtain the compound (I-15).

The carbamoyl derivatives

In formula, CONR¹⁸R¹⁹ is optionally substituted carbamoyl, and the othersymbols are the same as described above.

The compound (I-16) having a carboxyl group as substituent of ring A insolvent; for example, N,N-dimethylformamide, tetrahydrofuran,dichloromethane, and the like; in the presence of dehydrating agent; forexample, dicyclohexylcarbodiimide, carbonyldiimidazole,dicyclohexylcarbodiimide-N-hydroxybenzotriazole, and the like; isreacted with primary amine or secondary amine (aniline, 2-aminopyridine,dimethylamine etc.) at −80° C. to 100° C., preferably −20° C. to 40° C.,for 0.1 to 24 hours, preferably 1 to 12 hours, to obtain the compound(I-17).

The acylamino derivative-2

In formula, NHR²⁰ is optionally substituted amino; NR²⁰COR²¹ isoptionally substituted acyl amino, optionally substituted ureido,carboxy amino having substituent on oxygen atom, and the other symbolsare the same as described above.

The compound (I-18) having an optionally substituted amino group on ringA in the presence or the absence of solvent; for example,tetrahydrofuran, dichloromethane, and the like; in the presence or theabsence of base; for example, pyridine, triethylamine, and the like; isreacted with reagent including acid chloride, acid anhydride,chloroformate ester derivatives, isocyanate derivatives (benzoylchloride, 2-furoyl chloride, acetic anhydride, benzyl chloroformate,di-t-butyl dicarbonate, phenyl isocyanate etc.), at −80° C. to 100° C.,preferably −20° C. to 40° C., for 0.1 to 24 hours, preferably 1 to 12hours. Or alternatively, the compound (I-18) having an optionallysubstituted amino group on ring A in solvent; for example,N,N-dimethylformamide, tetrahydrofuran, dichloromethane, and the like;in the presence of dehydrating agent; for example,dicyclohexylcarbodiimide, carbonyldiimidazole,dicyclohexylcarbodiimide-N-hydroxybenzotriazole, and the like; isreacted with carboxylic acid having substituent corresponding to targetcompound; for example, benzoic acid, 2-pyridinecarboxylic acid, and thelike; at 80° C. to 100° C., preferably −20° C. to 40° C., for 0.1 to 24hours, preferably 1 to 12 hours, to obtain the compound (I-19).

The alkylamino derivatives

In formula, NHR²⁰ is optionally substituted amino, R²² is lower alkyl.

The compound(I-18) having an amino group on ring A in solvent; forexample, dichloromethane, tetrahydrofuran, and the like; in the presenceor the absence of acid; for example, acetic acid, and the like; isreacted with aldehyde having substituent corresponding to targetcompound; for example, benzaldehyde, pyridine-2-carboaldehyde, and thelike; and reducing agent; for example, sodium borohydride, sodiumtriacetoxyborohydride, and the like; at −80° C. to 100° C., preferably0° C. to 40° C., for 0.5 to 150 hours, preferably 1 to 24 hours, toobtain the compound (I-20).

The substituted alkoxy derivatives

In formula, R²³ is optionally substituted lower alkyl, an optionallysubstituted carbocyclic group or an optionally substituted heterocyclicgroup, etc., and the other symbols are the same as described above.

The compound (I-21) having a hydroxy group as substituent of A ring insolvent; for example, N,N-dimethylformamide, tetrahydrofuran, and thelike; in the presence of base; for example potassium carbonate, sodiumhydroxide, sodium hydride, and the like; is reacted with alkylatingagent having substituent corresponding to target compound; for example,benzylchloride, methyl iodide, and the like; at −80° C. to 100° C.,preferably 0° C. to 40° C., for 0.5 to 150 hours, preferably 1 to 24hours, or alternatively, the compound (I-18) in solvent; for example,N,N-dimethylformamide, tetrahydrofuran, and the like; under Mitsunobureagent; for example triphenylphosphine-azodicarboxylic acid ethylester, and the like; is reacted with alcohol; for example,2-aminoethanol, and the like; at −80° C. to 100° C., preferably 0° C. to40° C., for 0.5 to 72 hours, preferably 1 to 24 hours, to obtain thecompound (I-22).

The introduction of substituent with palladium coupling reaction

In formula, Hal is halogen, G is optionally substituted lower alkenyl,optionally substituted lower alkynyl, optionally substituted loweralkoxycarbonyl, an optionally substituted carbocyclic group or anoptionally substituted heterocyclic group etc., and the other symbolsare the same as described above.

The compound (I-23) having halogen as substituent of A ring in solvent;for example, tetrahydrofuran, N,N-dimethylformamide, 1,2dimethoxyethane,methanol, and the like; in the presence of base; for example,triethylamine, sodium carbonate, and the like; palladium catalyst; forexample, palladium acetate, palladium chloride, and the like; andligand; for example triphenylphosphine, and the like; is reacted withcompound having substituent corresponding to target compound(styrene,propargyl alcohol, aryl boronic acid, carbon monoxide), with or withoutmicrowave irradiation, at −80° C. to 150° C., preferably 0° C. to 100°C., for 0.5 to 72 hours, preferably 1 to 24 hours, to obtain thecompound (I-24).

The oxime derivatives

In formula, in R²⁴ is a hydrogen atom or optionally substituted loweralkyl etc., R²⁵ is a hydrogen atom, optionally substituted lower alkyl,optionally substituted lower alkenyl or an optionally substitutedcarbocyclic group or an optionally substituted heterocyclic group etc.,and the other symbols are the same as described above.

The compound (I-25) having an acyl group as substituent of A ring insolvent; for example, methanol, ethanol, and the like; in the presenceor the absence of additives; for example, potassium acetate, and thelike; is reacted with hydroxylamine having substituent corresponding totarget compound (hydroxylamine, methoxylamine, O-benzylhydroxylamine,etc.) or the salt thereof, at 0° C. to 100° C., preferably 0° C. to 40°C., for 0.5 to 150 hours, preferably 1 to 72 hours, to obtain thecompound (I-26).

Production of optical active compounds

For example, Optical active compound aq, one embodiment of thepharmaceutical composition of the present invention can be synthesizedin the following method.

1) n=2

1-1) X=S

wherein R⁵ is hydrogen, optionally substituted lower alkyl, optionallysubstituted lower alkenyl, optionally substituted lower alkynyl, loweralkoxycarbonyl, optionally substituted carbamoyl, an optionallysubstituted cabocyclic group or an optionally substituted heterocyclicgroup, R²⁵ is a chiral sulfoxide having optionally substituted loweralkyl, optionally substituted lower alkenyl, optionally substitutedcarbocyclic group or optionally substituted hetererocyclic group, R^(3a)and R^(3b) are each independently hydrogen, halogen, hydroxy, optionallysubstituted lower alkyl, optionally substituted lower alkenyl,optionally substituted lower alkoxycarbonyl, optionally substitutedcarbamoyl, an optionally substituted carbocyclic group or an optionallysubstituted heterocyclic group, optionally substituted acyl, carboxy oroptionally substituted amino, R²⁷ is optionally substituted lower alkyl,optionally substituted lower alkenyl, R^(2a) and R^(2b) are eachindependently hydrogen, hydroxy, optionally substituted lower alkyl,optionally substituted lower alkenyl, optionally substituted amino,optionally substituted amidino, optionally substituted acyl, optionallysubstituted carbamoyl, optionally substituted carbamoylcarbonyl,optionally substituted lower alkylsulfonyl, optionally substitutedarylsulfonyl, an optionally substituted carbocyclic group or anoptionally substituted heterocyclic group, L is an leaving group such ashalogen, methanesulfonyloxy, trifluoromethylsulfonyloxy and the like,and other symbols are the same as described above.

The above compounds ak and al can be synthesized according to the methoddescribed in (1)T, Fujisawa et al., Tetrahedron Lett., 37, 3881-3884(1996), (2)D. H. Hua et al, Sulfur Reports, vol. 21, pp. 211-239 (1999),(3)Y. Koriyama et al., Tetrahedron, 58, 9621-9628 (2002), (4)T. Vilavanet al, Cuuent Organic Chemistry, 9, 1315-1392 (2005) and the like, or byoptical resolution of each intermediate or final compound, or by themethod described below. Examples of methods for optical resolution areseparation of optical isomers using an optically active column, kineticresolution by an enzyme reaction or the like, crystallization ofdiastereomers by salt formulation using a chiral acid or a chiral base,and a preferential crystallization etc.

Step 1

Compound ak can be obtained by reacting Compound aj, which iscommercially available or can be prepared by a known method, with achiral reagent having a substituent corresponding to the target compoundsuch as para-toluene, tert-butylsulfine amide or the like at 60° C. to120° C., preferably 80° C. to 100° C. in a solvent such as ether,tetrahydrofuran, toluene, benzene or the like or a mixed solvent such asether-tetrahydrofuran or the like for 0.5 to 24 hours, preferably 0.5 to5 hours in the presence of moleculer sieves or magnesium sulfate or thelike, under continuous evaporation by Dean-Stark apparatus, or in thepresence of a chiral reagent having a substituent corresponding to thetarget compound such as para-toluene, tert-butylsulfine amide ane thelike according to the method described in the above literatures.

Step 2

Compound al can be diastereoselectively obtained by reacting compound akwith a metal, which is lithium, aluminum, zinc, titanium or the like,enolate of acetate ester or the like possessing a substituentcorresponding to the target compound which is commercially available orprepared by a known method, at −100° C. to 0° C., preferably −80° C. to−50° C. for 0.5 to 24 hours, preferably 0.5 hours in a solvent such asether, tetrahydrofuran, toluene, methylene chloride or a mixed solventof ethertetrahydrofuran or the like, or obtained according to the methoddescribed in the above literature (1) or (3). Alternatively, ketenesilylacetate of acetate ester which is prepared from ester acetate or thelike possessing a substituent corresponding to the target compound canbe used.

Step 3

Compound am can be obtained by reacting Compound al in a solvent such asmethanol, ethanol ether, tetrahydrofuran, 1,4-dioxane, methylenechloride, ethyl acetate or the like, which contains hydrogen chloride,trifluoroacetic acid or the like, or in trifluoroacetcic acid without asolvent, or at −30° C. to 100° C., preferably −10° C. to 90° C. for 0.5to 12 hours, preferably 0.5 to 5 hours.

Step 4

To a solution of Compound am in a solvent such as ether,tetrahydrofuran, toluene or the like or a mixed solvent such asether-tetrahydrofuran is added a reductant such as aboran-tetrahydrofuran complex, a boran-dimethylsulfide complex, aboran-triethylamine complex, a boran-pyridine complex or the like, orether of tetrahydrofuran solution of them at −30° C. to 30° C.,preferably −10° C. to 20° C. and the mixture is reacted for 0.5 to 12hours, preferably 0.5 to 5 hours to obtain Compound an.

Step 5

To a solution of Compound an in a solvent such as methylene chloride,toluene or the like or a mixed solvent of methylene chloride-water orthe like is added calcium carbonate, potassium carbonate or the like,and added thiophosgene at −30° C. to 50° C., preferably −10° C. to 25°C., followed by reacting for 0.5 to 12 hours, preferably 0.5 to 5 hoursto obtain Compound ao.

Step 6

To a solution of Compound ao in a solvent such as methylene chloride,tetrahydrofuran, toluene or the like are added oxalyl chloride, thionylchloride or the like and a catalytic amount of N,N-dimethylformamide at−30° C. to 50° C., preferably −10° C. to 20° C. The mixture is reactedat 0° C. to 100° C., preferably 20° C. to 90° C. for 0.5 to 12 hours,preferably 0.5 to 5 hours to obtain Compound ap. Alternatively, Compoundap can be obtained by halogenation according to the method described inComprehensive Organic Transformations, Richard C Larock (Mcgraw-Hill) orby reacting Compound ao with a sulfonylation reagent such asmethanesulfonyl chloride, p-toluene sulfonyl chloride or the like in thepresence of a base such as diisopropylethylamine, triethylamine or thelike in a solvent such as toluene, dichloromethane or the like at −80°C. to 50° C., preferably −20° C. to 20° C. for 0.1 to 24 hours,preferably 0.5 to 12 hours.

Step 7

To a solution of Compound ap in a solvent such as ethyl acetate,methylene chloride, tetrahydrofuran, toluene or the like is added 15 to30% aqueous ammonia or a reagent having a substituent corresponding tothe target compound such as tert-butyl amine at −30° C. to 50° C.,preferably −10° C. to 30° C. The mixture is reacted at −10° C. to 30°C., preferably 0° C. to 30° C. for 0.5 to 72 hours to obtain Compoundaq-i or Compound aq-ii.

In the case that thus-obtained Compound aq-i or Compound aq-ii is acompound wherein R^(2a) and/or R^(2b) is hydrogen, the targetsubstituent R^(2a) or R^(2b) can be introduced by the usual method, ifnecessary.

1-2) Introduction of R^(3a) and R^(3b)

wherein each symbols are the same as described above.

To obtain Compound aq-iii or aq-iv wherein R^(3a) and R^(3b) aresubstituted at the carbon atom neighboring to X, R^(3a) and R^(3b) maybe introduced by conducting Step 3′ and Step 4′ instead of Step 3 andStep4.

Step 3′

To a solution of Compound al in a solvent such as ether, tetrahydrofuranor the like or a mixed solvent such as ether-tetrahydrofuran or the likeis added a Grignard reagent having a substituent corresponding to thetarget compound such as methyl magnesium chloride, ethyl magnesiumbromide or the like at −100° C. to 50° C., preferably −80° C. to 30° C.to obtain Compound am′. Alternatively, after conversion of Compound alto Weinreb amide thereof, the compound is reacted sequentially with aGrignard reagent having a substituent corresponding to the targetcompound such as R^(3 a) MgBr, R^(3 b) MgBr or the like to obtainCompound am′, The reaction may be conducted for 0.2 to 24 hours,preferably 0.2 to 5 hours.

Step 4′

Compound an′ can be synthesized according to the above-mentioned Step 3.Compound an can be obtained by reacting Compound am′ in a solvent suchas methanol, ethanol, ether, tetrahydrofuran, 1,4-dioxane, methylenechloride, ethyl acetate or the like which includes hydrogen chloride,trifluoroacetic acid or the like, without a solvent, or intrifluoroacetic acid without a solvent at −30° C. to 100° C., preferably−10° C. to 90° C. for 0.5 to 12 hours, preferably 0.5 to 5 hours.

Then, the target Compound aq-iii or aq-iv can be obtained by conductingthe similar methods to Steps 5 to 7 mentioned in the above 1-1),

1-3) X═O

wherein R²⁸ is alkyl or optionally substituted alkylsulfonyl, optionallysubstituted carbocyclic sulfonyl or optionally substituted heterocyclicsulfonyl and other symbols are the same as described above.

The target compound can be obtained by conducting the following stepsinstead of Steps 5 to 7 described in the above 1-1).

Step 5′

Compound ao′ can be obtained by reacting Compound an′ with anisothiocyanate having the substituent corresponding to the targetcompound such as ally isothiocyanate, tert-butylisothiocyanate or thelike or a thiocarbamoyl halide having the substituent corresponding tothe target compound such as N,N-dimethylthiocarbamoyl chloride,N,N-diethylthiocarbamoyl chloride or the like in a solvent such astoluene, chloroform, tetrahydrofuran or the like at 0° C. to 150° C.,preferably 20° C. to 100° C. for 0.5 to 120 hours, preferably 1 to 72hours.

Step 6′

Compound ap″ can be obtained by reacting Compound ao′ with an alkylatingagent such as methyl iodide, diethyl sulfate, benzylbromide or the likeor a sulfonating agent such as p-toluensulfonyl chloride in the presenceor absence of a base such as diisopropylethylamine, triethylamine,pyridine, sodium hydroxide or the like in a solvent such as methanol,ethanol, dimethylformamide, tetrahydrofuran or the like at 0° C. to 200°C., preferably 40° C. to 150° C. for 0.1 to 48 hours, preferably 0.5 to24 hours.

Step 7

Compound aq-v or aq-vi can be obtained by reacting Compound ap′ in thepresence or absence of a base such as diisopropylethylamine,triethylamine, pyridine, sodium hydroxide or the like, in the presenceor absence of a metallic oxide such as silver oxide, mercury oxide,manganese dioxide or the like, in a solvent such as dimethylformamide,tetrahydrofuran, dichloromethane or the like at 0° C. to 200° C.,preferably 10° C. to 150° C. for 1 to 120 hours, preferably 0.5 to 100hours.

1-4) X═N

wherein each symbols are the same as described above.Step 6″

Compound ap′″ can be obtained by reacting Compound ao′ with an azidationagent such as sodium azide, trimethylsillylazide or the like in thepresence or absence of an acid such as trifluoroacetic acid or the likein a solvent such as chloroform, tetrahydrofuran or the like at −10° C.to 200° C., preferably 0° C. to 100° C. for 0.1 to 48 hours, preferably0.5 to 24 hours.

Step 7′

Compound ar can be obtained by reacting Compound ap′″ with an alkylatingagent such as methyl iodide, diethyl sulfate, benzylbromide or the likeor a sulfonating agent such as p-toluensulfonyl chloride in the presenceor absence of a base such as diisopropylethylamine, triethylamine,pyridine, sodium hydroxide or the like in a solvent such as methanol,ethanol, dimethylformamide, tetrahydrofuran or the like at 0° C. to 200°C., preferably 40° C. to 150° C. for 0.1 to 48 hours, preferably 0.5 to24 hours.

Step 8″

To a solution of Compound ar in a solvent such as tetrahydrofuran, ethylacetate, methanol or the like is added a catalytic reduction catalystsuch as 10% Pd/C, and the mixture is reacted under hydrogen atmosphereat normal pressures to 5 atm, preferably at normal pressure to 2 atm at10° C. to 100° C., preferably 20° C. to 80° C. for 0.5 to 48 hours,preferably 6 to 20 hours to obtain Cyclized Compound aq-vii or aq-viii.Alternatively, Cyclized Compound aq-vii or aq-viii can be obtained byreducing a azide group of Compound or by the method described in“Comprehensive Organic Transformations, Richard C Larock (Mcgraw-Hill)”.If necessary, the compound obtained by reduction may be treated with abase such as triethylamine, sodium hydroxide or the like to obtainCompound aq-vii or aq-viii.

2) n=3

wherein the each symbols are the same as defined above.Step 2″

Compound al′ can be obtained by reacting Compound ak with a Grignardreagent having a substituent corresponding to the target compound suchas an allyl Grignard reagent in a solvent such as ether,tetrahydrofuran, toluene or the like or a mixed solvent such asether-tetrahydrofuran at −80° C. to 50° C., preferably −40° C. to 30° C.for 0.5 to 12 hours, preferably 0.5 to 8 hours.

Step 3″

Compound an″ can be obtained by hydroboration, wherein Compound al′ isreacted with a reductant such as a boran-tetrahydrofuran complex, aboran-dimethylsulfide complex, a boran-triethylamine complex, aboran-pyridine complex or the like or an ether or tetrahydrofuransolution of them in a solvent such as ether, tetrahydrofuran, toluene orthe like or a mixed solvent such as ether-tetrahydrofuran or the like at−30° C. to 30° C., preferably −15° C. to 20° C. for 0.5 to 12 hours,preferably 0.5 to 5 hours.

Substituents R^(3a) and R^(3b) can be introduced into thus-obtainedCompound an″ by the method according to the above-mentioned 1-2).

3) Conversion of Substituents (1)

wherein R^(13a) and R^(13b) are amino-protecting groups and the othersymbols are the same as defined above.Synthesis of Compound as-1

To a solution of Compound aq-1 in a solvent such as tetrahydrofuran,toluene, xylene or the like are added trisdibenzyliden acetonedipalladium, palladium acetate or palladium(0) prepared in situ and aphosphine ligand such as tri-tert-butylphosphine, dicyclohexylbiphenylphosphine or the like, and further added a reagent having thesubstituent corresponding to the target compound such as lithiumhexamethyl disilazide at −10° C. to 30° C., followed by reacting at 30°C. to 120° C., preferably 50° C. to 100° C. for 0.5 to 48 hours,preferably 3 to 20 hours to obtain Compound as-1.

An amino protecting group may be a group which is deprotected by themethod described in “Protective Groups in Organic Synthesis, Theodora WGreen (John Wiley & Sons)” etc. and the examples are loweralkoxy-carbonyl, lower alkenyloxycarbonyl, trialkylsillyl, acyl,methansulfonyl, trifiuoroethansulfonyl, toluensulfonyl and the like.

4) Conversion of Substituent (2)

Synthesis of Compound as-2

To a solution of aq-2 in a solvent such as tetrahydrofuran, ethylacetate, methanol or the like is added a catalytic reduction catalystsuch as 10% Pd/C, and then the mixture is reacted at normal pressure to5 atm, preferably normal pressure to 2 atm under hydrogen atmosphere for0.5 to 48 hours, preferably 6 to 20 hours to obtain Compound as-2.Alternatively. Compound as-2 can be obtained by the method described in“Comprehensive Organic Transformations, Richard C Larock (McGraw-Hill)”.

5) Conversion of Substituent (3)

wherein R¹⁴ is hydroxy, optionally substituted lower alkyl, optionallysubstituted lower alkoxy, optionally substituted lower alkylthio,optionally substituted lower amino, optionally substituted aromaticcarbocyclicoxy or heterocyclic oxy, optionally substituted aromaticcarbocyclicamino or heterocyclic amino, optionally substituted aromaticcarbocyclicthio or heterocyclicthio, cyano, azide, optionallysubstituted carbocyclic group, optionally substituted heterocyclicgroup, optionally substituted carbamoyl or the like and the othersymbols are the same as defined above.Synthesis of Compound as-3

To a solution of Compound aq-3 in a solvent such as tetrahydrofuran,ethanol or the like is added a reagent having the substituentcorresponding to the target compound such as ethanol, methanethiol,dimethyl amine or the like at −10° C. to 30° C. and the mixture isreacted for 0.5 to 12 hours, preferably 1 to 8 hours to obtain Compoundas-3.

Then, the similar reaction described in the above “4) Conversion ofsubstituent (2)” may be conducted, and further a coupling reaction maybe conducted according to the above-mentioned method for producingCompound (I-19), if necessary.

In all of above mentioned steps, if a compound having substituent whichinterrupts the reaction; (for example, hydroxy, mercapto, amino, formyl,carbonyl, carboxyl, etc.), the substituent of the compound is protectedby methods described in Protective Groups in Organic Synthesis, TheodoraW Green (John Wiley & Sons) beforehand, and is deprotected at preferablestep.

The compound (I) in this invention presented below; in particular, X isS, and E is a bond or methylene; is preferable.

1) A Compound represented by the general formula (I′),

-   wherein, t is 0 or 1, the other symbols are the same as above (a),    with the proviso that the compounds represented below;-   i) wherein n+m is 2, R⁵ is a hydrogen atom, and ring A is    non-substituted phenyl;-   ii) wherein n is 2, no is 0, R^(2a) is a hydrogen atom, R^(2b) is a    hydrogen atom or acetyl, R⁵ is methyl, and ring A is phenyl or    4-methoxyphenyl;-   iii) wherein n is 2, m is 0, R^(2a) is a hydrogen atom, R^(2b) is a    hydrogen atom or acetyl, R⁵ is ethyl, and ring A is    3,4-dimethoxyphenyl;-   iv) wherein n is 2, m is 0, R^(2a) is a hydrogen atom, R^(2b) is a    hydrogen atom or acetyl, and R⁵ and ring A are phenyl;-   v) wherein n is 2, m is 0, R^(2a) and R^(2b) are a hydrogen atom, R⁵    and ring A are taken together to form

-   and-   vi) wherein n+m is 1 or 2; R⁵ is a hydrogen atom; and ring A is    phenyl substituted by one or two substituent selected from hydroxy,    halogen, lower alkyl, lower alkoxy, nitro, amino, lower alkyl    carbonylamino, mercapto, lower alkylthio, carbamoyl, lower    alkylamino, lower alkyl carbamoyl and lower alkoxycarbonyl;    non-substituted phenyl, or non-substituted naphthyl; are excluded.

In addition, in formula (I′), preferable is the compound representedbelow.

-   2) The compound, wherein n is 1 and m is 0 (this compound is    represented by nm-1),-   3) the compound, wherein n is 2 and m is 0 (this compound is    represented by nm-2),-   4) the compound, wherein n is 3 and m is 0 (this compound is    represented by nm-3),-   5) the compound, wherein R^(2a) is a hydrogen atom: R^(2b) is a    hydrogen atom, optionally substituted lower alkyl, optionally    substituted acyl, optionally substituted lower alkylsulfonyl, or    optionally substituted amidino (this compound is represented by    R2-1),-   6) the compound, wherein R^(2a) is a hydrogen atom; R^(2b) is a    hydrogen atom, optionally substituted lower alkyl or optionally    substituted acyl (this compound is represented by R2-2),-   7) the compound, wherein NR^(2a)R^(2b) is represented by the    following formula:

-   wherein each symbols are the same as described above,-   R⁶, R⁷ and R⁸ are each independently a hydrogen atom, lower alkyl or    acyl,-   Y is optionally substituted lower alkylene, optionally substituted    lower alkenylene or optionally substituted lower alkynylene,-   Z is O or S (this compound is represented by R2-3),-   8) the compound, wherein NR^(2a)R^(2b) is NH₂ (this compound is    represented by R2-4),-   9) the compound, wherein ring A is substituted phenyl or substituted    pyridyl (this compound is represented by A-1),-   10) the compound, wherein ring A is represented by the following    formula:

-   wherein R⁹, R¹⁰ and R¹¹ is a hydrogen atom or G,-   G is halogen, hydroxy, cyano, nitro, mercapto, optionally    substituted lower alkyl, optionally substituted lower alkoxy,    optionally substituted lower alkenyl, optionally substituted lower    alkynyl, optionally substituted acyl, optionally substituted    acyloxy, carboxy, optionally substituted lower alkoxycarbonyl,    optionally substituted lower alkoxycarbonyloxy; optionally    substituted aryloxycarbonyloxy, optionally substituted amino,    optionally substituted carbamoyl, optionally substituted    carbamoyloxy, optionally substituted lower alkylthio, optionally    substituted arylthio, optionally substituted lower alkylsulfonyl,    optionally substituted arylsulfonyl, optionally substituted lower    alkylsulfinyl, optionally substituted arylsulfinyl, optionally    substituted lower alkylsulfonyloxy, optionally substituted    arylsulfonyloxy, optionally substituted sulfamoyl, an optionally    substituted carbocyclic group, optionally substituted    carbocyclicoxy, an optionally substituted heterocyclic group or    optionally substituted heterocyclicoxy, each G may be different    (this compound is represented by A-2),-   11) the compound, wherein ring A is represented by the following    formula:

-   wherein R⁹ and R¹⁰ are each independently a hydrogen atom, halogen,    hydroxy, optionally substituted lower alkyl, cyano, nitro,    optionally substituted lower alkoxy, optionally substituted acyl,    optionally substituted amino, optionally substituted carbamoyl,    optionally substituted carbamoyloxy, optionally substituted lower    alkylsulfonyl, optionally substituted arylsulfonyl, optionally    substituted lower alkylsulfonyloxy, optionally substituted    arylsulfonyloxy, an optionally substituted carbocyclic group,    optionally substituted carbocyclicoxy, an optionally substituted    heterocyclic group or optionally substituted heterocyclicoxy, G is    the same as described above 10) (this compound is represented by    A-3),-   12) the compound, wherein ring A is represented by the following    formula:

-   wherein R⁹ and R¹⁰ is the same as described in 11), G is the same as    described in 10) (this compound is represented by A-4),-   13) the compound, wherein ring A, R⁹, and R¹⁰ are defined in 11), G    is optionally substituted amino (this compound is represented by    A-5),-   14) the compound, wherein ring A, R⁹ and R¹⁰ are defined in 11), G    is optionally substituted arylcarbonylamino or optionally    substituted heterocyclic carbonylamino,-   15) the compound, wherein ring A, R⁹ and R¹⁰ are defined in 11), G    is optionally substituted heterocyclic carbonylamino (this compound    is represented by A-6),-   16) the compound, wherein ring A is defined in 11), G is represented    by the following formula:

-   wherein Q¹, Q² and Q³ are each independently a bond, optionally    substituted lower alkylene or optionally substituted lower    alkenylene:-   Q⁴ is optionally substituted lower alkylene or optionally    substituted lower alkenylene;-   W¹ and W² are each independently O or S;-   W³ is O, S or NR¹²;-   R¹² is a hydrogen atom, lower alkyl, hydroxy lower alkyl, lower    alkoxy lower alkyl, lower alkoxycarbonyl lower alkyl, carbocyclic    lower alkyl or acyl;-   R¹⁴ is a hydrogen atom or lower alkyl;-   ring B is an optionally substituted carbocyclic group or an    optionally substituted heterocyclic group;-   Alk² is optionally substituted lower alkyl; and-   R⁹ and R¹⁰ are the same as described in 11) (this compound is    represented by A-7),-   17) the compound, wherein ring A, R⁹ and R¹⁰ are the group defined    in 11); G is the group defined in 16); ring B is aryl optionally    substituted with one or more substituents selected from halogen,    hydroxy, optionally substituted lower alkyl, optionally substituted    lower alkoxy, optionally substituted acyl, optionally substituted    amino, cyano, optionally substituted carbamoyl, an optionally    substituted carbocyclic group, optionally substituted carbocyclicoxy    or an optionally substituted heterocyclic group or-   heteroaryl optionally substituted with one or more substituents    selected from halogen, hydroxy, optionally substituted lower alkyl,    optionally substituted lower alkoxy, optionally substituted acyl,    optionally substituted amino, cyano, optionally substituted    carbamoyl, an optionally substituted carbocyclic group, optionally    substituted carbocyclicoxy or an optionally substituted heterocyclic    group;-   and the other symbols are the same as described in 16) (this    compound is represented by A-8),-   18) the compound, wherein ring A, R⁹ and R¹⁰ are defined in 11), G    is represented by the following formula;

-   wherein each symbols are the same as described in 16)-   (this compound is represented by A-9),-   19) the compound, wherein ring A is represented by the following    formula:

-   wherein G is defined in 16), ring B is optionally substituted aryl    or optionally substituted heteroaryl, either R⁹ or R¹⁰ is a hydrogen    atom; and the other is a hydrogen atom, halogen, optionally    substituted lower alkyl, cyano, nitro, optionally substituted lower    alkoxy, optionally substituted amino, optionally substituted    carbamoyl, optionally substituted lower alkylsulfonyl, an optionally    substituted carbocyclic group or an optionally substituted    heterocyclic group (this compound is represented by A-10),-   20) the compound, wherein ring A is represented by the following    formula:

-   wherein G is defined in 18), the other symbols are the same as    described in 19) (this compound is represented by A-11),-   21) the compound, wherein ring A is represented by the following    formula:

-   wherein G is defined in 16), ring B is optionally substituted    phenyl, optionally substituted 5- to 6-membered heteroaryl,    optionally substituted benzothiazolyl or optionally substituted    benzothienyl, and R⁹ and R¹⁰ are the same as described in 19) (this    compound is represented by A-12),-   22) the compound, wherein ring A is represented by the following    formula:

-   wherein G is defined in 18), ring B is defined in 21), R⁹ and R¹⁰    are the same as described in 19) (this compound is represented by    A-13),-   23) the compound, wherein ring A is represented by the following    formula:

-   wherein R⁹ is a hydrogen atom, halogen, optionally substituted lower    alkyl, cyano, nitro, optionally substituted lower alkoxy, optionally    substituted amino, optionally substituted carbamoyl, optionally    substituted lower alkylsulfonyl, an optionally substituted    carbocyclic group or an optionally substituted heterocyclic group,    ring B is the same as described in 21): and R¹² is a hydrogen atom    or lower alkyl (this compound is represented by A-14),-   24) the compound, wherein R⁵ is a hydrogen atom or C1 to C3 alkyl    (this compound is represented by R5-1),-   25) the compound, wherein R⁵ is C1 to C3 alkyl (this compound is    represented by R5-2),-   26) the compound, wherein R⁵ is methyl (this compound is represented    by R5-3),-   27) the compound, wherein R^(3a) and R^(3b) are each independently a    hydrogen atom, halogen, hydroxy, optionally substituted lower alkyl,    optionally substituted lower alkoxy or optionally substituted aryl    (this compound is represented by R3-1),-   28) the compound wherein, R^(3a) is a hydrogen atom, halogen,    hydroxy, optionally substituted lower alkyl, optionally substituted    lower alkoxy or optionally substituted aryl, R^(3b) is a hydrogen    atom, one R³ is a hydrogen atom when n is 2, one or two R^(2a) is    (are) a hydrogen atom(s) when n is 3 (this compound is represented    by R3-2),-   29) the compound, wherein R^(3a) and R^(3b) are all hydrogen atoms    (this compound is represented by R3-3), and-   in a compound represented by the general formula (I′), a compound,    wherein the combination of n, m, R^(2a), R^(2b), ring A, R^(3a), and    R^(3b) (nm, R², A, R⁵, R³) is the following compound.-   (nm, R², A, R⁵    R³)=(nm-1,R2-1,A-1,R5-1,R3-1),(nm-1,R2-1,A-1,R5-1,R3-2),(nm-1,R2-1,A-1,R5-2,R3-1),(nm-1,R2-1,A-1,R5-2,R3-2),(nm-1,R2-1,A-1,R5-3,R3-1),(nm-1,R2-1,A-1,R5-3,R3-2),(nm    -1,R2-1,A-2,R5-1,R3-1),(nm-1,R2-1,A-2,R5-1,R3-2),(nm-1,R2-1,A-2,R5-2,R3-1),(nm-1,R2-1,A-2,R5-2,R3-2),(nm-1,R2-1,A-2,R5-3,R3-1),(nm-1,R2-1,A-2,R5-3,R3-2),(nm-1,R    2-1,A-3,R5-1,R3-1),(nm-1,R2-1,A-3,R5-1,R3-2),(nm-1,R2-1,A-3,R5-2,R3-1),(nm-1,R2-1,A-3,R5-2,R3-2),(nm-1,R2-1,A-3,R5-3,R3-1),(nm-1,R2-1,A-3,R5-3,R3-2),(nm-1,R2-1,A-4,R5-1,R3-1),(nm-1,R2-1,A-4,R5-1,R3-2),(nm-1,R2-1,A-4,R5-2,R3-1),(nm-1,R2-1,A-4,R5-2,R3-2),(nm-1,R2-1,A-4,R5-3,R3-1),(nm-1,R2-1,A-4,R5-3,R3-2),(nm-1,R2-1,A-5,R5-1,R3-1),(nm-1,R2-1,A-5,R5-1,R3-2),(nm-1,R2-1,A-5,R5-2,R3-1),(nm-1,R2-1,A5,R    5-2,R3-2),(nm-1,R2-1,A-5,R5-3,R3-1),(nm-1,R2-1,A-5,R5-3,R3-2),(nm1,R2-1,A-6,R5-1,R3-1),(nm-1,R2-1,A-6,R5-1,R3-2),(nm-1,R2-1,A-6,R5-2,R3-1,),(nm-1,R2-1,A-6,R5-2,R3-2),(nm-1,R2-1,A-6,R5-3,R3-1),(nm-1,R2-1,A-6,R5-3,R3-2),(nm-1,R2-1,A-7,R5-1,R3-1),(nm-1,R2-1,A-7,R5-1,R3-2),(nm-1,R2-1,A-7,R5-2,R3-1),(nm-1,R2-1,A-7,R5-2,R3-2),(nm-1,R2-1,A-7,R5-3,R3-1),(nm-1,R2-1,A-7,R5-3,R3-2),(nm-1,R2-1,A-8,R5-1,R3-1),    (nm-1,R2-1,A-8,R5-1,R3-2),(nm-1,R2-1,A-8,R5-2,R3-1),(nm-1,R2-1,A-8,R5-2,R3-2),(nm-1,R2-1,A-8,R5-3,R3-1),(nm-1,R2-1,A-8,R5-3,R3-2),(nm-1,R2-1,A-9,R5-1,R3-1),(nm-1,R2-1,A-10,R5-1,R3-2),(nm-1,R2-1,A-10,R5-2,R3-1),(nm-1,R2-1,A-10,R5-2,R3-2),nm    -1,R2-1,A-9,R5-3,R3-1(nm-1,R2-1,A-9,R5-3,R3-2),(nm-1,R2-1,A-10,R5-1,R3-1),(nm-1,R2-1,A-10,R5-1,R3-2),(nm-1,R2-1,A-10,R5-2,R3-1),(nm-1,R2-1,A-10,R5-2,R3-2),(nm-1,R2-1,A-10,R5-3,R3-1),(nm-1,R2-1,A-10,R5-2,R3-1),(nm-1,R2-1,A-10,R5-1,R3-1),(nm-1,R2-1,A-11,R5-1,R3-2),(nm-1,R2-1,A-11,R5-2,R3-1),(nm-1,R2-1,A-11,R5-2,R3-2),    (nm-1,R2-1,A-11,R5-3,R3-1),(nm-1,R2-1,A-10,R5-3,R3-2),(nm-1,R2-1,A-12,R5-1,R3-1),(nm-1,R2-1,A-12,R5-1,R3-2),(nm-1,R2-1,A-12,R5-2,R3-1),(nm-1,R2-1,A-12,R5-2,R3-2),(nm-1,R2-1,A-12,R5-3,R3-1),(nm-1,R2-1,A-12,R5-3,R3-2),(nm-1,R2-1,A-13,R5-1,R3-1),(nm-1,R2-1,A-13,R5-1,R3-2),(nm-1,R2-1,A-13,R5-2,R3-1),(nm-1,R2-1,A-13,R5-2,R    3-2),(nm-1,R2-1,A-13,R5-3,R3-1),(nm-1,R2-1,A-13,R5-3,R3-2),(nm-1,R2-1,A-14,R5-1,R3-1),(nm-1,R2-1,A-14,R5-1,R3-2),(nm-1,R2-1,A-14,R5-2,R3-1),(nm-1,R2-1,A-14,R5-2,R3-2),(nm-1,R2-1,A-14,R5-3,R3-1),(nm-1,R2-1,A-14,R5-3,R3-2),(nm-1,R2-2,A-1,R5-1,R3-1),(nm-1,R2-2,A-1,R5-1,R3-2),(nm-1,R2-2,A-1,R5-2,R3-1),(nm-1,R2-2,A-1,R5-2,R3-2),(nm-1,R2-2,A-1,R5-3,R3-1),(nm-1,R2-2,A-1,R5-3,R3-2),(nm-1,R2-2,A-2,R5-1,R3-1),(nm-1,R2-2,A-2,R5-1,R3-2),(nm-1,R2-2,A-2,R5-2,R3-1),(nm-1,R2-2,A-2,R5-2,R3-2),(nm-1,R2-2,A-2,R5-3,R3-1),(nm-1,R2-2,A-2,R5-3,R3-2),(nm-1,R2-2,A-3,R5-1,R3-1),(nm-1,R2-2,A-3,R5-1,R3-2),(nm-1,R2-2,A-3,R5-2,R3-1),(nm-1,R2-2,A-3,R5-2,R3-2),(nm-1,R2-2,A-3,R5-3,R3-1),(nm-1,R2-2,A-3,R5-3,R3-2),(nm-1,R2-2,A-4,R5-1,R3-1),    (nm-1,R2-2,A-4,R5-3,R3-1),(nm-1,R2-2,A-4,R5-3,R3-2),(nm-1,R2-2,A-5,R5-1,R3-1),(nm-1,R2-2,A-5,R5-1,R3-2),(nm-1,R2-2,A-5,R5-2,R3-1),(nm-1,R2-2,A-5,R5-2,R3-2),(nm-1,R2-2,A-5,R5-1,R3-2),(nm-1,R2-2,A-5,R5-2,R3-1),(nm-1,R2-2,A-5,R5-2,R3-2),(nm    -1,R2-2,A-5,R5-3,R3-1),(nm-1,R2-2,A-5,R5-3,R3-2),(nm-1,R2-2,A-6,R5-1,R3-1),(nm-1,R2-2,A-6,R5-1,R3-2),(nm-1,R2-2,A-6,R5-2,R3-1),(nm-1,R2-2,A-6,R5-2,R3-2),(nm-1,R2-2,A-6,R5-3,R3-1),(nm-1,R2-2,A-6,R5-3,R3-2),(nm-1,R2-2,A-7,R5-1,R3-1),(nm-1,R2-2,A-7,R5-1,R3-2),(nm-1,R2-2,A-7,R5-2,R3-1),(nm-1,R2-2,A-7,R5-R2,R3-2),(nm-1,R2-2,A-7,R5-3,R3-1),(nm-1,R2-2,A-7,R5-3,R3-2),(nm-1,R2-2,A-8,R5-1,R3-1),(nm-1,R2-2,A-8,R5-1,R3-2),(nm-1,R2-2,A-8,R5-2,R3-1),(nm-1,R2-2,A-8,R5-2,R3-2),(nm-1,R2-2,A-8,R5-3,R3-1),(nm-1,R2-2,A-8R5-3,R3-2,(nm-1,R2-2,A-9,R5-1),R3-1),(nm-1,R2-2,A-9,R5-1,R3-2),(nm-1,R2-2,A-9,R5-2,R3-1),(nm-1,R2-2,A-9,R5-2,R3-2),(nm-1,R2-2,A-9,R5-3,R3-1),(nm-1,R2-2,A-9,R5-3,R3-2),(nm-10,R2-2,A-10,R5-1,R3-1),(nm-1,R2-2,A-10,R5-1,R3-2),(nm-1,R2-2,A-10,R5-2,R3-1),(nm-1,R2-2,A-10,R5-2,R3-2),(nm-1,R2-2,A-10,R5-3,R3-1),(nm-1,R2-2,A-10,R5-3,R3-2),(nm-1,R2-2,A-11,R5-1,R3-1),(nm-1,R2-2,A-1    1,R5-1,R3-2),(nm-1,R2-2,A-11,R5-2,R3-1),(nm-1,R2-2,A-11,R5-2,R3-2),(nm-1,R2-2,A    -11,R5-3,R3-1),(nm-1,R2-2,A-11,R5-3,R3-2),(nm-1,R2-2,A-12,R5-1,R3-1),(nm-1,R2-2,A-12,R5-1,R3-2),(nm-1,R2-2,A-12,R5-2,R3-1),(nm-1,R2-2,A-12,R5-2,R3-2),(nm-1,R2-2,A-12,R5-3,R3-1),(nm-1,R2-2,A-12,R5-3,R3-2),(nm-1,R2-2,A-13,R5-1,R3-1),(nm-1,R2-2,A-13,R5-1,R3-2),(nm-1,R2-2,A-13,R5-2,R3-1),(nm-1,R2-2,A-13,R5-2,R3-2),(nm-1,R2-2,A-13,R5-3,R3-1),(nm-1,R2-2,A-13,R5-3,R3-2),(nm-1,R2-2,A-14,R5-1,R3-1),(nm-1,R2-2,A-14,R5-1,R3-2),(nm-1,R2-2,A-14,R5-2,R3-1),(nm-1,R2-2,A-14,R5-2,R3-2),(nm-1,R2-2,A-14,R5-3,R3-1),(nm-1,R2-2,A-14,R5-3,R3-2),(nm-1,R2-3,A-1,R5-1,R3-1),(nm-1,R2-3,A-1,R5-1,R3-2),(nm-1,R2-3,A-1,R5-2,R3-1),(nm-1,R2-3,A-1,R5-2,R3-2),(nm-1,R2-3,A-1,R5-3,R3-1),(nm-1,R2-3,A-1,R5-3,R3-2),(nm-1,R2-3,A-2,R5-1,R3-1),(nm    -1,R2-3,A-2,R5-1,R3-2),(nm-1,R2-3,A-2,R5-2,R3-1),(nm-1,R2-3,A-2,R5-2,R3-2),(nm-1,R2-3,A-2,R5-3,R3-1),(nm-1,R2-3,A-2,R5-3,R3-2),(nm-1,R2-3,A-3,R5-1,R3-1),(nm-1,R2-3,A-3,R5-1,R3-2),(nm-1,R2-3,A-3,R5-2,R3-1),(nm-1,R2-3,A-3,R5-2,R3-2),(nm-1,R2-3,A-3,R5-3,R3-1),(nm-1,R2-3,A-3,R5-3,R3-2),(nm-1,R2-3,A-4,R5-1,R3-1),(nm-1,R2-3,A-4,R5-1,R3-2),(nm-1,R2-3,A-4,R5-2,R3-1),(nm-1,R2-3,A-4,R5-2,R3-2),(nm-1,R2-3,A-4,R5-3,R3-1),(nm-1,R2-3,A-4,R5-3,R3-2),(nm-1,R2-3,A-5,R5-1,R3-1),(nm-1,R2-3,A-5,R5-1,R3-2),(nm-1,R2-3,A-5,R5-2,R3-1),(nm-1,R2-3,A-5,R5-2,R3-2),(nm-1,R2-3,A-5,R5-3,R3-1),(nm-1,R2-3,A-5,R5-3,R3-2),(nm-1,R2-3,A-6,R5-1,R3-1),(nm-1,R2-3,A-6,R5-1,R3-2),(nm-1,R2-3,A-6,R5-2,R3-1),(nm-1,R2-3,A-6,R5-2,R3-2),(nm-1,R2-3,A-6,R5-3,R3-1),(nm-1,R2-3,A-6,R5-3,R3-2),(nm-1,R2-3,A-7,R5-1,R3-1),(nm-1,R2-3,A-7,R5-1,R3-2),(nm-1,R2-3,A-7,R5-2,R3-1),(nm-1,R2-3,A-7,R5-2,R3-2),(nm-1,R2-3,A-7,R5-3,R3-1),(nm-1,R2-3,A-7,R5-3,R3-2),(nm-1,R2-3,A-8,R5-1,R3-1),(nm-1,R2-3,A-8,R5-1,R3-2),    (nm-1,R2-3,A-8,R5-2,R3-1),(nm-1,R2-3,A-8,R5-2,R3-2),(nm-1,R2-3,A-8,R5-3,R3-1),(nm-1,R2-3,A-8,R5-3,R3-2),(nm-1,R2-3,A-9,R5-1,R3-1),(nm-1,R2-3,A-9,R5-1,R3-2),(nm-1,R2-3,A-9,R5-2,R3-1),(nm-1,R2-3,A-9,R5-2,R3-2),(nm-1,R2-3,A-9,R5-3,R3-1),(nm    -1,R2-3,A-9,R5-3,R3-2),(nm-1,R2-3,A-10,R5-1,R3-1),(nm-1,R2-3,A-10,R5-1,R3-2),(nm-1,R2-3,A-10,R5-2,R3-1),(nm-1,R2-3,A-10,(R5-2,R3-2),(nm-1,R2-3,A-10,R5-3,R3-1),(nm-1,R2-3,A-10,R5-3,R3-2),(nm-1,R2-3,A-11,R5-1,R3-1),(nm-1,R2-3,A-11,R5-1,R3-2),    (nm-1,R2-3,A-11,R5-2,R3-1),(nm-1,R2-3,A-11,R5-2,R3-2),(nm-1,R2-3,A-11,R5-3,R3-1),(nm-1,R2-3,A-11,R5-3,R3-2),(nm-1,R2-3,A-12,R5-1,R3-1),(nm-1,R2-3,A-12,R5-1,R3-2),(nm-1,R2-3,A-12,R5-2,R3-1),(nm-1,R2-3,A-12,R5-2,R3-2),(nm-1,R2-3,A-12,R5-3,R3-1),(nm-1,R2-3,A-12,R5-3,R3-2),(nm-1,R2-3,A-13,R5-1,R3-1),(nm-1,R2-3,A-13,R5-1,R3-2),(nm-1,R2-3,A-13,R5-2,R3-1),(nm-1,R2-3,A-13,R5-2,R3-2),(nm-1,R2-3,A-13,R5-3,R3-1),(nm-1,R2-3,A-13,R5-3,R3-2),(nm-1,R2-3,A-14,R5-1,R3-1),(nm-1,R2-3,A-14,R5-1,R3-2),(nm-1,R2-3,A-14,R5-2,R3-1),(nm-1,R2-3,A-14,R5-2,R3-2),(nm-1,R2-3,A-1    4,R5-3,R3-1),(nm-1,R2-3,A-14,R5-3,R3-2),(nm-1,R2-4,A-1,R5-1,R3-1),(nm-1,R2-4,A-1,R5-1,R3-2),(nm-1,R2-4,A-1,R5-2,R3-1),(nm-1,R2-4,A-1,R5-2,R3-2),(nm-1,R2-4,A-1,R5-3,R3-1),(nm-1,R2-4,A-1,R5-3,R3-2),(nm-1,R2-4,A-2,R5-1,R3-1),(nm-1,R2-4,A-2,R5-1,R3-2),(nm-1,R2-4,A-2,R5-2,R3-1),(nm-1,R2-4,A-2,R5-2,R3-2),(nm-1,R2-4,A-2,R5-3,R3-1),(nm-1,R2-4,A-2,R5-3,R3-2),(nm-1,R2-4,A-3,R5-1,R3-1),(nm-1,R2-4,A-3,R5-1,R3-2),(nm-1,R2-4,A-3,R5-2,R3-1),(nm-1,R2-4,A-3,R5-2,R3-2),(nm-1,R2-4,A-3,R5-3,R3-1),(nm-1,R2-4,A-3,R5-3,R3-2),(nm-1,R2-4,A-4,R5-1,R3-1),(nm-1,R2-4,A-4,R5-1,R3-2),(nm-1,R2-4,A-4,R5-2,R3-1),(nm-1,R2-4,A-4,R5-2,R3-2),(nm-1,R2-4,A-4,R5-3,R3-1),    (nm-1,R2-4,A-4,R5-3,R3-2),(nm-1,R2-4,A-5,R5-1,R3-1),(nm-1,R2-4,A-5,R5-1,R3-2),(nm-1,R2-4,A-5,R5-2,R3-1),(nm-1,R2-4,A-5,R5-2,R3-2),(nm-1,R2-4,A-5,R5-3,R3-1),(nm-1,R2-4,A-5,R5-3,R3-2),(nm-1,R2-4,A-6,R5-1,R3-1),(nm-1,R2-4,A-6,R5-1,R3-2),(nm    -1,R2-4,A-6,R5-2,R3-1),(nm-1,R2-4,A-6,R5-2,R3-2),(nm-1,R2-4,A-6,R5-3,R3-1),(nm-1,R2-4,A-6,R5-3,R3-2),(nm-1,R2-4,A-7,R5-1,R3-1),(nm-1,R2-4,A-7,R5-1,R3-2),(nm-1,R2-4,A-7,R5-2,R3-1),(nm-1,R2-4A-7,R5-2,R3-2),(nm-1,R2-4,A-7,R5-3,R3-1),(nm-1,R2-4,A-7,R5-3,R3-2),(nm-1,R2-4,A-8,R5-1,R3-1),(nm-1,R2-4,A-8,R5-1,R3-2),(nm-1,R2-4,A-8,R5-2,R3-1),(nm-1,R2-4,A-8,R5-2,R3-2),(nm-1,R2-4,A-8,R5-3,R3-1),(nm-1,R2-4,A-8,R5-3,R3-2),(nm-1,R2-4,A-9,R5-1,R3-1),(nm-1,R2-4,A-9,R5-1,R3-2),(nm-1,R2-4,A-9,R5-2,R3-1),(nm-1,R2-4,A-9,R5-2,R3-2),(nm-1,R2-4,A-9,R5-3,R3-1),(nm-1,R2-4,A-9,R5-3,R3-2),(nm-1,R2-4,A-10,R5-1,R3-1),(nm-1,R2-4,A-10,R5-1,R3-2),(nm-1,R2-4,A-10,R5-2,R3-1),(nm-1,R2-4,A-10,R5-2,R3-2),(nm-1,R2-4,A-10,R5-3,R3-1),(nm-1,R2-4,A-1    0,R5-3,R3-2),(nm-1,R2-4,A-11,R5-1,R3-1),(nm-1,R2-4,A-11,R5-1,R3-2),(nm-1,R2-4,A    -11,R5-2,R3-1),(nm-1,R2-4,A-11,R5-2,R3-2),(nm-1,R2-4,A-11,R5-3,R3-1),(nm-1,R2-4,A-11,R5-3,R3-2),(nm-1,R2-4,A-12,R5-1,R3-1),(nm-1,R2-4,A-12,R5-1,R3-2),(nm-1,R2-4,A-12,R5-2,R3-1),(nm-1,R2-4,A-12,R5-2,R3-2),(nm-1,R2-4,A-12,R5-3,R3-1),(nm-1,R2-4,A-12,R5-3,R3-2),(nm-1,R2-4,A-13,R5-1,R3-1),(nm-1,R2-4,A-13,R5-1,R3-2),(nm-1,R2-4,A-13,R5-2,R3-1),(nm-1,R2-4,A-13,R5-2,R3-2),(nm-1,R2-4,A-13,R5-3,R3-1),(nm-1,R2-4,A-13,R5-3,R3-2),(nm-1,R2-4,A-14,R5-1,R3-1),(nm-1,R2-4,A-14,R5-1,R3-2),(nm-1,R2-4,A-14,R5-2,R3-1),(nm-1,R2-4,A-14,R5-2,R3-2),(nm-1,R2-4,A-14,R5-3,R3-1),(nm-1,R2-4,A-14,R5-3,R3-2),-   (nm-2,R2-1,A-1,R5-1,R3-1),(nm-2,R2-1,A-1,R5-1,R3-2),(nm-2,R2-1,A-1,R5-2,R3-1),(nm-2,R2-1,A-1,R5-2,R3-2),(nm-2,R2-1,A-1,R5-3,R3-1),(nm-2,R2-1,A-1,R5-3,R3-2),(nm-2,R2-1,A-2,R5-1,R3-1),(nm-2,R2-1,A-2,R5-1,R3-2),(nm-2,R2-1,A-2,R5-2,R3-1),(nm-2,R2-1,A-2,R5-2,R3-2),(nm-2,R2-1,A-2,R5-3,R3-1),(nm-2,R2-1,A-2,R5-3,R3-2),nm-2,R2-1,A-3,R5-1,R3-1),(nm-2,R2-1,A-3,R5-1,R3-2),(nm-2,R2-1,A-3,R5-2,R3-1),(nm-2,R2-1,A-3,R5-2,R3-2),(nm-2,R2-1,A-3,R5-3,R3-1),(nm-2,R2-1,A-3,R5-3,R3-2),(nm-2,R2-1,A-4,R5-1,R3-1),(nm-2,R2-1,A-4,R5-1,R3-2),(nm-2,R2-1,A-4,R5-2,R3-1),(nm-2,R2-1,A-4,R5-2,R3-2),(nm-2,R2-1,A-4,R5-3,R3-1),(nm-2,R2-1,A-4,R5-3,R3-2),(nm-2,R2-1,A-5,R5-1,R3-1),(nm-2,R2-1,A-5,R5-1,R3-2),(nm-2,R2-1,A-5,R5-2,R3-1),(nm-2,R2-1,A-5,R5-2,R3-2),(nm-2,R2-1,A-5,R5-3,R3-1),(nm-2,R2-1,A-5,R5-3,R3-2),(nm-2,R2-1,A-6,R5-1,R3-1),(nm-2,R2-1,A-6,R5-1,R3-2),(nm-2,R2-1,A-6,R5-2,R3-1),(nm-2,R2-1,A-6,R5-2,R3-2),(nm-2,R2-1,A-6,R5-3,R3-1),(nm-2,R2-1,A-6,R5-3,R3-2),(nm-2,R2-1,A-7,R5-1,R3-1),(nm-2,R2-1,A-7,R5-1,R3-2),(nm-2,R2-1,A-7,R5-2,R3-1),(nm-2,R2-1,A-7,R5-2,R3-2),(nm-2,R2-1,A-7,R5-3,R3-1),(nm-2,R2-1,A-7,R5-3,R3-2),(nm-2,R2-1,A-8,R5-1,R3-1),    (nm-2,R2-1,A-8,R5-1,R3-2),(nm-2,R2-1,A-8,R5-2,R3-1),(nm-2,R2-1,A-8,R5-2,R3-2),(nm-2,R2-1,A-8,R5-3,R3-1),(nm-2,R2-1,A-8,R5-3,R3-2),(nm-2,R2-1,A-9,R5-1,R3-1),(nm-2,R2-1,A-9,R5-1,R3-2),(nm-2,R2-1,A-9,R5-2,R3-1),(nm-2,R2-1,A-9,R5-2,R3-2),(nm    -2,R2-1,A-9,R5-3,R3-1),(nm-2,R2-1,A-9,R5-3,R3-2),(nm-2,R2-1,A-10,R5-1,R3-1),(nm-2,R2-1,A-10,R5-1,R3-2),(nm-2,R2-1,A-10,R5-2,R3-1),(nm-2,R2-1,A-10,R5-2,R3-1),(nm-2,R2-1,A-10,R5-3,R3-1),(nm-2,R2-1,A-10,R5-3,R3-2),(nm-2,R2-1,A-11,R5-1,R3-1),(nm-2,R2-1,A-11,R5-1,R3-2),(nm-2,R2-1,A-11,R5-2,R3-1),(nm-2,R2-1,A-11,R5-2,R3-2),    (nm-2,R2-1,A-11,R5-3,R3-1),(nm-2,R2-1,A-11,R5-3,R3-2),(nm-2,R2-1,A-12,R5-1,R3-1),(nm-2,R2-1,A-12,R5-1,R3-2),(nm-2,R2-1,A-12,R5-2),(R3-1),(nm-2,R2-1,A-12,R5-2,R3-2),(nm-2,R2-1,A-12,R5-3,R3-1),(nm-2,R2-1,A-12,R5-3,R3-2),(nm-2,R2-1,A-13,R5-1,R3-1),(nm-2,R2-1,A-13,R5-1,R3-2),(nm-2,R2-1,A-13,R5-2,R3-1),(nm-2,R2-1,A-13,R5-2,R3-2),(nm-2,R2-1,A-13,R5-3,R3-1),(nm-2,R2-1,A-13,R5-3,R3-2),(nm-2,R2-1,A-14,R5-1,R3-1),(nm-2,R2-1,A-14,R5-1,R3-2),(nm-2,R2-1,A-14,R5-2,R3-1),(nm-2,R2-1,A-14,R5-2,R3-2),(nm-2,R2-1,A-14,R5-3,R3-1),(nm-2,R2-1,A-14,R5-3,R3-2),(nm-2,R2-2,A-1,R5-1,R3-1),(nm-2,R2-2,A-1,R5-1,R3-2),(nm-2,R2-2,A-1,R5-2,R3-1),(nm-2,R2-2,A-1,R5-2,R3-2),(nm-2,R2-2,A-1,R5-3,R3-1),(nm-2,R2-2,A-1,R5-3,R3-2),(nm-2,R2-2,A-2,R5-1,R3-1),(nm-2,R2-2,A-2,R5-1,R3-2),(nm-2,R2-2,A-2,R5-2,R3-1),(nm-2,R2-2,A-2,R5-2,R3-2),(nm-2,R2-2,A-2,R5-3,R3-1),(nm-2,R2-2,A-2,R5-3,R3-2),(nm-2,R2-2,A-3,R5-1,R3-1),(nm-2,R2-2,A-3,R5-1,R3-2),(nm-2,R2-2,A-3,R5-2,R3-1),(nm-2,R2-2,A-3,R5-2,R3-2),(nm-2,R2-2,A-3,R5-3,R3-1),(nm-2,R2-2,A-3,R5-3,R3-2),(nm-2,R2-2,A-4,R5-1,R3-1),    (nm-2,R2-2,A-4,R5-1,R3-2),(nm-2,R2-2,A-4,R5-2,R3-1),(nm-2,R2-2,A-4,R5-2,R3-2),(nm-2,R2-2,A-4,R5-3,R3-1),(nm-2,R2-2,A-4,R5-3,R3-2),(nm-2,R2-2,A-5,R5-1,R3-1),(nm-2,R2-2,A-5,R5-1,R3-2),(nm-2,R2-2,A-5,R5-2,R3-1),(nm-2,R2-2,A-5,R5-2,R3-2),(nm    -2,R2-2,A-5,R5-3,R3-1),(nm-2,R2-2,A-5,R5-3,R3-2),(nm-2,R2-2,A-6,R5-1,R3-1),(nm-2,R2-2,A-6,R5-1,R3-2),(nm-2,R2-2,A-6,R5-2,R3-1),(nm-2,R2-2,A-6,R5-2,R3-2),(nm-2,R2-2,A-6,R5-3,R3-1),(nm-2,R2-2,A-6,R5-3,R3-2),(nm-2,R2-2,A-7,R5-1,R3-1),(nm-2,R2-2,A-7,R5-1,R3-2),(nm-2,R2-2,A-7,R5-2,R3-1),(nm-2,R2-2,A-7,R5-2,R3-2),(nm-2,R2-2,A-7,R5-3,R3-1),(nm-2,R2-2,A-7,R5-3,R3-2),(nm-2,R2-2,A-8,R5-1,R3-1),(nm-2,R2-2,A-8,R5-1,R3-2),(nm-2,R2-2,A-8,R5-2,R3-1),(nm-2,R2-2,A-8,R5-2,R3-2),(nm-2,R2-2,A-8,R5-3,R3-1),(nm-2,R2-2,A-8,R5-3,R3-2),(nm-2,R2-2,A-9,R5-1,R3-1),(nm-2,R2-2,A-9,R5-1,R3-2),(nm-2,R2-2,A-9,R5-2,R3-1),(nm-2,R2-2,A-9,R5-2,R2-2),(nm-2,R2-2,A-9,R3,R3-1),(nm-2,R2-2,A-9,R5-3,R3-2),(nm-2,R2-2,A-10,R5-1,R3-1),(nm-2,R2-2,A-10,R5-1,R3-2),(nm-2,R2-2,A-10,R5-2,R3-1),(nm-2,R2-2,A-10,R5-2,R3-2),(nm-2,R2-2,A-10,R5-3,R3-1),(nm-2,R2-2,A-10,R5-3,R3-2),(nm-2,R2-2,A-11,R5-1,R3-1),(nm-2,R2-2,A-1    1,R5-1,R3-2),(nm-2,R2-2,A-11,R5-2,R3-1),(nm-2,R2-2,A-11,R5-2,R3-2),(nm-2,R2-2,A    -11,R5-3,R3-1),(nm-2,R2-2,A-11,R5-3,R3-2),(nm-2,R2-2,A-12,R5-1,R3-1),(nm-2,R2-2,A-12,R5-1,R3-2),(nm-2,R2-2,A-12,R5-2,R3-1),(nm-2,R2-2,A-12,R5-2R3-2),(nm-2,R2-2,A-12,R5-3,R3-1),(nm-2,R2-2A-12,R5-3,R3-2),(nm-2,R2-2,A-13,R5-1,R3-1),(nm-2,R2-2,A-13,R5-1,R3-2),(nm-2,R2-2,A-13,R5-2,R3-1),(nm-2,R2-2,A-13,R5-2,R3-2),(nm-2,R2-2,A-13,R5-3,R3-1),(nm-2,R2-2,A-13,R5-3,R3-2),(nm-2,R2-2,A-14,B5-1,R3-1),(nm-2,R2-2,A-14,R5-1,R3-2),(nm-2,R2-2,A-14,R5-2,R3-1),(nm-2,R2-2,A-14,R5-2,R3-2),(nm-2,R2-2,A-14,R5-3,R3-1),(nm-2,R2-2,A-14,R5-3,R3-2),(nm-2,R2-3,A-1,R5-1,R3-1),(nm-2,R2-3,A-1,R5-1,R3-2),(nm-2,R2-3,A-1,R5-2,R3-1),(nm-2,R2-3,A-1,R5-2,R3-2),(nm-2,R2-3,A-1,R5-3,R3-1),(nm-2,R2-3,A-1,R5-3,R3-2),(nm-2,R2-3,A-2,R5,-1,R3-1),(nm    -2,R2-3,A-2,R5-1,R3-2),(nm-2,R2-3,A-2,R5-2,R3-1),(nm-2,R2-3,A-2,R5-2,R3-2),(nm-2,R2-3,A-2,R5-3,R3-1),(nm-2,R2-3,A-2,R5-3,R3-2),(nm-2,R2-3,A-3,R5-1,R3-1),(nm-2,R2-3,A-3,R5-1,R3-2),(nm-2,R2-3,A-3,R5-2,R3-1),(nm-2,R2-3,A-3,R5-2,R3-2),(nm-2,R2-3,A-3,R5-3,R3-1),(nm-2,R2-3,A-3,R5-3,R3-2),(nm-2,R2-3,A-4,R5-1,R3-1),(nm-2,R2-3,A-4,R5-1,R3-2),(nm-2,R2-3,A-4,R5-2,R3-1),(nm-2,R2-3,A-4,R5-2,R3-2),(nm-2,R2-3,A-4,R5-3,R3-1),(nm-2,R2-3,A-4,R5-3,R3-2),(nm-2,R2-3,A-5,R5-1,R3-1),(nm-2,R2-3,A-5,R5-1,R3-2),(nm-2,R2-3,A-5,R5-2,R3-1),(nm-2,R2-3,A-5,R5-2,R3-2),(nm-2,R2-3,A-5,R5-3,R3-1),(nm-2,R2-3,A-5,R5-3,R3-2),(nm-2,R2-3,A-6,R5-1,R3-1),(nm-2,R2-3,A-6,R5-1,R3-2),(nm-2,R2-3,A-6,R5-2,R3-1),(nm-2,R2-3,A6,R5-2,R3-2),(nm-2,R2-3,A-6,R5-3,R3-1),(nm-2,R2-3,A-6,R5-3,R3-2),(nm-2,R2-3,A-7,R5-1,R3-1),(nm-2,R2-3,A-7,R5-1,R3-2),(nm-2,R2-3,A-7,R5-2,R3-1),(nm-2,R2-3,A-7,R5-2,R3-2),(nm-2,R2-3,A-7,R5-3,R3-1),(nm-2,R2-3,A-7,R5-3,R3-2),(nm-2,R2-3,A-8,R5-1,R3-1),(nm-2,R2-3,A-8,R5-1,R3-2),    (nm-2,R2-3,A-8,R5-2,R3-1),(nm-2,R2-3,A-8,R5-2,R3-2),(nm-2,R2-3,A-8,R5-3,R3-1),(nm-2,R2-3,A-8,R5-3,R3-2),(nm-2,R2-3,A-9,R5-1,R3-1),(nm-2,R2-3,A-9,R5-1,R3-2),(nm-2,R2-3,A-9,R5-2,R3-1),(nm-2,R2-3,A-9,R5-2,R3-2),(nm-2,R2-3,A-9,R5-3,R3-1),(nm    -2,R2-3,A-9,R5-3,R3-2),(nm-2,R2-3,A-10,R5-1,R3-1),(nm-2,R2-3,A-10,R5-1,R3-2),(nm-2,R2-3,A-10,R5-2,R3-1),(nm-2,R2-3,A-10,R5-2,R3-2),(nm-2,R2-3,A-10,R5-3,R3-1),(nm-2,R2-3,A-10,R5-3,R3-2),(nm-2,R2-3,A-11,R5-1,R3-1),(nm-2,R2-3,A-11,R5-1,R3-2),    (nm-2,R2-3,A-11,R5-2,R3-1),(nm-2,R2-3,A-11,R5-2,R3-2),(nm-2,R2-3,A-11,R5-3,R3-1),(nm-2,R2-3,A-11,R5-3,R3-2),(nm-2,R2-3,A-12,R5-1,R3-1),(nm-2,R2-3,A-12,R5-1,R3-2),(nm-2,R2-3,A-12,R5-2,R3-1),(nm-2,R2-3,A-12,R5-2,R3-2),(nm-2,R2-3,A-12,R5-3,R3-1),(nm-2,R2-3,A-12,R5-3,R3-2),(nm-2,R2-3,A-13,R5-1,R3-1),(nm-2,R2-3,A-13,R5-1,R3-2),(nm-2,R2-3,A-13,R5-2,R3-1),(mn-2,R2-3,A-13,R5-2,R3-2),(nm-2,R2-3,A-13,R5-3,R3-1),(nm-2,R2-3,A-13,R5-3,R3-2),(nm-2,R2-3,A-14,R5-1,R3-1),(nm-2,R2-3,A-14,R5-1,R3-2),(nm-2,R2-3,A-14,R5-2,R3-1),(nm-2,R2-3,A-14,R5-2,R3-2),(nm-2,R2-3,A-1    4,R5-3,R3-1),(nm-2,R2-3,A-14,R5-3,R3-2),(nm-2,R2-4,A-1,R5-1,R3-1),(nm-2,R2-4,A-1,R5-1,R3-2),(nm-2,R2-4,A-1,R5-2,R3-1),(nm-2,R2-4,A-1,R5-2,R3-2),(nm-2,R2-4,A-1,R5-3,R3-1),(nm-2,R2-4,A-1,R5-3,R3-2),(nm-2,R2-4,A-2,R5-1,R3-1),(nm-2,R2-4,A-2,R5-1,R3-2),(nm-2,R2-4,A-2,R5-2,R3-1),(nm-2,R2-4,A-2,R5-2,R3-2),(nm-2,R2-4,A-2,R5-3,R3-1),(nm-2,R2-4,A-2,R5-3,R3-2),(nm-2,R2-4,A-3,R5-1,R3-1),(nm-2,R2-4,A-3,R5-1,R3-2),(nm-2,R2-4,A-3,R5-2,R3-1),(nm-2,R2-4,A-3,R5-2,R3-2),(nm-2,R2-4,A-3,R5-3,R3-1),(nm-2,R2-4,A-3,R5-3,R3-2),(nm-2,R2-4,A-4,R5-1,R3-1),(nm-2,R2-4,A-4,R5-1,R3-2),(nm-2,R2-4,A-4,R5-2,R3-1),(nm-2,R2-4,A-4,R5-2,R3-2),(nm-2,R2-4,A-4,R5-3,R3-1),    (nm-2,R2-4,A-4,R5-3,R3-2),(nm-2,R2-4,A-5,R5-1,R3-1),(nm-2,R2-4,A-5,R5-1,R3-2),(nm-2,R2-4,A-5,R5-2,R3-1),(nm-2,R2-4,A-5,R5-2,R3-2),(nm-2,R2-4,A-5,R5-3,R3-1),(nm-2,R2-4,A-5,R5-3,R3-2),(nm-2,R2-4,A-6,R5-1,R3-1),(nm-2,R2-4,A-6,R5-1,R3-2),(nm    -2,R2-4,A-6,R5-2,R3-1),(nm-2,R2-4,A-6,R5-2,R3-2),(nm-2,R2-4,A-6,R5-3,R3-1),(nm-2,R2-4,A-6,R5-3,R3-2),(nm-2,R2-4,A-7,R5-1,R3-1),(nm-2,R2-4,A-7,R5-1,R3-2),(nm-2,R2-4,A-7,R5-2,R3-1),(nm-2,R2-4,A-7,R5-2,R3-2),(nm-2,R2-4,A-7,R5-3,R3-1),(nm-2,R2-4,A-7,R5-3,R3-2),(nm-2,R2-4,A-8,R5-1,R3-1),(nm-2,R2-4,A-8,R5-1,R3-2),(nm-2,R2-4,A-8,R5-2,R3-1),(nm-2,R2-4,A-8,R5-2,R3-2),(nm-2,R2-4,A-8,R5-3,R3-1),(nm-2,R2-4,A-8,R5-3,R3-2),(nm-2,R2-4A-9,R5-1,R3-1),(nm-2,R2-4,A-9,R5-1,R3-2),(nm-2,R2-4,A-9,R5-2,R3-1),(nm-2,R2-4,A-9,R5-2,R3-2),(nm-2,R2-4,A-9,R5-3,R3-1),(nm-2,R2-4,A-9,R5-3,R3-2),(nm-2,R2-4,A-10,R5-1,R3-1),(nm-2,R2-4,A-10,R5-1,R3-2),(nm2,R2-4,A-10,R5-2,R3-1),(nm-2,R2-4,A-10,R5-2,R3-2),(nm-2,R2-4,A-10,R5-3,R3-1),(nm-2,R2-4,A-1    0,R5-3,R3-2),(nm-2,R2-4,A-11,R5-1,R3-1),(nm-2,R2-4,A-11,R5-1,R3-2),(nm-2,R2-4,A    -11,R5-2,R3-1),(nm-2,R2-4,A-11,R5-2,R3-2),(nm-2,R2-4,A-11,R5-3,R3-1),(nm-2,R2-4,A-11,R5-3,R3-2),(nm-2,R2-4,A-12,R5-1,R3-1),(nm-2,R2-4,A-12,R5-1,R3-2),(nm-2,R2-4,A-12,R5-2,R3-1),(nm-2,R2-4,A-12,R5-2,R3-2),(nm-2,R2-4,A-12,R5-3,R3-1),(nm-2,R2-4,A-12,R5-3,R3-2),(nm-2,R2-4,A-13,R5-1,R3-1),(nm-2,R2-4,A-13,R5-1,R3-2),(nm-2,R2-4,A-13,R5-2,R3-1),(nm-2,R2-4,A-13,R5-2,R3-2),(nm-2,R2-4,A-13,R5-3,R3-1),(nm-2,R2-4,A-13,R5-3,R3-2),(nm-2,R2-4,A-14,R5-1,R3-1),(nm-2,R2-4,A-14,R5-1,R3-2),(nm-2,R2-4,A-14,R5-2,R3-1),(nm-2,R2-4,A-14,R5-2,R3-2),(nm-2,R2-4,A-14,R5-3,R3-1),(nm-2,R2-4,A-14,R5-3,R3-2),-   (nm-3,R2-1,A-1,R5-1,R3-1),(nm-3,R2-1,A-1,R5-1,R3-2),(nm-3,R2-1,A-1,R5-2,R3-1),(nm-3,R2-1,R5-2,R3-2),(nm-3,R2-1,A-1,R5-3,R3-1),(nm-3,R2-1,A-1,R5-3,R3-2),(nm    -3,R2-1,A-2,R5-1,R3-1),(nm-3,R2-1,A-2,R5-1,R3-2),(nm-3,R2-1,A-2,R5-2,R3-1),(nm-3,R2-1,A-2,R5-2,R3-2),(nm-3,R2-1,A-2,R5-3,R3-1),(nm-3,R2-1,A-2,R5-3,R3-2),(nm-3,R2-1,A-3,R5-1,R3-1),(nm-3,R2-1,A-3,R5-1,R3-2),(nm-3,R2-1,A-3,R5-2,R3-1),(nm-3,R2-1,A-3,R5-2,R3-2),(nm-3,R2-1,A-3,R5-3,R3-1),(nm-3,R2-1,A-3,R5-3,R3-2),(nm-3,R2-1,A-4,R5-1,R3-1),(nm-3,R2-1,A-4,R5-1,R3-2),(nm-3,R2-1,A-4,R5-2,R3-1),(nm-3,R2-1,A-4,R5-2,R3-2),(nm-3,R2-1,A-4,R5-3,R3-1),(nm-3,R2-1,A-4,R5-3,R3-2),(nm-3,R2-1,A-5,R5-1,R3-1),(nm-3,R2-1,A-5,R5-1,R3-2),(nm-3,R2-1,A-5,R5-2,R3-1),(nm-3,R2-1,A-5,R5-2,R3-2),(nm-3,R2-1,A-5,R5-3,R3-1),(nm-3,R2-1,A-5,R5-3,R3-2),(nm-3,R2-1,A-6,R5-1,R3-1),(nm-3,R2-1,A-6,R5-1,R3-2),(nm-3,R2-1,A6,R5-2,R3-1),(nm-3,R2-1,A-6,R5-2,R3-2),(nm-3,R2-1),A-6,R5-3,R3-1,(nm-3,R2-1,A-6,R5-3,R3-2),(nm-3,R2-1,A-7,R5-1,R3-1),(nm-3,R2-1,A-7,R5-1,R3-2),(nm-3,R2-1,A-7,R5-2,R3-1),(nm-3,R2-1,A-7,R5-2,R3-2),(nm-3,R2-1,A-7,R5-3,R3-1),(nm-3,R2-1,A-7,R5-3,R3-2),(nm-3,R2-1,A-8,R5-1,R3-1),    (nm-3,R2-1,A-8,R5-1,R3-2),(nm-3,R2-1,A-8,R5-2,R3-1),(nm-3,R2-1,A-8,R5-2,R3-2),(nm-3,R2-1,A-8,R5-3,R3-1),(nm-3,R2-1,A-8,R5-3,R3-2),(nm-3,R2-1,A-9,R5-1,R3-1),(n    m-3,R2-1,A-9,R5-1,R3-2),(nm-3,R2-1,A-9,R5-2,R3-1),(nm-3,R2-1,A-9,R5-2,R3-2),(nm    -3,R2-1,A-9,R5-3,R3-1),(nm-3,R2-1,A-9,R5-3,R3-2),(nm-3,R2-1,A-10,R5-1,R3-1),(nm-3,R2-1,A-10,R5-1,R3-2),(nm-3,R2-1,A-10,R5-2,R3-1),(nm-3,R2-1,A-10,R5-2,R3-2),(nm-3,R2-1,A-10,R5-3,R3-1),(nm-3,R2-1,A-10,R5-3,R3-2),(nm-3,R2-1,A-11,R5-1,A-11,R5-1,R3-1),(nm3,R2-1,A-11,R5-1,R3-2),(nm-3,R2-1,A-11,R5-2,R3-1),(nm-3,R2-1,A-11,R5-2,R3-2),    (nm-3,R2-1,A-11,R5-3,R3-1),(nm-3,R2-1,A-11,R5-3,R3-2),(nm-3,R2-1,A-12,R5-1,R3-1),(nm-3,R2-1,A-12,R5-1,R3-2),(nm-3,R2-1,A-12,R5-2,R3-1),(nm-3,R2-1,A-12,R5-2,R3-2),(nm-3,R2-1,A-12,R5-3,R3-1),(nm-3,R2-1,A-12,R5-3,R3-2),(nm-3,R2-1,A-13,R5-1,R3-1),(nm-3,R2-1,A-13,R5-1,R3-2),(nm-3,R2-1,A-13,R5-2,R3-1),(nm-3,R2-1,A-13,R5-2,R3-2),(nm-3,R2-1,A-13,R5-3,R3-1),(nm-3,R2-1,A-13,R5-3,R3-2),(nm-3,R2-1,A-14,R5-1,R3-1),(nm-3,R2-1,A-14,R5-1,R3-2),(nm-3,R2-1,A-14,R5-2,R3-1),(nm-3,R2-1,A-14,R5-2,R3-2),(nm-3,R2-1,A-14,R5-3,R3-1),(nm-3,R2-1,A-14,R5-3,R3-2),(nm-3,R2-2,A-1,R5-1,R3-1),(nm-3,R2-2,A-1,R5-1,R3-2),(nm-3,R2-2,A-1,R5-2,R3-1),(nm-3,R2-2,A-1,R5-2,R3-2),(nm-3,R2-2,A-1,R5-3,R3-1),(nm-3,R2-2,A-1,R5-3,R3-2),(nm-3,R2-2,A-2,R5-1,R3-1),(nm-3,R2-2,A-2,R5-1,R3-2),(nm-3,R2-2,A-2,R5-2,R3-1),(nm-3,R2-2,A-2,R5-2,R3-2),(nm-3,R2-2,A-2,R5-3,R3-1),(nm-3,R2-2,A-2,R5-3,R3-2),(nm-3,R2-2,A-3,R5-1,R3-1),(nm-3,R2-2,A-3,R5-1,R3-2),(nm-3,R2-2,A-3,R5-2,R3-1),(nm-3,R2-2,A-3,R5-2,R3-2),(nm-3,R2-2,A-3,R5-3,R3-1),(nm-3,R2-2,A-3,R5-3,R3-2),(nm-3,R2-2,A-4,R5-1,R3-1),    (nm-3,R2-2,A-4,R5-1,R3-2),(nm-3,R2-2,A-4,R5-2,R3-1),(nm-3,R2-2,A-4,R5-2,R3-2),(nm-3,R2-2,A-4,R5-3,R3-1),(nm-3,R2-2,A-4,R5-3,R3-2),(nm-3,R2-2,A-5,R5-1,R3-1),(nm-3,R2-2,A-5,R5-1,R3-2),(nm-3,R2-2,A-5,R5-2,R3-1),(nm-3,R2-2,A-5,R5-2,R3-2),(nm    -3,R2-2,A-5,R5-3,R3-1),(nm-3,R2-2,A-5,R5-3,R3-2),(nm-3,R2-2,A-6,R5-1,R3-1),(nm-3,R2-2,A-6,R5-1,R3-2),(nm-3,R2-2,A-6,R5-2,R3-1),(nm-3,R2-2,A-6,R5-2,R3-2),(nm-3,R2-2,A-6,R5-3,R3-1),(nm-3,R2-2,A-6,R5-3,R3-2),(nm-3,R2-2,A-7,R5-1,R3-1),(nm-3,R2-2,A-7,R5-1,R3-2),(nm-3,R2-2,A-7,R5-2,R3-1),(nm-3,R2-2,A-7,R5-2,R3-2),(nm-3,R2-2,A-7,R5-3-1),(nm-3,R2-2,A-7,R5-3,R3-2),(nm-3,R2-2,A-8,R5-1,R3-1),(nm-3,R2-2,A-8,R5-1,R3-2),(nm-3,R2-2,A-8,R5-2,R3-1),(nm-3,R2-2,A-8,R5-2,R3-2),(nm-3,R2-2,A-8,R5-3,R3-1),(nm-3,R2-2,A-8,R5-3,R3-2),(nm-3,R2-2,A-9,R5-1,R3-1),(nm-3,R2-2,A-9,R5-1,R3-2),(nm-3,R2-2,A-9,R5-2,R3-1),(nm-3,R2-2,A-9,R5-2,R3-2),(nm-3,R2-2,A-9,R5-3,R3-1),(nm-3,R2-2,A-9,R5-3,R3-2),(nm-3,R2-2,A-10,R5-1,R3-1),(nm-3,R2-2,A-10,R5-1,R3-2),(nm-3,R2-2,A-10,R5-2,R3-1),(nm-3,R2-2,A-10,R5-2,R3-2),(nm-3,R2-2,A-10,R5-3,R3-1),(nm-3,R2-2,A-10,R5-3,R3-2),(nm-3,R2-2,A-11,R5-1,R3-1),(nm-3,R2-2,A-1    1,R5-1,R3-2),(nm-3,R2-2,A-11,R5-2,R3-1),(nm-3,R2-2,A-11,R5-2,R3-2),(nm-3,R2-2,A    -11,R5-3,R3-1),(nm-3,R2-2,A-11,R5-3,R3-2),(nm-3,R2-2,A-12,R5-1,R3-1),(nm-3,R2-2,A-12,R5-1,R3-2),(nm-3,R2-2,A-12,R5-2,R3-1),(nm-3,R2-2,A-12,R5-2,R3-2),(nm-3,R2-2,A-12,R5-3,R3-1),(nm-3,R2-2,A-12,R5-3,R3-2),(nm-3,R2-2,A-13,R5-1,R3-1),(nm-3,R2-2,A-13,R5-1,R3-2),(nm-3,R2-2,A-13,R5-2,R3-1),(nm-3,R2-2,A-13,R5-2,R3-2),(nm-3,R2-2,A-13,R5-3,R3-1),(nm-3,R2-2,A-13,R5-3,R3-2),(nm-3,R2-2,A-14,R5-1,R3-1),(nm-3,R2-2,A-14,R5-1,R3-2),(nm-3,R2-2,A-14,R5-2,R3-1),(nm-3,R2-2,A-14,R5-2,R3-2),(nm-3,R2-2,A-14,R5-3,R3-1),(nm-3,R2-2,A-14,R5-3,R3-2),(nm-3,R2-3,A-1,R5-1,R3-1),(nm-3,R2-3,A-1,R5-1,R3-2),(nm-3,R2-3,A-1,R5-2,R3-1),(nm-3,R2-3,A-1,R5-2,R3-2),(n    m-3,R2-3,A-1,R5-3,R3-1),(nm-3,R2-3,A-1,R5-3,R3-2),(nm-3,R2-3,A-2,R5-1,R3-1),(nm-3,R2-3,A-2,R5-1,R3-2),(nm-3,R2-3,A-2,R5-2,R3-1),(nm-3,R2-3,A-2,R5-2,R3-2),(nm-3,R2-3,A-2,R5-3,R3-1),(nm-3,R2-3,A-2,R5-3,R3-2),(nm-3,R2-3,A-3,R5-1,R3-1),(nm-3,R2-3,A-3,R5-1,R3-2),(nm-3,R2-3,A-3,R5-2,R3-1),(nm-3,R2-3,A-3,R5-2,R3-1),(nm-3,R2-3,A-3,R5-3,R3-1),(nm-3,R2-3,A-3,R5-3,R3-2),(nm-3,R2-3,A-4,R5-1,R3-1),(nm-3,R2-3,A-4,R5-1,R3-2),(nm-3,R2-3,A-4,R5-2,R3-1),(nm-3,R2-3,A-4,R5-2,R3-2),(nm-3,R2-3,A-4,R5-3,R3-1),(nm-3,R2-3,A-4,R5-3,R3-2),(nm-3,R2-3,A-5,R5-1,R3-1),(nm-3,R2-3,A-5,R5-1,R3-2),(nm-3,R2-3,A-5,R5-2,R3-1),(nm-3,R2-3,A-5,R5-2,R3-2),(nm-3,R2-3,A-5,R5-3,R3-1),(mn-3,R2-3,A-5,R5-3,R3-2),(nm-3,R2-3,A-6,R5-1,R3-1),(nm-3,R2-3,A-6,R5-1,R3-2),(nm-3,R2-3,A-6,R5-2,R3-1),(nm-3,R2-3,A-6,R5-2,R3-2),(nm-3,R2-3,A-6,R5-3,R3-1),(nm-3,R2-3),A-6,R5-3,R3-2),(nm-3,R2-3,A-7,R5-1,R3-1),(nm-3,R2-3,A-7,R5-1,R3-2),(nm-3,R2-3,A-7,R5-2,R3-1),(nm-3,R2-3,A-7,R5-2,R3-2),(nm-3,R2-3,A-7,R5-3,R3-1),(nm-3,R2-3,A-7,R5-3,R3-2),(nm-3,R2-3,A-8,R5-1,R3-1),(nm-3,R2-3,A-8,R5-1,R3-2),    (nm-3,R2-3,A-8,R5-2,R3-1),(nm-3,R2-3,A-8,R5-2,R3-2),(nm-3,R2-3,A-8,R5-3,A-8,R5-3,R3-1),(nm-3,R2-3,A-8,R5-3,R3-2),(nm-3,R2-3,A-9,R5-1,R3-1),(nm-3,R2-3,A-9,R5-1,R3-2),(nm-3,R2-3,A-9,R5-2,R3-1),(nm-3,R2-3,A-9,R5-2,R3-2),(nm-3,R2-3,A-9,R5-3,R3-1),(nm    -3,R2-3,A-9,R5-3,R3-2),(nm-3,R2-3,A-10,R5-1,R3-1),(nm-3,R2-3,A-10,R5-1,R3-2),(nm-3,R2-3,A-10,R5-2,R3-1),(nm-3,R2-3,A-10,R5-2,R3-2),(nm-3,R2-3,A-10,R5-3,R3-1),(nm-3,R2-3,A-10,R5-3,R3-2),(nm-3,R2-3,A-11,R5-1,R3-1),(nm-3,R2-3,A-11,R5-1,R3-2),    (nm-3,R3-3,A-11,R5-2,R3-1),(nm-3,R2-3,A-11,R5-2,R3-2),(nm-3,R2-3,A-11,R5-3,R3-1),(nm-3,R2-3,A-11,R5-3,R3-2),(nm-3,R2-3,A-12,R5-1,R3-1),(nm-3,R2-3,A-12,R5-1,R3-2),(nm-3,R2-3,A-12,R5-2,R3-1),(nm-3,R2-3,A-12,R5-2,R3-2),(nm-3,R2-3,A-12,R5-3,R3-1),(nm-3,R2-3,A-12,R5-3,R3-2),(nm-3,R2-3,A-13,R5-1,R3-1),(nm-3,R2-3,A-13,R5-1,R3-2),(nm-3,R2-3,A-13,R5-2,R3-1),(nm-3,R2-3,A-13,R5-2,R3-2),(nm-3,R2-3,A-13,R5-3,R3-1),(nm-3,R2-3,A-13,R5-3,R3-2),(nm-3,R2-3,A-14,R5-1,R3-1),(nm-3,R2-3,A-14,R5-1,R3-2),(nm-3,R2-3,A-14,R5-2,R3-1),(nm-3,R2-3,A-14,R5-2,R3-2),(nm-3,R2-3,A-1    4,R5-3,R3-1),(nm-3,R2-3,A-14,R5-3,R3-2),(nm-3,R2-4,A-1,R5-1,R3-1),(nm-3,R2-4,A-1,R5-1,R3-2),(nm-3,R2-4,A-1,R5-2,R3-1),(nm-3,R2-4,A-1,R5-2,R3-2),(nm-3,R2-4,A-1,R5-3,R3-1),(nm-3,R2-4,A-1,R5-3,R3-2),(nm-3,R2-4,A-2,R5-1,R3-1),(nm-3,R2-4,A-2,R5-1,R3-2),(nm-3,R2-4A-2,R5-2,R3-1),(nm-3,R2-4,A-2,R5-2,R3-2),(nm-3,R2-4,A-2,R5-3,R3-1),(nm-3,R2-4,A-2,R5-3,R3-2),(nm-3,R2-4,A-3,R5-1,R3-1),(nm-3,R2-4,A-3,R5-1,R3-2),(nm-3,R2-4,A-3,R5-2,R3-1),(nm-3,R2-4,A-3,R5-2,R3-2),(nm-3,R2-4,A-3,R5-3,R3-1),(nm-3,R2-4,A-3,R5-3,R3-2),(nm-3,R2-4,A-4,R5-1,R3-1),(nm-3,R2-4,A-4,R5-1,R3-2),(nm-3,R2-4,A-4,R5-2,R3-1),(nm-3,R2-4,A-4,R5-2),(nm-3,R2-4,A-4,R5-3,R3-1),    (nm-3,R2-4,A-4,R5-3,R3-2),(nm-3,R2-4,A-5,R5-1,R3-1),(nm-3,R2-4,A-5,R5-1,R3-2),(nm-3,R2-4,A-5,R5-2,R3-1),(nm-3,R2-4,A-5,R5-2,R3-2),(nm-3,R2-4,A-5,R5-3,R3-1),(nm-3,R2-4,A-5,R5-3,R3-2),(nm-3,R2-4,A-6,R5-1,R3-1),(nm-3,R2-4,A-6,R5-1,R3-2),(nm    -3,R2-4,A-6,R5-2,R3-1),(nm-3,R2-4,A-6,R5-2,R3-2),(nm-3,R2-4,A-6,R5-3,R3-1),(nm-3,R2-4,A-6,R5-3,R3-2),(nm-3,R2-4,A-7,R5-1,R3-1),(nm-3,R2-4,A-7,R5-1,R3-2),(nm-3,R2-4,A-7,R5-2,R3-1),(nm-3,R2-4,A-7,R5-2,R3-2),(nm-3,R2-4,A-7,R5-3,R3-1),(nm-3,R2-4,A-7,R5-3,R3-2),(nm-3,R2-4,A-8R5-1,R3-1),(nm-3,R2-4,A-8,R5-1,R3-2),(nm-3,R2-4,A-8,R5-2,R3-1),(nm-3,R2-4,A-8,R5-2,R3-2),(nm-3,R2-4,A-8,R5-3,R3-1),(nm-3,R2-4,A-8,R5-3,R3-2),(nm-3,R2-4,A-9,R5-1,R3-1),(nm-3,R2-4,A-9,R5-1,R3-2),(nm-3,R2-4,A-9,R5-2,R3-1),(nm-3,R2-4,A-9,R5-2,R3-2),(nm-3,R2-4,A-9,R5-3,R3-1),(nm-3,R2-4,A-9,R5-3,R3-2),(nm-3,R2-4,A-10,R5-1,R3-1),(nm-3,R2-4,A-10,R5-1,R3-2),(nm-3,R2-4,A-10,R5-2,R3-1),(nm-3,R2-4,A-10,R5-2,R3-2),(nm-3,R2-4,A-10,R5-3,R3-1),(nm-3,R2-4,A-1    0,R5-3,R3-2),(nm-3,R2-4,A-11,R5-1,R3-1),(nm-3,R2-4,A-11,R5-1,R3-2),(nm-3,R2-4,A    -11,R5-2,R3-1),(nm-3,R2-4,A-11,R5-2,R3-2),(nm-3,R2-4,A-11,R5-3,R3-1),(nm-3,R2-4,A-11,R5-3,R3-2),(nm-3,R2-4,A-12,R5-1,R3-1),(nm-3,R2-4,A-12,R5-1,R3-2),(nm-3,R2-4,A-12,R5-2,R3-1),(nm-3,R2-4,A-12,R5-2,R3-2),(nm-3,R2-4,A-12,R5-3,R3-1),(nm-3,R2-4,A-12,R5-3,R3-2),(nm-3,R2-4,A-13,R5-1,R3-1),(nm-3,R2-4,A-13,R5-1,R3-2),(nm-3,R2-4,A-13,R5-2,R3-1),(nm-3,R2-4,A-13,R5-2,R3-2),(nm-3,R2-4,A-13,R5-3,R3-1),(nm-3,R2-4,A-13,R5-3,R3-2),(nm-3,R2-4,A-14,R5-1,R3-1),(nm-3,R2-4,A-14,R5-1,R3-2),(nm-3,R2-4,A-14,R5-2,R3-1),(nm-3,R2-4,A-14,R5-2,R3-2),(nm-3,R2-4,A-14,R5-3,R3-1),(nm-3,R2-4,A-14,R5-3,R3-2),    and (nm-3,R2-4,A-14,R5-3,R3-3).

In the compound represented by the general formula (I′), a compound,wherein the combination of n, m, R^(2a), R^(2b),ring A, R⁵, R^(3a), andR^(3b) (nm, R², A, R⁵, R³) is one of the above compound, and E is abond.

The compounds of the invention can be employed in the treatment and/orprevention of disease associated with the generation, secretion ordeposition of β-amyloid protein, such as dementia of the Alzheimer'stype (Alzheimer's disease, senile dementia of Alzheimer type), Down'ssyndrome, memory impairment, prion disease (Creutzfeldt-Jakob disease),mild cognitive impairment (MCI), Dutch type of hereditary cerebralhemorrhage with amyloidosis, cerebral amyloid angiopathy, other type ofdegenerative dementia, mixed dementia with Alzheimer's and vasculartype, dementia with Parkinson's Disease, dementia with progressivesupranuclear palsy, dementia with Cortico-basal degeneration,Alzheimer's disease with diffuse Lewy body disease, age-related maculardegeneration, Parkinson's Disease, amyloid angiopathy and so on.

The compounds of the invention can be administrated in combination withother pharmaceutical agents such as other therapeutic drugs forAlzheimer's disease, acetylcholinesterase inhibitors and so on. Thecompounds of the invention can be treated with concomitantly with theanti-dementia agents such as Donepezil Hydrochloride, Tacrine,Galantamine, Rivastigmine, Zanapezil, Memantine, Vinpocetine.

When the present compound is administered to a human, it can beadministered orally as powders, granules, tablets, capsules, pills,solutions, or the like, or parenterally as injectables, suppositories,transdermal absorbable agents, absorbable agents, or the like. Inaddition, the present compound can be formulated into pharmaceuticalpreparations by adding pharmaceutical additives such as excipients,binders, wetting agents, disintegrating agents, lubricants and the like,which are suitable for formulations and an effective amount of thepresent compound,

A dose is different depending on state of disease, an administrationroute, and an age and a weight of a patient, and is usually 0.1 μg to 1g/day, preferably 0.01 to 200 mg/day when orally administered to anadult, and is usually 0.1 μg to 10 g/day, preferably 0.1 to 2 g/day whenparenterally administered,

Following examples and test examples illustrate the present invention inmore detail, but the present invention is not limited by these examples,

In example, the meaning of each abbreviation is following.

-   Me methyl-   Et ethyl-   iPr or Pr^(i) isopropyl-   Ph phenyl-   Bn benzyl-   Boc t-butoxycarbonyl-   TBDPS t-butyldiphenylsilyl

EXAMPLE Reference Example 1 The Synthesis of Compound 588

Step 1

Under nitrogen atmosphere, the compound (1-1)(7.98 g) was dissolved intodiethyl ether (330 ml)-tetrahydrofuran (36 ml), vinylmagnesium chloridein tetrahydrofuran solution (1.32 mol/L, 44.8 ml) was added undercooling with dry ice-acetone bath, and stirred for 20 min. Then, thereaction solution was stirred for 30 min under cooling with ice-waterbath and stirred for 35 min at room temperature. And then, saturatedammonium chloride solution was added to the mixture, the mixture wasextracted with ethyl acetate, and organic layer was washed withsaturated ammonium chloride solution, saturated sodium hydrogencarbonatesolution, and brine, and dried over anhydrous magnesium sulfate, and thesolvent was evaporated. Then, the residue was purified by silica gelcolumn chromatography to afford the compound (1-2)(6.00 g).

¹H-NMR(CDCl₃): 1.63(3H, s), 2.08(1H, br), 5.20(1H, dd, J=10.6, 1.6 Hz),5.31(1H, dd, J=17.1, 1.6 Hz), 6.09(1H, m), 7.46(1H, m), 7.52(1H, dd,J=3,4, 2.6 Hz), 7.80(1H, dd, J=3.9, 2.6 Hz), 8,06(1H, br)

Step 2

The compound (1-2)(6.36 g) was dissolved into acetic acid (30 ml), andadded thiourea (1.50 g), 1 mol/L hydrochloride-acetic acid solution(20.7 ml). The reaction mixture was stirred at room temperature for 3hours, then stirred at 40° C. for 3 hours, then stirred at roomtemperature for 66 hours, and at 40° C. for 19 hours. Thiourea (0.450g), and 1 mol/L hydrochloric acid-acetic acid solution (7.53 ml) wasadded, and stirred at 40° C. for 23 hours. After the consumption of thecompound (1-2), the solvent was evaporated under reduced pressure, thenthe obtained residue was crystallized from methanol-diethyl ether toafford the compound (1-3)(5.23 g) as crystal. On the other hand,filtrate was evaporated under reduced pressure, and the compound(1-3)(3,00 g) was obtained as a crude solid product.

¹H-NMR(DMSO-d₆): 2.09(3H, s), 4.10(2H, d, J=7.3 Hz), 5.94(1H, t, J=7.7Hz), 7.50(1H, s), 7.75(1H, s), 7.87(1H, s), 9.17(3H, br), 11.46(1H, s)

Step 3

The compound (1-3)(5.23 g) dissolved in trifluoroacetic acid (25 ml) wasadded methanesulfonic acid (2.14 ml) dropwise under cooling withice-water bath. After addition, the reaction mixture was stirred at roomtemperature for 3.5 hours. After the consumption of the compound (1-3),the solvent was evaporated under reduced pressure. To the residueobtained was added water and sodium carbonate and then extracted withethyl acetate. The organic layer was washed with saturated sodiumhydrogencarbonate solution, and was dried over anhydrous magnesiumsulfate, and the solvent was evaporated under reduced pressure to affordthe compound (1-4)(4.90 g) as a crude product.

¹H-NMR(CDCl3): 1.53(3H, s), 1.90(1H, m), 2.09(1H, m), 2.74(1H, m),2.97(1H, m), 4.32(2H, br), 7.34(1H, t, J=1.6 Hz), 7.37(1H, t, J=1.8 Hz),7.86(1H, t, J=1.8 Hz)

Step 4

Under nitrogen atmosphere, the compound (1-4)(4.90 g) dissolved intetrahydrofuran was added di-t-butyl-dicarbonate (2.97 g) andtriethylamine (1.89 ml) under cooling with ice-water bath and thenstirred for 2 hours. The reaction mixture was stirred at roomtemperature for 3 hours. The reaction mixture was added water, and thenextracted with ethyl acetate. The organic layer was washed with water,and dried over anhydrous magnesium sulfate, then the solvent wasevaporated under reduced pressure. Then the obtained residue wascrystallized from ethyl acetate-diethyl ether to afford the compound(1-5)(4.62 g) as crystal.

¹H-NMR(CDCl₃): 1.36(9H, s), 1.72(3H, s), 2.10(1H, m), 2.41(1H,m),2.62(1H, m), 2.75(1H, m), 7.22(1H, s), 7.48(1H, s), 8.29(1H, s)

Step 5

The compound (1-5)(1.00 g) was dissolved into tetrahydrofuran (8.7 ml),and 1 mol/L lithium hydroxide (4.43 ml) was added and stirred at 50° C.for 4 hours. Water was added to the reaction mixture, and the mixturewas extracted with ethyl acetate, and the organic layer was washed withwater, brine successively, and dried over anhydrous magnesium sulfate,and the solution was evaporated under reduced pressure. The obtainedresidue was purified by medium-pressured silica gel columnchromatography to afford the compound (1-6)(0.668 g).

¹H-NMR(CDCl₃): 1.51(9H, s), 1.63(3H, s), 2.06(1H, m), 2.40(1H, m),2.68-2.74(2H, m), 3.83(2H, br), 6.51(1H, t, J=1.8 Hz), 6.72-6.74(2H, m)

Step 6

The compound (1-6)(20.0 mg) was dissolved into 4 mol/L hydrochloric acidin 1,4-dioxane, and the mixture was stirred for 16 hours. The reactionsolvent was evaporated under reduced pressure and the obtained residuewas crystallized from methanol-diethyl ether to afford the compound(588)(14.7 mg).

¹H-NMR(DMSO-d₆): 1.59(3H, s), 2.09-2.76(4H, m), 6.44(1H, t, J=1.6 Hz),6.60(1H, t J=1.9 Hz), 6.71(1H, t, J=2.0 Hz), 10.4(1H, s)

Reference Example 2 The Synthesis of Compound 835

Step 1

The compound (2-1)(2020 mg) was dissolved into chloroform (20 ml), thenwater(4 ml) and sodium thiocyanate (1470 mg) were added at roomtemperature with stirring, and then sulfuric acid (1.94 ml) was addeddropwise under cooling with ice-water bath. After an addition wascomplete, the reaction mixture was warmed to room temperature and thenstirred for 345 minutes, then stirred at 60 ° C. overnight. Because thecompound (2-1) was remained(checked by TLC), the reaction mixture wascooled to room temperature, then sodium thiocyanate (1470 mg), water (5ml) and sulfuric acid (1.94 ml) were added successively. After thereaction mixture was warmed to 60° C., the mixture was stirred for 1day. Saturated sodium bicarbonate solution was added to the reactionmixture to be basic condition under cooling with ice-water bath, andthen the reaction mixture was extracted with ethyl acetate. The organiclayer was washed with brine, then dried over anhydrous magnesiumsulfate. The solvent was evaporated and the obtained residue waspurified by silica gel column chromatography to afford the compound(2-2)(968 mg).

¹H-NMR(CDCl₃, 270 MHz): 1.99 (3H, s), 3.55 (1H, d, J=16.1 Hz), 3.69(1H,d, J=16.1 Hz), 7.12-7.64 (8H, m), 7.82-7.95 (2H, m)

Step 2

The compound (2-2)(842 mg) was dissolved into ethano (8.4 ml), sodiumdihydrogen phosphate and an aqueous solution of sodium borohydride(113.2 mg) in water (2.8 ml) were added successively under cooling withice-water bath with stirring, and the mixture was stirred for 30minutes. After the consumption of the compound (2-2)(checked by TLC),ethyl acetate and water were added to the reaction mixture under coolingwith ice-water bath, and then stirred for a few minutes. The reactionmixture was extracted with ethyl acetate. The organic layer was washedwith water, brine successively, and dried over anhydrous magnesiumsulfate. The solvent was evaporated to afford the compound (2-3)(904.8mg) as a crude product.

Step 3

To a solution of compound (23)(900 mg) in toluene (10 ml) was added asolution of thionyl chloride (0.7 ml) in toluene (5 ml) under coolingwith ice-water bath with stirring, and then stirred for 1 hour at thesame temperature. After the consumption of the compound (2-3)(checked byTLC), the reaction solvent was evaporated under reduced pressure toafford the compound (2-4)(1076.8 mg) as a crude product.

Step 4

The compound. (2-4)(1070 mg) was dissolved into about 7 mol/L ammonia inmethanol (20 ml) at room temperature, then the mixture was stirred for 1day. After the consumption of the compound (2-4)(checked by TLC), thereaction solvent was evaporated under reduced pressure to afford thecompound (835)(2633 mg) as a crude product.

Reference Example 3 The Synthesis of Compound 561

Step 1

To tetrahydrofuran (30 ml) under cooling with ice-water bath withstirring, lithium aluminum hydride (0.63 g) was added portionwise, thena solution of compound (3-1)(1.94 g) in tetrahydrofuran (40 ml) wasadded dropwise. The reaction mixture was reacted for 20 minutes at roomtemperature, then reacted for 3 hours under reflux. Then ice was addedin small portions under cooling, and then stirred for 1 day at roomtemperature. The reaction mixture was filtered and the filtrate wasevaporated under reduced pressure, and the residue was purified bysilica gel column chromatography to afford the compound (3-2)(0.90 g).

¹H-NMR(CDCl₃): 1.22(3H, s), 3.08(1H, d, J=12.5 Hz), 3.34(1H, d, J=12.5Hz), 3.85(1H, d, J=11.0 Hz), 4.11(1H, d, J=11.0 Hz), 7.21-7.25(1H, m),7.34-7.40(2H, m), 7.46-7.50(2H, m).

Step 2

The compound (3-2)(0.90 g) was dissolved into tetrahydrofuran (15 ml),t-butylisothiocyanate (0.69 g) in tetrahydrofuran (5 ml) was added undercooling with ice-water bath with stirring. The reaction mixture wasstirred for 3 days at room temperature, water was added and extractedwith dichloromethane. The organic layer,was dried over anhydrousmagnesium sulfate, then the solvent was evaporated under reducedpressure. The residue was purified by silica gel column chromatographyto afford the compound (3-3)(1.33 g).

¹H-NMR(CDCl₃): 1.12(9H, s), 1.34(3H, s), 3.15(1H, br), 3.76(1H, d,J=11.2 Hz), 3.87(1H, dd, J=14.2, 4.6 Hz), 4.13(1H, d, J=11.2 Hz),4.23(1H, dd, J=14,2, 6.6 Hz), 5.18(1H ,br), 6.01(1H, br), 7.23-7.28(1H,m), 7.34-7.41(4H, m).

Step 3

The compound (3-3)(315 mg) was dissolved into acetonitrile (3 ml),triphenylphosphine (440 mg), and carbon tetrachloride (520 mg) inacetonitrile 3 ml) were added under cooling with ice-water bath withstirring. The reaction mixture was stirred for 1 hour at roomtemperature, and then potassium carbonate (460 mg) was added and stirredfor 2 days at room temperature. Then water was added to the reactionmixture and the mixture was extracted with dichloromethane. The organiclayer was dried over anhydrous magnesium sulfate, and then the solventwas evaporated under reduced pressure. The residue was purified bysilica gel column chromatography to afford the compound (3-4)(0.23 g).

¹H-NMR(CDCl3): 1.30(9H, s), 1.36(3H, s), 3.13(1H, d, J=12.2 Hz),3.24(1H, dd, J=12.2, 2.3 Hz), 3.51(1H, br), 3.53(1H, d, J=15.2 Hz),3.99(1H, dd, J=15.2, 2.3 Hz), 7.20-7.25(1H, m), 7.30-7.36(2H, m),7.39-7.43(2H, m).

Step 4

To the compound (3-4)(0.22 g), conc. hydrochloric acid (4.5 ml) wasadded, then stirred for 2 hours under reflux, and then the reactionsolvent was evaporated under reduced pressure. The obtained residue wascrystallized from methanol-diethyl ether to afford the compound(561)(0.16 g).

¹H-NMR,(DMSO-d₆): 1.33(3H, s), 3.33-3.49(2H, m), 3.65-3.96(2H, m),7.29(1H, t, J=7.6 Hz), 7.40(2H, t, J=7.6 Hz), 7.48(2H, t, J=7.6 Hz).

Reference Example 4 The Synthesis of Compound 534

Step 1

The compound (4-1)(0.72 g) was dissolved into N,N-dimethylformamide (15ml), then sodium azide (0.31 g) was added. The reaction mixture wasstirred at 100° C. for 13 hours, then water was added and the mixturewas extracted with diethyl ether, the organic layer was dried overanhydrous magnesium sulfate to afford the compound (4-2)(0.71 g) as acrude product.

Step 2

To a solution of the compound (4-2)(0.71 g) in tetrahydrofuran (10 ml),lithium aluminum hydride (0.14 g) was added portionwise under coolingwith ice-water bath with stirring, then stirred for 2 hours at roomtemperature. After the consumption of the starting material, ice wasadded in small portions, then stirred for 18 hours at room temperature.The reaction mixture was filtered then filtrate was evaporated underreduced pressure to afford the compound (4-3)(0.89 g) as a crudeproduct.

Step 3

The compound (4-3)(0.89 g) was dissolved into tetrahydrofuran (10 ml),then t-butylisothiocyanate (0.56 g) in tetrahydrofuran (5 ml) was addedunder cooling with ice-water bath with stirring. The reaction mixturewas stirred for 4 hours at room temperature, and water was added, andthen extracted with dichloromethane, and the organic layer was driedover anhydrous magnesium sulfate. Then the residue was purified bysilica gel column chromatography to afford the compound (4-4)(0.72 g).

¹H-NMR(CDCl₃): 1.39(9H, s), 2.08(3H, s), 2.09-2.15(2H, m), 3.37-3.44(1H,m), 3.80-3.87(1H, m), 5.97(1H, br.), 6.86(1H, br.), 7.28-7.43(5H, m).

Step 4

The compound (4-4)(120 mg) was dissolved into acetonitrile (2 ml),triphenylphosphine (170 mg), and carbon tetrachloride (200 mg) inacetonitrile (1 ml) were added under cooling with ice-water bath withstirring. The reaction mixture was stirred for 5 hours at roomtemperature, and then potassium carbonate (177 mg) was added and stirredfor 5 days at room temperature. Then water was added to the reactionmixture and the mixture was extracted with dichloromethane, the organiclayer was dried over anhydrous magnesium sulfate, then the solvent wasevaporated under reduced pressure. The residue was purified by silicagel column chromatography to afford the compound (4-5)(0.06 g),

¹H-NMR(CDCl₃): 1.35(9H, s), 1.59(3H, s), 1.91(1H, ddd, J=13.5, 8.8, 5.0Hz), 2.06(1H, dt, J=13.5, 5.0 Hz), 3.00(1H, ddd, J=15.1, 8.8, 5.0 Hz),3.30(1H, dt, J=15.1, 5.0 Hz), 7.24-7.38(5H, m).

Step 5

To the compound (4-5)(0.06 g), conc. hydrochloric acid (3 ml) was added,then the mixture was stirred for 1 hour under reflux, and the solventwas evaporated under reduced pressure. The obtained residue wascrystallized from methanol-water to afford the compound (534)(0.02 g).

¹H-NMR(DMSO-d₆): 1.43(3H, s), 1.77(1H, dt. J=8.4, 3.4 Hz), 2.11(1H, d,J=9.2 Hz), 2.48-2.50(1H, m), 2.83-2.99(1H,), 6.12(1H, br), 6,65(1H, br),7.21-7.24(1H, m), 7.31-7,37(4H, m).

Reference Example 5 The Synthesis of Compound 1008

Step 1

The compound (5-1)(3.00 g) was dissolved into ethanol (30 ml), andthiourea (1.13 g) was added, and then the mixture was refluxed for 26hours, and the solvent was evaporated under reduced pressure. Theobtained residue was crystallized from ethyl acetate/hexane to affordthe compound (5-2)(4.03 g).

¹H-NMR(DMSO-d₆): 1.95(2H, quint, J=6.8 Hz), 3.13(2H, t, J=6.8 Hz),3.21(2H, t, J=6.8 Hz), 3.85(3H, s), 7.06(2H, d, J=8.8 Hz), 7.95(2H, d,J=8.8 Hz), 9.18(4H, br).

Step 2

The compound (5-2)(1.00 g) was dissolved into tetrahydrofuran (25 ml),then di-t-butyl-dicarbonate (1.74 g), and triethylamine (0.88 g) wereadded, and then the mixture was stirred for 3 hours at room temperature.Water was added to the reaction mixture, and the mixture was extractedwith dichloromethane. The organic layer was dried over anhydrousmagnesium sulfate, and then the solvent was evaporated, under reducedpressure. The residue was purified by silica gel column chromatographyto afford the compound (5-3)(1.24 g).

¹H-NMR(CDCl₃): 1.50(9H, 5), 2.07-2.17(2H, m), 2.98(2H, t, J=7.8 Hz),3.09(2H, t, J=6.3 Hz), 6.95(2H, d, J=8.9 Hz), 7.95(2H, d, J=8.9 Hz),

Step 3

The compound (5-3)(1.18 g) was dissolved into tetrahydrofuran (12 ml),then 0.9 mol/L methylmagnesium bromide in tetrahydrofuran solution (10.1ml) was added under cooling with acetonitrile-dry ice bath withstirring, and then reaction mixture was stirred for 1 hour, then stirredfor 30 minutes at room temperature. After the reaction, saturatedammonium chloride solution was added under cooling with ice-water bathwith stirring, then the mixture was extracted with diethyl ether, andthe organic layer was dried over anhydrous magnesium sulfate, and thenthe solvent was evaporated under reduced pressure. The obtained residuewas purified by silica gel column chromatography to afford the compound(5-4)(0.39 g),

¹H-NMR(CDCl₃): 1.51(9H, s), 1.63(3H, s), 1.55-1.65(2H, m), 1.87-1.91(2H,m), 2.96-3.12(2H, m), 6.86(2H, d, J=8.9 Hz), 7.36(2H, d, J=8.9 Hz).

Step 4

The compound (5-4)(0.24 g) was dissolved into trifluoroacetic acid (6ml), and stirred for 20 hours at room temperature, then the reactionsolvent was evaporated under reduced pressure. To the residue, water andsaturated sodium hydrogencarbonate was added, and then extracted withdichloromethane. The organic layer was dried over anhydrous sodiumsulfate, and then the solvent was evaporated under reduced pressure. Theresidue was purified by silica gel column chromatography to afford thecompound (1008)(0.06 g).

¹H-NMR(CDCl₃): 1.54(3H, s), 1.77-1.87(1H, m), 1.90-1.97(1H, m),2.20-2.36(2H, m), 2.67-2.79(2H, m), 3.81(3H, s), 5.30(2H, br), 6.87(2H,d, J=9.0 Hz), 7.33(2H, d, J=9.0 Hz).

Reference Example 6 The Synthesis of Compound 783

Step 1

The compound (6-1)(0.55 g) was dissolved into methanol (7 ml), andmethyl iodide (0.36 g) was added at room temperature with stirring. Themixture was stirred at room temperature for 18 hours, then the reactionsolvent was evaporated under reduced pressure to afford the compound(6-2)(0.92 g) as a crude product.

Step 2

The compound (6-2)(0.92 g) was dissolved into tetrahydrofuran (7 ml),then triethylamine (0.24 g) and silver oxide (1.1 g) was added. Themixture was stirred at room temperature for 3 days, then the insolubleswas removed by filtration, then the filtrate was evaporated underreduced pressure, and then the obtained residue was purified by silicagel column chromatography to afford the compound (6-3)(0.31 g).

¹H-NMR(CDCl₃): 1.35(9H, s), 1.60(3H, s), 1.92(1H, ddd, J=9.2, 5.8, 3.4Hz), 2,07(1H, dt, J=9.2, 3.4 Hz), 3.00(1H, ddd, J=9.2, 5.8, 3.4 Hz),3.30(1H, dt, J=9.2, 3.4 Hz), 7.24-7.38(5H, m).

Step 3

To the compound (6-3)(0.22 g), conc. hydrochloric acid (3 ml) was added,then the mixture was stirred for 1 hour under reflux, and then thereaction solvent was evaporated under reduced pressure. The obtainedresidue was crystallized from water to afford the compound (783)(0.13g).

¹H-NMR(DMSO-d₆): 1.44(3H, s), 1.78(1H, dt, J=12.4, 4.2 Hz), 2.12(1H, d,J=8.9 Hz), 2.51-2.52(1H, m), 2.96(1H, d, J=4.2 Hz), 6.12(1H, br),6.66(1H, br), 7.21-7.24(1H, m), 7.32-7.37(4H, m).

Reference Example 7 The Synthesis of Compound 69

Step 1

A solution of the compound (7-1)(1.93 g), diphenylphosploryl azide (1.60g), and triethylamine (0.59 g) in toluene (20 ml) was stirred at 80° C.for 3 hours, and water was added, and then the mixture was extractedwith diethyl ether. The organic layer was dried over anhydrous sodiumsulfate, and then the solvent was evaporated under reduced pressure. Theobtained residue was purified by silica gel column chromatography toafford the compound (7-2)(1.69 g).

¹H-NMR(CDCl₃): 1.00(9H, s), 1.72(3H, s), 2.17-2.22(2H, m), 3.49-3.58(1H,m), 3.70-3.80(1H, m), 7.20-7.42(10H, m), 7.58-7.63(5H, m).

Step 2

The compound (7-2)(1.68 g) was dissolved into toluene (9 ml), and3,4-dimethoxybenzylalcohol (0.79 g) was added, the mixture was refluxedfor 8 hours. To the reaction mixture, water was added, then the mixturewas extracted with dichloromethane, and the organic layer was dried overanhydrous sodium sulfate, and the solvent was evaporated under reducedpressure. The obtained residue was purified by silica gel columnchromatography to afford the compound (7-3)(2.09 g).

¹H-NMR(CDCl₃): 1.03(9H, s), 1.87(3H, s), 2.04(2H, m), 3.48(1H, m),3.51(1H, m), 3.62(3H, s), 3.65(3H, s), 4.95(1H, d, J=12.2 Hz), 5.03(1H,d, J=12.2 Hz), 6.80-7.09(3H, m), 7.22-7.42(10H, m), 7.56-7.64(5H, m).

Step 3

The compound (7-3)(2.09 g) was dissolved into 1,4-dioxane (15 ml), and 4mol/L hydrochloric acid-1,4-dioxane (15 ml) solution was added, thenstirred at room temperature for 24 hours. To the reaction mixture, waterand 1 mol/L—sodium hydroxide solution were added and extracted withdichloromethane, then the organic layer was dried over anhydrous sodiumsulfate, and then the solvent was evaporated under reduced pressure. Theobtained residue was purified by silica gel column chromatography toafford the compound (7-4)(0.45 g).

¹H-NMR(CDCl₃): 1.57(3H, s), 1.07-1.98(2H,), 3.48-3.56(1H, 3.72-3.86(1H,m), 7.23-7.45(15H, m).

Step 4

The compound (7-4)(0.44 g) was dissolved into tetrahydrofuran (15 ml),t-butylisothiocyanate (0.41 g) and diisopropylethylamine (0.46 g) wereadded. After the mixture was stirred at room temperature for 3 days,water was added, and extracted with dichloromethane, then the organiclayer was dried over anhydrous sodium sulfate, and then the solvent wasevaporated under reduced pressure. The obtained residue was purified bysilica gel column chromatography to afford the compound (7-5)(0.17 g).

¹H-NM(CDCl₃): 1.79(3H, s), 1.82-2.20(2H, 3.71-3.81(2H, m), 5.09(1H, br),7.30-7.52(5H, m).

Step 5

The compound (7-5)(0.17 g) was dissolved into tetrahydrofuran (3.4 ml),then methyl iodide (0.11 g) was added at room temperature with stirring.The mixture was stirred for 23 hours, the reaction solvent wasevaporated under reduced pressure to afford the compound (7-6)(0.28 g)as a crude product.

Step 6

The compound (7-6)(0.28 g) was dissolved into tetrahydrofuran (5 ml),then triethylamine (74 mg) and silver oxide (0.34 g) were added. Themixture was stirred at room temperature for 20 hours, then insolubleswere removed by filtration, and then the filtrate was evaporated underreduced pressure. The obtained residue was purified by silica gel columnchromatography to afford the compound (7-7)(0.14 g).

¹H-NMR(CDCl₃): 1.36(9H, s), 1.49(3H, s), 1.96-2.09(2H, m), 2.77-3.83(1H,m), 4.05-4.10(1H, m), 7.19(1H, t, J=7.3 Hz), 7.31(2H, t, J=7.3 Hz),7.44(2H, d, J=7.3 Hz).

Step 7

To the compound (7-7)(0.12 g) conc. hydrochloric acid (9 ml) was added,then stirred for 1 hour under reflux, and then the reaction solvent wasevaporated under reduced pressure. The obtained residue was crystallizedfrom methanol-water to afford the compound (69)(0.10 g).

¹H-NMR(DMSO-d₆): 1.65(3H, s), 2.28-2.35(1H, m), 2.39-2.44(1H, m),3.97(1H, dt, J=7.8, 3.0 Hz), 4.53(1H, dt, J=7.8, 3.0 Hz), 7.32-7.44(5H,m), 8.44(2H, br), 10.33(1H, s).

Reference Example 8 The Synthesis of Compound 256

Step 1

The compound (8-1)(4890 mg) was dissolved into N,N-dimethylformamide(100 ml), then sodium azide (5720 mg) was added at room temperature withstirring, and the solution was warmed to 80° C., and stirred for 12hours. After the consumption of the compound (8-1)(checked by TLC), thereaction mixture was cooled to room temperature, then diethyl ether andwater were added, and then the mixture was extracted with diethyl ether.The organic layer was washed with brine, and dried over magnesiumsulfate. The solvent was evaporated under reduced pressure to afford thecompound (8-2)(4940 mg) as a crude product.

Step 2

To the suspension of lithium aluminum hydride (1080 mg) intetrahydrofuran (90 ml) under nitrogen atmosphere under cooling withice-water bath, the compound (8-2)(4940 mg) in tetrahydrofuran (15 ml)solution was added, the reaction mixture was stirred for 30 minutes.After the consumption of the compound (8-2)(checked by TLC), 1 mol/Lsodium hydroxide solution was added under cooling with ice-water bath,then stirred for a while. The generated gel was removed with filtration,and the filtrate was extracted with diethyl ether. The organic layer waswashed with brine, and dried over magnesium sulfate. The solvent wasevaporated under reduced pressure to afford the compound (8-3)(4219.1mg) as a crude product.

Step 3

The compound (8-3)(800 mg) was dissolved into acetonitrile (16 ml), thecompound (8-4)(1840 mg) was added with stirring at room temperature, andstirred for 13 hours. After the consumption of the compound(8-3)(checked by TLC), the reaction solvent was evaporated under reducedpressure, the obtained residue was purified by silica gel columnchromatography to afford the compound (8-5)(1550.7 mg).

8-5-(Z): ¹H-NMR(CDCl₃, 270 MHz): 1.49 (18H, s), 2.06 (3H, d, J=1.4 Hz),3.91-4.00 (2H, m), 5.54 (1H, td, 7.1, 1.4 Hz), 7.12-7.41 (5H, m),8.17-8.25 (1H, m), 11.47 (1H, s)

8-5-(E): ¹H-NMR(CDCl₃, 270 MHz): 1.49 (9H, s), 1.52 (9H,s), 2.09 (3H, d,J=1.5 Hz), 4.24 (2H, dd, J=6.6, 5.3 Hz), 5.80 (1H, td, J=6.6, 1.5 Hz),7.21-7.48 (5H, m), 8.28-8.38 (1H, m), 11.51 (1H, s)

Step 4

The compound (8-5)(474.1 mg) was dissolved into trifluoroacetic acid(4.5 ml) under cooling with ice-water bath, then warmed to roomtemperature, and stirred for 4 hours. After the consumption of thecompound (8-5)(checked by NMR), the reaction mixture was poured intofloating ice—1 mol/L sodium hydroxide solution to be neutralized, thenthe mixture was extracted with ethyl acetate. The organic layer waswashed with brine, and dried over magnesium sulfate. The solvent wasevaporated under reduced pressure to afford the compound (8-6)(326.4 mg)as a crude product,

Step 5

The compound (8-6)(326.4 mg) was dissolved into 1,4-dioxane (2.4 ml),sodium hydroxide (195 mg) and water (1.2 ml) were added successively,then di-t-butyl dicarbonate (0.84 ml) was added under cooling withice-water bath. The reaction mixture was warmed to room temperature, andstirred for 15 hours, then the consumption of the compound (8-6) waschecked by LC-MS. After added water to the reaction mixture, the mixturewas extracted with ethyl acetate. The organic layer was washed withbrine, and dried over magnesium sulfate. The solvent was evaporatedunder reduced pressure, and the obtained residue was purified by silicagel column chromatography to afford the compound (8-7)(113.6 mg).

¹H-NMR(CDCl₃, 400 MHz): 1.46 (9H, s), 1.51 (9H, s), 1.64 (3H, s), 2.06(1H, ddd, J=13.4, 11.4, 5.0 Hz), 2.27 (1H, dt, J=13.4, 4.6 Hz), 3.15(1H, ddd, J=12.9, 11.3, 4.6 Hz), 3,70 (1H, dt, J=12.9, 4.7 Hz),7.23-7.29 (1H, m), 7.33-7.38 (4H, m)

Step 6

The compound (8-7)(110 mg) was dissolved into 4 mol/L hydrochloricacid-1,4-dioxane solution (1 ml) under cooling ice-water bath, themixture was warmed to room temperature, and stirred for 2 days, then theconsumption of the compound (8-7) was checked by LC-MS, and diethylether and water were added at room temperature. After separation ofdiethyl ether layer, water layer was evaporated under reduced pressure.To the obtained residue, methanol was added, then the generated crystalwas filtered. The methanol in the filtrate was evaporated under reducedpressure to afford the compound (256)(69 mg).

¹H-NMR(DMSO-d₆, 400 MHz): 1.57 (3H, s), 1.87-1.96 (1H, m), 2.30 (1H, dt,J=13.6, 3.8 Hz), 2.60 (1H, td, J=12.0, 3.7 Hz), 3.25 (1H, ddd, J=12.8,8.2, 4.4 Hz), 6.93 (2H,s), 7.27-7.44 (5H, m), 7.94 (1H, s), 8.63 (1H,s)

Reference Example 9 The Synthesis of Compound 24

Step 1

The compound (9-1)(0.39 g) was dissolved into chloroform (20 ml), iodine(1.53 g), potassium thiocyanate (1.25 g), catalytic amount oftetrabutylammonium chloride, and water (1 ml) were added at roomtemperature, then stirred for 15 hours. To the reaction mixture, 10%thiosodium sulfate solution and water were added, and the mixture wasextracted with dichloromethane. The organic layer was dried overanhydrous sodium sulfate, the solvent was evaporated under reducedpressure. The obtained residue was purified by silica gel columnchromatography to afford the compound (9-2)(0.56 g).

¹H-NMR(CDCl₃): 1.95(3H, s), 3.62(2H, s), 7.30-7.40(4H, m).

Step 2

To a solution of the compound (9-2)(0.56 g) in tetrahydrofuran (10 ml),t-butylamine (0.24 g) was added and stirred at room temperature for 18hours. The reaction solvent was evaporated under reduced pressure, thenthe obtained residue was purified by silica gel column chromatography toafford the compound (9-3)(190 mg).

¹H-NMR(CDCl3): 1.43(9H, s), 1.56(3H, s), 3.27(1H, d, J=10.6 Hz),3.36(1H, d, J=10.6 Hz), 7.28(2H, d, J=8.2 Hz), 7.43(2H, d, J=8.2 Hz).

Step 3

To the compound (9-3)(190 mg), conc. hydrochloric acid (3 ml) was added,then stirred at 100° C. for 3 hours. To the reaction mixture, 6 mol/Lsodium hydroxide was added to neutralize, the mixture was extracted withdichloromethane. The organic layer was dried with anhydrous sodiumsulfate, and the solvent was evaporated under reduced pressure. Theobtained residue was purified by silica gel column chromatography, thencrystallized from dichloromethane/n-hexane to afford the compound(24)(110 mg).

¹H-NMR(CDCl₃): 1.62(3H, s), 3.47(1H, d, J=10.6 Hz), 3.52(1H, d, J=10.6Hz), 4.59(2H, br), 7.29(2H, d, J=8.6 Hz), 7.39(2H, d, J=8.6 Hz).

Reference Example 10 The Synthesis of Compound 48

Step 1

The compound (10-1)(79.6 mg) and (10-2)(120 mg) were dissolved intoN,N-dimethylformamide (3 ml), then 1-hydroxybenzotriazole (54.6 mg) andN,N′-diisopropylcarbodiimide (0.063 ml) were added, then the reactionmixture was stirred overnight at room temperature. Then after theconsumption of the compound (10-1), water was added, and the mixture wasextracted with ethyl acetate. The organic layer was washed with brine,and dried over magnesium sulfate, and the solvent was evaporated underreduced pressure. The obtained residue was purified by silica gel columnchromatography to afford the compound (10-3)(110.2 mg) as a crudeproduct of diastereomer.

¹H-NMR(CDCl₃): 0.78-1.00 (6H, m), 1.14 (9/2H, s), 1.16 (9/2H, s) 1.52(3/2H, s), 1.54 (3/2H, s) 1.86-2.28 (3H, m), 2.56-2.89 (2H, m), 3.80(3/2H, s), 3.81 (3/2H, s) 4.04-4.14 (1H, m), 6.80-6.91 (2H, 7.08-7.22(2H, m), 7.30-7.51 (6H, m), 7.61-7.76 (4H, m)

Step 2

The compound (10-3)(100 mg) was dissolved into tetrahydrofuran (3 ml)under nitrogen atmosphere, then 1 mol/L tetrabutylammonium fluoride intetrahydrofuran (0.18 ml) was added at 0° C. with stirring, then thereaction mixture was stirred at 0° C. for 5 minutes. After theconsumption of the compound (10-3), water was added, and the mixture wasextracted with ethyl acetate. The organic layer was washed with brine,and dried over magnesium sulfate, then the solvent was evaporated underreduced pressure. The obtained residue was purified by silica gel columnchromatography to afford the compound (48)(40.7 mg) as a mixture ofdiastereomers.

¹H-NMR(CDCl₃): 0.80-0.90 (3H, m) 1.01-1.12(3H, m) 1.70 (3H, m),2.02-2.31(2H, m) 2.39--2.55 (1H, m), 2.61-2.90 (2H,) 3.53-3.70 (1H, m)3.81 (3H, m), 3.96-4.08(1H, m) 6.87-6.96 (2H, m), 7.13-7.22 (2H, m)

Reference Example 11 The Synthesis of Compound 707

Step 1

The compound (11-1)(150 mg) was dissolved into acetonitrile (5 ml), thenthe compound (11-2)(219.6 mg) was added at room temperature withstirring, and then the reaction mixture was warmed to 60° C., andstirred for 25 hours. The compound (11-1) was remained (checked by TLC).The reaction solvent was evaporated under reduced pressure, then theobtained residue was purified by silica gel column chromatography toafford the compound (11-1)(211.4 mg). ¹H-NMR(CDCl₃, 400 MHz): 1.46 (9H,s), 1.50 (9H, s), 1.57 (3H, s), 1.90 (1H, ddd, J=13.7, 10.0, 3.8 Hz)2.11 (1H, ddd, J=13.7, 6.5, 3.7 Hz) 2.68-2.76 (1H, m), 2.86-2.93 (1H,m), 3.88 (3H, s), 6.91 (1H, t, J=8.6 Hz) 6.99-7.03 (1H,), 7.06 (1H, dd,J=13.0, 2.2 Hz), 10.14 (1H, s), 13.93 (1H, s)

Step 2

The compound (11-3)(210 mg) was dissolved into 4 mol/L hydrochloric acidin 1,4-dioxane (4 ml) under cooling with ice-water bath, then themixture was warmed to room temperature and stirred for 67 hours. Afterthe consumption of the compound (11-3)(checked by LC/MS), the reactionsolvent was evaporated under reduced pressure. The obtained residue wascrystallized from methanol-diethyl ether, and crystal was collected byfiltration and washed with diethyl ether to afford compound (707)(140.2mg).

¹H-NMR(DMSO-d₆, 400 MHz): 1.56 (3H, s), 1.90-2.01 (1H, m), 2.43-2.62(2H, m), 2.95-3.03 (1H,), 3.84 (3H, s), 7.10-7.27 (3H, m), 7.76 (3H, brs), 8.26 (1H, br s), 9.42 (1H, s)

Reference Example 12 The Synthesis of Compound 845

Step 1

The compound (12-1)(50 mg) and piperidine (17,9 mg) were dissolved intoN,N-dimethylformamide (2 ml), thenO-(7-azahenzotriazo-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate(79.8 mg) was added, and then the mixture was stirred at roomtemperature for 40 hours. After the consumption of the compound (12-1),the solvent was evaporated under reduced pressure with heating. To theobtained residue, saturated sodium hydrogencarbonate solution was added,and extracted with ethyl acetate. The organic layer was washed withbrine, and dried over magnesium sulfate, then the solvent was evaporatedunder reduced pressure. The obtained residue was purified by silica gelcolumn chromatography to afford the compound (845)(30.7 mg).

¹H-NMR(CDCl₃): 1.60 (3H, s), 1.51-1.82 (6H, m), 1.87-1.98 (1H, m),2.09-2.19(1H, m), 2.91-2.97 (2H, m), 3.64-3.68 (4H,), 6.73 (1H, d,J=4.05 Hz), 7.14(1H, d, J=4.05 Hz)

Reference Example 13 The Synthesis of Compound 1262

Step 1

The compound (13-1)(50.0 mg) was dissolved into tetrahydrofuran (1 ml)under nitrogen atmosphere, then triethylamine (19 μl), and4-bromobenzoyl chloride (30.1 mg) were added under cooling withice-water bath, and stirred for 40 minutes. The reaction solvent wasevaporated under reduced pressure, and then the obtained residue wasdissolved into ethyl acetate. The solution was washed with saturatedsodium hydrogencarbonate solution, and dried over magnesium sulfate, andthen the solvent was evaporated under reduced pressure. The generatedcrystal was collected by filtration to afford the compound (13-2)(57.2mg).

¹H-NMR(CDCl₃): 1.48(9H, s), 1.68(3H, s), 2.08(1H, m), 2.44(1H, m),2.65(1H, m), 2.76(1H, m), 7.18(1H, s), 7.32(1H, s), 7.64(2H, d, J=8.2Hz), 7.78(2H, d, J=8.2 Hz), 8.15(1H, s), 8.25(1H, br)

Step 2

The compound (13-2)(62.3 mg) was dissolved into 4 mol/L hydrochloricacid-1,4-dioxane and stirred for 24 hours. The reaction solvent wasevaporated under reduced pressure. The obtained residue was crystallizedfrom methanol/diethyl ether to afford the compound (1262)(44.7 mg).

¹H-NMR(DMSO-d₆): 1.67(3H, s), 2.10(1H, m), 2.50-2.61(3H, m), 7.33(1H,s), 7.74(1H, s), 7.77(2H, d, J=8,6 Hz), 7.91(2H, d, J=8.6 Hz), 8.08(1H,s), 10.6(1H, s)

Reference Example 14 The Synthesis of Compound 753

Step 1

The compound (14-1)(46 mg) was dissolved into dichloromethane (2 ml),then 4-chlorobenzaldehyde (20 mg) and acetic acid (17 mg) was added atroom temperature, and then stirred for 20 minutes, and then sodiumtriacetoxyborohydride (45 mg) was added under cooling with ice-waterbath. The mixture was stirred at room temperature for 14 hours, and thenwater was added and extracted with dichloromethane. The organic layerwas dried over sodium sulfate, and then the solvent was evaporated underreduced pressure. The obtained residue was purified by silica gel columnchromatography to afford the compound (14-2)(52 mg).

¹H-NMR(CDCl₃): 1.50(9H, s), 1.64(3H, s), 2.02-2.10(1H, m), 2.40(1H, dt,J=14.0 4.1 Hz), 2.62-2.74(2H, m), 4.30(2H, s), 6.49(1H, ddd, J=7.8, 2.0,0.8 Hz), 6.52(1H, t, J=2.0 Hz), 6.60(1H, ddd, J=7.8, 2.0, 0.8 Hz),7.16(1H, t, J=7.8 Hz), 7.18-7.33(4H, m).

Step 2

To the compound (14-2)(52 mg), 4 mol/L hydrochloric acid in 1,4-dioxanesolution (4 ml) was added, then the mixture was stirred at roomtemperature for 4 days, and then the reaction solvent was evaporatedunder reduced pressure. The obtained residue was crystallized frommethanol/diethyl ether to afford the compound (753)(42 mg),

¹H-NMR(DMSO-d₆): 1.58(3H, s), 2.00(1H, ddd, J=14.3, 11.3, 3.3Hz),2.49-2.57(2H, m), 3.07(1H, dt, J=12.7, 3.3 Hz), 4.27(2H, s),6.47(1H, d, J=8.2 Hz), 6.51-6.53(2H, m), 7.08(1H, t, J=8.2 Hz), 7.37(4H,s), 8.80(2H, br).

Reference Example 15 The Synthesis of Compound 1135

Step 1

To a solution of the compound (15-1)(101 mg), 2-propanol (56 μl), andtriphenylphosphine (189 mg) in tetrahydrofuran (2 ml), diethylazodicarboxylate (2.2 mol/L) in toluene (328 μl) was added dropwise,then stirred for 1 hour at room temperature. After the consumption ofthe compound (15-1), the solvent was evaporated under reduced pressure.The obtained residue was purified by silica gel column chromatography toafford the compound (15-2)(280 mg) as a mixture of triphenylphosphineoxide and diethyl hydrazodicarboxylate.

Step 2

To the suspension of 5-chloropyridine-2-carboxylic acid (47 mg) intoluene (1 ml), N,N-dimethylformamide (1 drop) and thionylchloride (91μl) were added and stirred at. 100° C. for 1 hour. The solvent wasevaporated under reduced pressure, then the obtained residue wasdissolved into tetrahydrofuran (1 ml), and then the mixture of thecompound (15-2) (280 mg), and pyridine (194 μl) in tetrahydrofuran (0.5ml) were added dropwise at 0° C. and stirred for 10 minutes. After theconsumption of the compound (15-2), water was added and the mixture wasextracted with ethyl acetate. The organic layer, was washed with water,and then the solvent was evaporated under reduced pressure. The obtainedresidue was purified by silica gel column chromatography to afford thecompound (15-3)(68 mg) as a mixture of diethyl hydrazodicarboxylate.

Step 3

To the compound (15-3)(68 mg) as a mixture of diethylhydrazodicarboxylate, 4 mol/L in hydrochloric acid in 1,4-dioxanesolution (1 ml) was added, then the mixture was stirred at roomtemperature for 16 hours. After the consumption of the compound (44),the reaction solvent was evaporated under reduced pressure. The obtainedresidue was crystallized from 2-propanol/diethyl ether to afford thecompound (1135)(36 mg).

¹H-NMR(DMSO-d₆): 1.30(3H, d, J=6.4 Hz), 1.31(3H, d, J=6.4 Hz), 1.65(3H,s), 2.04-2.11(1H, m), 2.50-2.64(2H, m), 3.12-3.16(1H, m), 4.61(1H, sep,J=6.4 Hz), 6.66(1H, t, J=2.0 Hz), 7.48(1H, t, J=2.0 Hz), 7.60(1H, t,J=2.0 Hz), 8.16 (1H, dd, J=8.4, 0.8 Hz), 8.22(1H, dd, J=8.4, 2.4 Hz),8.79(1H, dd, J=2.4, 0.8 Hz), 10.33(1H, s), 10.72(1H, s).

Reference Example 16 The Synthesis of Compound 161

Step 1

The compound (16-1)(200 mg), palladium acetate (4.7 mg), andtri-(o-tolyl)phosphine (12.5 mg), were dissolved intoN,N-dimethylformamide (2 ml) under nitrogen atmosphere, thenn-butylamine (0.196 ml), and p-chlorostyrene (0.074 ml) were added atroom temperature with stirring, then the solution was warmed to 80° C.,and stirred for 3 hours. After the consumption of the compound(16-1)(checked by TLC), the reaction mixture was cooled to roomtemperature, and saturated ammonium chloride solution was added to themixture. The mixture was extracted with ethyl acetate, the organic layerwas washed with water and brine, and dried over magnesium sulfate, andthen the solvent was evaporated under reduced pressure. The obtainedresidue was purified by silica gel column chromatography to afford thecompound (16-2)(213.1 mg).

¹H-NMR(CDCl₃, 400 MHz): 1.54 (18H, s), 1.64 (3H, s), 1.96 (1H, ddd,J=13.7, 9.1, 4.0 Hz) 2.10 (1H, ddd, J=13.7, 8.1, 3.4 Hz) 2.86 (1H, ddd,J=12.3, 9.1, 3.4 Hz), 3.03 (1H, ddd, J=12.3, 8.1, 4.0 Hz), 7.08 (1H, d,J=16.4 Hz) 7.15 (1H, d, J=16.4 Hz), 7.27-7.40 (5H, m) 7.44 (2H, d, J=8.8Hz), 7.58 (1H, s)

Step 2

The compound (16-2)(213 mg) was dissolved into 4 mol/L, hydrochloricacid in 1,4-dioxane (5 ml) under cooling with ice-water bath, then themixture was warmed to room temperature and stirred for 63 hours. Afterthe consumption of the compound (16-2)(checked by LC/MS), the reactionmixture was diluted with diethyl ether. The generated crystal wascollected by filtration, and washed with diethyl ether to afford thecompound (161)(108.6 mg).

¹H-NMR(DMSO-d₆, 400 MHz): 1.69 (3H, s), 2.08-2.18 (1H, m), 2.56-2.70(2H, m), 3.13-3.20 (1H, m), 7.23 (1H, d, J=8.0 Hz), 7.31 (1H, d, J=17.0Hz), 7.35 (1H, d, J=17.0 Hz), 7.45 (2H, d, J=8.6 Hz), 7.46 (1H, t, 7.6Hz), 7.59 (1H, d, J=2.0 Hz), 7.61-7.64 (1H, m), 7.64 (2H, d, J=8.6 Hz),8.53-9.50 (2H, br), 10.67 (1H, br s)

Reference Example 17 The Synthesis of Compound 597

Step 1

The solution of compound (17-1)(135 mg), O-metbxylhydroxylaminehydrochloride (39 mg), and potassium acetate (27 mg) in methanol (3 ml)was stirred at room temperature for 16 hours, then water was added. Themixture was extracted with dichloromethane, the organic layer was driedover anhydrous sodium sulfate, then the solvent was evaporated underreduced pressure. The obtained residue was purified by silica gel columnchromatography to afford the compound (17-2)(110 mg).

¹H-NMR(CDCl₃): 1.51(9H, s), 1.70(3H, s), 2.14(1H, ddd, J=14.4, 11.4, 3.4Hz), 2.22(3H, s), 2.48(1H, m), 2.65(1H, dt, J=12.6, 11.4 Hz), 2.78(1H,ddd, J=12.6, 5.6, 3.4 Hz), 4.00(3H, s), 7.30(1H, d, J=7.8 Hz), 7.38(1H,d, J=7.8 Hz), 7.54-7.57(2H, m).

Step 2

To the compound (17-2)(110 mg), 4 mol/L hydrochloric acid in 1,4-dioxane(4.5 ml) solution was added and stirred for 4 days at room temperature,then the reaction solvent was evaporated under reduced pressure. Theobtained residue was crystallized from methanol/diethyl ether to affordcompound (597)(65 mg).

¹H-NMR(DMSO-d₆): 1.67(3H, s), 2.08-2.15(1H, m), 2.20(3H, s),2.56-2.64(2H, m), 3.14-3.17(1H, m), 3.92(3H, s), 7.37(1H, d, J=8.0 Hz),7.48(1H, d, J=8.0 Hz), 7.56(1H, s), 7.62(1H, d, J=8.0 Hz).

Reference Example 18 The Synthesis of Compounds 134 and 135

Step 1

The compound (18-1) (2020 mg) was dissolved into chloroform (20 ml), andwater (4 ml) and sodium thiocyanate(1470 mg) were added to the solutionwith stirring at room temperature. Sulfuric acid (1.94 ml) was addeddropwise to the reaction mixture under cooling with ice-water bath.After the addition was completed, the reaction mixture was warmed toroom temperature and then stirred for 345 minutes, then stirred at 60°C. for overnight. Because the compound (18-1) was remained (checked byTLC), the reaction mixture was cooled to room temperature, then sodiumthiocyanate (1470 mg), water (5 ml) and sulfuric acid (1.94 ml) wereadded successively. After the reaction mixture was warmed to 60° C., themixture was stirred for 1 day. A saturated sodium bicarbohydratesolution was added to the reaction mixture to be basic condition undercooling with ice-water bath, and then the reaction mixture was extractedwith ethyl acetate. The organic layer was washed with brine, then driedover anhydrous magnesium sulfate. The solvent was evaporated underreduced pressure and the obtained residue was subjected to silica gelchromatography to afford the compound (18-2) (968 mg).

¹H-NMR(CDCl₃, 270 MHz): 1.99 (3H, s), 3.55 (1H, d, J=16.1 Hz), 3.69 (1H,d, J=16.1 Hz), 7.12-7.64 m), 7.82-7.95 (2H, m)

Step 2

The compound (18-2) (842 mg) was dissolved into ethanol (8.4 ml). Sodiumdihydrogen phosphate(1600 mg) and sodium borohydride (113.2 mg) in water(2.8 ml) were added to the solution successively under cooling withice-water bath with stirring, and the mixture was stirred for 30 minutesat the same temperature. After the consumption of the compound (18-2)(checked by TLC), ethyl acetate and water were added to the mixtureunder cooling with ice-water bath, and then stirred for a few minutes.The reaction mixture was extracted with ethyl acetate. The organic layerwas washed with water and brine successively, and dried over anhydrousmagnesium sulfate. The solvent was evaporated under reduced pressure toafford the compound (18-3) (904.8 mg) as a crude product.

Step 3

To a stirring solution of the compound (18-3) (900 mg) in toluene (10ml) was added a solution of thionyl chloride (0.7 ml) in toluene (5 ml)under cooling with ice-water bath, and stirred for 1 hour at the sametemperature. After the consumption of the compound (18-3)(checked byTLC), the reaction solution was concentrated under reduced pressure toafford the compound (18-4)(1076.8 mg) as a crude product.

Step 4

The compound (18-4) (1070 mg) was dissolved into ca. 7 mol/L ammonia inmethanol (20 ml) at room temperature, then the mixture was stirred for 1day. After the consumption of the compound (18-4)(checked by TLC), thereaction solution was concentrated under reduced pressure to afford thecompound (18-5) (2633 mg) as a crude product.

Step 5

The compound (18-5)(2633 mg) was dissolved into tetrahydrofuran (10 ml),and 4-dimethylaminopyridine (43.2 mg) and di-t-butyl dicarbonate (0.976ml) were added to the solution successively under cooling with ice-waterbath with stirring. The reaction mixture was warmed to room temperatureand then stirred for 260 minutes. Because the compound (18-5) wasremained (checked by TLC) in the reaction solution, di-t-butyldicarbonate (0.488 ml) was added to the reaction mixture at roomtemperature and then stirred at the same temperature for overnight.After, addition of water, the reaction mixture was extracted with ethylacetate. The organic layer was washed with brine, then dried overanhydrous magnesium sulfate. The solvent was evaporated under reducedpressure and the obtained residue was subjected to silica gel columnchromatography to afford the compound (18-6a) (99.6 mg) and the compound(18-6b) (183.2 mg).

18-6a: ¹H-NMR(CDCl₃, 400 MHz): 1.49 (9H, s), 1.80 (3H, s), 2.22 (1H, t,J=13.6 Hz), 2.36 (1H, dd, J=14.2, 3.4 Hz), 4.63 (1H, dd, J=12.6, 3.4Hz), 7.27-7.47 (10H, m)

18-6b: ¹H-NMR(CDCl₃, 400 MHz): 1.53 (9H, s), 1.72 (3H, s), 2.34 (1H, t,J=13.0 Hz), 2.66 (1H, dd, J=14.0, 2.5 Hz), 3.86 (1H, dd, J=12.4, 2.5Hz), 7.20-7.45 (10H, m)

Step 6

The compound (18-6a) (99.6 mg) was dissolved into a 4 mol/L hydrogenchloride in 1,4-dioxane solution (4 ml) on ice bath, and the mixture waswarmed to room temperature and then stirred for 6 days. After theconsumption of the compound (18-6a) (checked by LC-MS), the reactionmixture was concentrated under reduced pressure. The obtained residuewas crystallized from dichloromethane-ethyl acetate, and the crystalswere collected by filtration and washed with ethyl acetate to afford thecompound (441) (52.4 mg).

¹H-NMR(DMSO-d₆, 400 MHz): 1.83 (3H, s), 2.43 (1H, t, J=13.2 Hz), 2.55(1H, dd, J=14.0, 2.8 Hz), 5.10 (1H, dd, J=12.4, 2.8 Hz), 7.34-7.48 (6H,m), 7.53-7.57 (4H,

Step 7

The compound (18-6b) (183 mg) was dissolved into a 4 mol/L of hydrogenchloride in 1,4-dioxane solution (8 ml) on ice bath, and the mixture waswarmed to room temperature and then stirred for 6 days. Because thecompound (18-6b) was remained. (checked by LC-MS), 4 mol/L of hydrogenchloride in 1,4-dioxanesolution (2 ml) was added to the reaction mixtureat room temperature, and then the mixture was stirred at 40° C. forovernight. The reaction mixture was concentrated under reduced pressure,a saturated sodium bicarbonate aqueous solution was added to be basiccondition, and the reaction mixture was extracted with ethyl acetate.The organic layer was washed with brine, and then dried over anhydrousmagnesium sulfate. After the solvent was evaporated under reducedpressure, the obtained residue was subjected to silica gel columnchromatography and crystallized from dichloromethane-diisopropyl ether.The crystals were collected by filtration and washed with diisopropylether to afford the compound (835) (32,2. mg).

¹H-NMR(CDCl₃, 400 MHz): 1.64 (3H, s), 1.95 (1H, t, J=13.2 Hz), 2.52 (1H,dd, J=13.8, 3.0 Hz), 3.84 (1H, dd, J=12.6, 3.0 Hz), 4.16-4.76 (2H, br),7.20-7.39 (10H, m)

Reference Example 19

Step 1

After the compound (19-1) was added dropwise to sulfuric acid (279 ml)under cooling on acetonitrile/dry ice bath with stirring, the mixture offuming nitric acid (42 ml) and sulfuric acid (98 ml) was added dropwiseto the mixture. After stirred for 16 minutes, the reaction mixture wasgradually added into ice. The precipitated crystals were collected byfiltration and dried to afford the compound (19-2) (77.79 g).

¹H-NMR (CDCl₃) δ: 2.71 (3H, d, J=4.9 Hz), 7.34 (1H, t, J=9.3 Hz), 8.40(1H, ddd, J=9.3, 6.2, 3.0 Hz), 8.78 (1H, dd, J=6.2, 3.0 Hz).

Step 2

After the mixed solution of the compound (19-2) (73.94 g),(R)-(+)-2-methyl-2-propane sulfinamide (53.82 g) and tetraethylorthotitanate (230.20 g) in tetrahydrofuran (500 ml) was heated andrefluxed for 2.5 hours. The reaction mixture was gradually poured intoice and the precipitated insoluble was removed by filtration. Thefiltrate was extracted with ethyl acetate, and the organic layer wasdried over anhydrous magnesium sulfate. The solvent was evaporated underreduced pressure and the obtained residue was crystallized from ethylacetate/ n-hexane to afford the compound (19-3) (85.44 g).

¹H-NMR. (CDCl₃) δ: 1.34 (9H, s), 2.81 (3H, d, J=3.5 Hz), 7.29 (1H, t,J=8.9 Hz), 8.31 (1H, dt, J=8.9, 2.9 Hz), 8.55 (1H, dd, J=6.3, 2.9 Hz).

Step 3

A solution of t-butyl acetate (6.08 g) in tetrahydrofuran (10 ml) wasadded dropwise to a solution of 2M lithium diisopropylamide intetrahydrofuran/n-heptane/ethyl benzene (27.9 ml) under cooling onacetone/dry ice bath with stirring. After stirred for 20 minutes, asolution of chlorotitanium triisopropoxide (17.5 ml) in tetrahydrofuran(30 ml) was added dropwise to the mixture. The mixture was stirred for 1hour and a solution of the compound (19-3) (5.00 g) in tetrahydrofuran(10 ml) was added dropwise to the mixture. After reacted for 1 hour, themixture was gradually poured into an aqueous solution of ammoniumchloride under cooling on ice-water bath with stirring, and theprecipitated insoluble was removed by filtration. The filtrate wasextracted with ethyl acetate, and the organic layer was dried overanhydrous sodium sulfate, and the solvent was evaporated under reducedpressure. The residue was subjected to silica gel chromatography toafford the compound (19-4) (5.49 g).

¹H-NMR (CDCl₃) δ: 1.30 (9H, s), 1.35 (9H, s), 1.86 (3H, s), 3.11 (1H,dd, J=16.2, 2.1 Hz), 3.26 (1H, dd, J=16.2, 2.1 Hz), 5.55 (1H, s), 7.18(1H, dd, J=11.1, 8.9 Hz), 8.18 (1H, ddd, J=8.9, 4.0, 2.9 Hz), 8.53 (1H,dd, J=7.0, 2.9 Hz).

-   Ration of diastereomers: S:R97/3, HPLC Column: AS-RH, Detection: 254    nm: Column temp.: 25° C., Mobile phase: 40% MeCNaq., Flow rate: 0.5    ml/min.    -   It is known that stereochemistry of the obtained compound (19-4)        is preferentially afforded (S) isomer as described in Literature        A, and each of diastereomers can be arbitrarily synthesized by        using appropriate metal species or reaction conditions.        Literature A-   (1) T. Fujisawa et al., Tetrahedron Lett., 37, 3881-3884    (1996), (2) D. H. Hua et al, Sulfur Reports, vol. 21., pp. 211-239    (1999), (3) Y. Kori ouzo et al., Tetrahedron, 58, 9621-9628    (2002), (4) Yong Qin et al., J. Org. Chem., 71, 1588-1591 (2006)    Step 4

To the compound (19-4) (12.74 g) was added a solution of 4M hydrochloricacid in 1,4-dioxane (50 ml). After the mixture was stirred at 80° C. for1 hour, diethyl ether (50 ml) was added to the mixture. The precipitatedcrystals were collected by filtration, and dried to afford the compound(19-5) (7.67 g),

¹H-NMR (DMSO-d₆) δ: 1.76 (3H, s), 3.25 (2H, s), 7.62 (1H, dd, J=11.4,9.4 Hz),

Step 5

To a stirred solution of the compound (19-5) (141.32 g) intetrahydrofuran (707 ml) was added dropwise a solution of 1M borantetrahydrofuran complex in tetrahydrofuran (2029 ml) under cooling onice-water bath. After reacted for 3 hours 6 minutes, the mixture wasadded into the mixture of sodium bicarbonate (511 g), ice (1500 g) andethyl acetate (3000 ml) at room temperature with stirring. The mixturewas extracted with ethyl acetate, and the organic layer was dried overanhydrous magnesium sulfate, and the solvent was evaporated underreduced pressure to afford the compound (19-6) (115.46 g) as a crudeproduct.

Step 6

To the compound (19-6) (3.76 g) obtained in Step 5 was added toluene (25ml) and water (12.5 ml), Potassium carbonate (7.97 g) and thiophosgene(2.85 g) was added to the stirring mixture subsequently under cooling onice-water bath After reacted for 3 hours, water was added to the mixtureand extracted with toluene, and the organic layer was dried overanhydrous magnesium sulfate, and a part of the solvent was removed underreduced pressure to afford the compound (19-7) as a crude product.

Step 7

To a stirred solution of the compound (19-7) obtained in Step 6 intoluene (17.4 ml) was added thionyl chloride (6.67 g) andN,N-dimethylformamide (0.128 ml) at room temperature. After stirred for2 hours at 80° C., water was added to the mixture and extracted withtoluene. Solvent was evaporated under reduced pressure to afford thecompound (19-8) (4.03 g).

Step 8

To a stirred solution of the compound (19-8) (4.03 g) from Step 7 intetrahydrofuran (23.8 ml) was added,28% aqueous ammonia (23.8 ml) on icebath, and the mixture was stirred at room temperature for 3 days. Thesolvent of the reaction mixture was evaporated under reduced pressure,and then ethyl acetate was added. Hydrochloric acid (6 ml) was added tothe stirred mixture under cooling with ice-water bath, and theprecipitated crystals were washed with ethyl acetate and water, thendried to afford the compound (19-9) (2.14 g).

¹H-NMR. (DMSO-d₆) δ: 1.76 (3H, s), 2.13-2.24 (1H, m), 2.68-2.74 (2H, m),3.19-3.25 (1H, m), 7.63 (1H, dd, 11.4, 8.9 Hz), 8.07 (1H, dd, J=7.0, 3.5Hz), 8.36 (1H, dt, J=8.9, 3.5 Hz), 11.22 (1H, s).

Step 9

The compound (19-9) (100 mg) was dissolved into methanol (2 ml), 10%palladium carbon powder (50 mg) was added and then stirred at roomtemperature for 18 hours. The insoluble was removed by filtration, thesolvent of the filtrate was removed under reduced pressure. Sodiumcarbonate and water were added to the mixture. The mixture was extractedwith ethyl acetate, and the organic layer was dried over anhydroussodium sulfate, and a solvent was evaporated under reduced pressure toafford the compound (19-10) (68 mg).

Reference Example 20

Step 1

The compound (20-1) (9.13 g) and 3′-bromoacetopherione (15.0 g) weredissolved into tetrahydrofuran (250 ml), and tetraethoxy titanium (39.5ml) was added to the solution at room temperature with stirring and thenstirred at 75° C. for 5 hours. After the consumption of the compound(20-1), brine was added to the mixture. The precipitated titanium oxidewas removed by filtration, and the filtrate was extracted with ethylacetate. The organic layer was dried over anhydrous magnesium sulfate,and the solvent was evaporated under reduced pressure. The residue waspurified by column chromatography to afford the compound (20-2) (20.1g).

¹H-NMR(CDCl₃): 1.33 (9H, s), 2.75 (3H, s), 7.30 (1H, t. J=7.8) 7.59-7.63(1H, m), 7.79 (1H, d, J=7.8) 8.0 (1H, s).

Step 2

To a solution of diisopropylamine (42.1 ml) tetrahydrofuran (100 ml) wasadded dropwise n-butyl lithium in hexane solution (2.64 M, 79.5 ml) at−78° C. under nitrogen atmosphere. After stirred at. 0° C. for 30minutes, the mixture was cooled to −78° C. again and a solution oft-butyl acetate (26.9 ml) in tetrahydrofuran (100 ml) was added dropwiseto the mixture. After stirred −78° C. for 30 minutes,chloro(triisopropoxy)titanium in tetrahydrofuran (150 ml) was addeddropwise to the mixture. The mixture was stirred at the same temperaturefor 70 minutes, the compound (2) (20.1 g) in tetrahydrofuran (100 ml)was added dropwise to the mixture and stirred at −78° C. for 3 hours.After the consumption of the compound (20-2), an aqueous solution ofammonium chloride was added. The precipitated titanium oxide was removedby filtration and the filtrate was extracted with ethyl acetate. Theorganic layer was washed with brine, then dried over anhydrous magnesiumsulfate. The solvent was removed under reduced pressure to afford thecompound (20-3) as a crude product (26.4 g).

Step 3

The crude product of the compound (20-3) (26.4 g) was dissolved intotoluene (80 ml) and added dropwise to a 1.0 M diisobuty aluminum hydridein toluene (253 ml) with stirring at 0° C. The reaction mixture wasstirred at room temperature for 1.5 hours. After the consumption of thecompound (20-3), a 1M hydrochloric acid aqueous solution was added. Themixture was extracted with ethyl acetate, the organic layer was washedwith brine, then dried over anhydrous magnesium sulfate, and the solventwas evaporated under reduced pressure. The residue was purified bycrystallization to afford the compound (20-4) (18.1 g),

¹H-NMR(CDCl₃):1.28(9H,s,),1.71(3H,s),2.19-2.24(2H,m),3.27-3.32(1H,m),3.54-3.66(1H,m), 3.87-3.97 (1H, m), 5.10-5.11(1H, m), 7.22 (1H, t, 7.32-7.41 (2H, m),7.56-7.58 (1H, m)

Step 4

The compound (20-4) (18.1 g) was dissolved into methanol (130 ml) and a10% hydrochloric acid-methanol solution (130 ml) was added to thesolution with stirring at room temperature. Then, the reaction mixturewas stirred at room temperature for 4 hours. After consumption of thecompound (20-4), a 1M hydrochloric acid aqueous solution was added. Themixture was washed with ethyl acetate, the aqueous layer was neutralizedwith a 2M sodium hydroxide aqueous solution and extracted with ethylacetate. The organic layer was dried over anhydrous magnesium sulfate,and the solvent was evaporated under reduced pressure to afford thecrude product of the compound (20-5) (14.1 g).

Step 5

The crude product of the compound (20-5) (32.8 g) and potassiumcarbonate (37.1 g) were dissolved into a mixed solvent of toluene (450ml) and water (225 ml), and thiophosgene (15.3 ml) was added dropwise tothe mixture with stirring at 0° C. The reaction mixture was stirred at0° C. for 1 hour. After consumption of the compound (20-5), water wasadded. After the mixture was extracted with ethyl acetate, the organiclayer was washed with brine, and dried over anhydrous magnesium sulfate.The solvent was evaporated under reduced pressure to afford the crudeproduct of the compound (20-6) (38.4 g).

Step 6

The crude product of the compound (20-6) (38.4 g) was dissolved intotoluene (384 ml), and thionyl chloride (29.4 ml) andN,N-dimethylformamide (1.04 ml) were added dropwise to the solution withstirring at 0° C. The reaction mixture was stirred at 80° C. for 5hours. After consumption of the compound (6), the solvent was evaporatedunder reduced pressure to afford the crude product of the compound(20-7) (40.9 g).

Step 7

The crude product of the compound (20-7) (40.9 g) was dissolved intotetrahydrofuran (250 ml), and 25% aqueous ammonia (250 ml) was addeddropwise to the solution at 0° C. The reaction mixture was stirred atroom temperature for 16 hours. After consumption of the compound (6), asaturated solution of sodium hydrogencarbonate was added. The organiclayer was separated and the aqueous solution was extracted withdichloromethane. The combined organic layer was dried over anhydrousmagnesium sulfate, and the solvent was evaporated under reduced pressureto afford the crude product of the compound (20-8) (38.3 g).

Step 8

The crude product of the compound (20-8) (38.3 g) was dissolved intotetrahydrofuran (383 ml), and di-t-butyl dicarbonate (61.5 g) andN,N-dimethylaminopyridine (1.64 g) were added to the solution, and themixture was stirred at room temperature for 72 hours. After consumptionof the compound (20-8), the solvent was evaporated under reducedpressure and the residue was subjected to silica gel chromatography toafford the compound (20-9) (45.3 g).

¹H-NMR(CDCl₃): 1.54 (9H, s,), 1.57 (3H, s), 1.96 (2H, t, 2.80-2.92(1H,m), 3.00-3.13 (1H, m), 7.21 (1H, t, J=8.1) 7.28-7.41 (2H, m), 7.52-7.55(1H, m).

Step 9

The compound (20-9) (12.1 g), tris dibenzylidene acetone dipalladium(1.14 g) and dicyclohexyl biphenyl phosphine (0.88 g) were dissolvedinto toluene (125 ml) under nitrogen atmosphere, and a solution of 1.6Mlithium hexamethyl disilazide in tetrahydrofuran (46.9 ml) was addedwith stirring at room temperature. The reaction mixture was warmed to80° C. and then stirred for 16 hours. After consumption of the compound(20-9), the mixture was cooled to 0° C. and diethyl ether and a 1Mhydrochloric acid aqueous solution were added. After stirring at 0° C.for 10 minutes, the mixture was neutralized by the addition of asaturated aqueous solution of sodium carbonate. The mixture wasextracted with ethyl acetate, the organic layer was washed with brine,and dried over anhydrous magnesium sulfate. The solvent was evaporatedunder reduced pressure and the residue was subjected to silica gelchromatography to afford the compound (20-10) (6.84 g).

¹H-NMR(CDCl₃): 1.51 (9H, s,), 1.69 (3H, s), 2.01-2.12 (1H, m),2.40-2.51(1H, m), 2.67-2.76 (2H, m), 6.55-6.67 (3H, m), 7.15 (1H, t,J=8.1)

Reference Example The Synthesis of Compound 241

Indazole-3-carboxylic acid (71 mg) and the compound (19-10) (100 mg)were dissolved into methanol (5 ml), and4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylnmorpholinium chloride(173 mg) was added to the mixture with stirring at room temperature. Themixture was stirred for 5 hours. The reaction was quenched by theaddition of brine, and the reaction mixture was extracted with ethylacetate, dried over anhydrous magnesium sulfate and then concentrated.The crude product was purified by silica gel chromatography (NH₂-silicagel, 2-8% MeOH/CHCl₃) to afford the compound (241) (66 mg).

¹H-NMR (DMSO-d6) δ: 1.49 (3H, s), 1.78-1.86 (1H, m), 2.13-2.21 (1H, m),2.59-2.67 (1H, m), 2.96-3.02 (1H, m), 7.11 (1H, t, J=10.7 Hz), 7.29 (1H,t, J=7.8 Hz), 7.45 (1H, t, J=7.5 Hz), 7.66 (1H, d, J=8.8 Hz), 7.74-7.78(1H, m), 7.80-7.83 (1H, m), 8.21 (1H, d, J=8.6 Hz), 10.25 (1H, s).

Reference Example 22 The Synthesis of Compound 702

1-methylpyrazole-5-carboxylic acid (80 mg) and the compound (19-10) (145mg) were dissolved into methanol (3 ml), and4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride (251mg) was added to the mixture with stirring at room temperature, and themixture was stirred for 5 hours. The reaction was quenched by additionof brine, and the mixture was extracted with ethyl acetate, dried overanhydrous magnesium sulfate and concentrated. The crude product waspurified by silica gel chromatography (NH₂-silica gel, 0-4% MeOH/CHCl₃)to afford the compound (702) (146 mg).

¹H-NMR (CDCl₃) δ: 1.65 (3H, s), 1.91-1.98 (1H, m), 2.57-2.62 (1H, m),2.68-2.75 (1H, m), 2.92-2.97 (1H, m), 4.18 (3H, s), 6.82 (1H, br s),7.02-7.08 (1H, m), 7.28-7.32 (1H, m), 7.44 (1H, s), 7.92-7.96 (1H, m).

Reference Example 23 The Synthesis of the Compound 737

3-chloro-1-methylpyrazole-5-carboxylic acid (102 mg) and the compound(19-10) (145 mg) were dissolved into methanol (3 ml), and4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride (251mg) was added to the mixture with stirring at room temperature, and themixture was stirred for 5 hours. The reaction was quenched by additionof brine, and the mixture was extracted with ethyl acetate, dried overanhydrous magnesium sulfate and concentrated to afford crude product.The crude product was purified by silica gel chromatography (NH₂-silicagel, 33-78% AcOEt/Hexane) to afford the compound (737) (51 mg).

¹H-NMR (CDCl₃) δ: 1.59 (3H, s), 1.87-1.94 (1H, m), 2.47-2.53 (1H, m),2.67-2.73 (1H, m), 2.93-2.99 (1H, m), 4.10 (3H, s), 6.62 (1H, s), 7.04(1H, t, J=10.2 Hz), 7.33 (1H, d, J=4.3 Hz), 7.85 (1H, s).

Reference Example 24 The Synthesis of the Compound 949

5-fluoro-2-pyridine carboxylic acid (70.7 mg) was dissolved intomethanol (2 ml), and4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride(180.1 mg) was added to the mixture with stirring at room temperature.The mixture was stirred for 5 minutes and a solution of the compound(19-10) (119.9 mg) in methanol (2 ml) was added to the reaction solutionwith stirring under cooling with ice-water bath. After stirred for 3hours, a 0.5M aqueous solution of sodium hydroxide was added to themixture with stirring under cooling with ice-water bath, and the mixturewas extracted with ethyl acetate. The organic layer was washed withbrine, and dried over anhydrous magnesium sulfate. The solvent wasevaporated under reduced pressure and the obtained residue was subjectedto silica gel chromatography to afford the compound (949) (149.4 mg).

¹H-NMR (CDCl₃) δ: 1.63 (3H, s), 1.82-2.00 (1H, m), 2.43-2.58 (1H, m),2.72-2.82 (1H, m), 2.95-3.02 (1H, m), 7.06 (1H, dd, J=11,7, 9.0 Hz),7.43-7.48 (1H, m), 7.97-8.03 (1H, m), 8.15-8.18 (1H, m), 8.42 (1H, d,J=8.1 Hz),8.72 (1H, s), 9.91 (1H, br s)

Reference Example 25 The Synthesis of the Compound 943

5-trifluoromethyl-2-pyridine carboxylic acid (95.7 mg) was dissolvedinto methanol (2 ml), and4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride(180.1 mg) was added to the solution with stirring at room temperature.After stirring for 5 minutes, a solution of the compound (19-10) (119.9mg) in methanol (2 ml) was added to the reaction mixture with stirringunder cooling with ice-water bath. After stirring for 3 hours, a 0.5Naqueous solution of sodium hydroxide was added with stirring undercooling with ice-water bath, and the mixture was extracted with ethylacetate. The organic layer was washed with brine, and dried overanhydrous magnesium sulfate. The solvent was evaporated under reducedpressure, and the obtained residue was subjected to silica gelchromatography to afford the compound (943) (174.5 mg).

¹H-NMR (CDCl₃) δ: 1.63 (3H, s), 1.82-2.00 (1H, m), 2.36-2.52 (1H, m),2.72-2.82 (1H, m), 2.95-3.02 (1H, m), 7.07 (1H, dd, J=11.7, 8.1 Hz),7.39-7.42 (1H, m), 7.55-7.63 (1H, m), 7.96-8.02 (1H,), 8.33 (1H, dd,J=4.8, 9.0 Hz),8.45 (1H, d, J=2.4 Hz), 9.78 (1H, s).

Reference Example 26 The Synthesis of the Compound 578

Step 1

To a stirred solution of 2,5-dimethylfuran carboxylic acid (115 mg) andthe compound (20-10) (290 mg) in methanol (2 ml) was added4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride (273mg) at room temperature. After stirring for 2 hours, the reaction wasquenched by addition of a saturated aqueous solution of sodiumhydrogencarbonate, and the mixture was extracted with ethyl acetate. Themixture was washed with water and brine successively, dried andconcentrated to afford crude product (300 mg). The crude product waspurified by silica gel chromatography (silica gel, 50-66% AcOEt/hexane)to afford the compound (26-1) (221 mg).

¹H-NMR (CDCl₃) δ: 7.64-7.60 (1.0H, m), 7.43-7.41 (2.0H, m), 7.35 (1.0H,t, J=7.93 Hz), 7.04-7.02 (1.0H, m), 6.17 (1.0H, s), 2.80-2.61 (2.0H, m),2.59(3.0H, s), 2.56-2.52 (1.0H, m), 2.30 (3.0H, s), 2.19-2.06 (1.0H, m),1.71 (3.0H, s), 1.52 (9.0H, s).

Step 2

The compound (26-1) (221 mg) was dissolved into dichloroethane (1 ml)and trifluoroacetic acid (1 ml) was added to the solution with stirringat room temperature. After stirring for 1 hour 10 minutes, the solventwas evaporated. Ethyl acetate and an aqueous solution of sodiumcarbonate were added to the residue and the mixture was stirred for 1hour. The mixture was extracted with ethyl acetate and washed with anaqueous solution of sodium carbonate, water and brine successively. Theorganic layer was dried, and concentrated to afford crude product (154mg). The crude product was purified by recrystallization (hexane/AcOEt)to afford the compound (578) (24 mg).

(1H-NMR (CDCl₃) δ: 7.79 (1.0H, br s), 7.65-7.64 (1.0H, m), 7.48-7.41(1.0H, m), 7.31 (1.0H, t, J=8.01 Hz), 7.04-7.01 (1.0H, m), 6.23 (1.0H,br s), 2.93-2.65 (2.0H, m), 2.57 (3.0H, br s), 2.40 (1.0H, ddd, J=14.11,5.34, 3.43 Hz), 2.27 (3.0H, br s), 2.09-1.92 (1.0H, m), 1.67 (3.01H, s).

Reference Example 27 The Synthesis of the Compound 472

The compound (27-1) (256 mg) and 3-amino-5-chloropicolinic acidhydrochloride (266 mg) were suspended in methanol (2.6 ml), andN-methylmorpholine (153 μl) was added to the suspension, and the mixturewas stirred at room temperature. After stirred for 6 minutes,4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride (385mg) was added to the mixture, and stirred for 1 hour 10 minutes, andleft to stand for 13 hours 20 minutes additionally. The solvent wasevaporated, and ethyl acetate, methanol and an aqueous solution ofsodium carbonate were added to the residue and stirred for 40 minutes.The aqueous layer was removed, the organic layer was washed with asaturated aqueous solution of sodium hydrogencarbonate and brine, anddried over magnesium sulfate. The magnesium sulfate was removed byfiltration, the filtrate was concentrated under reduced pressure, andthe obtained residue was purified by silica gel chromatography (YamazenHI-FLASH column NH2-40W-M, ethyl acetate:hexane=1:1). The obtainedfraction was concentrated and the residue was crystallized from ethylacetate. The crystals were collected by filtration, washed with diethylether and dried to afford the compound (472) (82.0 mg).

¹H-NMR (DMSO-d₆) δ: 1.41 (3H, s), 1.72 (1H, ddd, J=13.7, 10.2, 3.6 Hz),2.02 (1H, m), 2.58 (1H, m), 2.90 (1H, ddd, J=11.9, 6,6, 3.6 Hz), 5.77(2H, brs), 7.09 (1H, dt, J=7.9, 1.3 Hz), 7.13 (2H, brs), 7.27 (1H, t,J=8.0 Hz), 7.33 (1H, d, J=2.2 Hz), 7.68-7.72 (2H, m), 7.85 (1H, d, J=2.0Hz), 10.23 (1H, s).

The other compounds were synthesized in the same way. The structuralformulas and physical constants are shown below.

TABLE 1 No. Structure 1

2

3

4

5

6

7

8

9

TABLE 2 No. Structure 10

11

12

13

14

15

16

17

18

TABLE 3 No. Structure 19

20

21

22

23

24

25

26

27

28

TABLE 4 No. Structure 29

30

31

32

33

34

35

36

37

38

39

TABLE 5 No. Structure 40

41

42

43

44

45

46

47

TABLE 6 No. Structure 48

49

50

51

52

53

54

55

TABLE 7 No. Structure 56

57

58

59

60

61

62

63

64

65

TABLE 8 No. Structure 66

67

68

69

70

71

72

73

74

TABLE 9 No. Structure 75

76

77

78

79

80

81

82

TABLE 10 No. Structure 83

84

85

86

87

88

89

90

91

TABLE 11 No. Structure 92

93

94

95

96

97

98

99

100

101

TABLE 12 No. Structure 102

103

104

105

106

107

108

109

TABLE 13 No. Structure 110

111

112

113

114

115

116

117

118

119

TABLE 14 No. Structure 120

121

122

123

124

125

126

127

128

129

TABLE 15 No. Structure 130

131

132

133

134

135

136

137

138

139

TABLE 16 No. Structure 140

141

142

143

144

145

146

147

TABLE 17 No. Structure 148

149

150

151

152

153

154

155

156

157

TABLE 18 No. Structure 158

159

160

161

162

163

TABLE 19 No. Structure 164

165

166

167

168

169

170

171

172

173

174

TABLE 20 No. Structure 175

176

177

178

179

180

181

182

183

184

185

TABLE 21 No. Structure 186

187

188

189

190

191

192

193

194

TABLE 22 No. Structure 195

196

197

198

199

200

201

202

203

204

TABLE 23 No. Structure 205

206

207

208

209

210

211

212

TABLE 24 No. Structure 213

214

215

216

217

218

219

220

221

222

TABLE 25 No. Structure 223

224

225

226

227

228

229

230

231

232

TABLE 26 No. Structure 233

234

235

236

237

238

239

240

241

242

243

TABLE 27 No. Structure 244

245

246

247

248

249

250

251

252

253

TABLE 28 No. Structure 254

255

256

257

258

259

260

261

262

263

264

TABLE 29 No. Structure 265

266

267

268

269

270

271

272

273

TABLE 30 No. Structure 274

275

276

277

278

279

280

281

TABLE 31 No. Structure 282

283

284

285

286

287

288

289

290

291

TABLE 32 No. Structure 292

293

294

295

296

297

298

299

TABLE 33 No. Structure 300

301

302

303

304

305

306

307

308

309

TABLE 34 No. Structure 310

311

312

313

314

315

316

317

TABLE 35 No. Structure 318

319

320

321

322

323

324

325

326

327

328

TABLE 36 No. Structure 329

330

331

332

333

334

335

336

337

338

339

TABLE 37 No. Structure 340

341

342

343

344

345

346

347

348

TABLE 38 No. Structure 349

350

351

352

353

354

355

356

357

TABLE 39 No. Structure 358

359

360

361

362

363

364

365

366

367

368

369

TABLE 40 No. Structure 370

371

372

373

374

375

376

377

378

TABLE 41 No. Structure 379

380

381

382

383

384

385

386

387

388

389

TABLE 42 No. Structure 390

391

392

393

394

395

396

397

TABLE 43 No. Structure 398

399

400

401

402

403

404

405

406

407

TABLE 44 No. Structure 408

409

410

411

412

413

414

415

416

TABLE 45 No. Structure 417

418

419

420

421

422

423

424

TABLE 46 No. Structure 425

426

427

428

429

430

431

432

433

TABLE 47 No. Structure 434

435

436

437

438

439

440

441 (race mate)

442

TABLE 48 No. Structure 443

444

445

446

447

448

449

450

451

452

453

TABLE 49 No. Structure 454

455

456

457

458

459

460

461

462

463

464

TABLE 50 No. Structure 465

466

467

468

469

470

471

472

473

474

TABLE 51 No. Structure 475

476

477

478

479

480

481

482

483

TABLE 52 No. Structure 484

485

486

487

488

489

490

491

492

TABLE 53 No. Structure 493

494

495

496

497

498

499

500

501

502

503

TABLE 54 No. Structure 504

505

506

507

508

509

510

511

512

513

514

TABLE 55 No. Structure 515

516

517

518

519

520

521

522

523

524

TABLE 56 No. Structure 525

526

527

528

529

530

531

532

533

534

535

TABLE 57 No. Structure 536

537

538

539

540

541

542

543

544

545

546

TABLE 58 No. Structure 547

548

549

550

551

552

553

554

555

TABLE 59 No. Structure 556

557

558

559

560

561

562

563

564

565

566

TABLE 60 No. Structure 567

568

569

570

571

572

573

574

TABLE 61 No. Structure 575

576

577

578

579

580

581

582

583

584

TABLE 62 No. Structure 585

586

587

588

589

590

591

TABLE 63 No. Structure 592

593

594

595

596

597

598

599

600

601

602

TABLE 64 No. Structure 603

604

605

606

607

608

609

610

611

612

613

TABLE 65 No. Structure 614

615

616

617

618

619

620

621

622

623

624

TABLE 66 No. Structure 625

626

627

628

629

630

631

632

633

634

635

TABLE 67 No. Structure 636

637

638

639

640

641

642

643

TABLE 68 No. Structure 644

645

646

647

648

649

650

651

652

653

654

655

656

TABLE 69 No. Structure 657

658

659

660

661

662

663

664

665

TABLE 70 No. Structure 666

667

668

669

670

671

672

673

674

TABLE 71 No. Structure 675

676

677

678

679

680

681

682

683

TABLE 72 No. Structure 684

685

686

687

688

689

690

691

692

TABLE 73 No. Structure 693

694

695

696

697

698

699

700

701

702

TABLE 74 No. Structure 703

704

705

706

707

708

709

710

711

712

TABLE 75 No. Structure 713

714

715

716

717

718

719

TABLE 76 No. Structure 720

721

722

723

724

725

726

727

728

729

TABLE 77 No. Structure 730

731

732

733

734

735

736

737

738

739

TABLE 78 No. Structure 740

741

742

743

744

745

746

747

748

749

TABLE 79 No. Structure 750

751

752

753

754

755

756

757

758

759

TABLE 80 No. Structure 760

761

762

763

764

765

766

767

768

769

TABLE 81 No. Structure 770

771

772

773

774

775

776

777

TABLE 82 No. Structure 778

779

780

781

782

783

784

785

786

787

788

789

TABLE 83 No. Structure 790

791

792

793

794

795

796

797

798

TABLE 84 No. Structure 799

800

801

802

803

804

805

806

807

808

809

TABLE 85 No. Structure 810

811

812

813

814

815

816

817

818

TABLE 86 No. Structure 819

820

821

822

823

824

825

826

827

TABLE 87 No. Structure 828

829

830

831

832

833

834

835 (race mate)

836

TABLE 88 No. Structure 837

838

839

840

841

842

843

844

845

TABLE 89 No. Structure 846

847

848

849

850

851

852

853

854

855

TABLE 90 No. Structure 856

857

858

859

860

861

862

863

864

TABLE 91 No. Structure 865

866

867

868

869

870

871

872

873

874

TABLE 92 No. Structure 875

876

877

878

879

880

881

882

TABLE 93 No. Structure 883

884

885

886

887

888

889

890

891

TABLE 94 No. Structure 892

893

894

895

896

897

898

899

900

901

TABLE 95 No. Structure 902

903

904

905

906

907

908

909

910

911

912

TABLE 96 No. Structure 913

914

915

916

917

918

919

920

TABLE 97 No. Structure 921

922

923

924

925

926

927

928

929

930

TABLE 98 No. Structure 931

932

933

934

935

936

937

938

TABLE 99 No. Structure 939

940

941

942

943

944

945

946

947

TABLE 100 No. Structure 948

949

950

951

952

953

954

955

TABLE 101 No. Structure 956

957

958

959

960

961

962

963

TABLE 102 No. Structure 964

965

966

967

968

969

970

TABLE 103 No. Structure 971

972

973

974

975

976

977

TABLE 104 No. Structure 978

979

980

981

982

983

984

985

986

TABLE 105 No. Structure 987

988

989

990

991

992

993

994

995

TABLE 106 No. Structure 996

997

998

999

1000

1001

1002

1003

1004

TABLE 107 No. Structure 1005

1006

1007

1008

1009

1010

1011

1012

1013

TABLE 108 No. Structure 1014

1015

1016

1017

1018

1019

1020

1021

TABLE 109 No. Structure 1022

1023

1024

1025

1026

1027

1028

1029

1030

TABLE 110 No. Structure 1031

1032

1033

1034

1035

1036

1037

1038

1039

TABLE 111 No. Structure 1040

1041

1042

1043

1044

1045

1046

1047

1048

TABLE 112 No. Structure 1049

1050

1051

1052

1053

1054

1055

1056

1057

TABLE 113 No. Structure 1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

TABLE 114 No. Structure 1068

1069

1070

1071

1072

1073

1074

1075

TABLE 115 No. Structure 1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

TABLE 116 No. Structure 1086

1087

1088

1089

1090

1091

1092

1093

1094

TABLE 117 No. Structure 1095

1096

1097

1098

1099

1100

1101

1102

TABLE 118 No. Structure 1103

1104

1105

1106

1107

1108

1109

1110

1111

TABLE 119 No. Structure 1112

1113

1114

1115

1116

1117

1118

TABLE 120 No. Structure 1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

TABLE 121 No. Structure 1129

1130

1131

1132

1133

1134

1135

1136

TABLE 122 No. Structure 1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

TABLE 123 No. Structure 1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

TABLE 124 No. Structure 1157

1158

1159

1160

1161

1162

1163

1164

TABLE 125 No. Structure 1165

1166

1167

1168

1169

1170

1171

1172

1173

TABLE 126 No. Structure 1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

TABLE 127 No. Structure 1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

TABLE 128 No. Structure 1195

1196

1197

1198

1199

1200

1201

1202

1203

TABLE 129 No. Structure 1204

1205

1206

1207

1208

1209

1210

1211

1212

TABLE 130 No. Structure 1213

1214

1215

1216

1217

1218

1219

1220

1221

TABLE 131 No. Structure 1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

TABLE 132 No. Structure 1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

TABLE 133 No. Structure 1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

TABLE 134 No. Structure 1253

1254

1255

1256

1257

1258

1259

1260

1261

TABLE 135 No. Structure 1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

TABLE 136 No. Structure 1274

1275

1276

1277

1278

1279

1280

1281

1282

TABLE 137 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 1 213.4 305.33 285 (dec.) 4 amorphous 219 5 215, 262 6 147-148 8 214-217 9 oil 220 18181-183 23 213.4 272.2 305.3 24 116-117 26 182-184 30 267.4 33 253.3305.3 37 amorphous 219, 275 38 240-244 (dec.) 39 285.2 42 187-188 43218.1 275.7 48 230 275 57 197-198 58 234-240 62 198-201 69 194-195 71216.9 268.6 73 266-269 77 δ in d20-DMSO: 1.67 (3H, s), 2.13-2.06 (1H,m), 422.543 2.63-2.55 (2H, m), 3.16-3.13 (4H, m), 3.65-3.63 (2H, m),4.76-4.73 (2H, m), 7.15-7.08 (2H, m), 7.30 (1H, t, J = 8.0 Hz), 7.35(1H, s), 7.42 (1H, t, J = 8.0 Hz), 7.60 (1H, d, J = 8.0 Hz), 7.69 (1H,d, J = 8.0 Hz), 7.73 (1H, brs), 7.86 (1H, d, J = 8.0 Hz), 10.52 (1H, s)78 ¹H-NMR (CDCl₃) δ: 1.76 (3H, s), 2.02 (1H, s), 2.58 365[M + 1] (1H, d,J = 14.1 Hz), 2.78 (2H, d, J = 6.9 Hz), 3.80 (3H, d, J = 13.1 Hz), 4.54(2H, s), 6.45 (1H, s), 6.55- 6.57 (2H, m), 6.66 (1H, d, J = 8.7 Hz),7.10 (1H, t, J = 7.0 Hz), 7.22 (2H, td, J = 7.7, 1.4 Hz), 7.34 (1H, d, J= 9.1 Hz), 7.56 (1H, d, J = 7.7 Hz). 80 220.4 280.4

TABLE 138 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 85 147-1481.54(3H, s), 1.75-1.86(1H, m), 2.08-2.18(1H, m), 2.33(3H, s),2.63-2.74(1H, m), 2.81-2.90(1H, m), 4.36(2H, br), 7.13(2H, d, J = 8.6Hz), 7.20(2H, d, J = 8.6 Hz)(solvent: CDCl3) 86 141-142 91 372[M + 1]201 298 206 216 96 309 97 δ in d13-DMSO: 1.64(3H, s), 2.03-1.97(1H, m),2.63-2.57(2H, m), 3.28-3.25(1H, m), 7.22(1H, q, J = 12.4, 9.0 Hz),7.82-7.77(2H, m), 8.60(1H, s), 8.79(1H, s), 10.37(1H, s) 99 221-224 101264-265 104 amorphous 229, 280 113 1.58 (s, 3H), 1.88 (ddd, J = 14.1,10.9, 3.7 Hz, 1H), 2.24 (ddd, J = 14.1, 5.9, 3.5 Hz, 1H), 2.73 (ddd, J =12.3, 10.9, 3.5 Hz, 1H), 2.88 (ddd, J = 12.3, 5.9, 3.7 Hz, 1H), 3.83 (d,J = 15.4 Hz, 1H), 3.87 (d, J = 15.4 Hz, 1H), 7.02-7.04 (m, 1H),7.25-7.31 (m, 2H), 7.36 (d, J = 2.0 Hz, 1H), 7.45-7.50 (m, 2H), 8.52 (d,J = 5.2 Hz, 1H), 9.43 (s, 1H) (solvent: CDCl3) 114 214.5 306.5 115 δ ind6-DMSO: 1.47(3H, s), 1.80-1.74(1H, m, 2.22- 2.18(1H, m), 2.60-2.55(1H,m), 2.96-2.93(1H, m), 6.14(1H, s), 6.93(1H, s), 7.09-7.04(2H, m), 7.63-7.61(1H, m), 7.68-7.66(1H, m), 9.85(1H, s), 11.63(1H, brs) 120 amorphous213 121 166-167 125 >300 126 amorphous 229, 271 127 280-285 128 159-163129 219-222 130 128-131 1.56 (3H, s), 1.83-1.93 (1H, m), 2.16 (1H, dq, J= 344[M + 1] 13.85, 3.41 Hz), 2.29 (3H, s), 2.72-2.77 (1H, m), 2.90-2.94(1H, m), 4.13 (3H, s), 6.42 (1H, s), 7.10- 7.14 (1H, m), 7.32 (1H, d, J= 7.91 Hz), 7.37-7.38 (1H, m), 7.60-7.63 (1H, m), (solvent: CDCl3) 132147-150 134 228.5

TABLE 139 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 139 287-2901.77 (s, 3H), 2.10 (ddd, J = 14.0, 10.8, 3.6 Hz, 1H), 2.64-2.70 (4H, m),2.76 (td, J = 12.8, 3.6 Hz, 1H), 2.90 (dt, J = 12.8, 3.6 Hz, 1H), 7.05(ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.41 (t, J = 8.0 Hz, 1H), 7.69-7.72 (m,2H), 8.32 (dd, J = 8.0, 0.8 Hz, 1H), 8.40 (dd, J = 8.0, 2.0 Hz, 1H),9.14 (dd, J = 2.0, 0.8 Hz, 1H) (solvent: CDCl3 + CD3OD) 141 δ ind17-DMSO: 1.41(3H, s), 1.75-1.70(1H, m), 2.03-1.99(1H, m), 2.62-2.56(1H,m), 2.94-2.89(1H, m), 3.89(3H, s), 6.88(1H, d, J = 8.8 Hz), 7.05(1H, d,J = 7.6 Hz), 7.24(1H, t, J = 8.0 Hz), 7.66-7.63(3H, m), 8.45-8.44(1H,m), 9.90(1H, s) 148 362[M + 1] 200 286 208 212 218 262 149 143-145 157 δin d6-DMSO: 1.20(6H, d, J = 6.6 Hz), 1.41(3H, s), 1.65-1.77(1H, m),1.96-2.07(1H, m), 2.55-2.63(1H, m), 2.85-2.95(1H, m), 4.04-4.16(1H, m),5.79(2H, bs), 7.07(1H, d, J = 8.1 Hz), 7.25(1H, t, J = 8.1 Hz),7.72-7.78(3H, m), 7.93(1H, s), 8.64(1H, s), 9.96(1H, s). 159 amorphous285 161 247-251 163 amorphous 164 91-96 1.68(s, 3H), 2.07-2.15(m, 1H),3.13-3.20(m, 1H), 7.12(d, J = 7.6 Hz, 1H), 7.46(t, J = 7.6 Hz, 1H),7.90-7.94(m, 2H), 8.83(br s, 1H), 8.96(br s, 1H), 9.31(br s, 1H),10.36(s, 1H), 10.86(s, 1H) 165 246-248 166 amorphous 220, 275 176amorphous 217, 278 178 224-225 181 261.5 189 259 193 266-268 196 212 202117-118 0.85(3H, t, J = 7.3 Hz), 1.02-1.19(1H, m), 1.34- 1.54(1H, m),1.72-1.89(3H, m), 2.04-2.15(1H, m), 2.61-2.82(2H, m), 3.80(3H, s),4.32(2H, br), 6.85(2H, d, J = 8.9 Hz), 7.18(2H, d, J = 8.9 Hz) (solvent:CDCl3)

TABLE 140 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 204 205-2081.64 (d, J = 1.2 Hz, 3H), 1.95 (ddd, J = 14.0, 10.8, 3.6 Hz, 1H), 2.45(ddd, J = 14.0, 6.4, 3.6 Hz, 1H), 2.75 (ddd, J = 12.4, 10.8, 3.6 Hz,1H), 2.99 (ddd, J = 12.4, 6.4, 3.6 Hz, 1H), 7.09 (dd, J = 11.6, 8.8 Hz,1H), 7.47 (dd, J = 7.2, 2.8 Hz, 1H), 8.03 (ddd, J = 8.8, 4.4, 2.8 Hz,1H), 8.89 (s, 2H), 9.75 (s, 1H) (solvent: CDCl3) 213 oil 216, 272 214212.2 292.3 356.5 216 242.7 220 191-193 363[M + 3] 361[M + 1] 287 2851.58(3H, s), 1.87(1H, ddd, J = 13.9, 10.5, 3.7), 222 2.13(1H, ddd, J =13.9, 6.3, 3.7), 2.25(3H, s), 224 oil 2.68(1H, ddd, J = 12.1, 10.5,6.2), 2.89(1H, ddd, J = 12.1, 6.3, 3.7), 5.23(2H, s), 7.28-7.48(4H, m),7.60(1H, s), 7.75(1H, d, J = 8.0), 8.56(1H, dd, J = 5.0, 1.4), 8.70(1H,d, J = 1.4) (solvent: CDCl3) 227 213 232 1H-NMR (CDCl3) δ: 1.59 (3H, s),1.83-1.90 (1H, 378[M + 1] m), 2.35-2.47 (4H, m), 2.60-2.67 (1H, m),2.87-2.92 (1H, m), 4.70 (2H, br s), 6.87-6.98 (2H, m), 7.16 (1H, d, J =6.6 Hz), 7.27 (2H, d, J = 7.8 Hz), 7.61 (2H, d, J = 8.1 Hz). 233 oil224, 272 235 196-200 238 ¹H-NMR (CDCl₃) δ: 1.68 (3H, s), 1.97-2.00 (1H,362[M + 1] m), 2.53 (1H, dt, J = 14.4, 3.7 Hz), 2.63-2.79 (2H, m), 4.52(2H, s), 6.56-6.66 (3H, m), 7.17 (1H, t, J = 8.0 Hz), 7.43-7.52 (3H, m),7.81 (4H, dd, J = 11.6, 5.7 Hz). 241 187-190 1H-NMR (DMSO-d6) δ: 1.49(3H, s), 1.78-1.86 (1H, m), 2.13-2.21 (1H, m), 2.59-2.67 (1H, m), 2.96-3.02 (1H, m), 7.11 (1H, t, J = 10.7 Hz), 7.29 (1H, t, J = 7.8 Hz), 7.45(1H, t, J = 7.5 Hz), 7.66 (1H, d, J = 8.8 Hz), 7.74-7.78 (1H, m),7.80-7.83 (1H, m), 8.21 (1H, d, J = 8.6 Hz), 10.25 (1H, s). 243 182-1841.46(s, 3H), 1.75-1.83(m, 1H), 2.08-2.16(m, 1H), 2.55-2.63(m, 1H),2.92-2.98(m, 1H), 4.02(s, 3H), 7.11(d, J = 8.0 Hz, 1H), 7.31(t, J = 8.0Hz, 1H), 7.77(d, J = 8.0 Hz, 1H), 7.82(br s, 1H), 8.41(d, J = 1.2 Hz,1H), 8.90(d, J = 1.2 Hz, 1H), 10.38(s, 1H) (solvent: CDCl3)

TABLE 141 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 244 222-224251 351[M + 1] 200 311 204 275 215 285 255 238-239 256 oil 215, 257 259amorphous 1.58(3H, s), 2.01(1H, ddd, J = 15.2, 12.2, 3.4), 2.46- 2292.56(2H, m), 3.07(1H, ddd, J = 13.3, 5.7, 3.5), 298 4.24(2H, s) 6.53(1H,d, J = 7.6), 6.59-6.61(2H, m), 7.09-7.12(1H, m), 7.11(2H, d, J = 7.6),7.24(2H, d, J = 7.6), 8.82(2H, br) (solvent: DMSO-d6) 263 383[M + 1] 200287 284 267 114-115 268 214.5 298.2 271 oil 229, 276 275 (CDCl3)1.66(3H, d, J = 1.2 Hz), 1.98(1H, ddd, J = 14.0, 10.4, 3.7 Hz), 2.47(1H,ddd, J = 14.0, 6.7, 3.5 Hz), 2.79(1H, ddd, J = 12.0, 10.4, 3.5 Hz),3.02(1H, ddd, J = 12.0, 6.7, 3.7 Hz), 4.45(2H, br), 6.16(2H, br),7.04-7.11(2H, m), 7.38(1H, dd, J = 7.2, 2.9 Hz), 7.88(1H, d, J = 2.0Hz), 7.96(1H, ddd, J = 8.9, 4.2, 2.9 Hz), 9.88(1H, s) 277 216 228 281279 214.5 292.3 281 amorphous 1.55(3H, s), 1.83(1H, ddd, J = 13.9, 10.6,3.9), 233 2.10(1H, ddd, J = 13.9, 6.5, 3.6), 2.67(1H, ddd, J = 301 12.2,10.6, 3.6), 2.87(1H, ddd, J = 12.2, 6.5, 3.9), 4.49(2H, d, J = 5.6),4.85(1H, br), 6.38(1H, dt, J = 8.5, 0.9), 6.59(1H, ddd, J = 7.2, 5.2,0.9), 7.21- 7.24(2H, m), 7.28-7.32(2H, m), 7.40(1H, ddd, J = 8.5, 7.2,1.8), 8.11(1H, ddd, J = 5.2, 1.8, 0.8) (solvent: CDCl3) 282 146-147 284181.5 293 1.57 (s, 3H), 1.78-1.89 (m, 1H), 2.10-2.19 (m, 1H), 2.69 (ddd,J = 11.9, 10.8, 3.5 Hz, 1H), 2.83-2.91 (m, 1H), 7.15-7.35 (m, 5H)(solvent: CDCl3) 299 293.5

TABLE 142 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 301 (CDCl3)1.53(3H, s), 1.80(1H, ddd, J = 14.0, 10.4, 3.6 Hz), 2.12(1H, ddd, J =14.0, 6.0, 3.6 Hz), 2.75(1H, ddd, J = 12.0, 10.4, 3.6 Hz), 2.85(1H, ddd,J = 12.0, 6.0, 3.6 Hz), 3.64(2H, s), 4.32(2H, br), 6.55(1H, ddd, J =8.0, 2.0, 0.8 Hz), 6.66(1H, t, J = 2.0 Hz), 6.70(1H, ddd, J = 8.0, 2.0,0.8 Hz), 7.11(1H, t, J = 8.0 Hz) 302 122-126 1.41(s, 3H), 1.67-1.76(m,1H), 1.98-2.06(m, 1H), 2.55-2.63(m, 1H), 2.86-2.94(m, 1H), 3.19(s, 6H),5.75(s, 2H), 7.08(d, J = 8.0 Hz, 1H), 7.26(t, J = 8.0 Hz, 1H), 7.73(d, J= 8.0 Hz, 1H), 7.76(br s, 1H), 8.16(s, 1H), 8.73(s, 1H), 10.00(s, 1H)(solvent: CDCl3) 306 231, 258, 289 307 1.83 (ddd, J = 13.9, 10.3, 3.6Hz, 1H), 2.13 (ddd, J = 13.6, 6.2, 3.5 Hz, 1H), 2.53 (s, 3H), 2.66-2.75(m, 1H), 2.90 (ddd, J = 12.2, 6.3, 3.8 Hz, 1H), 7.09 (d, J = 7.8 Hz,1H), 7.32 (t, J = 8.0 Hz, 1H), 7.37 (s, 1H), 7.63 (d, J = 7.8 Hz, 1H),8.79 (s, 1H) (solvent: CDCl3) 308 167-188 309 241-244 319 308.9 329238-239 330 213.4 263.9 332 212.2 333 154-158 339 217-218 341 amorphous216 249 342 184-187 344 (DMSO) 1.49(3H, s), 1.73-1.85(1H, m), 2.15-2.28(1H, m), 2.54-2.66(1H, m), 2.92-3.04(1H, m), 5.86(2H, s),7.03-7.25(3H, m), 7.40-7.48(2H, m), 7.64-7.78(3H, m), 10.31(1H, s),11.74(1H, s) 353 279.3 364.5 354 102-103 356 amorphous 1.73 (s, 3H),2.09-2.17 (m, 1H), 2.40(s, 3H), 2.65- 267 2.73 (m, 2H), 3.15-3.23 (m,1H), 3.81(s, 3H), 7.07 (d, J = 7.2 Hz, 2H), 7.29 (br s, 1H), 7.36 (d, J= 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 7.78 (br s, 1H), 7.90 (d, J =7.2 Hz, 2H), 8.00 (br s, 1H), 10.32 (s, 1H) (solvent: DMSO-d6) 357amorphous 224, 298

TABLE 143 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 358 1.57 (3H,s), 1.80-1.91 (1H, m), 2.15-2.18 (1H, m), 360[M + 1] 2.70-2.94 (2H, m),3.94 (3H, s), 4.67 (2H, s), 6.75 (1H, s), 7.05-7.08 (1H, m), 7.31 (1H,t, J = 7.91 Hz), 7.53 (1H, t, J = 1.98 Hz), 7.64-7.67 (1H, m), 8.64 (1H,s). (solvent: CDCl3) 359 212-214 1.46(s, 3H), 1.73-1.83(m, 1H),2.13-2.20(m, 1H), 2.54-2.61(m, 1H), 2.62(s, 3H), 2.93-3.00(m, 1H),5.84(br s, 2H), 7.12(dd, J = 12.0, 8.8 Hz, 1H), 7.73- 7.78(m, 1H),7.81(dd, J = 7.2, 2.4 Hz, 1H), 8.68 (s, 1H), 9.13(s, 1H), 10.59(s,1H)(solvent: CDCl3) 360 amorphous 222 361 280.4 364 oil 344[M + 1] 227,271 367 (CDCl3) 1.78(3H, s), 2.07(1H, ddd, J = 14.0, 12.4, 3.6 Hz),2.61(1H, br d, J = 14.0 Hz), 2.84(1H, td, J = 12.4, 3.2 Hz), 2.94(1H,td, J = 12.4, 3.6 Hz), 4.08(3H, s), 7.07(1H, ddd, J = 8.0, 2.0, 0.8 Hz),7.40(1H, t, J = 8.0 Hz), 7.63(1H, ddd, J = 8.0, 2.0, 0.8 Hz), 7.74(1H,t, J = 2.0 Hz), 8.18(1H, d, J = 1.2 Hz), 9.02(1H, d, J = 1.2 Hz),9.56(1H, s) 375 217 380 181-182 0.86 (t, J = 7.2 Hz, 3H), 1.82-1.98 (m,3H), 2.24 (br, 1H), 2.74 (td, J = 12.0, 3.6 Hz, 1H), 2.84 (dt, J = 12.0,4.0 Hz, 1H), 7.08 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.37 (t, J = 8.0 Hz,1H), 7.58 (t, J = 2.0 Hz, 2H), 7.76 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H),7.88 (dd, J = 8.4, 2.4 Hz, 1H), 8.25 (dd, J = 8.4, 0.8 Hz, 1H), 8.57(dd, J = 2.4, 0.8 Hz, 1H), 9.84 (s, 1H) (solvent: CDCl3) 383 oil 225,269, 288 389 amorphous 292 393 213.4 316.0 395 amorphous 217, 269 396211-213 1.64 (s, 3H), 1.96 (ddd, J = 14.0, 10.4, 4.0 Hz, 1H), 2.44 (ddd,J = 14.0, 6.8, 3.6 Hz, 1H), 2.75 (ddd, J = 12.4, 10.4, 3.6 Hz, 1H),,2.99 (ddd, J = 12.4, 6.8, 4.0 Hz, 1H), 4.50 (2H, br), 7.08 (dd, J =11.6, 8.8 Hz, 1H), 7.45 (dd, J = 6.8, 2.8 Hz, 1H), 8.01 (ddd, J = 8.8,4.4, 2.8 Hz, 1H), 8.16 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 8.43 (d, J = 8.0Hz, 1H), 8.89 (dd, J = 2.0, 0.8 Hz, 1H), 9.91 (s, 1H) (solvent: CDCl3)401 106-107

TABLE 144 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 405 192-1941.41(s, 3H), 1.68-1.77(m, 1H), 1.96-2.05(m, 1H), 2.55-2.63(m, 1H),2.88-2.95(m, 1H), 4.15(s, 3H), 5.74(s, 2H), 7.13(d, J = 8.0 Hz, 1H),7.29(t, J = 8.0 Hz, 1H), 7.44(d, J = 8.8 Hz, 1H), 7.75(d, J = 8.0 Hz,1H), 7.86(br s, 1H), 8.20(d, J = 8.8 Hz, 1H), 10.73(s, 1H) (solvent:CDCl3) 406 276.9 408 221-224 1.74(3H, s), 2.28(2H, m), 2.67(2H, m),2.91(3H, s), 3.82(3H, s), 6.90(2H, d, J = 9.0), 7.19(2H, d, J = 9.0)(solvent: CDCl3) 409 oil 215 410 178-182 1.37(d, J = 6.0 Hz, 6H),1.42(s, 3H), 1.70-1.78(m, 1H), 2.00-2.08(m, 1H), 2.53-2.61(m, 1H), 2.88-2.95(m, 1H), 5.36(quintet, J = 6.0 Hz, 1H), 7.11(d, J = 8.0 Hz, 1H),7.29(t, J = 8.0 Hz, 1H), 7.75(d, J = 8.0 Hz, 1H), 7.80(br s, 1H),8.32(d, J = 1.2 Hz, 1H), 8.87(d, J = 1.2 Hz, 1H), 10.32(s, 1H) (solvent:CDCl3) 411 218, 264 413 251-254 415 amorphous 226, 290 417 137-139 422(CDCl3) 1.45(3H, s), 1.70-1.84(1H, m), 1.96- 2.04(1H, m), 2.88-2.96(1H,m), 3.04-3.14(1H, m), 6.86(1H, d, J = 15.9 Hz), 6.42(1H, d, J = 15.9Hz), 7.22- 7.41(5H, m) 426 211.0 312.4 427 216 429 oil 211 259 430(DMSO) 1.07(3H, s), 1.53-1.66(4H, m), 2.50- 2.70(2H, m), 2.92-3.10(2H,m), 5.48(1H, s), 7.11- 7.21(3H, m), 7.23-7.29(2H, m) 432 oil 216, 272436 254-256 441 181-165 443 ¹H-NMR (CDCl₃) δ: 1.55 (4H, s), 1.74-1.80(1H, 362[M + 1] m), 2.13-2.17 (1H, m), 2.68-2.73 (2H, m), 4.33 (1H, brs), 4.48 (2H, d, J = 4.0 Hz), 4.76 (2H, t, J = 20.1 Hz), 6.52 (1H, dd, J= 7.9, 1.8 Hz), 6.63-6.65 (2H, m), 7.13 (1H, t, J = 7.8 Hz), 7.45-7.51(2H, m), 7.79-7.82 (4H, m).

TABLE 145 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 444 214-2151.41(s, 3H), 1.66-1.76(m, 1H), 1.97-2.05(m, 1H), 2.53-2.62(m, 1H),2.62(s, 3H), 2.86-2.93(m, 1H), 5.79(br s, 2H), 7.12(d, J = 8.0 Hz, 1H),7.28(t, J = 8.0 Hz, 1H), 7.74(d, J = 8.0 Hz, 1H), 7.81(br s, 1H),8.68(s, 1H), 9.14(s, 1H), 10.52(s, 1H) (solvent: CDCl3) 445 92-931.57(3H, s), 1.86(1H, ddd, J = 13.9, 10.4, 3.7), 219 2.13(1H, ddd, J =13.9, 6.5, 3.6), 2.25(3H, s), 252 446 oil 2.35(3H, s), 2.70(1H, ddd, J =12.2, 10.4, 3.6), 2.89(1H, ddd, J = 12.2, 6.5, 3.7), 4.35(2H, br),5.19(2H, s), 7.17(2H, d, J = 8.0), 7.31-7.34(4H, m), 7.50(1H, ddd, J =5.8, 3.0, 1.8), 7.55-7.60(1H, m) (solvent: CDCl3) 448 δ in d6-DMSO:1.41(3H, s), 1.67-1.75(1H, m), 1.98-2.05(1H, m), 2.52-2.61(1H, m),2.86-2.94(1H, m), 5.79(2H, bs), 7.14(1H, d, J = 7.8 Hz), 7.30(1H, t, J =7.8 Hz), 7.73(1H, bd, J = 7.8 Hz), 7.81(1H, t, J = 1.8 Hz), 8.94(1H, m),9.11(1H, m), 10.63(1H, bs). 452 132-134 456 147-149 457 153-155 465194.6 466 211 470 281 (dec.) 482 1.60 (s, 3H), 1.91 (ddd, J = 14.0,10.8, 4.0 Hz, 1H), 2.23 (ddd, J = 14.0, 6.4, 3.6 Hz, 1H), 2.77 (ddd, J =12.0, 10.8, 3.6 Hz, 1H), 2.93 (ddd, J = 12.0, 6.4, 4.0 Hz, 1H), 7.16(ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.61 (t, J =2.0 Hz, 1H), 7.75 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 8.14 (d, J = 1.6 Hz,1H), 8.80 (d, J = 1.6 Hz, 1H), 9.79 (s, 1H) (solvent: CDCl3) 483 224-227211, 289 490 1.64 (3H, s) 2.03-2.12 (1H, m) 2.49-2.62 (m) 3.12- 3.16 (1Hm) 7.22 (1H, dd, J = 4.2 Hz) 7.27 (1H, bs) 7.75 (1H bs) 7.87 (1H, dd, J= 4.2 Hz) 8.04 (1H, s) 8.12 (1H, dd, J = 4.2 Hz) 10.64 (1H, s) 10.72(1H, s) (solvent: DMSO-d6) 491 1.58 (s, 3H), 1.85-1.96 (m, 1H),2.15-2.24 (m, 1H), 2.50 (s, 3H), 2.67 (s, 3H), 2.71-2.81 (m, 1H), 2.90-2.98 (m, 1H), 7.13 (d, J = 6.2 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.40(s, 1H), 7.55 (d, J = 7.6 Hz, 1H) (solvent: CDCl3) 493 216

TABLE 146 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 494 δ ind6-DMSO: 1.37(3H, s), 1.62-1.70(1H, m), 366[M + 1] 2.0-2.12(1H, m),2.40-2.50(1H, m), 2.79-2.83(1H, m), 3.82(3H, s), 4.52(2H, d, J = 5.4Hz), 6.19(1H, m), 6.54(1H, d, J = 7.8 Hz), 6.62(1H, d, J = 8.1 Hz),6.75(1H, s), 7.01(1H, t, J = 8.1 Hz), 7.14-7.25(2H, m), 7.51(1H, d, J =8.1 Hz), 7.60(1H, d, J = 7.5 Hz). 496 152-154 497 δ in d6-DMSO: 1.48(3H,s), 1.83-1.77(1H, m), 2.61-2.56(1H, m), 2.99-2.95(1H, m), 3.86(3H, s),6.07(1H, s), 6.95(1H, s), 7.03-7.02(1H, m), 7.09- 7.06(1H, m),7.58-7.57(1H, m), 7.64-7.62(1H, m), 9.83(1H, s) 498 122-125 500 181-184501 155-156 502 137-138 504 209-219 511 211-214 1.58 (s, 3H), 1.90 (ddd,J = 14.0, 10.0, 3.6 Hz, 1H), 2.15 (ddd, J = 14.0, 6.8, 3.6 Hz, 1H), 2.77(ddd, J = 12.4, 10.0, 3.6 Hz, 1H), 2.94 (ddd, J = 12.4, 6.8, 3.6 Hz,1H), 4.34 (2H, br), 7.17 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.38 (t, J =8.0 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.56 (td, J = 2.0 Hz, 1H), 7.70(ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 8.08 (d, J = 1.6 Hz), 9.70 (s, 1H)(solvent: CDCl3) 515 204-206 1.61 (s, 3H), 1.90 (ddd, J = 14.0, 10.8,3.6 Hz, 1H), 2.22 (ddd, J = 14.0, 6.0, 3.6 Hz, 1H), 2.77 (ddd, J = 12.4,10.8, 3.6 Hz, 1H), 2.93 (ddd, J = 12.4, 60, 3.6 Hz, 1H), 7.15 (ddd, J =8.0, 2.0, 0.8 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.65 (t, J = 2.0 Hz,1H), 7.80 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 8.89 (s, 2H), 9.77 (s, 1H)(solvent: CDCl3) 516 292.3 525 105-106 528 173-174 1.60 (s, 3H), 1.89(ddd, J = 14.0, 10.8, 3.6 Hz, 1H), 2.22 (ddd, J = 14.0, 6.4, 3.2 Hz,1H), 2.44 (s, 3H), 2.77 (ddd, J = 12.4, 10.8, 3.2 Hz, 1H), 2.91 (ddd, J= 12.4, 6.4, 3.6 Hz, 1H), 4.50 (br, 2H), 7.11 (ddd, J = 8.0, 2.0, 0.8Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.67- 7.71 (m, 2H), 7.74 (ddd, J =8.0, 2.0, 0.8 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.44(d, J = 1.6 Hz,1H), 9.98 (s, 1H) (solvent: CDCl3) 532 305.3 533 180-181 534 201-204 549100-101 551 139-141 554 216

TABLE 147 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 556 (CDCl3)1.67(3H, d, J = 1.2 Hz), 1.98(1H, ddd, J = 14.0, 10.4, 3.7 Hz), 2.47(1H,ddd, J = 14.0, 6.7, 3.5 Hz), 2.79(1H, ddd, J = 12.0, 10.4, 3.5 Hz),3.02(1H, ddd, J = 12.0, 6.7, 3.7 Hz), 4.11(3H, s), 4.45(2H, br),7.10(1H, dd, J = 11.7, 8.8 Hz), 7.41(1H, dd, J = 6.9, 2.8 Hz), 8.04(1H,ddd, J = 8.8, 4.0, 2.8 Hz), 8.20(1H, d, J = 1.4 Hz), 9.06(1H, d, J = 1.4Hz), 9.51(1H, s) 558 358[M + 1] 200 282 559 224 560 δ in d10-DMSO:1.72(3H, s), 2.12-2.05(1H, m), 2.71-2.61(2H, m), 3.22-3.19(1H, m),6.52(1H, s), 7.26(1H, q, J = 11.6, 9.2 Hz), 7.55(1H, s), 7.66- 7.62(2H,m), 7.79-7.77(1H, m), 7.90-7.88(1H, m), 8.07(1H, s), 10.42(1H, s),11.55(1H, s) 561 235-240 567 oil 212 570 186-187 573 112-114 577 δ ind19-DMSO: 2.14-2.07(1H, m), 2.88-2.70(3H, m), 3.07, 3.26(2H, abq, J =12.0 Hz), 3.73(3H, s), 5.40(2H, s), 6.51(1H, s), 6.85(1H, d, J = 12.0Hz), 7.34(1H, d, J = 8.0 Hz) 584 152-153 586 δ in d7-DMSO: 1.71(3H, s),2.10-2.04(1H, m), 2.69-2.59(2H, m), 3.20-3.17(1H, m), 4.00(3H, s),7.13(1H, d, J = 7.4 Hz), 7.33-7.23(3H, m), 7.55(1H, d, J = 8.4 Hz),7.72-7.68(1H, m), 7.92-7.90(1H, m), 10.60(1H, s) 588 155-156 593 oil 226595 oil 1.56(3H, s), 1.86(1H, ddd, J = 13.9, 10.1, 3.7), 220 2.11(1H,ddd, J = 13.9, 6.6, 3.6), 2.32(3H, s), 2.70(1H, ddd, J = 12.3, 10.1,3.6), 2.90(1H, ddd, J = 12.3, 6.6, 3.7), 5.25(2H, s), 7.29-7.35(4H, m),7.47(1H, dt, J = 6.8, 2.0), 7.56-7.58(1H, m), 8.59(2H, d, J = 6.0)(solvent: CDCl3) 596 215 597 192-194 600 178-180 601 181-192 1.59 (3H,s), 1.85-1.95 (1H, m), 2.15-2.22 (1H, m), 375[M + 1] 2.72-2.78 (1H, m),2.88-2.96 (1H, m), 4.31 (3H, s), 7.13 (1H, d, J = 7.25 Hz), 7.33 (1H, t,J = 7.91 Hz), 7.59 (1H, s), 7.68 (1H, d, J = 7.91 Hz), 7.75 (1H, s),(solvent: CDCl3) 602 272-285 (dec.)

TABLE 148 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 605 230-2331.63 (s, 3H), 1.94 (ddd, J = 14.0, 10.4, 3.6 Hz, 1H), 2.44 (ddd, J =14.0, 6.4, 3.6 Hz, 1H), 2.75 (ddd, J = 12.4, 10.4, 3.6 Hz, 1H),, 2.98(ddd, J = 12.4, 6.4, 3.6 Hz, 1H), 4.50 (2H, br), 7.06 (dd, J = 11.6, 8.8Hz, 1H), 7.40 (dd, J = 7.2, 2.8 Hz, 1H), 7.59 (ddd, J = 8.8, 8.0, 2.8Hz, 1H), 7.99 (ddd, J = 8.8, 4.4, 2.8 Hz, 1H), 8.33 (dd, J = 8.8, 4.4Hz, 1H), 8.45 (d, J = 2.8 Hz, 1H), 9.78 (s, 1H) (solvent: CDCl3) 608213.4 304.1 611 200-202 613 238 618 1.74(s, 3H), 1.97-2.07(m, 1H),2.45-2.55(m, 1H), 2.77-2.85(m, 1H), 2.84(s, 3H), 2.90-2.96(m, 1H),7.11(d, J = 8.0 Hz, 1H), 7.42(t, J = 8.0 Hz, 1H), 7.57(d, J = 8.8 Hz,1H), 7.70(d, J = 8.0 Hz, 1H), 7.74(br s, 1H), 8.29(d, J = 8.8 Hz, 1H),10.12(s, 1H) (solvent: CDCl3) 620 212, 253 625 107-109 629 δ ind14-DMSO: 1.66(3H, s), 2.11-2.05(1H, m), 2.37(3H, s), 2.63-2.53(2H, m),3.14-3.11(1H, m), 7.08-7.04(2H, t, J = 7.0 Hz), 7.43-7.35(4H, m), 7.83-7.80(2H, m), 10.39(1H, s), 11.69(1H, s) 630 1.28 (3H, t, J = 7.7 Hz),1.96 (1H, ddd, J = 3.8, 9.9, 301[M + 1] 13.7 Hz), 2.19 (1H, ddd, J =3.5, 7.0, 13.7 Hz), 2.74 (1H, ddd, J = 3.6, 9.9, 12.2 Hz), 2.93 (1H,ddd, J = 3.8, 7.0, 12.1 Hz), 4.05-4.49 (4H, m), 7.40-7.50 (3H, m),7.77-7.86 (1H, m) (solvent: CDCl3) 634 (CDCl3) 1.67(3H, d, J = 1.2 Hz),1.98(1H, ddd, J = 14.0, 10.4, 3.7 Hz), 2.47(1H, ddd, J = 14.0, 6.7, 3.5Hz), 2.79(1H, ddd, J = 12.0, 10.4, 3.5 Hz), 3.02(1H, ddd, J = 12.0, 6.7,3.7 Hz), 4.11(3H, s), 4.45(2H, br), 7.10(1H, dd, J = 11.7, 8.8 Hz),7.41(1H, dd, J = 6.9, 2.8 Hz), 8.04(1H, ddd, J = 8.8, 4.0, 2.8 Hz),8.20(1H, d, J = 1.4 Hz), 9.06(1H, d, J = 1.4 Hz), 9.51(1H, s) 636118-119 637 229, 275 643 155-157 1.60 (s, 3H), 1.90 (ddd, J = 14.0,10.4, 3.6 Hz, 1H), 2.20 (ddd, J = 14.0, 6.8, 3.6 Hz, 1H), 2.77 (ddd, J =12.0, 10.4, 3.6 Hz, 1H),, 2.93 (ddd, J = 12.0, 6.8, 3.6 Hz, 1H), 4.59(brs, 1H), 7.16 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.37 (t, J = 8.0 Hz,1H), 7.67 (t, J = 2.0 Hz, 1H), 7.71 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H),7.87 (dd, J = 10.0, 1.2 Hz, 1H), 8.73 (d, J = 1.2 Hz, 1H), 9.74 (s, 1H)(solvent: CDCl3) 644 201-203

TABLE 149 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 645 oil1.58(3H, s), 1.87(1H, ddd, J = 14.0, 10.4, 3.6), 222 2.16(1H, ddd, J =14.0, 6.3, 3.5), 2.34(3H, s), 2.70(1H, ddd, J = 12.3, 10.4, 3.5),2.90(1H, ddd, J = 12.3, 6.3, 3.6), 5.38(2H, s), 7.18-7.33(3H, m),7.43(1H, d, J = 8.0), 7.49-7.60(2H, m), 7.69(1H, dt, J = 7.7, 1.9),8.59(1H, ddd, J = 4.9, 1.9, 1.1) (solvent: CDCl3) 649 161-162 651193-196 1.59 (s, 3H), 1.90 (ddd, J = 14.0, 10.4, 3.6 Hz, 1H), 2.18 (ddd,J = 14.0, 6.4, 3.6 Hz, 1H), 2.76 (ddd, J = 12.4, 10.4, 3.6 Hz, 1H),,2.93 (ddd, J = 12.4, 6.4, 3.6 Hz, 1H), 4.42 (br, 2 H), 7.17 (ddd, J =8.0, 2.0, 0.8 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.64 (t, J = 2.0 Hz,1H), 7.77 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 8.20 (dd, J = 8.0, 2.0 Hz,1H), 8.44 (dd, J = 8.0, 0.8 Hz, 1H), 8.91 (dd, J = 2.0, 0.8 Hz, 1H),9.87 (s, 1H) (solvent: CDCl3) 652 δ in d21-DMSO: 1.67(3H, s),2.14-2.07(1H, m), 2.62-2.57(2H, m), 3.17-3.14(1H, m), 5.74(1H, s),7.14(1H, d, J = 8.0 Hz), 7.44(1H, t, J = 8.0 Hz), 7.85- 7.81(2H, m),8.01(1H, d, J = 12.0 Hz), 8.16(1H, d, J = 8.0 Hz), 8.77(1H, s),10.95(1H, s) 653 193-194 654 oil 257 657 199-203 660 amorphous 223, 266661 δ in d9-DMSO: 1.30(3H, t, J = 7.0 Hz), 1.69(3H, s), 2.10-2.04(1H,m), 2.20(3H, s), 2.67-2.62(2H, m), 3.20-3.17(1H, m), 4.40(2H, q, J =14.0, 7.0 Hz), 6.83(1H, s), 7.25(1H, q, J = 12.0, 9.0 Hz), 7.62-7.61(1H, m), 7.85-7.83(1H, m), 10.42(1H, s) 664 amorphous 225, 267 667amorphous 226 673 oil 224 677 amorphous 216 680 159-160 1.63(3H, s),1.65-1.80(1H, m), 2.53-2.64(1H, m), 2.75-2.88(2H, m), 3.83(3H, s),4.32(2H, br), 6.87- 6.96(2H, m), 7.19-7.33(2H, m) (solvent: CDCl3) 681 δin d6-DMSO: 1.43(3H, s), 1.66-1.74(1H, m), 338[M + 1] 2.02-2.07(1H, m),2.56-2.63(1H, m), 2.85-2.90(1H, m), 5.80(2H, bs), 6.91 (1H, d, J = 7.8Hz), 6.96- 6.98(2H, m), 7.25(1H, t, J = 7.8 Hz), 7.2-7.36(2H, m),7.40(1H, m), 7.89-7.92(1H, m), 9.42(1H, bs), 10.78(1H, bs). 683 166-168

TABLE 150 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 687 164-1671.60 (3H, s), 1.84-1.95 (1H, m), 2.21-2.26 (1H, m), 388[M + 1] 2.73-2.94(2H, m), 3.92 (3H, s), 4.25 (3H, s), 7.10 (1H, d, J = 7.58 Hz), 7.34(1H, t, J = 7.91 Hz), 7.40 (1H, s), 7.57 (1H, br s), 7.66 (1H, d, J =7.91 Hz), 8.67 (1H, s), (solvent: CDCl3) 692 (CDCl3) 1.50(3H, s),1.75-1.88(1H, m), 2.00- 2.10(1H, m), 2.91-2.99(1H, m), 3.08-3.18(1H, m),6.21(1H, d, J = 15.9 Hz), 6.59(1H, d, J = 15.9 Hz), 7.42- 7.47(3H, m),7.59(1H, dd, J = 8.6, 2.0 Hz), 7.74- 7.83(4H, m) 698 269 700 177-178 7011.61(s, 3H), 1.90(m, 1H), 2.25(m, 1H), 2.81(m, 1H), 2.92(m, 1H), 3.86(s,3H), 6.71(t-like, J = 1.8 Hz, 1H), 7.12(t-like, J = 1.8 Hz, 1H),7.53(t-like, J = 1.8 Hz, 1H), 7.89(dd, J = 8.3 Hz, 2.4 Hz, 1H), 8.24(d,J = 8.3 Hz, 1H), 8.58(d, J = 2.4 Hz, 1H), 9.85(br, 1H) (solvent: CDCl3)702 1H-NMR(CDCl3) δ: 1.65 (3H, s), 1.91-1.98 (1H, m), 2.57-2.62 (1H, m),2.68-2.75 (1H, m), 2.92-2.97 (1H, m), 4.18 (3H, s), 6.82 (1H, br s),7.02-7.08 (1H, m), 7.28-7.32 (1H, m), 7.44 (1H, s), 7.92-7.96 (1H, m).707 167-174 709  99-100 0.82(3H, t, J = 7.3 Hz), 1.72-1.90(3H, m). 2.06-2.15(1H, m), 2.61-2.82(2H, m), 3.80(3H, s), 4.36(2H, br), 6.86(2H, d, J= 8.9 Hz), 7.17(2H, d, J = 8.9 Hz) (solvent: CDCl3) 717 157-162 1.58 (s,3H), 1.90 (ddd, J = 14.0, 10.4, 3.6 Hz, 1H), 2.15 (ddd, J = 14.0, 6.8,3.6 Hz, 1H), 2.76 (ddd, J = 12.4, 10.4, 3.6 Hz, 1H), 2.94 (ddd, J =12.4, 6.8, 3.6 Hz, 1H), 3.49 (1H, S), 3.76 (2H, br), 7.17 (ddd, J = 8.0,2.0, 0.8 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.38 (d, J = 1.6 Hz, 1H),7.50 (t, J = 2.0 Hz, 1H), 7.73 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 8.22 (d,J = 2.4 Hz), 9.26 (d, J = 2.4 Hz, 1H), 10.12 (s, 1H) (solvent: CDCl3)719 oil 226 254 720 133-138 725 amorphous 1.62 (s, 3H), 1.96-2.03(m,1H), 2.38-2.49 (m, 1H), 265 2.63-2.71 (m, 1H), 3.05-3.12 (m, 1H), 6.73(dd, J = 3.2, 1.6 Hz, 2H), 7.35(d, J = 3.2 Hz, 1H), 7.37 (br s, 1H),7.57 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.77 (br s, 1H),7.96(br s, 1H), 8.01(br s, 1H), 10.35 (s, 1H) (solvent: DMSO-d6) 728179-182 729 187-169

TABLE 151 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 730 211.0289.9 731 91-94 732 amorphous 211 735 166-168 737 1H-NMR (CDCl3) δ: 1.59(3H, s), 1.87-1.94 (1H, m), 2.47-2.53 (1H, m), 2.67-2.73 (1H, m),2.93-2.99 (1H, m), 4.10 (3H, s), 6.62 (1H, s), 7.04 (1H, t, J = 10.2Hz), 7.33 (1H, d, J = 4.3 Hz), 7.85 (1H, br s). 738 181-183 739 285 740250 (dec.) 743 148-150 1.60 (s, 3H), 179-2.93 (m, 4H), 4.46 (2H, br),7.09 (d, J = 2.0 Hz, 1H), 7.12 (ddd, J = 7.6, 2.0, 0.8 Hz, 1H), 7.18 (t,J = 2.0 Hz, 1H), 7.36 (d, J = 7.6, 2.0, 0.8 Hz, 1H), 7.43 (t, J = 7.6Hz, 1H), 8.21 (d, J = 2.0 Hz) (solvent: CDCl3) 744 δ in d8-DMSO:1.47(3H, s), 1.82-1.78(1H, m), 2.22-2.18(1H, m), 2.62-2.56(1H, m),3.00-2.96(1H, m), 6.79(1H, s), 6.63(1H, s), 7.08-7.03(1H, m), 7.51(1H,s), 7.64-7.57(2H, m), 9.57(1H, s), 11.25(1H, s) 753 amorphous 225, 299756 110-111 1.55(3H, s), 1.76-1.87(1H, m), 2.08-2.17(1H, m), 2.35(3H,s), 2.65-2.76(1H, m), 2.82-2.92(1H, m), 4.35(2H, br), 7.01-7.25(4H, m)(solvent: CDCl3) 758 156-157 766 336[M + 1] 203 260 212 767  98-100 7681.60 (3H, d, J = 1.3 Hz), 1.89-1.99 (1H, m), 2.29 362[M + 1] 213 (3H,s), 2.37-2.42 (1H, m), 2.70-2.75 (1H, m), 2.96- 263 3.00 (1H, m), 4.12(3H, s), 6.39 (1H, s), 7.04 (1H, dd, J = 11.5, 8.9 Hz), 7.18 (1H, dd, J= 6.9, 2.6 Hz), 7.60 (1H, s), 7.82-7.86 (1H, m), (solvent: CDCl3) 771417[M + 1] 201 341 774 ¹H-NMR (CDCl₃) δ: 1.77 (3H, s), 2.11-2.21 (1H,400[M + 1] m), 2.71-2.80 (1H, m), 2.87-2.99 (2H, m), 6.91 (1H, d, J =6.9 Hz), 7.28 (2H, s), 7.47 (1H, t, J = 8.1 Hz), 7.75 (1H, t, J = 8.6Hz), 8.04 (1H, dd, J = 8.6, 2.3 Hz), 8.29 (1H, d, J = 8.2 Hz), 8.46 (1H,d, J = 2.2 Hz).

TABLE 151 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 781 1.63 (s,3H), 1.92 (ddd, J = 14.0, 10.8, 4.0 Hz, 1H), 2.29 (m, 1H), 2.78 (ddd, J= 12.4, 10.8, 3.6 Hz, 1H),, 2.91 (ddd, J = 12.4, 6.4, 4.0 Hz, 1H), 3.94(3H, s), 7.09 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.34 (dd, J = 8.8, 2.8Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.68 (t, J = 2.0 Hz, 1H), 7.71 (ddd,J = 8.0, 2.0, 0.8 Hz, 1H), 8.24 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 2.8Hz, 1H), 9.86 (s, 1H) (solvent: CDCl3) 783 205-206 786 1.66(3H, s),2.10(1H, m), 2.57-2.64(2H, m), 3.16(1H, m), 6.74(1H, s), 7.30(1H, s),7.36(1H, s), 7.74(1H, s), 7.98(1H, s), 8.06(1H, s), 10.33(1H, s),10.47(1H, s) (solvent: DMSO-d6) 790 amorphous 223, 290 791 δ ind18-DMSO: 1.41(3H, s), 1.76-1.69(1H, m), 2.02-1.98(1H, m), 2.62-2.55(1H,m), 2.92-2.89(1H, m), 7.13(1H, d, J = 7.6 Hz), 7.29(1H, t, J = 7.6 Hz),7.62-7.59(2H, m), 8.71(1H, s), 9.28(1H, s), 10.46(1H, brs) 792 299.4 793269 (dec.) 797 213.4 312.4 799 215, 240 800 225, 275 802 1.63 (s, 3H),1.92 (ddd, J = 14.0, 11.2, 3.6 Hz, 1H), 2.28 (br, 1H), 2.78 (ddd, J =12.4, 11.2, 3.6 Hz, 1H), 2.81 (s, 3H), 2.92 (ddd, J = 12.4, 6.4, 4.0 Hz,1H), 7.10 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H),7.56 (t, J = 2.0 Hz, 1H), 7.65 (d, J = 2.4 Hz, 1H), 7.74 (ddd, J = 8.0,2.0, 0.8 Hz, 1H), 8.41 (d, J = 2.4 Hz, 1H), 10.03 (s, 1H) (solvent:CDCl3) 803 271 804 135-136 810 47-48 811 138-139 813 204-205 182 (s,3H), 1.89-1.94 (m, 1H), 2.78 (ddd, J = 12.4, 6.4, 3.6 Hz, 1H), 4.50 (2H,br), 7.06 (dd, J = 11.6, 8.8 Hz, 1H), 7.40 (dd, J = 7.2, 2.8 Hz, 1H),7.59 (ddd, J = 8.8, 8.0, 2.8 Hz, 1H), 7.99 (ddd, J = 8.8, 4.4, 2.8 Hz,1H), 8.33 (dd, J = 8.8, 4.4 Hz, 1H), 8.45 (d, J = 2.8 Hz, 1H), 9.78 (s,1H)(solvent: CDCl3) 814 oil 218, 272 816 214.5

TABLE 152 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 820 (CDCl3)1.66(3H, d, J = 1.2 Hz), 1.98(1H, ddd, J = 14.0, 10.4, 3.7 Hz), 2.47(1H,ddd, J = 14.0, 6.7, 3.5 Hz), 2.79(1H, ddd, J = 12.0, 10.4, 3.5 Hz),3.02(1H, ddd, J = 12.0, 6.7, 3.7 Hz), 4.45(2H, br), 6.16(2H, br),7.04-7.11(2H, m), 7.38(1H, dd, J = 7.2, 2.9 Hz), 7.88(1H, d, J = 2.0Hz), 7.96(1H, ddd, J = 8.9, 4.2, 2.9 Hz), 9.88(1H, s) 822 279 827134-137 214.5 284.0 832 212, 299 833 oil 212, 273 834 217, 287 835139-140 836 221.6 279.3 840 223-225 848 oil 223, 254 849 143-145 850 δin d16-DMSO: 1.41(3H, s), 1.75-1.70(1H, m), 2.02-1.99(1H, m),2.61-2.56(1H, m), 2.93-2.88(1H, m), 7.13(1H, d, J = 8.0), 7.29(1H, t, J= 7.8 Hz), 7.35(1H, q, J = 8.4, 2.4 Hz), 7.66-7.63(2H, m), 8.52-8.47(1H, m), 8.81 (1H, s), 10.44(1H, s) 851 82-83 1.55(3H, s),1.76-1.88(1H, m), 2.10-2.18(1H, m), 2.66-2.77(1H, m), 2.82-2.91(1H, m),3.81(3H, s), 6.73-6.78(1H, m), 6.88-6.92(2H, m), 7.21-7.29(1H, m)(solvent: CDCl3) 855 oil 219 859 350[M + 1] 200 274 208 254 863 192-1941.39(t, J = 7.2 Hz, 3H), 1.42(s, 3H), 1.71-1.79(m, 1H), 2.02-2.10(m,1H), 2.55-2.62(m, 1H), 2.88- 2.96(m, 1H), 4.47(q, J = 7.2 Hz, 2H),5.70-6.20(br s, 2H), 7.11(d, J = 8.0 Hz, 1H), 7.29(t, J = 8.0 Hz, 1H),7.75(d, J = 8.0 Hz, 1H), 7.80(br s, 1H), 8.38(d, J = 1.2 Hz, 1H),8.87(d, J = 1.2 Hz, 1H), 10.34(s, 1H) (solvent: CDCl3) 866 293.5 8691.65 (s, 3H), 1.90-2.01 (m, 3H), 2.32 (br, 1H), 2.80 (td, J = 12.0, 3.6Hz, 1H), 2.85 (t, J = 8.0 Hz, 2H), 2.92 (ddd, J = 12.0, 5.6, 3.6, 1H),3.75 (t, J = 8.0 Hz, 2H), 7.11 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.37 (t,J = 8.0 Hz, 1H), 7.70 (t, J = 2.0 Hz, 1H), 7.73-7.76 (m, 2H), 8.22 (d, J= 7.6 Hz, 1H), 8.48 (d, J = 2.0 Hz, 1H), 10.00 (s, 1H) (solvent: CDCl3)871 212-213

TABLE 153 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 875 oil 222,271 876 oil 222 878 oil 211 881 141-144 887 262.7 892 251 (dec.) 893 δin d12-DMSO: 1.70(3H, s), 2.10-2.04(1H, m), 2.69-2.59(2H, m),3.20-3.17(1H, m), 6.80(1H, brs), 7.26-7.20(1H, m), 7.88-7.81(3H, m),10.35(1H, s)13.53(1H, brs) 895 378[M + 1] 202 302 208 216 221 265 896amorphous 219, 264 897 212-214 900 205-207 1.61 (s, 3H), 1.91 (ddd, J =14.0, 10.8, 4.0 Hz, 1H), 2.23 (ddd, J = 14.0, 6.4, 3.6 Hz, 1H), 2.77(ddd, J = 12.4, 10.8, 3.6 Hz, 1H), 2.92 (ddd, J = 12.4, 6.4, 4.0 Hz,1H), 7.15 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H),7.65 (t, J = 2.0 Hz, 1H), 7.79 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 8.99 (s,2H), 9.78 (s, 1H) (solvent: CDCl3) 906 212.2 273.4 350.5 908 δ ind15-DMSO: 1.66(3H, s), 2.11-2.05(1H, m), 2.37(3H, s), 2.63-2.54(2H, m),3.16-3.11(1H, m), 3.16(3H, s), 7.08-6.96(3H, m), 7.49-7.41(3H, m),7.85-7.81(2H, m), 10.52(1H, s)11.69(1H, s) 910 oil 211, 276 916 131-132926 1.89(3H, s), 2.15(1H, m), 2.71-2.82(2H, m), 2.96(1H, m), 3.04(3H, d,J = 4.9), 7.35(1H, dd, J = 8.7, 1.8), 7.50-7.55(2H, m), 7.74(1H, s),7.82-7.90(3H, s), 10.40(1H, br), 11.36(1H, Br) (solvent: CDCl₃) 9281.20(t, J = 7.6 Hz, 3H), 1.53(br s, 3H), 1.82-1.97(m, 1H), 2.39(s, 3H),2.61(q, J = 7.6 Hz, 2H), 2.99- 3.07(m, 1H), 6.93(br s, 1H), 7.33(d, J =8.4 Hz, 2H), 7.54-7.58(m, 2H), 7.87(d, J = 8.4 Hz, 2H), 10.13(s, 1H)(solvent: CDCl3) 930 132.1-134.4 328[M + 1] 931 299 933 amorphous 212,259

TABLE 154 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 935 161-1651.62 (s, 3H), 1.91 (ddd, J = 14.0, 10.4, 4.0 Hz, 1H), 2.24 (ddd, J =14.0, 6.4, 3.6 Hz, 1H), 2.80 (ddd, J = 12.0, 10.4, 3.6 Hz, 1H), 2.93(ddd, J = 12.0, 6.4, 4.0 Hz, 1H), 7.15 (ddd, J = 8.0, 2.0, 1.2 Hz, 1H),7.39 (t, J = 8.0 Hz, 1H), 7.66 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 7.75 (t,J = 2.0 Hz, 1H), 7.80-7.84 (m, 2H), 7.93 (ddd, J = 8.0, 2.0, 1.2 Hz),8.21 (d, J = 8.4 Hz, 1H), 8.38 (d, J = 8.0 Hz, 1H), 8.41 (d, J = 8.0 Hz,1H), 10.25 (s, 1H) (solvent: CDCl3) 936 169-170 939 δ in d6-DMSO:1.72(3H, s), 2.11-2.05(1H, m), 2.70-2.60(2H, m), 3.21-3.18(1H, m),7.20(1H, d, J = 9.2 Hz), 7.28(1H, q, J = 11.6, 9.2 Hz), 8.56-7.54(2H,m), 7.69(1H, s), 7.90-7.85(2H, m), 10.69(1H, s), 12.17(1H, brs) 941 220944 amorphous 219, 256 946 1.61 (s, 3H), 1.91 (ddd, J = 14.0, 10.8, 3.6Hz, 1H), 2.26 (ddd, J = 14.0, 6.4, 3.6 Hz, 1H), 2.77 (ddd, J = 12.4,10.8, 3.6 Hz, 1H),, 2.92 (ddd, J = 12.4, 6.4, 3.6 Hz, 1H), 7.13 (ddd, J= 8.0, 2.0, 1.2 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.61 (t, J = 2.0 Hz,1H), 7.72 (ddd, J = 8.0, 2.0, 1.2 Hz, 1H), 7.91 (d, J = 2.4 Hz, 1H),8.49 (d, J = 2.4 Hz, 1H), 9.75 (s, 1H)(solvent: CDCl3) 947 215.7 276.9960 261.5 964 185-187 966 oil 216 968 107-109 970 1.57 (s, 3H),1.78-1.89 (m, 1H), 2.10-2.19 (m, 1H), 2.69 (ddd, J = 11.9, 10.8, 3.5 Hz,1H), 2.83-2.91 (m, 1H), 7.15-7.35 (m, 5H) (solvent: CDCl3) 971 (DMSO)1.49(3H, s), 1.73-1.86(1H, m), 2.16- 2.30(1H, m), 2.54-2.65(1H, m),2.92-3.03(1H, m), 5.86(2H, s), 7.04-7.18(2H, m), 7.38-7.50(3H, m),7.66-7.78(2H, m), 10.35(1H, s), 11.84(1H, s) 972 1.51 (3H, s) 1.91-1.95(1H, m) 2.37 (3H, s) 3.00-3.05 (1H, m) 7.24 (1H s) 7.33 (2H, d J = 9.0Hz) 7.66 (1H, s) 7.85 (2H, d J = 9.0 Hz) 8.03 (1H, s) 10.37 (1H, s)(solvent: DMSO-d6) 974 amorphous 219 978 oil 222 984 255.7 318.4 990126-129 994 130-131

TABLE 155 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 998 amorphous229, 290 1005 191-193 1006 88-90 2.42-2.47(2H, m), 2.80-2.86(2H, m),7.78(6H, s), 6.83(4H, d, J = 8.9 Hz), 7.22(4H, d, J = 8.9 Hz) (solvent:CDCl3) 1008 125-126 1010 90-91 1014 206-210 1020 216.9 245.1 1028105-106 1034 212.2 286.4 1035 247-251 (dec.) 1037 amorphous 224, 2721039 amorphous 217 249 1043 277-281 1044 (DMSO) 1.12(3H, s), 1.60(2H, d,J = 6.2 Hz), 1.73(2H, d, J = 8.6 Hz), 2.65-2.90(2H, m), 2.93-3.13(2H,m), 5.55(1H, s), 7.34-7.52(3H, m), 7.68(1H, s), 7.79- 7.90(3H, m) 10521.75(s, 3H), 2.12-2.21(m, 1H), 2.40(s, 3H), 2.65- 2.73(m, 2H),3.17-3.23(m, 1H), 7.37(d, J = 8.4 Hz, 2H), 7.40-7.44(m, 1H), 7.77(br s,1H), 7.92-7.99(m, 5H), 8.47(br s, 1H), 8.70(d, J = 4.8 Hz, 1H), 10.37(s,1H), 10.41(s, 1H) (solvent: CDCl3) 1055 169-170 1.56(3H, s),1.78-1.89(1H, m), 2.04-2.15(1H, m), 2.68-2.79(1H, m), 2.86-2.95(1H, m),4.32(2H, br), 6.94-7.02(4H, m), 7.05-7.12(1H, m), 7.25-7.37(4H,m)(solvent: CDCl3) 1056 219 1059 262-287 1061 216 1062 136-137 1.53(3H,s), 1.76-1.88(1H, m), 2.03-2.13(1H, m), 2.63-2.73(1H, m), 2.85-2.94(1H,m), 4.35(2H, br), 7.23-7.32(4H, m) (solvent: CDCl3) 1064 84-85 1.52(3H,s), 1.73-1.89(1H, m), 1.97-2.07(1H, m), 2.64-2.81(1H, m), 2.82-2.91(1H,m),2.87(3H, s), 3.77(3H, s), 4.10(1H, brs), 6.84(2H, d, J = 8.9 Hz),7.28(2H, d, J = 8.6 Hz) (solvent: CDCl3) 1067 162-165 1068 132-134 2301069 194-196 1074 324[M + 1] 200 248 207 1076 amorphous 217

TABLE 156 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 1084 146-1491087 311.2 1088 amorphous 1.55(3H, s), 1.83(1H, ddd, J = 13.9, 10.5,3.7), 229 2.09(1H, ddd, J = 13.9, 6.6, 3.6), 2.67(1H, ddd, J = 318 12.3,10.5, 3.6), 2.88(1H, ddd, J = 12.3, 6.6, 3.7), 4.48(2H, d, J = 6.0),4.91(1H, br), 6.33(1H, dd, J = 8.8, 0.8), 7.19(1H, d, J = 7.3,7.23-7.30(2H, m), 7.35(1H, dd, J = 8.8, 2.8), 8.05(1H, dd, J = 2.8, 0.8)(solvent: CDCl3) 1094 216, 322 1100 278 (dec.) 1107 oil 1.58(3H, s),1.90(1H, ddd, J = 13.9, 10.1, 3.7), 226 2.14(1H, ddd, J = 13.9, 6.8,3.6), 2.69(1H, ddd, J = 284 12.2, 10.1, 3.6), 2.94(1H, ddd, J = 12.2,6.8, 3.7), 3.81(3H, s), 4.62(2H, s), 6.90(2H, d, J = 8.8), 7.30(2H, d, J= 8.8), 7.43(1H, t, J = 7.4), 7.57(1H, ddd, J = 7,4, 1.6, 1.2), 7.81(1H, ddd, J = 7.6, 1.6, 1.2), 7.95(1H, t, J = 1.6) (solvent : CDCl3)1109 134-140 1110 109-110 1111 118-119 1114 121-124 1115 187-170 1.63(s, 3H), 1.93 (ddd, J = 14.0, 10.4, 4.0 Hz, 1H), 2.24 (ddd, J = 14.0,6.4, 3.6 Hz, 1H), 2.81 (ddd, J = 12.4, 10.4, 3.6 Hz, 1H), 2.96 (ddd, J =12.4, 6.4, 4.0 Hz, 1H), 4.49 (br, 2 H), 7.19 (ddd, J = 8.0, 2.0, 0.8 Hz,1H), 7.42 (t, J = 8.0 Hz, 1H), 7.74 (t, J = 2.0 Hz, 1H), 7.84 (ddd, J =8.0, 2.0, 0.8 Hz, 1H), 7.88-7.95 (m, 2H), 8.22-8.26 (m, 2H), 9.80 (s,1H), 9.89 (s, 1H) (solvent: CDCl3) 1116 oil 220, 255, 307 1119 153-1571120 213-214 1124 169-172 225 1125 195-198 222 256 289 1131 189-191 1132175-180 (dec) 1133 amorphous 219, 292 1135 255-260 (dec.) 1139 140-1411140 oil 218 1142 182-186 (dec.)

TABLE 157 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 1147 214.5275.7 1150 221.6 279.3 1153 156-159 1160 1.64 (3H, s) 2.02-2.12 (1H, m)2.54-2.63 (1H, m) 3.11-3.16 (1H, m) 7.28 (1H, s) 7.70 (1H, dd J = 8.1Hz) 7.85 (1H, s) 8.04-8.17 (2H, m) 8.28 (1H s) 8.74 (1H d J = 5.1 Hz)10.81 (1H, s) 10.96 (1H, s) (solvent: DMSO-d6) 1161 192-193 1166 290-295444[M + 3] 442[M + 1] 368 366 1172 1.55 (3H, s) 1.94-2.03 (1H, m)2.18-2.27 (1H, m) 2.32 (3H, s) 3.03-3.07 (1H, m) 7.05 (1H, s) 7.09 (1H,s) 7.14 (1H, s) 7.37 (2H, d J = 9.0 Hz) 7.66 (2H, d, J = 9.0 Hz) 10.65(1H, s) 10.70 (1H, s) (solvent: DMSO-d6) 1181 194-195 1.60(3H, s),1.81-1.93(1H, m), 2.13-2.22(1H, m), 2.70-2.81(1H, m), 2.86-2.96(1H, m),4.36(2H, br), 7.29-7.46(5H, m), 7.53-7.61(4H, m) (solvent: CDCl3) 1184149-150 1185 225.1 280.4 1193 182-183 1194 344[M + 1] 209 268 214 2611197 250-255 (dec.) 1199 274-283 1205 oil E 213, 273 Z 219, 275 1207106-108 1211 1.77 (s, 3H), 1.98-2.54 (m, 2H), 2.81 (s, 3H), 2.81- 2.94(m, 2H), 3.93 (s, 3H), 7.03 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.08 (d, J= 2.4 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.63 (t, J = 2.0 Hz, 1H), 7.69(ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 8.14 (d, J = 2.4 Hz, 1H), 10.13 (s, 1H)(solvent: CDCl3) 1213 406[M + 1] 20 330 209 213

TABLE 158 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 1215 amorphous1.64 (s, 3H), 2.07 (ddd, J = 14.1, 11.5, 3.8 Hz, 1H), 2.17 (s, 3H), 2.39(ddd, J = 14.1, 5.3, 3.5 Hz, 1H), 2.72 (ddd, J = 12.6, 11.5, 3.5 Hz,1H), 2.80 (ddd, J = 12.6, 5.3, 3.8 Hz, 1H), 3.21 (t, J = 8.9 Hz, 2H),4.58 (t, J = 8.9 Hz, 2H), 6.76 (d, J = 8.4 Hz, 1H), 6.97-7.02 (m, 1H),7.08-7.11 (m, 1H) (solvent: CDCl3) 1216 305.3 1217 263-266 1221amorphous 220, 253 1223 226.3 280.4 1224 δ in d11-DMSO: 1.46(3H, s),1.83-1.77(1H, m), 2.18-2.15(1H, m), 2.61-2.56(1H, m), 2.99-2.95(1H, m),7.08(1H, q, J = 12.0, 8.4 Hz), 7.72-7.66(2H, m), 7.79(2H, d, J =9.2)9.67(1H, s) 1228 oil 224 1230 232-234 1240 216.9 285.2 1241 194-1951242 δ in d21-DMSO: 1.41(3H, m), 1.75-1.68(1H, m), 2.04-1.99(1H, m),2.61-2.56(1H, m), 2.89(4H, s), 5.75(2H, brs), 7.07(1H, d, J = 4.0 Hz),7.25(1H, t, J = 8.0 Hz), 7.72(1H, d, J = 8.0 Hz), 7.75(1H, s), 7.83(1H,brs), 7.96(1H, s), 8.67(1H, s), 9.96(1H, s) 1243 amorphous 1.58(3H, s),2.00(1H, ddd, J = 14.3, 11.5, 3.1), 223 2.53(1H, m), 2.56(1H, m),3.07(1H, dt, J = 12.5, 299 3.1), 4.26(2H, s), 6.47-6.56(3H, m),7.07-7.15(1H, m), 7.12(2H, t, J = 8.8), 7.39(2H, dd, J = 8.8, 5.6),8.76(2H, br) (solvent: DMSO-d6) 1244 268-288 1.68 (s, 3H), 2.11 (ddd, J= 15.2, 12.0, 4.0 Hz, 1H), 219 2.57-2.64 (m, 2H), 3.16 (dt, J = 12.0,4.0 Hz, 1H), 288 7.13 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H), 7.46 (t, J = 8.0Hz, 1H), 7.89 (t, J = 2.0 Hz, 1H), 7.97 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H),8.35 (d, J = 8.0 Hz, 1H), 8.52 (dd, J = 8.0, 2.4 Hz, 1H), 9.12 (d, J =2.4 Hz, 1H), 10.68 (s, 1H), 10.92 (s, 1H) (solvent: DMSO-d6) 1245 oil286 1247 211 1255 242.7 1257 amorphous 211 1258 352[M + 1] 228 276 3011261 179-180 1262 278-281

TABLE 159 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 1263 1H-NMR(δin d6-DMSO): 1.41(3H, s), 1.65- 387[M + 1] 1.77(1H, m), 1.95-2.07(1H,m), 2.54-2.63(1H, m), 2.84-2.94(1H, m), 3.39-3.46(2H, m), 3.53-3.61(2H,m), 4.83(1H, t, J = 5.4 Hz), 5.79(2H, bs), 7.07(1H, d, J = 7.5 Hz),7.25(1H, t, J = 7.8 Hz), 7.73(1H, d, J = 7.8 Hz), 7.76(1H, m),7.87-7.93(1H, m), 8.02(1H, d, J = 1.2 Hz), 8.63(1H, d, J = 1.2 Hz),9.97(1H, s). 1264 1H-NMR(δ in d6-DMSO): 1.41(3H, s), 1.65- 413[M + 1]1.77(1H, m), 1.95-2.07(1H, m), 2.53-2.63(1H, m), 2.84-2.95(1H, m),3.73(8H, s), 5.79(2H, bs), 7.09(1H, d, J = 7.8 Hz), 7.26(1H, t, J = 7.8Hz), 7.72(1H, d, J = 7.8 Hz), 7.75-7.78(1H, m), 8.34(1H, d, J = 1.2 Hz),8.76(1H, d, J = 1.2 Hz), 10.08(1H, bs). 1265 1H-NMR (DMSO-d6) δ: 1.42(3H, s), 1.70-1.76 (1H, m), 2.02-2.05 (1H, m), 2.56-2.59 (1H, m), 2.87-2.93 (2H, m), 7.07 (1H, d, J = 7.6 Hz), 7.23-7.26 (3H, m), 7.72-7.74(2H, m), 7.93 (1H, s), 8.60 (1H, s), 9.99 (1H, s). 1266 1H-NMR(δ ind6-DMSO): 1.43(3H, s), 1.70- 369[M + 1] 1.81(1H, m), 1.97-2.10(1H, m),2.55-2.64(1H, m), 2.89-2.95(1H, m), 5.84(2H, bs), 7.17(1H, d, J = 7.8Hz), 7.33(1H, t, J = 7.8 Hz), 9.98(1H, d, J = 1.2 Hz), 10.01(1H, d, J =1.2 Hz), 10.74(1H, bs). 1267 1H-NMR (CDCl3) δ: 1.82-1.91 (1H, m), 2.04(3H, 338[M + 1] s), 2.22 (1H, ddd, J = 13.8, 5.2, 3.6 Hz), 2.67 (1H, dt,J = 16.7, 5.8 Hz), 2.80 (1H, dt, J = 12.4, 4.7 Hz), 6.95 (2H, d, J = 8.1Hz), 7.06 (2H, td, J = 7.8, 1.2 Hz), 7.18 (1H, td, J = 7.6, 1.1 Hz),7.27 (1H, d, J = 1.7 Hz), 7.32 (1H, d, J = 7.9 Hz), 7.42-7.44 (2H, m),7.80 (1H, dd, J = 8.0, 1.9 Hz). 1268 1H-NMR (CDCl3) δ: 1.62 (3H, s),1.89 (1H, t, J = 327[M + 1] 12.3 Hz), 2.27-2.30 (1H, m), 2.69-2.76 (1H,m), 2.85-2.88 (1H, m), 7.11 (1H, dd, J = 11.4, 7.7 Hz), 7.30-7.53 (2H,m), 7.63 (1H, s), 7.71 (1H, d, J = 6.9 Hz). 1269 1H-NMR (DMSO-d6) δ:1.40 (3H, s), 1.70-1.73 (1H, m), 1.99-2.02 (1H, m), 2.57-2.60 (1H, m),2.88- 2.90 (1H, m), 3.29 (3H, s), 3.52 (4H, s), 5.75 (2H, br s), 7.07(1H, d, J = 7.6 Hz), 7.25 (1H, t, J = 7.7 Hz), 7.72 (1H, d, J = 8.3 Hz),7.75 (1H, s), 7.92 (1H, br s), 8.03 (1H, s), 8.64 (1H, s), 9.96 (1H, s).1271 1H-NMR(δ in d6-DMSO): 1.41(3H, s), 1.65- 397[M + 1] 1.75(1H, m),1.99-2.06(5H, m), 2.52-2.61(1H, m), 2.85-2.93(1H, m), 3.55(4H, t, J =6.6 Hz), 5.79(2H, bs), 7.05(1H, d, J = 7.8 Hz), 7.25(1H, t, J = 7.8 Hz),7.70-7.75(1H, m), 7.73-7.77(1H, m), 7.97(1H, d, J = 1.2 Hz), 8.72(1H, d,J = 1.2 Hz), 10.00(1H, s).

TABLE 160 MS UV No. mp (° C.) 1H-NMR(δ) (m/z) (λ max: nm) 1272 (CDCl3)1.61(3H, s), 1.85-1.96(1H, m), 2.17- 2.27(1H, m), 2.69-2.79(1H, m),2.87-2.97(1H, m), 7.17 (1H, d, J = 8.1 Hz), 7.38 (1H, t, J = 8.1 Hz),7.48- 7.74(5H, m), 8.40(2H, d, J = 7.5 Hz) 1273 1H-NMR (CDCl3) δ: 1.58(3H, s), 1.89 (1H, t, J = 395[M + 1] 11.2 Hz), 2.27 (1H, s), 2.75-2.82(2H, m), 6.61 (1H, dd, J = 20.3, 8.4 Hz), 7.10 (1H, d, J = 7.2 Hz), 7.37(1H, dd, J = 15.0, 8.8 Hz), 7.90 (1H, d, J = 7.6 Hz), 8.10 (1H, d, J =3.2 Hz), 9.37 (1H, d, J = 4.9 Hz), 9.69 (1H, s). 1274 1H-NMR (CDCl3) δ:1.61 (3H, s), 1.84-1.93 (1H, 327[M + 1] m), 2.30 (1H, t, J = 13.1 Hz),2.77-2.86 (2H, m), 6.64 (1H, dd, J = 20.6, 8.6 Hz), 7.13 (1H, d, J = 7.9Hz), 7.38-7.43 (1H, m), 7.93 (1H, d, J = 8.1 Hz), 8.13 (1H, s), 9.40(1H, d, J = 4.9 Hz), 9.72 (1H, s). 1275 1H-NMR (DMSO-d6) δ: 1.40 (3H,s), 1.70-1.72 (1H, m), 2.01-2.04 (1H, m), 2.18 (6H, s), 2.44 (2H, t, J =6.3 Hz), 2.56-2.59 (1H, m), 2.86-2.92 (1H, m), 7.06 (1H, d, J = 7.6 Hz),7.25 (1H, t, J = 7.7 Hz), 7.71-7.73 (3H, m), 8.02 (1H, s), 8.64 (1H, s),9.95 (1H, s). 1276 1H-NMR (DMSO-d6) δ: 1.70-1.73 (1H, m), 1.99- 2.02(1H, m), 2.57-2.60 (1H, m), 2.88-2.91 (1H, m), 3.04 (3H, s), 3.43 (3H,t, J = 6.3 Hz), 3.79-3.81 (2H, m), 5.75 (3H, br s), 7.08 (1H, d, J = 7.3Hz), 7.26 (1H, t, J = 7.8 Hz), 7.72 (1H, d, J = 7.8 Hz), 7.76 (1H, s),8.04 (1H, s), 8.09 (1H, br s), 8.70 (1H, s), 10.01 (1H, s). 1279 1H-NMR(CDCl3) δ: 1.73 (3H, s), 2.04 (1H, dt, J = 328[M + 1] 18.2, 6.5 Hz),2.45 (1H, d, J = 13.6 Hz), 2.78 (2H, t, J = 11.8 Hz), 2.89 (2H, t, J =11.5 Hz), 6.60 (1H, s), 6.99 (1H, d, J = 8.2 Hz), 7.34 (1H, t, J = 8.0Hz), 7.48 (1H, s), 7.70 (1H, d, J = 8.2 Hz). 1280 1H-NMR(δ in d6-DMSO):1.42(3H, s), 1.68- 426[M + 1] 1.82(1H, m), 2.02-2.09(1H, m), 2.23(3H,s), 2.43(4H, t, J = 5.1 Hz), 2.53-2.61(1H, m), 2.87-2.95(1H, m),3.73(4H, t, J = 5.1 Hz), 6.01 (2H, bs), 7.07(1H, d, J = 7.8 Hz),7.26(1H, t, J = 7.8 Hz), 7.73(1H, d, J = 7.8 Hz), 7.73-7.78(1H, m),8.33(1H, d, J = 1.2 Hz), 8.72(1H, d, J = 1.2 Hz), 10.06(1H, s). 12811H-NMR(δ in d6-DMSO): 1.40(3H, s), 1.30- 427[M + 1] 1.50(2H, m),1.69-1.76(1H, m), 1.82-1.88(2H, m), 2.01-2.07(1H, m), 2.52-2.61(1H, m),2.86-2.94(1H, m), 3.76-3.83(1H, m), 4.10-4.18(2H, m), 4.82(1H, d, J =4.2 Hz), 5.91(2H, bs), 7.07(1H, d, J = 7.8 Hz), 7.26(1H, t, J = 7.8 Hz),7.70-7.77(2H, m), 8.33(1H, d, J = 1.2 Hz), 8.70(1H, d, J = 1.2 Hz),10.02(1H, s).

TABLE 161

MS(m/z) 2 336[M + 1] 7 394[M + 1] 10 431[M + 3] 429[M + 1] 11 356[M + 1]12 354[M + 1] 13 363[M + 3] 361[M + 1] 14 394[M + 1] 15 409[M + 1] 16425[M + 1] 17 374[M + 1] 19 362[M + 3] 360[M + 1] 20 438[M + 1] 21380[M + 3] 378[M + 1] 22 380[M + 3] 378[M + 1] 25 354[M + 1] 27 338[M +1] 28 356[M + 1] 29 372[M + 1] 31 378[M + 1] 32 417[M + 1] 34 358[M + 1]35 398[M + 3] 396[M + 1] 36 370[M + 1] 40 416[M + 1] 340 41 414[M + 1]44 362[M + 3] 360[M + 1] 45 365[M + 1] 46 362[M + 1] 47 416[M + 3]414[M + 1] 49 394[M + 3] 392[M + 1] 50 292[M + 1] 51 388[M + 1] 52360[M + 1] 284 53 380[M + 1] 54 332[M + 1] 55 412[M + 3] 410[M + 1] 56397[M + 1] 395[M + 1] 59 412[M + 1] 60 422[M + 1] 420[M + 1] 61 394[M +1] 63 366[M + 1] 64 441[M + 1] 365 65 384[M + 1] 66 398[M + 1] 67386[M + 1] 310 68 376[M + 1] 70 372[M + 1] 72 330[M + 1] 74 322[M + 1]75 412[M + 1] 76 363[M + 3] 361[M + 1] 79 310[M + 1] 81 386[M + 1] 82306[M + 1] 83 336[M + 1] 84 380[M + 1] 87 415[M + 1] 88 426[M + 1] 89370[M + 1] 90 354[M + 1] 92 417[M + 1] 93 407[M + 1] 94 350[M + 1] 95406[M + 3] 404[M + 1] 98 398[M + 3] 396[M + 1] 100 332[M + 1] 102424[M + 3] 422[M + 1] 103 444[M + 1] 105 424[M + 1] 348 106 490[M + 1]414 107 414[M + 3] 412[M + 1] 108 332[M + 1] 109 412[M + 1] 110 404[M +1] 111 469[M + 1] 393 112 377[M + 1] 116 408[M + 1] 117 413[M + 1] 118372[M + 1] 119 424[M + 1] 122 338[M + 1] 124 471[M + 1] 131 412[M + 3]410[M + 1] 133 404[M + 1] 135 416[M + 1] 136 380[M + 1] 137 327[M + 1]138 394[M + 1] 140 456[M + 1] 142 446[M + 1] 143 399[M + 1] 144 432[M +1] 145 394[M + 3] 392[M + 1] 146 433[M + 3] 431[M + 1] 147 324[M + 1]150 418[M + 1] 151 458[M + 3] 456[M + 1] 152 371[M + 1] 153 398[M + 1]154 401[M + 1] 155 322[M + 1] 156 332[M + 3] 330[M + 1] 158 394[M + 1]

TABLE 162 160 427[M + 1] 162 416[M + 3] 414[M + 1] 167 392[M + 3]390[M + 1] 168 380[M + 3] 378[M + 1] 169 346[M + 1] 170 356[M + 1] 171334[M + 1] 172 376[M + 3] 374[M + 1] 173 424[M + 3] 422[M + 1] 174369[M + 1] 175 410[M + 1] 177 357[M + 1] 179 334[M + 1] 180 426[M + 1]182 396[M + 3] 394[M + 1] 183 372[M + 1] 184 346[M + 1] 185 330[M + 1]186 393[M + 3] 391[M + 1] 187 374[M + 1] 188 423[M + 1] 190 278[M + 1]191 448[M + 1] 192 436[M + 3] 434[M + 1] 194 384[M + 1] 195 369[M + 1]197 382[M + 1] 198 355[M + 1] 199 361[M + 1] 200 356[M + 1] 280 201452[M + 1] 203 397[M + 1] 205 427[M + 1] 206 386[M + 1] 310 207 384[M +1] 208 386[M + 3] 384[M + 1] 209 371[M + 1] 210 366[M + 1] 211 442[M +1] 366 212 345[M + 1] 215 425[M + 3] 423[M + 1] 217 362[M + 1] 218322[M + 1] 219 347[M + 1] 221 444[M + 1] 222 329[M + 1] 223 413[M + 1]225 402[M + 1] 226 390[M + 1] 228 383[M + 1] 229 366[M + 1] 230 368[M +1] 231 336[M + 1] 234 378[M + 1] 236 392[M + 1] 237 348[M + 1] 239384[M + 1] 240 341[M + 1] 242 446[M + 1] 245 374[M + 1] 246 390[M + 1]314 247 374[M + 1] 248 370[M + 1] 249 336[M + 1] 250 366[M + 1] 252401[M + 1] 253 397[M + 1] 254 434[M + 1] 257 321[M + 1] 258 398[M + 1]260 440[M + 1] 261 308[M + 1] 262 466[M + 3] 464[M + 1] 264 336[M + 1]265 435[M + 1] 266 432[M + 1] 430[M + 1] 269 372[M + 1] 296 270 338[M +1] 272 349[M + 1] 273 406[M + 3] 404[M + 1] 274 380[M + 1] 276 398[M +3] 396[M + 1] 278 404[M + 1] 280 433[M + 3] 431[M + 1] 283 322[M + 1]285 340[M + 1] 286 433[M + 3] 431[M + 1] 287 440[M + 1] 288 354[M + 1]289 341[M + 1] 290 363[M + 3] 361[M + 1] 291 317[M + 1] 292 426[M + 1]294 424[M + 3] 422[M + 1] 295 394[M + 3] 392[M + 1] 296 389[M + 1] 297448[M + 3] 446[M + 1] 298 363[M + 3] 361[M + 1] 300 356[M + 1] 303366[M + 1] 304 402[M + 1] 305 407[M + 3] 405[M + 1] 310 411[M + 1]

TABLE 163 311 388[M + 1] 312 428[M + 1] 313 453[M + 1] 314 368[M + 1]315 322[M + 1] 316 386[M + 1] 317 328[M + 1] 318 362[M + 1] 320 327[M +1] 321 392[M + 1] 322 404[M + 1] 328 323 394[M + 1] 324 384[M + 1] 325399[M + 1] 326 440[M + 1] 364 327 314[M + 1] 328 384[M + 1] 331 360[M +1] 334 412[M + 1] 335 316[M + 1] 336 356[M + 1] 337 428[M + 1] 338466[M + 3] 464[M + 1] 340 344[M + 1] 343 399[M + 1] 345 412[M + 1] 346384[M + 1] 347 430[M + 1] 348 341[M + 1] 349 335[M + 1] 350 412[M + 1]351 322[M + 1] 352 327[M + 1] 355 397[M + 1] 362 366[M + 1] 363 376[M +3] 374[M + 1] 365 366[M + 1] 366 409[M + 1] 368 384[M + 1] 369 396[M +3] 394[M + 1] 371 398[M + 3] 396[M + 1] 372 348[M + 1] 373 358[M + 1]374 364[M + 1] 376 412[M + 1] 377 425[M + 1] 378 380[M + 3] 378[M + 1]379 377[M + 1] 381 409[M + 1] 382 340[M + 1] 384 388[M + 1] 385 384[M +1] 386 352[M + 1] 387 376[M + 1] 388 440[M + 1] 390 407[M + 1] 331 391362[M + 1] 392 390[M + 1] 394 363[M + 3] 361[M + 1] 397 460[M + 3]458[M + 1] 398 408[M + 1] 399 372[M + 1] 400 374[M + 1] 402 372[M + 1]296 403 436[M + 1] 404 376[M + 3] 374[M + 1] 407 449[M + 3] 447[M + 1]412 410[M + 1] 414 331[M + 1] 416 282[M + 1] 418 322[M + 1] 419 420[M +3] 418[M + 1] 420 332[M + 1] 421 388[M + 3] 386[M + 1] 423 412[M + 3]410[M + 1] 424 370[M + 1] 425 380[M + 3] 378[M + 1] 428 350[M + 1] 431391[M + 1] 433 454[M + 3] 452[M + 1] 434 448[M + 3] 446[M + 1] 435431[M + 3] 429[M + 1] 437 382[M + 1] 438 400[M + 1] 324 439 380[M + 1]440 358[M + 1] 442 394[M + 1] 318 447 370[M + 1] 449 336[M + 1] 450455[M + 1] 451 390[M + 3] 388[M + 1] 453 358[M + 1] 454 407[M + 1] 331455 296[M + 1] 458 382[M + 1] 459 392[M + 1] 460 431[M + 1] 461 369[M +1] 462 381[M + 3] 379[M + 1] 463 440[M + 3] 438[M + 1] 464 338[M + 1]262 467 387[M + 1] 468 439[M + 1] 363 469 360[M + 1] 471 363[M + 3]361[M + 1]

TABLE 164 472 376[M + 1] 473 414[M + 1] 474 334[M + 1] 475 317[M + 1]476 324[M + 1] 477 437[M + 1] 478 379[M + 1] 479 394[M + 1] 480 370[M +1] 481 431[M + 1] 484 314[M + 3] 312[M + 1] 485 448[M + 1] 486 350[M +1] 487 338[M + 1] 488 306[M + 1] 489 335[M + 1] 492 380[M + 1] 495334[M + 1] 499 370[M + 1] 503 412[M + 1] 505 363[M + 3] 361[M + 1] 506386[M + 1] 507 400[M + 1] 508 372[M + 1] 509 414[M + 1] 338 510 374[M +1] 512 320[M + 1] 513 420[M + 3] 418[M + 1] 514 372[M + 1] 517 369[M +1] 518 376[M + 1] 519 411[M + 1] 520 395[M + 1] 521 372[M + 1] 522390[M + 1] 523 414[M + 1] 524 341[M + 1] 526 426[M + 1] 527 381[M + 3]379[M + 1] 529 320[M + 1] 530 390[M + 3] 388[M + 1] 531 410[M + 1] 535356[M + 1] 536 372[M + 1] 537 377[M + 1] 538 406[M + 1] 539 411[M + 1]540 354[M + 1] 541 342[M + 1] 542 361[M + 1] 543 344[M + 1] 544 412[M +1] 545 366[M + 1] 546 383[M + 1] 547 430[M + 1] 428[M + 1] 548 427[M +1] 550 340[M + 1] 552 400[M + 1] 553 304[M + 1] 555 383[M + 1] 557304[M + 1] 562 374[M + 1] 563 366[M + 1] 564 395[M + 1] 565 336[M + 1]566 427[M + 1] 351 568 362[M + 3] 360[M + 1] 569 356[M + 1] 571 356[M +1] 572 473[M + 3] 471[M + 1] 574 381[M + 3] 379[M + 1] 575 360[M + 1]576 384[M + 1] 578 344[M + 1] 579 370[M + 1] 580 347[M + 1] 581 409[M +1] 582 334[M + 1] 583 392[M + 1] 585 358[M + 1] 587 348[M + 1] 589407[M + 3] 405[M + 3] 590 410[M + 3] 408[M + 1] 591 460[M + 1] 384 592380[M + 3] 378[M + 1] 594 390[M + 1] 598 394[M + 1] 599 377[M + 1] 603398[M + 3] 396[M + 1] 604 395[M + 1] 606 358[M + 1] 607 362[M + 1] 609413[M + 1] 610 409[M + 1] 612 385[M + 1] 614 322[M + 1] 615 441[M + 1]616 346[M + 3] 344[M + 1] 270 268 617 406[M + 3] 404[M + 1] 619 404[M +1] 621 366[M + 1] 623 422[M + 1] 346 624 370[M + 1] 626 402[M + 1] 627398[M + 3] 396[M + 1] 628 413[M + 1] 631 370[M + 1] 632 414[M + 3]412[M + 1]

TABLE 165 633 322[M + 1] 635 420[M + 1] 638 408[M + 1] 639 386[M + 1]310 640 370[M + 1] 641 437[M + 1] 642 380[M + 1] 646 395[M + 1] 647334[M + 1] 648 403[M + 1] 650 370[M + 1] 655 362[M + 1] 656 308[M + 1]658 430[M + 1] 659 340[M + 3] 388[M + 1] 662 330[M + 1] 663 334[M + 1]665 316[M + 1] 666 345[M + 1] 668 430[M + 1] 669 377[M + 1] 670 368[M +3] 366[M + 1] 671 334[M + 1] 672 442[M + 1] 674 340[M + 1] 675 306[M +1] 676 392[M + 1] 678 386[M + 1] 679 426[M + 1] 682 414[M + 3] 412[M +1] 684 384[M + 1] 685 389[M + 1] 686 446[M + 1] 688 414[M + 1] 689306[M + 1] 690 348[M + 1] 691 452[M + 1] 693 371[M + 1] 694 448[M + 1]695 364[M + 1] 696 392[M + 3] 390[M + 1] 697 358[M + 1] 699 426[M + 1]703 451[M + 3] 449[M + 1] 704 342[M + 1] 705 372[M + 1] 706 368[M + 1]708 383[M + 1] 710 396[M + 3] 394[M + 1] 711 351[M + 1] 712 376[M + 1]713 398[M + 3] 396[M + 1] 714 366[M + 1] 715 454[M + 1] 716 381[M + 3]379[M + 1] 718 386[M + 1] 721 322[M + 1] 722 377[M + 1] 723 440[M + 1]364 724 457[M + 3] 455[M + 1] 726 362[M + 1] 727 366[M + 1] 734 370[M +1] 736 338[M + 1] 741 404[M + 1] 742 351[M + 1] 745 386[M + 1] 746370[M + 1] 294 747 336[M + 1] 748 381[M + 3] 379[M + 1] 749 416[M + 1]340 750 437[M + 1] 751 362[M + 1] 752 352[M + 3] 350[M + 1] 754 366[M +1] 755 354[M + 1] 757 425[M + 1] 759 346[M + 1] 760 344[M + 1] 761402[M + 1] 762 251[M + 1] 763 355[M + 1] 764 362[M + 3] 360[M + 1] 765392[M + 3] 390[M + 1] 769 366[M + 1] 770 372[M + 1] 772 292[M + 1] 773424[M + 1] 775 396[M + 3] 394[M + 1] 776 388[M + 1] 777 383[M + 1] 778404[M + 1] 779 398[M + 1] 780 368[M + 1] 782 368[M + 1] 784 369[M + 1]785 431[M + 3] 429[M + 1] 787 473[M + 1] 397 788 375[M + 1] 789 467[M +1] 794 327[M + 1] 795 384[M + 1] 796 370[M + 1] 798 370[M + 1] 801404[M + 3] 402[M + 1] 805 376[M + 1] 806 411[M + 1] 807 356[M + 1]

TABLE 166 808 354[M + 1] 809 400[M + 1] 324 812 425[M + 1] 815 386[M +1] 817 377[M + 1] 818 398[M + 1] 819 352[M + 1] 821 336[M + 1] 823362[M + 1] 824 363[M + 1] 287 825 420[M + 1] 826 430[M + 1] 828 377[M +1] 829 437[M + 1] 830 370[M + 1] 831 327[M + 1] 837 324[M + 1] 248 838377[M + 1] 839 376[M + 3] 374[M + 1] 841 363[M + 3] 361[M + 1] 842386[M + 1] 843 466[M + 3] 464[M + 1] 844 381[M + 1] 845 324[M + 1] 248846 358[M + 1] 847 373[M + 1] 852 489[M + 1] 853 376[M + 1] 854 448[M +1] 856 420[M + 1] 344 857 341[M + 1] 858 383[M + 1] 860 370[M + 1] 861334[M + 3] 332[M + 1] 862 358[M + 1] 864 392[M + 1] 865 398[M + 3]396[M + 1] 867 399[M + 1] 868 430[M + 1] 870 362[M + 3] 360[M + 1] 872428[M + 1] 873 351[M + 1] 874 341[M + 1] 877 399[M + 1] 323 879 332[M +1] 880 363[M + 3] 361[M + 1] 882 426[M + 1] 883 360[M + 1] 884 320[M +1] 885 361[M + 1] 886 380[M + 1] 888 292[M + 1] 889 451[M + 1] 449[M +1] 890 400[M + 1] 891 292[M + 1] 894 347[M + 1] 898 412[M + 3] 410[M +1] 899 397[M + 1] 901 411[M + 1] 902 377[M + 1] 903 370[M + 1] 904422[M + 1] 905 392[M + 1] 907 308[M + 1] 909 393[M + 1] 911 415[M + 1]912 383[M + 1] 913 413[M + 1] 914 400[M + 1] 915 389[M + 1] 313 917358[M + 1] 918 433[M + 3] 431[M + 1] 919 354[M + 1] 920 381[M + 3]379[M + 1] 921 389[M + 1] 922 413[M + 1] 337 923 437[M + 1] 924 376[M +1] 925 390[M + 1] 927 355[M + 1] 929 370[M + 1] 932 380[M + 3] 378[M +1] 934 507[M + 1] 937 388[M + 1] 938 366[M + 1] 940 388[M + 1] 942378[M + 1] 943 413[M + 1] 945 372[M + 1] 948 462[M + 1] 949 363[M + 1]950 368[M + 1] 951 412[M + 1] 952 378[M + 1] 953 318[M + 1] 954 363[M +3] 361[M + 1] 955 406[M + 3] 404[M + 1] 956 292[M + 1] 957 398[M + 3]396[M + 1] 958 310[M + 1] 959 406[M + 3] 404[M + 1] 961 362[M + 3]360[M + 1] 962 327[M + 1] 963 392[M + 1]

TABLE 167 965 438[M + 3] 436[M + 1] 967 425[M + 3] 423[M + 1] 969413[M + 1] 973 386[M + 1] 975 407[M + 3] 405[M + 1] 976 358[M + 1] 977369[M + 1] 979 395[M + 1] 980 402[M + 1] 981 392[M + 3] 390[M + 1] 982366[M + 1] 983 379[M + 1] 985 408[M + 1] 986 440[M + 3] 438[M + 1] 987358[M + 1] 988 294[M + 1] 989 332[M + 1] 991 356[M + 1] 992 477[M + 1]993 416[M + 3] 414[M + 1] 995 425[M + 3] 423[M + 1] 996 416[M + 3]414[M + 1] 997 363[M + 3] 361[M + 1] 999 336[M + 1] 1000 388[M + 1] 3121001 374[M + 1] 1002 400[M + 1] 1003 394[M + 1] 1004 397[M + 1] 1007448[M + 1] 372 1009 366[M + 1] 1011 419[M + 1] 1012 316[M + 1] 1013431[M + 1] 1015 372[M + 1] 1016 470[M + 1] 1017 413[M + 1] 1018 386[M +1] 1019 433[M + 3] 431[M + 1] 1021 464[M + 1] 1022 384[M + 1] 1023407[M + 3] 405[M + 1] 1024 346[M + 1] 1025 455[M + 3] 453[M + 1] 1026425[M + 1] 1027 444[M + 1] 1029 410[M + 1] 1030 413[M + 1] 1031 404[M +1] 1032 472[M + 1] 396 1033 377[M + 1] 1036 350[M + 1] 1038 364[M + 1]1040 317[M + 1] 1041 407[M + 1] 1042 382[M + 1] 1045 425[M + 3] 423[M +1] 1046 366[M + 1] 1047 390[M + 1] 1048 440[M + 1] 1049 396[M + 1] 1050400[M + 1] 1051 315[M + 1] 1053 363[M + 3] 361[M + 1] 1054 360[M + 1]1057 427[M + 1] 1058 360[M + 1] 1060 381[M + 3] 379[M + 1] 1063 395[M +1] 1065 451[M + 1] 449[M + 1] 1066 485[M + 1] 1070 380[M + 3] 378[M + 1]1071 345[M + 1] 1072 381[M + 3] 379[M + 1] 1073 397[M + 1] 1075 342[M +1] 1077 344[M + 1] 1078 370[M + 1] 1079 387[M + 1] 1080 370[M + 1] 2941081 355[M + 1] 1082 398[M + 3] 396[M + 1] 1083 318[M + 1] 1085 439[M +3] 437[M + 1] 1086 428[M + 1] 1089 399[M + 1] 1090 398[M + 1] 1091434[M + 3] 432[M + 1] 1092 398[M + 3] 396[M + 1] 1093 401[M + 1] 1095400[M + 1] 1096 409[M + 1] 1097 384[M + 1] 1098 395[M + 1] 1099 511[M +4] 510[M + 3] 509[M + 2] 508[M + 1] 1101 350[M + 1] 1102 442[M + 1] 1103397[M + 1] 1105 372[M + 1] 1106 346[M + 1] 1108 383[M + 1] 1112 445[M +1]

TABLE 168 1113 358[M + 1] 1117 394[M + 1] 1118 336[M + 1] 260 1121392[M + 3] 390[M + 1] 1122 322[M + 1] 1123 316[M + 1] 1126 386[M + 1]1127 368[M + 1] 1128 416[M + 3] 414[M + 1] 1129 341[M + 1] 1130 432[M +1] 1134 396[M + 1] 1136 396[M + 3] 394[M + 1] 1137 292[M + 1] 1138413[M + 1] 1141 344[M + 1] 1143 384[M + 1] 1144 446[M + 1] 1145 390[M +1] 314 1146 405[M + 1] 1148 380[M + 1] 304 1149 364[M + 1] 1151 442[M +1] 1152 365[M + 1] 1154 318[M + 1] 1155 427[M + 1] 1156 368[M + 1] 1157366[M + 1] 1158 415[M + 3] 413[M + 1] 1159 414[M + 3] 412[M + 1] 1162370[M + 1] 294 1163 416[M + 3] 414[M + 1] 1164 396[M + 1] 320 1165361[M + 1] 1167 424[M + 1] 348 1168 428[M + 1] 1169 422[M + 1] 1170411[M + 1] 1171 390[M + 3] 388[M + 1] 1173 361[M + 1] 1174 342[M + 1]1175 430[M + 1] 1176 345[M + 1] 1177 376[M + 3] 374[M + 1] 1178 351[M +1] 1179 344[M + 1] 1180 398[M + 3] 396[M + 1] 1182 426[M + 1] 1183376[M + 3] 374[M + 1] 1186 374[M + 1] 298 1187 427[M + 1] 1188 350[M +1] 1189 408[M + 3] 406[M + 1] 1190 386[M + 1] 1191 377[M + 1] 1192335[M + 1] 1195 412[M + 3] 410[M + 1] 1196 380[M + 1] 1198 398[M + 1]322 1200 352[M + 1] 1201 424[M + 3] 422[M + 1] 1202 369[M + 1] 1203420[M + 1] 1204 398[M + 3] 396[M + 1] 1206 416[M + 1] 1208 344[M + 1]1209 422[M + 1] 1210 408[M + 1] 1212 391[M + 1] 1214 360[M + 1] 1218372[M + 1] 1219 470[M + 1] 1220 264[M + 1] 1222 362[M + 3] 360[M + 1]1225 413[M + 1] 1226 374[M + 1] 1227 425[M + 1] 1229 455[M + 3] 453[M +1] 1231 413[M + 1] 1232 340[M + 1] 1233 394[M + 1] 1234 416[M + 3]414[M + 1] 1235 427[M + 1] 1236 348[M + 1] 272 1237 353[M + 1] 1238419[M + 1] 1239 416[M + 3] 414[M + 1] 1246 474[M + 1] 1248 414[M + 1]1249 336[M + 1] 1250 352[M + 1] 1251 393[M + 1] 1252 357[M + 1] 1253430[M + 1] 1254 412[M + 1] 1256 333[M + 1] 1259 356[M + 1] 1260 348[M +1] 1270 374[M + 1] 1282 362[M + 1]

In above structural formula (Ia) to (Ih), the combination ofNR^(2a)R^(2b), R^(3c), R^(3d), R⁵ and G (NR^(2a)R^(2b), R^(3c), R^(3d),R⁵, G) are the following compounds.

-   (NHMe,H,H,Me,CONHPh),(NHMe,H,H,Me,CONH-3-pyridyl),(NHMe,H,H,Me,NHCOPh),(NHMe,H,H,Me,NHCO-2-furyl),(NHMe,H,H,Me,NHCONHPh),(NHMe,H,H,Me,NHCOCONHPh),(NHMe,H,H,Et,CONHPh),(NHMe,H,H,Et,CONH-3-pyridyl),(NHMe,H,H,Et,NHCOPh),(NHMe,H,H,Et,NHCO-2-furyl),(NHMe,H,H,Et,NHCONHPh),(NHMe,H,H,Et,NHCOCONHPh),(NHMe,H,H,CH2OH,CONHPh),(NHMe,H,H,CH2OH,CONH-3-pyridyl),(NHMe,H,H,CH2OH,NHCOPh),(NHMe,H,H,CH2OH,NHCO-2-furyl),(NHMe,H,H,CH2OH,NHCONHPh),(NHMe,H,H,CH2OH,NHCOCONHPh),(NHMe,H,Me,Me,CONHPh),(NHMe,H,Me,Me,CONH-3-pyridyl),(NHMe,H,Me,Me,NHCOPh),(NHMe,H,Me,Me,NHCO-2furyl),(NHMe,H,Me,Me,NHCONHPh),(NHMe,H,Me,Me,NHCOCONHPh),(NHMe,H,Me,Et,CONHPh),(NHMe,H,Me,Et,CONH-3-pyridyl),(NHMe,H,Me,Et,NHCOPh),(NHMe,H,Me,Et,NHCO-2-furyl),(NHMe,H,Me,Et,NHCONHPh),(NHMe,H,Me,Et,NHCOCONHPh),(NHMe,H,Me,CH2OH,CONHPh),(NHMe,H,Me,H,Me,CH2OH,CONH-3-pyridyl),(NHMe,H,Me,CH2OH,NHCOPh),(NHMe,H,Me,CH2OH,NHCO-2-furyl),(NHMe,H,Me,CH2OH,NHCONHPh),(NHMe,H,Me,CH2OH,NHCOCONHPh),(NHMe,H,Ph,Me,CONHPh),(NHMe,H,Ph,Me,CONH-3-pyridyl),(NHMe,H,Ph,Me,NHCOPh),(NHMe,H,Ph,Me,NHCO-2furyl),(NHMe,H,Ph,Me,NHCONHPh),(NHMe,H,Ph,Me,NHCOCONHPh),(NHMe,H,Ph,Et,CONHPh),(NHMe,H,Ph,Et,CONH-3-pyridyl),(NHMe,H,Ph,Et,NHCOPh),(NHMe,H,Ph,Et,NHCO-2-furyl),(NHMe,H,Ph,Et,NHCONHPh),(NHMe,H,Ph,Et,NHCOCONHPh),(NHMe,H,Ph,CH2OH,CONHPh),(NHMe,H,Ph,CH2OH,CONH-3-pyridyl),(NHMe,H,Ph,CH2OH,NHCOPh),(NHMe,H,Ph,CH2OH,NHCO-2-furyl),(NHMe,H,Ph,CH2OH,NHCONHPh),(NHMe,H,Ph,CH2OH,NHCOCONHPh),(NHMe,H,OH,Me,CONHPh),(NHMe,H,OH,Me,CONH-3-pyridyl),(NHMe,H,OH,Me,NHCOPh),(NHMe,H,OH,Me,NHCO-2-furyl),(NHMe,H,OH,Me,NHCONHPh),(NHMe,H,OH,Me,NHCOCONHPh),(NHMe,H,OH,Et,CONHPh),(NHMe,H,OH,Et,CONH-3-pyridyl),(NHMe,H,OH,Et,NHCOPh),(NHMe,H,OH,Et,NHCO-2-furyl),(NHMe,H,OH,Et,NHCONHPh),(NHMe,H,OH,Et,NHCOCONHPh),(NHMe,H,OH,CH2OH,CONHPh),(NHMe,H,OH,CH2OH,CONH-3-pyridyl),(NHMe,H,OH,CH2OH,NHCOPh),(NHMe,H,OH,CH2OH,NHCO-2-furyl),(NHMe,H,OH,CH2OH,NHCONHPh),(NHMe,H,OH,CH2OH,NHCOCONHPh),(NHMe,Me,H,Me,CONHPh),(NHMe,Me,H,Me,CONH-3-pyridyl),(NHMe,Me,H,Me,NHCOPh),(NHMe,Me,H,Me,NHCO-2-furyl),(NHMe,Me,H,Me,NHCONHPh),(NHMe,Me,H,Me,NHCOCONHPh),(NHMe,Me,H,Et,CONHPh),(NHMe,Me,H,Et,CONH-3-pyridyl),(NHMe,Me,H,Et,NHCOPh),(NHMe,Me,H,Et,NHCO-2-furyl),(NHMe,Me,H,Et,NHCONHPh),(NHMe,Me,H,Et,NHCOCONHPh),(NHMe,Me,H,CH2OH,CONHPh),(NHMe,Me,H,CH2OH,CONH-3-pyridyl),(NHMe,Me,H,CH2OH,NHCOPh),(NHMe,Me,H,CH2OH,NHCO-2-furyl),(NHMe,Me,H,CH2OH,NHCONHPh),(NHMe,Me,H,CH2OH,NHCOCONHPh),(NHMe,Me,Me,Me,CONHPh),(NHMe,Me,Me,Me,CONH-3-pyridyl),(NHMe,Me,Me,Me,NHCOPh),(NHMe,Me,Me,Me,NHCO-2-furyl),(NHMe,Me,Me,Me,NHCONHPh),(NHMe,Me,Me,Me,NHCOCONHPh),(NHMe,Me,Me,Et,CONHPh),(NHMe,Me,Me,Et,CONH-3-pyridyl),(NHMe,Me,Me,Et,NHCOPh),(NHMe,Me,Me,Et,NHCO-2-furyl),(NHMe,Me,Me,Et,NHCONHPh),(NHMe,Me,Me,Et,NHCOCONHPh),(NHMe,Me,Me,CH2OH,CONHPh),(NHMe,Me,Me,CH2OH,CONH-3-pyridyl),(NHMe,Me,Me,CH2OH,NHCOPh),(NHMe,Me,Me,CH2OH,NHCO-2-furyl),(NHMe,Me,Me,CH2OH,NHCONHPh),(NHMe,Me,Me,CH2OH,NHCOCONHPh),(NHMe,Me,Ph,Me,CONHPh),(NHMe,Me,Ph,Me,CONH-3-pyridyl),(NHMe,Me,Ph,Me,NHCOPh),(NHMe,Me,Ph,Me,NHCO-2-furyl),(NHMe,Me,Ph,Me,NHCONHPh),(NHMe,Me,Ph,Me,NHCOCONHPh),(NHMe,Me,Ph,Et,CONHPh),(NHMe,Me,Ph,Et,CONH-3-pyridyl),(NHMe,Me,Ph,Et,NHCOPh),(NHMe,Me,Ph,Et,NHCO-2-furyl),(NHMe,Me,Ph,Et,NHCONHPh),(NHMe,Me,Ph,Et,NHCOCONHPh),(NHMe,Me,Ph,CH2OH,CONHPh),(NHMe,Me,Ph,CH2OH,CONH-3-pyridyl),(NHMe,Me,Ph,CH2OH,NHCOPh),(NHMe,Me,Ph,CH2OH,NHCO-2-furyl),(NHMe,Me,Ph,CH2OH,NHCONHPh),(NHMe,Me,Ph,CH2OH,NHCOCONHPh),(NHMe,Me,OH,Me,CONHPh),(NHMe,Me,OH,Me,CONH-3-pyridyl),(NHMe,Me,OH,Me,NHCOPh),(NHMe,Me,OH,Me,NHCO-2-furyl),(NHMe,Me,OH,Me,NHCONHPh),(NHMe,Me,OH,Me,NHCOCONHPh),(NHMe,Me,OH,Et,CONHPh),(NHMe,Me,OH,Et,CONH-3-pyridyl),(NHMe,Me,OH,Et,NHCOPh),(NHMe,Me,OH,Et,NHCO-2-furyl),(NHMe,Me,OH,Et,NHCONHPh),(NHMe,Me,OH,Et,NHCOCONHPh),(NHMe,Me,OH,CH2OH,CONHPh),(NHMe,Me,OH,CH2OH,CONH-3-pyridyl),(NHMe,Me,OH,CH2OH,NHCOPh),(NHMe,Me,OH,CH2OH,NHCO-2-furyl),(NHMe,Me,OH,CH2OH,NHCONHPh),(NHMe,Me,OH,CH2OH,NHCOCONHPh),(NHMe,Ph,H,Me,CONHPh),(NHMe,Ph,H,Me,CONH-3-pyridyl),(NHMe,Ph,H,Me,NHCOPh),(NHMe,Ph,H,Me,NHCO-2-furyl),(NHMe,Ph,H,Me,NHCONPh),(NHMe,Ph,H,Me,NHCOCONHPh),(NHMe,Ph,H,Et,CONHPh),(NHMe,Ph,H,Et,CONH-3-pyridyl),(NHMe,Ph,H,Et,NHCOPh),(NHMe,Ph,H,Et,NHCO-2-furyl),(NHMe,Ph,H,Et,NHCONHPh),(NHMe,Ph,H,Et,NHCOCONHPh),(NHMe,Ph,H,CH2OH,CONHPh),(NHMe,Ph,H,CH2OH,CONH-3-pyridyl),(NHMe,Ph,H,CH2OH,NHCOPh),(NHMe,Ph,H,CH2OH,NHCO-2-furyl),(NHMe,Ph,H,CH2OH,NHCONHPh),(NHMe,Ph,H,CH2OH,NHCOCONHPh),(NHMe,Ph,Me,Me,CONHPh),(NHMe,Ph,Me,Me,CONH-3-pyridyl),(NHMe,Ph,Me,Me,NHCOPh),(NHMe,Ph,Me,Me,NHCO-2-furyl),(NHMe,Ph,Me,Me,NHCONHPh),(NHMe,Ph,Me,Me,NHCOCONHPh),(NHMe,Ph,Me,Et,CONHPh),(NHMe,Ph,Me,Et,CONH-3-pyridyl),(NHMe,Ph,Me,Et,NHCOPh),(NHMe,Ph,Me,Et,NHCO-2-furyl),(NHMe,Ph,Me,Et,NHCONHPh),(NHMe,Ph,Me,Et,NHCOCONHPh),(NHMe,Ph,Me,CH2OH,CONHPh),(NHMe,Ph,Me,CH2OH,CONH-3-pyridyl),(NHMe,Ph,Me,CH2OH,NHCOPh),(NHMe,Ph,Me,CH2OH,NHCO-2-furyl),(NHMe,Ph,Me,CH2OH,NHCONHPh),(NHMe,Ph,Me,CH2OH,NHCOCONHPh),(NHMe,Ph,Ph,Me,CONHPh),(NHMe,Ph,Ph,Me,CONH-3-pyridyl),(NHMe,Ph,Ph,Me,NHCOPh),(NHMe,Ph,Ph,Me,NHCO-2-furyl),(NHMe,Ph,Ph,Me,NHCONHPh),(NHMe,Ph,Ph,Me,NHCOCONHPh),(NHMe,Ph,Ph,Et,CONHPh),(NHMe,Ph,Ph,Et,CONH-3-pyridyl),(NHMe,Ph,Ph,Et,NHCOPh),(NHMe,Ph,Ph,Et,NHCO-2-furyl),(NHMe,Ph,Ph,Et,NHCONHPh),(NHMe,Ph,Ph,Et,NHCOCONHPh),(NHMe,Ph,Ph,CH2OH,CONHPh),(NHMe,Ph,Ph,CH2OH,CONH-3-pyridyl),(NHMe,Ph,Ph,CH2OH,NHCOPh),(NHMe,Ph,Ph,CH2OH,NHCO-2-furyl),(NHMe,Ph,Ph,CH2OH,NHCONHPh),(NHMe,Ph,Ph,CH2OH,NHCOCONHPh),(NHMe,Ph,OH,Me,CONHPh),(NHMe,Ph,OH,Me,CONH-3-pyridyl),(NHMe,Ph,OH,Me,NHCOPh),(NHMe,Ph,OH,Me,NHCO-2-furyl),(NHMe,Ph,OH,Me,NHCONHPh),(NHMe,Ph,OH,Me,NHCOCONHPh),(NHMe,Ph,OH,Et,CONHPh),(NHMe,Ph,OH,Et,CONH-3-pyridyl),(NHMe,Ph,OH,Et,NHCOPh),(NHMe,Ph,OH,Et,NHCO-2-furyl),(NHMe,Ph,OH,Et,NHCONHPh),(NHMe,Ph,OH,Et,NHCOCONHPh),(NHMe,Ph,OH,CH2OH,CONHPh),(NHMe,Ph,OH,CH2OH,CONH-3-pyridyl),(NHMe,Ph,OH,CH2OH,NHCOPh),(NHMe,Ph,OH,CH2OH,NHCO-2-furyl),(NHMe,Ph,OH,CH2OH,NHCONHPh),(NHMe,Ph,OH,CH2OH,NHCOCONHPh),-   (NHCH2CH2OH,H,H,Me,CONHPh),(NHCH2CH2OH,H,H,Me,CONH-3-pyridyl),(NHCH2CH2OH,H,Me,NHCOPh),(NHCH2CH2OH,H,H,Me,NHCO-2-furyl),(NHCH2CH2OH,H,H,Me,NHCONHPh),(NHCH2CH2OH,H,H,Me,NHCOCONHPh),(NHCH2CH2OH,H,H,Et,CONHPh),(NHCH2CH2OH,H,H,Et,CONH-3-pyridyl),(NHCH2CH2OH,H,H,Et,NHCOPh),(NHCH2CH2OH,H,H,Et,NHCO-2-furyl),(NHCH2CH2OH,H,H,Et,NHCONHPh),(NHCH2CH2OH,H,H,Et,NHCOCONHPh),(NHCH2CH2OH,H,H,CH2OH,CONHPh),(NHCH2CH2OH,H,H,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,H,H,CH2OH,NHCOPh),(NHCH2CH2OH,H,H,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,H,H,CH2OH,NHCONHPh),(NHCH2CH2OH,H,H,CH2OH,NHCOCONHPh),(NHCH2CH2OH,H,Me,Me,CONHPh),(NHCH2CH2OH,H,Me,Me,CONH-3-pyridyl),(NHCH2CH2OH,H,Me,Me,NHCOPh),(NHCH2CH2OH,H,Me,Me,NHCO-2-furyl),(NHCH2CH2OH,H,Me,Me,NHCONHPh),(NHCH2CH2OH,H,Me,Me,NHCOCONHPh),(NHCH2CH2OH,H,Me,Et,CONHPh),(NHCH2CH2OH,H,Me,Et,CONH-3-pyridyl),(NHCH2CH2OH,H,Me,Et,NHCOPh),(NHCH2CH2OH,H,Me,Et,NHCO-2-furyl),(NHCH2CH2OH,H,Me,Et,NHCONHPh),(NHCH2CH2OH,H,Me,Et,NHCOCONHPh),(NHCH2CH2OH,H,Me,CH2OH,CONHPh),(NHCH2CH2OH,H,Me,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,H,Me,CH2OH,NHCOPh),(NHCH2CH2OH,H,Me,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,H,Me,CH2OH,NHCONHPh),(NHCH2CH2OH,H,Me,CH2OH,NHCOCONHPh),(NHCH2CH2OH,H,Ph,Me,CONHPh),(NHCH2CH2OH,H,Ph,Me,CONH-3-pyridyl),(NHCH2CH2OH,H,Ph,Me,NHCOPh),(NHCH2CH2OH,H,Ph,Me,NHCO-2-furyl),(NHCH2CH2OH,H,Ph,Me,NHCONHPh),(NHCH2CH2OH,H,Ph,Me,NHCOCONHPh),(NHCH2CH2OH,H,Ph,Et,CONHPh),(NHCH2CH2OH,H,Ph,Et,CONH-3pyridyl),(NHCH2CH2OH,H,Ph,Et,NHCOPh),(NHCH2CH2OH,H,Ph,Et,NHCO-2-furyl),(NHCH2CH2OH,H,Ph,Et,NHCONHPh),(NHCH2CH2OH,H,Ph,Et,NHCOCONHPh),(NHCH2CH2OH,H,Ph,CH2OH,CONHPh),(NHCH2CH2OH,H,Ph,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,H,Ph,CH2OH,NHCOPh),(NHCH2CH2OH,H,Ph,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,H,Ph,CH2OH,NHCONHPh),(NHCH2CH2OH,H,Ph,CH2OH,NHCOCONHPh),(NHCH2CH2OH,H,OH,Me,CONHPh),(NHCH2CH2OH,H,OH,Me,CONH-3-pyridyl),(NHCH2CH2OH,H,OH,Me,NHCOPh),(NHCH2CH2OH,H,OH,Me,NHCO-2-furyl),(NHCH2CH2OH,H,OH,Me,NHCONHPh),(NHCH2CH2OH,H,OH,Me,NHCOCONHPh),(NHCH2CH2OH,H,OH,Et,CONHPh),(NHCH2CH2OH,H,OH,Et,CONH-3-pyridyl),(NHCH2CH2OH,H,OH,Et,NHCOPh),(NHCH2CH2OH,H,OH,Et,NHCO-2-furyl),(NHCH2CH2OH,H,OH,Et,NHCONHPh),(NHCH2CH2OH,H,OH,Et,NHCOCONHPh),(NHCH2CH2OH,H,OH,CH2OH,CONHPh),(NHCH2CH2OH,H,OH,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,H,OH,CH2OH,NHCOPh),(NHCH2CH2OH,H,OH,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,H,OH,CH2OH,NHCONHPh),(NHCH2CH2OH,H,OH,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Me,H,Me,CONHPh),(NHCH2CH2OH,Me,H,Me,CONH-3-pyridyl),(NHCH2CH2OH,Me,H,Me,NHCOPh),(NHCH2CH2OH,Me,H,Me,NHCO-2-furyl),(NHCH2CH2OH,Me,H,Me,NHCONHPh),(NHCH2CH2OH,Me,H,Me,NHCOCONHPh),(NHCH2CH2OH,Me,H,Et,CONHPh),(NHCH2CH2OH,Me,H,Et,CONH-3-pyridyl),(NHCH2CH2OH,Me,H,Et,NHCOPh),(NHCH2CH2OH,Me,H,Et,NHCO-2-furyl),(NHCH2CH2OH,Me,H,Et,NHCONHPh),(NHCH2CH2OH,Me,H,Et,NHCOCONHPh),(NHCH2CH2OH,Me,H,CH2OH,CONHPh),(NHCH2CH2OH,Me,H,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,Me,H,CH2OH,NHCOPh),(NHCH2CH2OH,Me,H,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,Me,H,CH2OH,NHCONHPh),(NHCH2CH2OH,Me,H,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Me,Me,Me,CONHPh),(NHCH2CH2OH,Me,Me,Me,CONH-3-pyridyl),(NHCH2CH2OH,Me,Me    ,Me,NHCOPh),(NHCH2CH2OH,Me,Me,Me,NHCO-2-furyl),(NHCH2CH2OH,Me,Me,Me,NHCONHPh),(NHCH2CH2OH,Me,Me,Me,NHCOCONHPh),(NHCH2CH2OH,Me,Me,Et,CONHPh),(NHCH2CH2OH,Me,Me,Et,CONH-3-pyridyl),(NHCH2CH2OH,Me,Me,Et,NHCOPh),(NHCH2CH2OH,Me,Me,Et,NHCO-2-furyl),(NHCH2CH2OH,Me,Me,Et,NHCONHPh),(NHCH2CH2OH,Me,Me,Et,NHCOCONHPh),(NHCH2CH2OH,Me,Me,CH2OH,CONHPh),(NHCH2CH2OH,Me,Me,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,Me,Me,CH2OH,NHCOPh),CH2OH,NHCO-2-furyl),(NHCH2CH2OH,Me,Me,CH2OH,NHCONHPh),(NHCH2CH2OH,Me,Me,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Me,Ph,Me,CONHPh),(NHCH2CH2OH,Me,Ph,Me,CONH-3-pyridyl),(NHCH2CH2OH,Me,Ph,Me,NRCOPh),(NHCH2CH2OH,Me,Ph,Me,NHCO-2-furyl),(NHCH2CH2OH,Me,Ph,Me,NHCONHPh),(NHCH2CH2OH,Me,Ph,Me,NHCOCONHPh),(NHCH2CH2OH,Me,Ph,Et,CONHPh),(NHCH2CH2OH,Me,Ph,Et,CONH-3-pyridyl),(NHCH2CH2OH,Me,Ph,Et,NHCOPh),(NHCH2CH2OH,Me,Ph,Et,NHCO-2-furyl),(NHCH2CH2OH,Me,Ph,Et,NHCONHPh),(NRCH2CH2OH,Me,Ph,Et,NHCOCONHPh),(NHCH2CH2OH,Me,Ph,CH2OH,CONHPh),(NHCH2CH2OH,Me,Ph,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,Me,Ph,CH2OH,NHCOPh),(NHCH2CH2OH,Me,Ph,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,Me,Ph,CH2OH,NHCONHPh),(NHCH2CH2OH,Me,Ph,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Me,OH,Me,CONHPh),(NHCH2CH2OH,Me,OH,Me,CONH-3-pyridyl),(NHCH2CH2OH,Me,OH,Me,NHCOPh),(NHCH2CH2OH,Me,OH,Me,NHCO-2-furyl),(NHCH2CH2OH,Me,OH,Me,NHCONHPh),(NHCH2CH2OH,Me,OH,Me,NHCOCONHPh),(NHCH2CH2OH,Me,OH,Et,CONHPh),(NHCH2CH2OH,Me,OH,Et,CONH-3-pyridyl),(NHCH2CH2OH,Me,OH,Et,NHCOPh),(NHCH2CH2OH,Me,OH,Et,NHCO-2-furyl),(NHCH2CH2OH,Me,OH,Et,NHCONHPh),(NHCH2CH2OH,Me,OH,Et,NHCOCONHPh),(NHCH2CH2OH,Me,OH,CH2OH,CONHPh),(NHCH2CH2OH,Me,OH,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,Me,OH,CH2OH,NHCOPh),(NHCH2CH2OH,Me,OH,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,Me,OH,CH2OH,NHCONHPh),(NHCH2CH2OH,Me,OH,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Ph,H,Me,CONHPh),(NHCH2CH2OH,Ph,H,Me,CONH-3-pyridyl),(NHCH2CH2OH,Ph,H,Me,NHCOPh),(NHCH2CH2OH,Ph,H,Me,NHCO-2-furyl),(NHCH2CH2OH,Ph,H,Me,NHCONHPh),(NHCH2CH2OH,Ph,H,Me,NHCOCONHPh),(NHCH2CH2OH,Ph,H,Et,CONHPh),(NHCH2CH2OH,Ph,H,Et,CONH-3-pyridyl),(NHCH2CH2OH,Ph,H,Et,NHCOPh),(NHCH2CH2OH,Ph,H,Et,NHCO-2-furyl),(NHCH2CH2OH,Ph,H,Et,NHCONHPh),(NHCH2CH2OH,Ph,H,Et,NHCOCONHPh),(NHCH2CH2OH,Ph,H,CH2OH,CONHPh),(NHCH2CH2OH,Ph,H,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,Ph,H,CH2OH,NHCOPh),(NHCH2CH2OH,Ph,H,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,Ph,H,CH2OH,NHCONHPh),(NHCH2CH2OH,Ph,H,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Ph,Me,Me,CONHPh),(NHCH2CH2OH,Ph,Me,Me,CONH-3-pyridyl),(NHCH2CH2OH,Ph,Me,Me,NHCOPh),(NHCH2CH2OH,Ph,Me,Me,NHCO-2-furyl),(NHCH2CH2OH,Ph,Me,Me,NHCONHPh),(NHCH2CH2OH,Ph,Me,Me,NHCOCONHPh),(NHCH2CH2OH,Ph,Me,Et,CONHPh),(NHCH2CH2OH,Ph,Me,Et,CONH-3-pyridyl),(NHCH2CH2OH,Ph,Me,Et,NHCOPh),(NHCH2CH2OH,Ph,Me,Et,NHCO-2-furyl),(NHCH2CH2OH,Ph,Me,Et,NHCONHPh),(NHCH2CH2OH,Ph,Me,Et,NHCOCONHPh),(NHCH2CH2OH,Ph,Me,CH2OH,CONHPh),(NHCH2CH2OH,Ph,Me,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,Ph,Me,CH2OH,NHCOPh),(NHCH2CH2OH,Ph,Me,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,Ph,Me,CH2OH,NHCONHPh),(NHCH2CH2OH,Ph,Me,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Ph,Ph,Me,CONHPh),(NHCH2CH2OH,Ph,Ph,Me,CONH-3-pyridyl),(NHCH2CH2OH,Ph,Ph,Me,NHCOPh),(NHCH2CH2OH,Ph,Ph,Me,NHCO-2-furyl),(NHCH2CH2OH,Ph,Ph,Me,NHCONHPh),(NHCH2CH2OH,Ph,Ph,Me,NHCOCONHPh),(NHCH2CH2OH,Ph,Ph,Et,CONHPh),(NHCH2CH2OH,Ph,Ph,Et,CONH-3-pyridyl),(NHCH2CH2OH,Ph    Ph,Et,NHCOPh),(NHCH2CH2OH,Ph,Ph,Et,NHCO-2-furyl),(NHCH2CH2OH,Ph,Ph,Et,NHCONHPh),(NHCH2CH2OH,Ph,Ph,Et,NHCOCONHPh),(NHCH2CH2OH,Ph,Ph,CH2OH,CONHPh),(NHCH2CH2OH,Ph,Ph,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,Ph,Ph,CH2OH,NHCOPh),(NHCH2CH2OH,Ph,Ph,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,Ph,Ph,CH2OH,NHCONHPh),(NHCH2CH2OH,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH2CH2OH,Ph,OH,Me,CONHPh),(NHCH2CH2OH,Ph,OH,Me,CONH-3-pyridyl),(NHCH2CH2OH,Ph,OH,Me,NHCOPh),(NHCH2CH2OH,Ph,OH,Me,NHCO-2-furyl),(NHCH2CH2OH,Ph,OH,Me,NHCONHPh),(NHCH2CH2OH,Ph,OH,Me,NHCOCONHPh),(NHCH2CH2OH,Ph,OH,Et,CONHPh),(NHCH2CH2OH,Ph,OH,Et,CONH-3-pyridyl),(NHCH2CH2OH,Ph,OH,Et,NHCOPh),(NHCH2CH2OH,Ph,OH,Et,NHCO-2-furyl),(NHCH2CH2OH,Ph,OH,Et,NHCONHPh),(NHCH2CH2OH,Ph,OH,Et,NHCOCONHPh),(NHCH2CH2OH,Ph,OH,CH2OH,CONHPh),(NHCH2CH2OH,Ph,OH,CH2OH,CONH-3-pyridyl),(NHCH2CH2OH,Ph,OH,CH2OH,NHCOPh),(NHCH2CH2OH,Ph,OH,CH2OH,NHCO-2-furyl),(NHCH2CH2OH,Ph,OH,CH2OH,NHCONHPh),(NHCH2CH2OH,Ph,OH,CH2OH,NHCOCONHPh),-   (NHCH2CONH2,H,H,Me,CONHPh),(NHCH2CONH2,H,H,Me,CONH-3-pyridyl),(NHCH2CONH2,H,H,Me,NHCOPh),(NHCH2CONH2,H,H,Me,NHCO-2-furyl),(NHCH2CONH2,H,H,Me,NHCONHPh),(NHCH2CONH2,H,H,Me,NHCOCONHPh),(NHCH2CONH2,H,H,Et,CONHPh),(NHCH2CONH2,H,H,Et,CONH-3-pyridyl),(NHCH2CONH2,H,H,Et,NHCOPh),(NHCH2CONH2,H,H,Et,NHCO-2-furyl),(NHCH2CONH2,H,H,Et,NHCONHPh),(NHCH2CONH2,H,H,Et,NHCOCONHPh),(NHCH2CONH2,H,H,CH2OH,CONHPh),(NHCH2CONH2,H,H,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,H,H,CH2OH,NHCOPh),(NHCH2CONH2,H,H,CH2OH,NHCO-2-furyl),(NHCH2CONH2,H,H,CH2OH,NHCONHPh),(NHCH2CONH2,H,H,CH2OH,NHCOCONHPh),(NHCH2CONH2,H,Me,Me,CONHPh),(NHCH2CONH2,H,Me,Me,CONH-3-pyridyl),(NHCH2CONH2,H,Me,Me,NHCOPh),(NHCH2CONH2,H,Me,Me,NHCO-2-furyl),(NHCH2CONH2,H,Me,Me,NHCONHPh),(NHCH2CONH2,H,Me,Me,NHCOCONHPh),(NHCH2CONH2,H,Me,Et,CONHPh),(NHCH2CONH2,H,Me,Et,CONH-3-pyridyl),(NHCH2CONH2,H,Me,Et,NHCOPh),(NHCH2CONH2,H,Me,Et,NHCO-2-furyl),(NHCH2CONH2,H,Me,Et,NHCONHPh),(NHCH2CONH2,H,Me,Et,NHCOCONHPh),(NHCH2CONH2,H,Me,CH2OH,CONHPh),(NHCH2CONH2,H,Me,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,H,Me,CH2OH,NHCOPh),(NHCH2CONH2,H,Me,CH2OH,NHCO-2-furyl),(NHCH2CONH2,H,Me,CH2OH,NHCONHPh),(NHCH2CONH2,H,Me,CH2OH,NHCOCONHPh),(NHCH2CONH2,H,Ph,Me,CONHPh),(NHCH2CONH2,H,Ph,Me,CONH-3-pyridyl),(NHCH2CONH2,H,Ph,Me,NHCOPh),(NHCH2CONH2,H,Ph,Me,NHCO-2-furyl),(NHCH2CONH2,H,Ph,Me,NHCONHPh),(NHCH2CONH2,H,Ph,Me,NHCOCONHPh),(NHCH2CONH2,H,Ph,Et,CONHPh),(NHCH2CONH2,H,Ph,Et,CONH-3-pyridyl),(NHCH2CONH2,H,Ph,Et,NHCOPh),(NHCH2CONH2,H,Ph,Et,NHCO-2-furyl),(NHCH2CONH2,H,Ph,Et,NHCONHPh),(NHCH2CONH2,H,Ph,Et,NHCOCONHPh),(NHCH2CONH2,H,Ph,CH2OH,CONHPh),(NHCH2CONH2,H,Ph,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,H,Ph,CH2OH,NHCOPh),(NHCH2CONH2,H,Ph,CH2OH,NHCO-2-furyl),(NHCH2CONH2,H,Ph,CH2OH,NHCONHPh),(NHCH2CONH2,H,Ph,CH2OH,NHCOCONHPh),(NHCH2CONH2,H,OH,Me,CONHPh),(NHCH2CONH2,H,Me,CONH-3-pyridyl),(NHCH2CONH2,H,OH,Me,NHCOPh),(NHCH2CONH2,H,OH,Me,NHCO-2-furyl),(NHCH2CONH2,H,OH,Me,NHCONHPh),(NHCH2CONH2,H,OH,Me,NHCOCONHPh),(NHCH2CONH2,H,OH,Et,CONHPh),(NHCH2CONH2,H,OH,Et,CONH-3-pyridyl),(NHCH2CONH2,H,OH,Et,NHCOPh),(NHCH2CONH2,H,OH,Et,NHCO-2-furyl),(NHCH2CONH2,H,OH,Et,NHCONHPh),(NHCH2CONH2,H,OH,Et,NHCOCONHPh),(NHCH2CONH2,H,OH,CH2OH,CONHPh),(NHCH2CONH2,H,OH,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,H,OH,CH2OH,NHCOPh),(NHCH2CONH2,H,OH,CH2OH,NHCO-2-furyl),(NHCH2CONH2,H,OH,CH2OH,NHCONHPh),(NHCH2CONH2,H,OH,CH2OH,NHCOCONHPh),(NHCH2CONH2,Me,H,Me,CONHPh),(NHCH2CONH2,Me,H,Me,CONH-3-pyridyl),(NHCH2CONH2,Me,H,Me,NHCOPh),(NHCH2CONH2,Me,H,Me,NHCO-2-furyl),(NHCH2CONH2,Me,H,Me,NHCONHPh),(NHCH2CONH2,Me,H,Me,NHCOCONHPh),(NHCH2CONH2,Me,H,Et,CONHPh),(NHCH2CONH2,Me,H,Et,CONH-3-pyridyl),(NHCH2CONH2,Me,H,Et,NHCOPh),(NHCH2CONH2,Me,H,Et,NHCO-2-furyl),(NHCH2CONH2,Me,H,Et,NHCONHPh),(NHCH2CONH2,Me,H,Et,NHCOCONHPh),(NHCH2CONH2,Me,H,CH2OH,CONHPh),(NHCH2CONH2,Me,H,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,Me,H,CH2OH,NHCOPh),(NHCH2CONH2,Me,H,CH2OH,NHCO-2-furyl),(NHCH2CONH2,Me,H,CH2OH,NHCONHPh),(NHCH2CONH2,Me,H,CH2OH,NHCOCONHPh),(NHCH2CONH2,Me,Me,Me,CONHPh),(NHCH2CONH2,Me,Me,Me,CONH-3-pyridyl),(NHCH2CONH2,Me,Me,Me,NHCOPh),(NHCH2CONH2,Me,Me,Me,NHCO-2-furyl),(NHCH2CONH2,Me,Me,Me,NHCONHPh),(NHCH2CONH2,Me,Me,Me,NHCOCONHPh),(NHCH2CONH2,Me,Me,Et,CONHPh),(NHCH2CONH2,Me,Me,Et,CONH-3-pyridyl),(NHCH2CONH2,Me,Me,Et,NHCOPh),(NHCH2CONH2,Me,Me,Et,NHCO-2-furyl),(NHCH2CONH2,Me,Me,Et,NHCONHPh),(NHCH2CONH2,1Me,Me,Et,NHCOCONHPh),(NHCH2CONH2,Me,Me,CH2OH,CONHPh),(NHCH2CONH2,Me,Me,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,Me,Me,CH2OH,NHCOPh),(NHCH2CONH2,Me,Me,CH2OH,NHCO-2-furyl),(NHCH2CONH2,Me,Me,CH2OH,NHCONHPh),(NHCH2CONH2,Me,Me,CH2OH,NHCOCONHPh),(NHCH2CONH2,Me,Ph,Me,CONHPh),(NHCH2CONH2,Me,Ph,Me,CONH-3-pyridyl),(NHCH2CONH2,Me,Ph,Me,NHCOPh),(NHCH2CONH2,Me,Ph,Me,NHCO-2-furyl),(NHCH2CONH2,Me,Ph,Me,NHCONHPh),(NHCH2CONH2,Me,Ph,Me,NHCOCONHPh),(NHCH2CONH2,Me,Ph,Et,CONHPh),(NHCH2CONH2,Me,Ph,Et,CONH-3-pyridyl),(NHCH2CONH2,Me,Ph,Et,NHCOPh),(NHCH2CONH2,Me,Ph,Et,NHCO-2-furyl),(NHCH2CONH2,Me,Ph,Et,NHCONHPh),(NHCH2CONH2,Me,Ph,Et,NHCOCONHPh),(NHCH2CONH2,Me,Ph,CH2OH,CONHPh),(NHCH2CONH2,Me,Ph,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,Me,Ph,CH2OH,NHCOPh),(NHCH2CONH2,Me,Ph,CH2OH,NHCO-2-furyl),(NHCH2CONH2,Me,Ph,CH2OH,NHCONHPh),(NHCH2CONH2,Me,Ph,CH2OH,NHCOCONHPh),(NHCH2CONH2,Me,OH,Me,CONHPh),(NHCH2CONH2,Me,OH,Me,CONH-3-pyridyl),(NHCH2CONH2,Me,OH,Me,NHCOPh),(NHCH2CONH2,Me,OH,Me,NHCO-2-furyl),(NHCH2CONH2,Me,OH,Me,NHCONHPh),(NHCH2CONH2,Me,OH,Me,NHCOCONHPh),(NHCH2CONH2,Me,OH,Et,CONHPh),(NHCH2CONH2,Me,OH,Et,CONH-3-pyridyl),(NHCH2CONH2,Me,OH,Et,NHCOPh),(NHCH2CONH2,Me,OH,Et,NHCO-2-furyl),(NHCH2CONH2,Me,OH,Et,NHCONHPh),(NHCH2CONH2,Me,OH,Et,NHCOCONHPh),(NHCH2CONH2,Me,OH,CH2OH,CONHPh),(NHCH2CONH2,Me,OH,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,Me,OH,CH2OH,NHCOPh),(NHCH2CONH2,Me,OH,CH2OH,NHCO-2-furyl),(NHCH2CONH2,Me,OH,CH2OH,NHCONHPh),(NHCH2CONH2,Me,OH,CH2OH,NHCOCONHPh),(NHCH2CONH2,Ph,H,Me,CONHPh),(NHCH2CONH2,Ph,H,Me,CONH-3-pyridyl),(NHCH2CONH2,Ph,H,Me,NHCOPh),(NHCH2CONH2,Ph,H,Me,NHCO-2-furyl),(NHCH2CONH2,Ph,H,Me,NHCONHPh),(NHCH2CONH2,Ph,H,Me,NHCOCONHPh),(NHCH2CONH2,Ph,H,Et,CONHPh),(NHCH2CONH2,Ph,H,Et,CONH-3-pyridyl),(NHCH2CONH2,Ph,H,Et,NHCOPh),(NHCH2CONH2,Ph,H,Et,NHCO-2-furyl),(NHCH2CONH2,Ph,H,Et,NHCONHPh),(NHCH2CONH2,Ph,H,Et,NHCOCONHPh),(NHCH2CONH2,Ph,H,CH2OH,CONHPh),(NHCH2CONH2,Ph,H,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,Ph,H,CH2OH,NHCOPh),(NHCH2CONH2,Ph,H,CH2OH,NHCO-2-furyl),(NHCH2CONH2,Ph,H,CH2OH,NHCONHPh),(NHCH2CONH2,Ph,H,CH2OH,NHCOCONHPh),(NHCH2CONH2,Ph,Me,Me,CONHPh),(NHCH2CONH2,Ph,Me,Me,CONH-3-pyridyl),(NHCH2CONH2,Ph,Me,Me,NHCOPh),(NHCH2CONH2,Ph,Me,Me,NHCO-2-furyl),(NHCH2CONH2,Ph,Me,Me,NHCONHPh),(NHCH2CONH2,Ph,Me,Me,NHCOCONHPh),(NHCH2CONH2,Ph,Me,Et,CONHPh),(NHCH2CONH2,Ph,Me,Et,CONH-3-pyridyl),(NHCH2CONH2,Ph,Me,Et,NHCOPh),(NHCH2CONH2,Ph,Me,Et,NHCO-2-furyl),(NHCH2CONH2,Ph,Me,Et,NHCONHPh),(NHCH2CONH2,Ph,Me,Et,NHCOCONHPh),(NHCH2CONH2,Ph,Me,CH2OH,CONHPh),(NHCH2CONH2,Ph,Me,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,Ph,Me,CH2OH,NHCOPh),(NHCH2CONH2,Ph,Me,CH2OH,NHCO-2-furyl),(NHCH2CONH2,Ph,Me,CH2OH,NHCONHPh),(NHCH2CONH2,Ph,Me,CH2OH,NHCOCONHPh),(NHCH2CONH2,Ph,Ph,Me,CONHPh),(NHCH2CONH2,Ph,Ph,Me,CONH-3-pyridyl),(NHCH2CONH2,Ph,Ph,Me,NHCOPh),(NHCH2CONH2,Ph,Ph,Me,NHCO-2-furyl),(NHCH2CONH2,Ph,Ph,Me,NHCONHPh),(NHCH2CONH2,Ph,Ph,Me,NHCOCONHPh),(NHCH2CONH2,Ph,Ph,Et,CONHPh),(NHCH2CONH2,Ph,Ph,Et,CONH-3-pyridyl),(NHCH2CONH2,Ph,Ph,Et,NHCOPh),(NHCH2CONH2,Ph,Ph,Et,NHCO-2-furyl),(NHCH2CONH2,Ph,Ph,Et,NHCONHPh),(NHCH2CONH2,Ph,Ph,Et,NHCOCONHPh),(NHCH2CONH2,Ph,Ph,CH2OH,CONHPh),(NHCH2CONH2,Ph,Ph,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,Ph,Ph,CH2OH,NHCOPh),(NHCH2CONH2,Ph,Ph,CH2OH,NHCO-2-furyl),(NHCH2CONH2,Ph,Ph,CH2OH,NHCONHPh),(NHCH2CONH2,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH2CONH2,Ph,OH,Me,CONHPh),(NHCH2CONH2,Ph,OH,Me,CONH-3-pyridyl),(NHCH2CONH2,Ph,OH,Me,NHCOPh),(NHCH2CONH2,Ph,OH,Me,NHCO-2-furyl),(NHCH2CONH2,Ph,OH,Me,NHCONHPh),(NHCH2CONH2,Ph,OH,Me,NHCOCONHPh),(NHCH2CONH2,Ph,OH,Et,CONHPh),(NHCH2CONH2,Ph,OH,Et,CONH-3-pyridyl),(NHCH2CONH2,Ph,OH,Et,NHCOPh),(NHCH2CONH2,Ph,OH,Et,NHCO-2-furyl),(NHCH2CONH2,Ph,OH,Et,NHCONHPh),(NHCH2CONH2,Ph,OH,Et,NHCOCONHPh),(NHCH2CONH2,Ph,OH,CH2OH,CONHPh),(NHCH2CONH2,Ph,OH,CH2OH,CONH-3-pyridyl),(NHCH2CONH2,Ph,OH,CH2OH,NHCOPh),(NHCH2CONH2,Ph,OH,CH2OH,NHCO-2-furyl),(NHCH2CONH2,Ph,OH,CH2OH,NHCONHPh),(NHCH2CONH2,Ph,OH,CH2OH,NHCOCONHPh),-   (NHCH(Bn)CONH2,H,H,Me,CONHPh),(NHCH(Bn)CONH2,H,H,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,H,Me,NHCOPh),(NHCH(Bn)CONH2,H,H,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,H,H,Me,NHCONHPh),(NHCH(Bn)CONH2,H,H,Me,NHCOCONHPh),(NHCH(Bn)CONH2,H,H,Et,CONHPh),(NHCH(Bn)CONH2,H,H,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,H,Et,NHCOPh),(NHCH(Bn)CONH2,H,H,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,H,H,Et,NHCONHPh),(NHCH(Bn)CONH2,H,H,Et,NHCOCONHPh),(NHCH(Bn)CONH2,H,H,CH2OH,CONHPh),(NHCH(Bn)CONH2,H,H,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,H,CH2OH,NHCOPh),(NHCH(Bn)CONH2,H,H,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,H,H,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,H,H,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,H,Me,Me,CONHPh),(NHCH(Bn)CONH2,H,Me,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,Me,Me,NHCOPh),(NHCH(Bn)CONH2,H,Me,Me,NHCO-2-furyl,(NHCH(Bn)CONH2,H,Me,Me,NHCONHPh),(NHCH(Bn)CONH2,H,Me,Me,NHCOCONHPh),(NHCH(Bn)CONH2,H,Me,Et,CONHPh),(NHCH(Bn)CONH2,H,Me,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,Me,Et,NHCOPh),(NHCH(Bn)CONH2,H,Me,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,H,Me,Et,NHCONHPh),(NHCH(Bn)CONH2,H,Me,Et,NHCOCONHPh),(NHCH(Bn)CONH2,H,Me,CH2OH,CONHPh),(NHCH(Bn)CONH2,H,Me,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,Me,CH2OH,NHCOPh),(NHCH(Bn)CONH2,H,Me,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,H,Me,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,H,Me,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,H,Ph,Me,CONHPh),(NHCH(Bn)CONH2,H,Ph,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,Ph,Me,NHCOPh),(NHCH(Bn)CONH2,H,Ph,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,H,Ph,Me,NHCONHPh),(NHCH(Bn)CONH2,H,Ph,Me,NHCOCONHPh),(NHCH(Bn)CONH2,H,Ph,Et,CONHPh),(NHCH(Bn)CONH2,H,Ph,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,Ph,Et,NHCOPh),(NHCH(Bn)CONH2,H,Ph,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,H,Ph,Et,NHCONHPh),(NHCH(Bn)CONH2,H,Ph,Et,NHCOCONHPh),(NHCH(Bn)CONH2,H,Ph,CH2OH,CONHPh),(NHCH(Bn)CONH2,H,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,Ph,CH2OH,NHCOPh),(NHCH(Bn)CONH2,H,Ph,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,H,Ph,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,H,Ph,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,H,OH,Me,CONHPh),(NHCH(Bn)CONH2,H,OH,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,OH,Me,NHCOPh),(NHCH(Bn)CONH2,H,OH,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,H,OH,Me,NHCONHPh),(NHCH(Bn)CONH2,H,OH,Me,NHCOCONHPh),(NHCH(Bn)CONH2,H,OH,Et,CONHPh),(NHCH(Bn)CONH2,H,OH,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,OH,Et,NHCOPh),(NHCH(Bn)CONH2,H,OH,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,H,OH,Et,NHCONHPh),(NHCH(Bn)CONH2,H,OH,Et,NHCOCONHPh),(NHCH(Bn)CONH2,H,OH,CH2OH,CONHPh),(NHCH(Bn)CONH2,H,OH,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,H,OH,CH2OH,NHCOPh),(NHCH(Bn)CONH2,H,OH,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,H,OH,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,H,OH,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Me,H,Me,CONHPh),(NHCH(Bn)CONH2,Me,H,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,H,Me,NHCOPh),(NHCH(Bn)CONH2,Me,H,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,H,Me,NHCONHPh),(NHCH(Bn)CONH2,Me,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Me,H,Et,CONHPh),(NHCH(Bn)CONH2,Me,H,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,H,Et,NHCOPh),(NHCH(Bn)CONH2,Me,H,Et,NHCO-2-furyl,(NHCH(Bn)CONH2,Me,H,Et,NHCONHPh),(NHCH(Bn)CONH2,Me,H,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Me,H,CH2OH,CONHPh),(NHCH(Bn)CONH2,Me,H,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,H,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Me,H,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,H,CH2OH,NHCONHPh),(NHCH(Br)CONH2,Me,H,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Me,Me,CONHPh),(NHCH(Bn)CONH2,Me,Me,Me,CONH-3-pyridyn,(NHCH(Bn)CONH2,Me,Me,Me,NHCOPh),(NHCH(Bn)CONH2,Me,Me,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,Me,Me,NHCONHPh),(NHCH(Bn)CONH2,Me,Me,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Me,Et,CONHPh),(NHCH(Bn)CONH2,Me,Me,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,Me,Et,NHCOPh),(NHCH(Br)CONH2,Me,Me,Et,NHCO-2-furyl),(NRCH(Bn)CONH2,Me,Me,Et,NHCONHPh),(NHCH(Bn)CONH2,Me,Me,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Me,CH2OH,CONHPh),(NHCH(Bn)CONH2,Me,Me,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,Me,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Me,Me,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,Me,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Me,Me,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Ph,Me,CONHPh),(NHCH(Bn)CONH2,Me,Ph,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,Ph,Me,NHCOPh),(NHCH(Bn)CONH2,Me,Ph,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,Ph,Me,NHCONHPh),(NHCH(Bn)CONH2,Me,Ph,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Me,Ph,Et,CONHPh),(NHCH(Bn)CONH2,Me,Ph,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,Ph,Et,NHCOPh),(NHCH(Bn)CONH2,Me,Ph,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,Ph,Et,NHCONHPh),(NHCH(Bn)CONH2,Me,Ph,Et,NHCOCO    NHPh),(NHCH(Bn)CONH2,Me,Ph,CH2OH,CONHPh),(NHCH(Bn)CONH2,Me,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,Ph,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Me,Ph,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,Ph,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Me,Ph,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Me,OH,Me,CONHPh),(NHCH(Bn)CONH2,Me,OH,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,OH,Me,NHCOPh),(NHCH(Bn)CONH2,Me,OH,Me,NHCO-2-furyl,(NHCH(Bn)CONH2,Me,OH,NHCONHPh),(NHCH(Bn)CONH2,Me,OH,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Me,OH,Et,CONHPh),(NHCH(Bn)CONH2,Me,OH,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,OH,Et,NHCOPh),(NHCH(Bn)CONH2,Me,OH,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,OH,Et,NHCONHPh),(NHCH(Bn)CONH2,Me,OH,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Me,OH,CH2OH,CONHPh),(NHCH(Bn)CONH2,Me,OH,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,Me,OH,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Me,OH,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,Me,OH,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Me,OH,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,H,Me,CONHPh),(NHCH(Bn)CONH2,Ph,H,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,H,Me,NHCOPh),(NHCH(Bn)CONH2,Ph,H,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,H,Me,NHCONHPh),(NHCH(Bn)CONH2,Ph,H,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,H,Et,CONHPh),(NHCH(Bn)CONH2,Ph,H,Et,CONH-3-pyridyl,(NHCH(Bn)CONH2,Ph,H,Et,NHCOPh),(NHCH(Bn)CONH2,Ph,H,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,H,Et,NHCONHPh),(NHCH(Bn)CONH2,Ph,H,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,H,CH2OH,CONHPh),(NHCH(Bn)CONH2,Ph,H,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,H,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Ph,H,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,H,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Ph,H,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Me,Me,CONHPh),(NHCH(Bn)CONH2,Ph,Me,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,Me,Me,NHCOPh),(NHCH(Bn)CONH2,Ph,Me,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,Me,Me,NHCONHPh),(NHCH(Bn)CONH2,Ph,Me,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Me,Et,CONHPh),(NHCH(Bn)CONH2,Ph,Me,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,Me,Et,NHCOPh),(NHCH(Bn)CONH2,Ph,Me,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,Me,Et,NHCONHPh),(NHCH(Bn)CONH2,Ph,Me,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Me,CH2OH,CONHPh),(NHCH(Bn)CONH2,Ph,Me,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,Me,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Ph,Me,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,Me,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Ph,Me,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Ph,Me,CONHPh),(NHCH(Bn)CONH2,Ph,Ph,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,Ph,Me,NHCOPh),(NHCH(Bn)CONH2,Ph,Ph,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,Ph,Me,NHCONHPh),(NHCH(Bn)CONH2,Ph,Ph,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Ph,Et,CONHPh),(NHCH(Bn)CONH2,Ph,Ph,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,Ph,Et,NHCOPh),(NHCH(Bn)CONH2,Ph,Ph,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,Ph,Et,NHCONHPh),(NHCH(Bn)CONH2,Ph,Ph,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,CONHPh),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,OH,Me,CONHPh),(NHCH(Bn)CONH2,Ph,OH,Me,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,OH,Me,NHCOPh),(NHCH(Br)CONH2,Ph,OH,Me,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,OH,Me,NHCONHPh),(NHCH(Bn)CONH2,Ph,OH,Me,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,OH,Et,CONHPh),(NHCH(Bn)CONH2,Ph,OH,Et,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,OH,Et,NHCOPh),(NHCH(Bn)CONH2,Ph,OH,Et,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,OH,Et,NHCONHPh),(NHCH(Bn)CONH2,Ph,OH,Et,NHCOCONHPh),(NHCH(Bn)CONH2,Ph,OH,CH2OH,CONHPh),(NHCH(Bn)CONH2,Ph,OH,CH2OH,CONH-3-pyridyl),(NHCH(Bn)CONH2,Ph,OH,CH2OH,NHCOPh),(NHCH(Bn)CONH2,Ph,OH,CH2OH,NHCO-2-furyl),(NHCH(Bn)CONH2,Ph,OH,CH2OH,NHCONHPh),(NHCH(Bn)CONH2,Ph,OH,CH2OH,NHCOCONHPh),-   (NHCH(Me)CH2OH,H,H,Me,CONHPh),(NHCH(Me)CH2OH,H,H,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,H,Me,NHCOPh),(NHCH(Me)CH2OH,H,H,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,H,H,Me,NHCONHPh),(NHCH(Me)CH2OH,H,H,Me,NHCOCONHPh),(NHCH(Me)CH2OH,H,H,Et,CONHPh),(NHCH(Me)CH2OH,H,H,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,H,Et,NHCOPh),(NHCH(Me)CH2OH,H,H,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,H,H,Et,NHCONHPh),(NHCH(Me)CH2OH,H,H,Et,NHCOCONHPh),(NHCH(Me)CH2OH,H,H,CH2OH,CONHPh),(NHCH(Me)CH2OH,H,H,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,H,CH2OH,NHCOPh),(NHCH(Me)CH2OH,H,H,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,H,H,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,H,H,CH2OH,NHCOCONHPh,(NHCH(Me)CH2OH,H,Me,Me,CONHPh),(NHCH(Me)CH2OH,Me,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,Me,Me,NHCOPh),(NHCH(Me)CH2OH,H,Me,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,H,Me,Me,NHCONHPh),(NHCH(Me)CH2OH,H,Me,Me,NHCOCONHPh),(NHCH(Me)CH2OH,H,Me,Et,CONHPh),(NHCH(Me)CH2OH,H,Me,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,Me,Et,NHCOPh),(NHCH(Me)CH2OH,H,Me,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,Et,NHCONHPh),(NHCH(Me)CH2OH,H,Me,Et,NHCOCONHPh),(NHCH(Me)CH2OH,H,Me,CH2OH,CONHPh),(NHCH(Me)CH2OH,H,Me,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,Me,CH2OH,NHCOPh),(NHCH(Me)CH2OH,H,Me,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,H,Me,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,H,Ph,Me,CONHPh),(NHCH(Me)CH2OH,H,Ph,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,Ph,Me,NHCOPh),(NHCH(Me)CH2OH,H,Ph,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,H,Ph,Me,NHCONHPh),(NHCH(Me)CH2OH,H,Ph,Me,NHCOCONHPh),(NHCH(Me)CH2OH,H,Ph,Et,CONHPh),(NHCH(Me)CH2OH,H,Ph,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,Ph,Et,NHCOPh),(NHCH(Me)CH2OH,H,Ph,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,Et,NHCONHPh),(NHCH(Me)CH2OH,H,Ph,Et,NHCOCONHPh),(NHCH(Me)CH2OH,H,Ph,CH2OH,CONHPh,(NHCH(Me)CH2OH,H,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,Ph,CH2OH,NHCOPh),(NHCH(Me)CH2OH,H,Ph,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,H,Ph,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,H,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,H,OH,Me,CONHPh),(NHCH(Me)CH2OH,H,OH,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,OH,Me,NHCOPh),(NHCH(Me)CH2OH,H,OH,Me,NHCO-2-furyl),NHCH(Me)CH2OH,H,OH,Me,NHCONHPh),(NHCH(Me)CH2OH,H,OH,Me,NHCOCONHPh),(NHCH(Me)CH2OH,H,OH,Et,CONHPh),(NHCH(Me)CH2OH,H,OH,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,OH,Et,NHCOPh),(NHCH(Me)CH2OH,H,OH,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,H,OH,Et,NHCONHPh),(NHCH(Me)CH2OH,H,OH,Et,NHCOCONHPh),(NHCH(Me)CH2OH,H,OH,CH2OH,CONHPh),(NHCH(Me)CH2OH,H,OH,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,H,OH,CH2OH,NHCOPh),(NHCH(Me)CH2OH,H,OH,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,H,OH,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,H,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,H,Me,CONHPh),(NHCH(Me)CH2OH,Me,H,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,H,Me,NHCOPh),(NHCH(Me)CH2OH,Me,H,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,H,Me,NHCONHPh),(NHCH(Me)CH2OH,Me,H,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Me,H,Et,CONHPh),(NHCH(Me)CH2OH,Me,H,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,H,Et,NHCOPh),(NHCH(Me)CH2OH,Me,H,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,H,Et,NHCONHPh),(NHCH(Me)CH2OH,Me,H,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Me,H,CH2OH,CONHPh),(NHCH(Me)CH2OH,Me,H,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,H,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Me,H,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,H,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Me,H,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Me,Me,CONHPh),(NHCH(Me)CH2OH,Me,Me,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,Me,Me,NH    COPh),(NHCH(Me)CH2OH,Me,Me,Me,NHCO-2-furyl,(NHCH(Me)CH2OH,Me,Me,Me,NHCONHPh),(NHCH(Me)CH2OH,Me,Me,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Me,Et,CONHPh),(NHCH(Me)CH2OH,Me,Me,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,Me,Et,NHCOPh),(NHCH(Me)CH2OH,Me,Me,Et,NHCO-2-furyl,(NHCH(Me)CH2OH,Me,Me,Et,NHCONHPh),(NHCH(Me)CH2OH,Me,Me,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Me,CH2OH,CONHPh),(NHCH(Me)CH2OH,Me,Me,CH2OH,CONH-3-pyridyl,(NHCH(Me)CH2OH,Me,Me,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Me,Me,CH2OH,NHCO-2-furyl,(NHCH(Me)CH2OH,Me,Me,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Me,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Ph,Me,CONHPh),(NHCH(Me)CH2OH,Me,Ph,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,Ph,Me,NHCOPh),(NHCH(Me)CH2OH,Me,Ph,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,Ph,Me,NHCONHPh),(NHCH(Me)CH2OH,Me,Ph,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Ph,Et,CONHPh),(NHCH(Me)CH2OH,Me,Ph,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,Ph,Et,NHCOPh),(NHCH(Me)CH2OH,Me,Ph,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,Ph,Et,NHCONHPh),(NHCH(Me)CH2OH,Me,Ph,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Me,Ph,CH2OH,CONHPh),(NHCH(Me)CH2OH,Me,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,Ph,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Me,Ph,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,Ph,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Me,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,OH,Me,CONHPh),(NHCH(Me)CH2OH,Me,OH,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,OH,Me,NHCOPh),(NHCH(Me)CH2OH,Me,OH,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,OH,Me,NHCONHPh),(NHCH(Me)CH2OH,Me,OH,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Me,OH,Et,CONHPh),(NHCH(Me)CH2OH,Me,OH,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,OH,Et,NHCOPh),(NHCH(Me)CH2OH,Me,OH,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,OH,Et,NHCONHPh),(NHCH(Me)CH2OH,Me,OH,NHCOCONHPh),(NHCH(Me)CH2OH,Me,OH,CH2OH,CONHPh),(NHCH(Me)CH2OH,Me,OH,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,Me,OH,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Me,OH,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,Me,OH,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Me,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,H,Me,CONHPh),(NHCH(Me)CH2OH,Ph,H,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,H,Me,NHCOPh),(NHCH(Me)CH2OH,Ph,H,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,H,Me,NHCONHPh),(NHCH(Me)CH2OH,Ph,H,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,H,Et,CONHPh),(NHCH(Me)CH2OH,Ph,H,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,H,Et,NHCOPh),(NHCH(Me)CH2OH,Ph,H,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,H,Et,NHCONHPh),(NHCH(Me)OCH2OH,Ph,B,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,H,CH2OH,CONHPh),(NHCH(Me)CH2OH,Ph,H,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,H,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Ph,H,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,H,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Ph,H,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Me,Me,CONHPh),(NHCH(Me)CH2OH,Ph,Me,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,Me,Me,NHCOPh),(NHCH(Me)CH2OH,Ph,Me,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,Me,Me,NHCONHPh),(NHCH(Me)CH2OH,Ph,Me,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Me,Et,CONHPh),(NHCH(Me)CH2OH,Ph,Me,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,Me,Et,NHCOPh),(NHCH(Me)CH2OH,Ph,Me,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,Me,Et,NHCONHPh),(NHCH(Me)CH2OH,Ph,Me,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Me,CH2OH,CONHPh),(NHCH(Me)CH2OH,Ph,Me,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,Me,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Ph,Me,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,Me,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Ph,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Ph,Me,CONHPh),(NHCH(Me)CH2OH,Ph,Ph,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,Ph,Me,NHCOPh),NHCH(Me)CH2OH,Ph,Ph,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,Ph,Me,NHCONHPh),(NHCH(Me)CH2OH,Ph,Ph,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Ph,Et,CONHPh),(NHCH(Me)CH2OH,Ph,Ph,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,Ph,Et,NHCOPh),(NHCH(Me)CH2OH,Ph,Ph,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,Ph,Et,NHCONHPh),(NHCH(Me)CH2OH,Ph,Ph,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,CONHPh),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,OH,Me,CONHPh),(NHCH(Me)CH2OH,Ph,OH,Me,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,OH,Me,NHCOPh),(NHCH(Me)CH2OH,Ph,OH,Me,NHCO-2-furyl),(NHCH(Me)CH2OH,OH,Me,NHCONHPh),(NHCH(Me)CH2OH,Ph,OH,Me,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,OH,Et,CONHPh),(NHCH(Me)CH2OH,Ph,OH,Et,CONH-3-pyridyl),(NHCH(Me)CH2OH)Ph,OH,Et,NHCOPh),(NHCH(Me)CH2OH,Ph,OH,Et,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,OH,Et,NHCONHPh),(NHCH(Me)CH2OH,Ph,OH,Et,NHCOCONHPh),(NHCH(Me)CH2OH,Ph,OH,CH2OH,CONHPh),(NHCH(Me)CH2OH,Ph,OH,CH2OH,CONH-3-pyridyl),(NHCH(Me)CH2OH,Ph,OH,CH2OH,NHCOPh),(NHCH(Me)CH2OH,Ph,OH,CH2OH,NHCO-2-furyl),(NHCH(Me)CH2OH,Ph,OH,CH2OH,NHCONHPh),(NHCH(Me)CH2OH,Ph,OH,CH2OH,NHCOCONHPh),-   (NHCH(Me)CONHMe,H,H,Me,CONHPh),(NHCH(Me)CONHMe,H,H,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,H,Me,NHCOPh),(NHCH(Me)CONHMe,H,H,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,H,H,Me,NHCONHPh),(NHCH(Me)CONHMe,H,H,Me,NHCOCONHPh),(NHCH(Me)CONHMe,H,H,Et,CONHPh),(NHCH(Me)CONHMe,H,H,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,H,Et,NHCOPh),(NHCH(Me)CONHMe,H,H,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,H,H,Et,NHCONHPh),(NHCH(Me)CONHMe,H,H,Et,NHCOCONHPh),(NHCH(Me)CONHMe,H,H,CH2OH,CONHPh),(NHCH(Me)CONHMe,H,H,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,H,CH2OH,NHCOPh),(NHCH(Me)CONHMe,H,H,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,H,H,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,H,H,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,H,Me,Me,CONHPh),(NHCH(Me)CONHMe,H,Me,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,Me,Me,NHCOPh),(NHCH(Me)CONHMe,H,Me,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,H,Me,Me,NHCONHPh),(NHCH(Me)CONHMe,H,Me,Me,NHCOCONHPh),(NHCH(Me)CONHMe,H,Me,Et,CONHPh),(NHCH(Me)CONHMe,H,Me,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,Me,Et,NHCOPh),(NHCH(Me)CONHMe,Me,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,H,Me,Et,NHCONHPh),(NHCH(Me)CONHMe,H,Me,Et,NHCOCONHPh),(NHCH(Me)CONHMe,H,Me,CH2OH,CONHPh),(NHCH(Me)CONHMe,H,Me,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,Me,CH2OH,NHCOPh),(NHCH(Me)CONHMe,H,Me,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,H,Me,CH2OH,    NHCONHPh),(NHCH(Me)CONHMe,H,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,H,Ph,Me,CONHPh),(NHCH(Me)CONHMe,H,Ph,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,Ph,Me,NHCOPh),(NHCH(Me)CONHMe,H,Ph,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,H,Ph,Me,NHCONHPh),(NHCH(Me)CONHMe,H,Ph,Me,NHCOCONHPh),(NHCH(Me)CONHMe,H,Ph,Et,CONHPh),(NHCH(Me)CONHMe,H,Ph,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,Ph,Et,NHCOPh),(NHCH(Me)CONHMe,H,Ph,EtNHCO-2-furyl),(NHCH(Me)CONHMe,H,Ph,Et,NHCONHPh),(NHCH(Me)CONHMe,H,Ph,Et,NHCOCONHPh),(NHCH(Me)CONHMe,H,Ph,CH2OH,CONHPh),(NHCH(Me)CONHMe,H,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,Ph,CH2OH,NHCOPh),(NHCH(Me)CONHMe,H,Ph,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,H,Ph,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,H,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,H,OH,Me,CONHPh),(NHCH(Me)CONHMe,H,OH,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,OH,Me,NHCOPh),(NHCH(Me)CONHMe,H,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,H,OH,Me,NHCONHPh),(NHCH(Me)CONHMe,H,OH,Me,NHCOCONHPh),(NHCH(Me)CONHMe,H,OH,Et,CONHPh),(NHCH(Me)CONHMe,H,OH,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,OH,Et,NHCOPh),(NHCH(Me)CONHMe,H,OH,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,H,OH,Et,NHCONHPh),(NHCH(Me)CONHMe,H,OH,Et,NHCOCONHPh),(NHCH(Me)CONHMe,H,OH,CH2OH,CONHPh),(NHCH(Me)CONHMe,H,OH,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,H,OH,CH2OH,NHCOPh),(NHCH(Me)CONHMe,H,OH,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,H,OH,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,H,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Me,H,Me,CONHPh),(NHCH(Me)CONHMe,Me,H,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,H,Me,NHCOPh),(NHCH(Me)CONHMe,Me,H,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,H,Me,NHCONHPh),(NHCH(Me)CONHMe,Me,H,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Me,H,Et,CONHPh),(NHCH(Me)CONHMe,Me,H,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,H,Et,NHCOPh),(NHCH(Me)CONHMe,Me,H,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,H,Et,NHCONHPh),(NHCH(Me)CONHMe,Me,H,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Me,H,CH2OH,CONHPh),(NHCH(Me)CONHMe,Me,H,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,H,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Me,H,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,H,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Me,Me,H,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Me,Me,CONHPh),(NHCH(Me)CONHMe,Me,Me,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,Me,Me,NHCOPh),(NHCH(Me)CONHMe,Me,Me,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,Me,Me,NHCONHPh),(NHCH(Me)CONHMe,Me,Me,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Me,Et,CONHPh),(NHCH(Me)CONHMe,Me,Me,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,Me,Et,NHCOPh),(NHCH(Me)CONHMe,Me,Me,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,Me,Et,NHCONHPh),(NHCH(Me)CONHMe,Me,Me,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Me,CH2OH,CONHPh),(NHCH(Me)CONHMe,Me,Me,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,Me,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Me,Me,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,Me,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Me,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Ph,Me,CONHPh),(NHCH(Me)CONHMe,Me,Ph,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,Ph,Me,NHCOPh),(NHCH(Me)CONHMe,Me,Ph,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,Ph,Me,NHCONHPh),(NHCH(Me)CONHMe,Me,Ph,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Ph,Et,CONHPh),(NHCH(Me)CONHMe,Me,Ph,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,Ph,Et,NHCOPh),(NHCH(Me)CONHMe,Me,Ph,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,Ph,Et,NHCONHPh),(NHCH(Me)CONHMe,Me,Ph,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Me,Ph,CH2OH,CONHPh),(NHCH(Me)CONHMe,Me,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,Ph,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Me,Ph,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,Ph,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Me,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Me,OH,Me,CONHPh),(NHCH(Me)CONHMe,Me,OH,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,OH,Me,NHCOPh),(NHCH(Me)CONHMe,Me,OH,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,OH,Me,NHCONHPh),(NHCH(Me)CONHMe,Me,OH,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Me,OH,Et,CONHPh),(NHCH(Me)CONHMe,Me,OH,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,OH,Et,NHCOPh),(NHCH(Me)NHMe,Me,OH,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,OH,Et,NHCONHPh),(NHCH(Me)CONHMe,Me,OH,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Me,OH,CH2OH,CONHPh),(NHCH(Me)CONHMe,Me,OH,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,Me,OH,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Me,OH,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,Me,OH,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Me,OH,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,H,Me,CONHPh),(NHCH(Me)CONHMe,Ph,H,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,H,Me,NHCOPh),(NHCH(Me)CONHMe,Ph,H,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,H,Me,NHCONHPh),(NHCH(Me)CONHMe,Ph,H,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,H,Et,CONHPh),(NHCH(Me)CONHMe,Ph,H,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,H,Et,NHCOPh),(NHCH(Me)CONHMe,Ph,H,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,H,Et,NHCONHPh),(NHCH(Me)CONHMe,Ph,H,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,H,CH2OH,CONHPh),(NHCH(Me)CONHMe,Ph,H,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,H,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Ph,H,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,H,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Ph,H,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Me,Me,CONHPh),(NHCH(Me)CONHMe,Ph,Me,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,Me,Me,NHCOPh),(NHCH(Me)CONHMe,Ph,Me,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,Me,Me,NHCONHPh),(NHCH(Me)CONHMe,Ph,Me,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Me,Et,CONHPh),(NHCH(Me)CONHMe,Ph,Me,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,Me,Et,NHCOPh),(NHCH(Me)CONHMe,Ph,Me,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,Me,Et,NHCONHPh),(NHCH(Me)CONHMe,Ph,Me,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Me,CH2OH,CONHPh),(NHCH(Me)CONHMe,Ph,Me,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,Me,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Ph,Me,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,Me,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Ph,Me,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Ph,Me,CONHPh),(NHCH(Me)CONHMe,Ph,Ph,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,Ph,Me,NHCOPh),(NHCH(Me)CONHMe,Ph,Ph,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,Ph,Me,NHCONHPh),(NHCH(Me)CONHMe,Ph,Ph,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Ph,Et,CO    NHPh),(NHCH(Me)CONHMe,Ph,Ph,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,Ph,Et,NHCOPh),(NHCH(Me)CONHMe,Ph,Ph,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,Ph,Et,NHCONHPh),(NHCH(Me)CONHMe,Ph,Ph,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,CONHPh),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Ph,Ph,CH2OH,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,OH,Me,CONHPh),(NHCH(Me)CONHMe,Ph,OH,Me,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,OH,Me,NHCOPh),(NHCH(Me)CONHMe,Ph,OH,Me,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,OH,Me,NHCONHPh),(NHCH(Me)CONHMe,Ph,OH,Me,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,OH,Et,CONHPh),(NHCH(Me)CONHMe,Ph,OH,Et,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,OH,Et,NHCOPh),(NHCH(Me)CONHMe,Ph,OH,Et,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,OH,Et,NHCONHPh),(NHCH(Me)CONHMe,Ph,OH,Et,NHCOCONHPh),(NHCH(Me)CONHMe,Ph,OH,CH2OH,CONHPh),(NHCH(Me)CONHMe,Ph,OH,CH2OH,CONH-3-pyridyl),(NHCH(Me)CONHMe,Ph,OH,CH2OH,NHCOPh),(NHCH(Me)CONHMe,Ph,OH,CH2OH,NHCO-2-furyl),(NHCH(Me)CONHMe,Ph,OH,CH2OH,NHCONHPh),(NHCH(Me)CONHMe,Ph,OH,CH2OH,NHCOCONHPh),-   (NHCOCH(iPr)OH,H,H,Me,CONHPh),(NHCOCH(iPr)OH,H,H,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,H,Me,NHCOPh),(NHCOCH(iPr)OH,H,H,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,H,H,Me,NHCONHPh),(NHCOCH(iPr)OH,H,H,Me,NHCOCONHPh),(NHCOCH(iPr)OH,H,H,Et,CONHPh),(NHCOCH(iPr)OH,H,H,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,Et,NHCOPh),(NHCOCH(iPr)OH,H,H,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,H,H,Et,NHCONHPh),(NHCOCH(iPr)OH,H,H,Et,NHCOCONHPh),(NHCOCH(iPr)OH,H,H,CH2OH,CONHPh),(NHCOCH(iPr)OH,H,H,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,H,CH2OH,NHCOPh),(NHCOCH(iPr)OH,H,H,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,H,H,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,H,H,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,H,Me,Me,CONHPh),(NHCOCH(iPr)OH,H,H,Me,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,Me,Me,NHCOPh),(NHCOCH(iPr)OH,H,Me,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,H,Me,Me,NHCONHPh),(NHCOCH(iPr)OH,H,Me,Me,NHCOCONHPh),(NHCOCH(iPr)OH,H,Me,Et,CONHPh),(NHCOCH(iPr)OH,H,Me,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,Me,Et,NHCOPh),(NHCOCH(iPr)OH,H,Me,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,H,H,Me,Et,NHCONHPh),(NHCOCH(iPr)OH,H,Me,Et,NHCOCONHPh),(NHCOCH(iPr)OH,H,Me,CH2OH,CONHPh),(NHCOCH(iPr)OH,H,Me,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,Me,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,H,Me,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,H,Me,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,H,Ph,Me,CONHPh),(NHCOCH(iPr)OH,H,Ph,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,Ph,Me,NHCOPh),(NHCOCH(iPr)OH,H,Ph,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,H,Ph,Me,NHCONHPh),(NHCOCH(iPr)OH,H,Ph,Me,NHCOCONHPh),(NHCOCH(iPr)OH,H,Ph,Et,CONHPh),(NHCOCH(iPr)OH,H,Ph,Et,CONH-3-pyridyl,(NHCOCH(iPr)OH,H,Ph,Et,NHCOPh),(NHCOCH(iPr)OH,H,Ph,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,H,Ph,Et,NHCONHPh),(NHCOCH(iPr)OH,H,Ph,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,Ph,CH2OH,NHCOPh),(NHCOCH(iPr)OH,H,Ph,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,H,Ph,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,H,Ph,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,H,OH,Me,CONHPh),(NHCOCH(iPr)OH,H,OH,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,OH,Me,NHCOPh),(NHCOCH(iPr)OH,H,OH,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,H,OH,Me,NHCONHPh),(NHCOCH(iPr)OH,H,OH,Me,NHCOCONHPh),(NHCOCH(iPr)OH,H,OH,Et,CONHPh),(NHCOCH(iPr)OH,H,OH,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,OH,Et,NHCOPh),(NHCOCH(iPr)OH,H,OH,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,H,OH,Et,NHCONHPh),(NHCOCH(iPr)OH,H,OH,Et,NHCOCONHPh),(NHCOCH(iPr)OH,H,OH,CH2OH,CONHPh),(NHCOCH(iPr)OH,H,OH,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,H,OH,CH2OH,NHCOPh),(NHCOCH(iPr)OH,H,OH,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,H,OH,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,H,OH,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Me,H,Me,CONHPh),(NHCOCH(iPr)OH,Me,H,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,H,Me,NHCOPh),(NHCOCH(iPr)OH,Me,H,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,H,Me,NHCONHPh),(NHCOCH(iPr)OH,Me,H,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Me,H,Et,CONHPh),(NHCOCH(iPr)OH,Me,H,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,H,Et,NHCOPh),(NHCOCH(iPr),OH,Me,H,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,H,Et,NHCONHPh),(NHCOCH(iPr)OH,Me,H,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Me,H,CH2OH,CONHPh),(NHCOCH(iPr)OH,Me,H,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,H,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,H,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,H,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Me,H,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Me,Me,CONHPh),(NHCOCH(iPr)OH,Me,Me,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,Me,Me,NHCOPh),(NHCOH(iPr)OH,Me,Me,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,Me,Me,NHCONHPh),(NHCOCH(iPr)OH,Me,Me,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Me,Et,CONHPh),(NHCOCH(iPr)OOH,Me,Me,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,Me,Et,NHCOPh),(NHCOCH(iPr)OH,Me,Me,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,Me,Et,NHCONHPh),(NHCOCH(iPr)OH,Me,Me,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Me,CH2OH,CONHPh),(NHCOCH(iPr)OH,Me,Me,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,Me,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,Me,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,Me,CH2OH,NHCONHPh),(NHCOC(iPr)OH,Me,Me,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Ph,Me,CONHPh),(NHCOCH(iPr)OH,Me,Ph,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,Ph,Me,NHCOPh),(NHCO(iPr)OH,Me,Ph,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,Ph,Me,NHCONHPh),(NHCOCH(iPr)OH,Me,Ph,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Ph,Et,CONHPh),(NHCOCH(iPr)OH,Me,Ph,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,Ph,Et,NHCOPh),(NHCOCH(iPr)OH,Me,Ph,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,Ph,Et,NHCONHPh),(NHCOCH(iPr)OH,Me,Ph,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Me,Ph,CH2OH,CONHPh),(NHCOCH(iPr)OH,Me,Ph,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,Ph,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,Ph,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,Ph,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Me,Ph,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Me,OH,Me,CONHPh),(NHCOCH(iPr)OH,Me,OH,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,OH,Me,NHCOPh),(NHCOCH(iPr)OH,Me,OH,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,OH,Me,NHCONHPh),(NHCOCH(iPr)OH,Me,OH,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Me,OH,Et,CONHPh),(NHCOCH(iPr)OH,Me,OH,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,OH,Et,NHCOPh),(NHCOCH(iPr)OH,Me,OH,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,OH,Et,NHCONHPh),(NHCOCH(iPr)OH,Me,OH,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Me,OH,CH2OH,CONHPh),(NHCOCH(iPr)OH,Me,OH,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,Me,OH,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Me,OH,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,Me,OH,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Me,OH,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,H,Me,CONHPh),(NHCOCH(iPr)OH,Ph,H,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,H,Me,NHCOPh),(NHCOCH(iPr)OH,Ph,H,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,H,Me,NHCONHPh),(NHCOCH(iPr)OH,Ph,H,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,H,Et,CONHPh),(NHCOCH(iPr)OH,Ph,H,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,H,Et,NHCOPh),(NHCOCH(iPr)OH,Ph,H,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,H,Et,NHCONHPh),(NHCOCH(iPr)OH,Ph,H,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,H,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,H,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,H,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Ph,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,H,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Ph,H,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Me,Me,CONHPh),(NHCOCH(iPr)OH,Ph,Me,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,Me,Me,NHCOPh),(NHCOCH(iPr)OH,Ph,Me,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,Me,Me,NHCONHPh),(NHCOCH(iPr)OH,Ph,Me,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Me,Et,CONHPh),(NHCOCH(iPr)OH,Ph,Me,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,Me,Et,NHCOPh),(NHCOCH(iPr)OH,Ph,Me,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,Me,Et,NHCONHPh),(NHCOCH(iPr)OH,Ph,Me,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Me,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,Me,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,Me,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Ph,Me,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,Me,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Ph,Me,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Ph,Me,CONHPh),(NHCOCH(iPr)OH,Ph,Ph,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,Ph,Me,NHCOPh),(NHCOCH(iPr)OH,Ph,Ph,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,Ph,Me,NHCONHPh),(NHCOCH(iPr)OH,Ph,Ph,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Ph,Et,CONHPh),(NHCOCH(iPr)OH,Ph,Ph,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,Ph,Et,NHCOPh),(NHCOCH(iPr)OH,Ph,Ph,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,Ph,Et,NHCONHPh),(NHCOCH(iPr)OH,Ph,Ph,Et,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr),OH,Ph,Ph,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,Ph,CH2OH,NHCONHPh),(NHCOCH,(iPr)OH,Ph,Ph,CH2OH,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,OH,Me,CONHPh),(NHCOCH(iPr)OH,Ph,OH,Me,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,OH,Me,NHCOPh),(NHCOCH(iPr)OH,Ph,OH,Me,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,OH,Me,NHCONHPh),(NHCOCH(iPr)OH,Ph,OH,Me,NHCOCONHPh),(NHCOCH(iPr)OH,Ph,OH,Et,CONHPh),(NHCOCH(iPr)OH,Ph,OH,Et,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,OH,Et,NHCOPh),(NHCOCH(iPr)OH,Ph,OH,Et,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,OH,Et,NHCONHPh),(NHCOCH(iPr)OH,Ph,OH,Et,NHCOCONHPh,(NHCOCH(iPr)OH,Ph,OH,CH2OH,CONHPh),(NHCOCH(iPr)OH,Ph,OH,CH2OH,CONH-3-pyridyl),(NHCOCH(iPr)OH,Ph,OH,CH2OH,NHCOPh),(NHCOCH(iPr)OH,Ph,OH,CH2OH,NHCO-2-furyl),(NHCOCH(iPr)OH,Ph,OH,CH2OH,NHCONHPh),(NHCOCH(iPr)OH,Ph,OH,CH2OH,NHCOCONHPh),-   (NHSO2Me,H,H,Me,CONHPh),(NHSO2Me,H,H,Me,CONH-3-pyridyl),(NHSO2Me,H,H,Me,NHCOPh),(NHSO2Me,H,H,Me,NHCO-2-furyl),(NHSO2Me,H,H,Me,NHCONHPh),(NHSO2Me,H,H,Me,NHCOCONHPh),(NHSO2Me,H,H,Et,CONHPh),(NHSO2Me,H,H,Et,CONH-3-pyridyl),(NHSO2Me,H,H,Et,NHCOPh),(NHSO2Me,H,H,Et,NHCO-2-furyl),(NHSO2Me,H,H,Et,NHCONHPh),(NHSO2Me,H,H,Et,NHCOCONHPh),(NHSO2Me,H,H,CH2OH,CONHPh),(NHSO2Me,H,H,CH2OH,CONH-3-pyridyl),(NHSO2Me,H,H,CH2OH,NHCOPh),(NHSO2Me,H,H,CH2OH,NHCO-2-furyl),(NHSO2Me,H,H,CH2OH,NHCONHPh),(NHSO2Me,H,H,CH2OH,NHCOCONHPh),(NHSO2Me,H,Me,Me,CONHPh),(NHSO2Me,H,Me,Me,CONH-3-pyridyl),(NHSO2Me,H,Me,Me,NHCOPh),(NHSO2Me,H,Me,Me,NHCO-2-furyl),(NHSO2Me,H,Me,Me,NH,CONHPh),(NHS2Me,H,Me,Me,NHCOCONHPh),(NHSO2Me,H,Me,Et,CONHPh),(NHSO2Me,H,Me,Et,CONH-3-pyridyl),(NHSO2Me,H,Me,Et,NHCOPh),(NHSO2Me,H,Me,Et,NHCO-2-furyl),(NHSO2Me,H,Me,Et,NHCONHPh),(NHSO2Me,H,Me,Et,NHCOCONHPh),(NHSO2Me,H,Me,CH2OH,CONHPh),(NHSO2Me,H,Me,CH2OH,CONH-3-pyridyl),(NHSO2Me,H,Me,CH2OH,NHCOPh),(NHSO2Me,H,Me,CH2OH,NHCO-2-furyl),(NHSO2Me,H,Me,CH2OH,NHCONHPh),(NHSO2Me,H,Me,CH2OH,NHCOCONHPh),(NHSO2Me,H,Ph,Me,CONHPh),(NHSO2Me,H,Ph,Me,CONH-3-pyridyl),(NHSO2Me,H,Ph,Me,NHCOPh),(NHSO2Me,H,Ph,Me,NHCO-2-furyl),(NHSO2Me,H,Ph,Me,NHCONHPh),(NHSO2Me,H,Ph,Me,NHCOCONHPh),(NHSO2Me,H,Ph,Et,CONHPh),(NHSO2Me,H,Ph,Et,CONH-3-pyridyl),(NHSO2Me,H,Ph,Et,NHCOPh),(NHSO2Me,H,Ph,Et,NHCO-2-furyl),(NHSO2Me,H,Ph,Et,NHCONHPh),(NHSO2Me,H,Ph,Et,NHCOCONHPh),(NHSO2Me,H,Ph,CH2OH,CONHPh),(NHSO2Me,H,Ph,CH2OH,CONH-3-pyridyl),(NHSO2Me,H,Ph,CH2OH,NHCOPh),(NHSO2Me,H,Ph,CH2OH,NHCO-2-furyl),(NHSO2Me,H,Ph,CH2OH,NHCONHPh),(NHSO2Me,H,Ph,CH2OH,NHCOCONHPh),(NHSO2Me,H,OH,Me,CONHPh),(NHSO2Me,H,OH,Me,CONH-3-pyridyl),(NHSO2Me,H,OH,Me,NHCOPh),(NHSO2Me,H,OH,Me,NHCO-2-furyl),(NHSO2Me,H,OH,Me,NHCONHPh),(NHSO2Me,H,OH,Me,NHCOCONHPh),(NHSO2Me,H,OH,Et,CONHPh),(NHSO2Me,H,OH,Et,CONH-3-pyridyl),(NHSO2Me,H,OH,Et,NHCOPh),(NHSO2Me,H,OH,Et,NHCO-2-furyl),(NHSO2Me,H,OH,Et,NHCONHPh),(NHSO2Me,H,OH,Et,NHCOCONHPh),(NHSO2Me,H,OH,CH2OH,CONHPh),(NHSO2Me,H,OH,CH2H,CONH-3-pyridyl),(NHSO2Me,H,OH,CH2OH,NHCOPh),(NHSO2Me,H,OH,CH2OH,NHCO-2-furyl),(NHSO2Me,H,OH,CH2OH,NHCONHPh),(NHSO2Me,H,OH,CH2OH,NHCOCONHPh),(NHSO2Me,Me,H,Me,CONHPh),(NHSO2Me,Me,H,Me,CONH-3-pyridyl),(NHSO2Me,Me,H,Me,NHCOPh),(NHSO2Me,Me,H,Me,NHCO-2-furyl),(NHSO2Me,Me,H,Me,NHCONHPh),(NHSO2Me,Me,H,Me,NHCOCONHPh),(NHSO2Me,Me,H,Et,CONHPh),(NHSO2Me,Me,H,Et,CONH-3-pyridyl),(NHSO2Me,Me,H,Et,NHCOPh),(NHSO2Me,Me,H,Et,NHCO-2-furyl),(NHSO2Me,Me,H,Et,NHCONHPh),(NHSO2Me,Me,H,Et,NHCOCONHPh),(NHSO2Me,Me,H,CH2OH,CONHPh),(NHSO2Me,Me,H,CH2OH,CONH-3-pyridyl),(NHSO2Me,Me,H,CH2OH,NHCOPh),(NHSO2Me,Me,H,CH2OH,NHCO-2-furyl),(NHSO2Me,Me,H,CH2OH,NHCONHPh),(NHSO2Me,Me,H,CH2OH,NHCOCONHPh),(NHSO2Me,Me,Me,Me,CONHPh),(NHSO2Me,Me,Me,Me,CONH-3-pyridyl),(NHSO2Me,Me,Me,Me,NHCOPh),(NHSO2Me,Me,Me,Me,NHCO-2-furyl),(NHSO2Me,Me,Me,Me,NHCONHPh),(NHSO2Me,Me,Me,Me,NHCOCONHPh),(NHSO2Me,Me,Me,Et,CONHPh),(NHSO2Me,Me,Me,Et,CONH-3-pyridyl),(NHSO2Me,Me,Me,Et,NHCOPh),(NHSO2Me,Me,Me,Et,NHCO-2-furyl),(NHSO2Me,Me,Me,Et,NHCONHPh),(NHSO2Me,Me,Me,Et,NHCOCONHPh),(NHSO2Me,Me,Me,CH2OH,CONHPh),(NHSO2Me,Me,Me,CH2OH,CONH-3-pyridyl),(NHSO2Me,Me,Me,CH2OH,NHCOPh),(NHSO2Me,Me,Me,CH2OH,NHCO-2-furyl),(NHSO2Me,Me,Me,CH2OH,NHCONHPh),(NHSO2Me,Me,Me,CH2OH,NHCOCONHPh),(NHSO2Me,Me,Ph,Me,CONHPh),(NHSO2Me,Me,Ph,Me,CONH-3-pyridyl),(NHSO2Me,Me,Ph,Me,NHCOPh),(NHSO2Me,Me,Ph,Me,NHCO-2-furyl),(NHSO2Me,Me,Ph,Me,NHCONHPh),(NHSO2Me,Me,Ph,Me,NHCOCONHPh),(NHSO2Me,Me,Ph,Et,CONHPh),(NHSO2Me,Me,Ph,Et,CONH-3-pyridyl),(NHSO2Me,Me,Ph,Et,NHCOPh),(NHSO2Me,Me,Ph,Et,NHCO-2-furyl),(NHSO2Me,Me,Ph,Et,NHCONHPh),(NHSO2Me,Me,Ph,Et,NHCOCONHPh),(NHSO2Me,Me,Ph,CH2OH,CONHPh),(NHSO2Me,Me,Ph,CH2OH,CONH-3-pyridyl),(NHSO2Me,Me,Ph,CH2OH,NHCOPh),(NHSO2Me,Me,Ph,CH2OH,NHCO-2-furyl),(NHSO2Me,Me,Ph,CH2OH,NHCONHPh),(NHSO2Me,Me,Ph,CH2OH,NHCOCONHPh),(NHSO2Me,Me,OH,Me,CONHPh),(NHSO2Me,Me,OH,Me,CONH-3-pyridyl),(NHSO2Me,Me,OH,Me,NHCOPh),(NHSO2Me,Me,OH,Me,NHCO-2-furyl),(NHSO2Me,Me,OH,Me,NHCONHPh),(NHSO2Me,Me,OH,Me,NHCOCONHPh),(NHSO2Me,Me,OH,Et,CONHPh),(NHSO2Me,Me,OH,Et,CONH-3-pyridyl),(NHSO2Me,Me,OH,Et,NHCOPh),(NHSO2Me,Me,OH,Et,NHCO-2-furyl),(NHSO2Me,Me,OH,Et,NHCONHPh),(NHSO2Me,Me,OH,Et,NHCOCONHPh),(NHSO2Me,Me,OH,CH2OH,CONHPh),(NHSO2Me,Me,OH,CH2OH,CONH-3-pyridyl),(NHSO2Me,Me,OH,CH2OH,NHCOPh),(NHSO2Me,Me,OH,CH2OH,NHCO-2-furyl),(NHSO2Me,Me,OH,CH2OH,NHCONHPh),(NHSO2Me,Me,OH,CH2OH,NHCOCONHPh),(NHSO2Me,Ph,H,Me,CONHPh),(NHSO2Me,Ph,H,Me,CONH-3-pyridyl),(NHSO2Me,Ph,H,Me,NHCOPh),(NHSO2Me,Ph,H,Me,NHCO-2-furyl),(NHSO2Me,Ph,H,Me,NHCONHPh),(NHSO2Me,Ph,H,Me,NHCOCONHPh),(NHSO2Me,Ph,H,Et,CONHPh),(NHSO2Me,Ph,H,Et,CONH-3-pyridyl),(NHSO2Me,Ph,H,Et,NHCOPh),(NHSO2Me,Ph,H,Et,NHCO-2-furyl),(NHSO2Me,Ph,H,Et,NHCONHPh),(NHSO2Me,Ph,H,Et,NHCOCONHPh),(NHSO2Me,Ph,H,CH2OH,CONHPh),(NHSO2Me,Ph,H,CH2OH,CONH-3-pyridyl),(NHSO2Me,Ph,H,CH2OH,NHCOPh),(NHSO2Me,Ph,H,CH2OH,NHCO-2-furyl),(NHSO2Me,Ph,H,CH2OH,NHCONHPh),(NHSO2Me,Ph,H,CH2OH,NHCOCONHPh),(NHSO2Me,Ph,Me,Me,CONHPh),(NHSO2Me,Ph,Me,Me,CONH-3-pyridyl),(NHSO2Me,Ph,Me,Me,NHCOPh),(NHSO2Me,Ph,Me,Me,NHCO-2-furyl),(NHSO2Me,Ph,Me,Me,NHCONHPh),(NHSO2Me,Ph,Me,Me,NHCOCONHPh),(NHSO2Me,Ph,Me,Et,CONHPh),(NHSO2Me,Ph,Me,Et,CONH-3-pyridyl),(NHSO2Me,Ph,Me,Et,NHCOPh),(NHSO2Me,Ph,Me,Et,NHCO-2-furyl),(NHSO2Me,Ph,Me,Et,NHCONHPh),(NHSO2Me,Ph,Me,Et,NHCOCONHPh),(NHSO2Me,Ph,Me,CH2OH,CONHPh),(NHSO2Me,Ph,Me,CH2OH,CONH-3-pyridyl),(NHSO2Me,Ph,Me,CH2OH,NHCOPh),(NHSO2Me,Ph,Me,CH2OH,NHCO-2-furyl),(NHSO2Me,Ph,Me,CH2OH,NHCONHPh),(NHSO2Me,Ph,Me,CH2OH,NHCOCONHPh),(NHSO2Me,Ph,Ph,Me,CONHPh),(NHSO2Me,Ph,Ph,Me,CONH-3-pyridyl),(NHSO2Me,Ph,Ph,Me,NHCOPh),(NHSO2Me,Ph,Ph,Me,NHCO-2-furyl),(NHSO2Me,Ph,Ph,Me,NHCONHPh),(NHSO2Me,Ph,Ph,Me,NHCOCONHPh),(NHSO2Me,Ph,Ph,Et,CONHPh),(NHSO2Me,Ph,Ph,Et,CONH-3-pyridyl),(NHSO2Me,Ph,Ph,Et,NHCOPh),(NHSO2Me,Ph,Ph,Et,NHCO-2-furyl),(NHSO2Me,Ph,Ph,Et,NHCONHPh),(NHSO2Me,Ph,Ph,Et,NHCOCONHPh),(NHSO2Me,Ph,Ph,CH2OH,CONHPh),(NHSO2Me,Ph,Ph,CH2OH,CONH-3-pyridyl),(NHSO2Me,Ph,Ph,CH2OH,NHCOPh),(NHSO2Me,Ph,Ph,CH2OH,NHCO-2-furyl),(NHSO2Me,Ph,Ph,CH2OH,NHCONHPh),(NHSO2Me,Ph,Ph,CH2OH,NHCOCONHPh),(NHSO2Me,Ph,OH,Me,CONHPh),(NHSO2Me,Ph,OH,Me,CONH-3-pyridyl),(NHSO2Me,Ph,OH,Me,NHCOPh),(NHSO2Me,Ph,OH,Me,NHCO-2-furyl),(NHSO2Me,Ph,OH,Me,NHCONHPh),(NHSO2Me,Ph,OH,Me,NHCOCONHPh),(NHSO2Me,Ph,OH,Et,CONHPh),(NHSO2Me,Ph,OH,Et,CONH-3-pyridyl),(NHSO2Me,Ph,OH,Et,NHCOPh),(NHSO2Me,Ph,OH,Et,NHCO-2-furyl),(NHSO2Me,Ph,OH,Et,NHCONHPh),(NHSO2Me,Ph,OH,Et,NHCOCONHPh),(NHSO2Me,Ph,OH,CH2OH,CONHPh),(NHSO2Me,Ph,OH,CH2OH,CONH-3-pyridyl),(NHSO2Me,Ph,OH,CH2OH,NHCOPh),(NHSO2Me,Ph,OH,CH2OH,NHCO-2-furyl),(NHSO2Me,Ph,OH,CH2OH,NHCONHPh),(NHSO2Me,Ph,OH,CH2OH,NHCOCONHPh),-   (NH2,H,H,Me,CONHPh),(NH2,H,H,Me,CONH-3-pyridyl),(NH2,H,H,Me,NHCOPh),(NH2,H,H,Me,NHCO-2-furyl),(NH2,H,H,Me,NHCONHPh),(NH2,H,H,Me,NHCOCONHPh),(NH2,H,H,Et,CONHPh),(NH2,H,H,Et,CONH-3-pyridyl),(NH2,H,H,Et,NHCOPh),(NH2,H,H,Et,NHCO-2-furyl),(NH2,H,H,Et,NHCONHPh),(NH2,H,H,Et,NHCOCONHPh),(NH2,H,H,CH2OH,CONHPh),(NH2,H,H,CH2OH,CONH-3-pyridyl),(NH2,H,H,CH2OH,NHCONHPh),(NH2,H,H,CH2OH,NHCOCONHPh),(NH2,H,Me,Me,CONHPh),(NH2,H,Me,Me,CONH-3-pyridyl),(NH2,H,Me,Me,NHCONHPh),(NH2,H,Me,Me,NHCOCONHPh),(NH2,H,Me,Et,CONHPh),(NH2,H,Me,Et,CONH-3-pyridyl),(NH2,H,Me,Et,NHCOPh),(NH2,H,Me,Et,NHCO-2-furyl),(NH2,H,Me,Et,NHCONHPh),(NH2,H,Me,Et,NHCOCONHPh),(NH2,H,Me,CH2OH,CONHPh),(NH2,H,Me,CH2OH,CONH-3-pyridyl),(NH2,H,Me,CH2OH,NHCONHPR(NH2,H,Me,CH2OH,NHCOCONHPh),(NH2,H,Ph,Me,CONHPh),(NH2,H,Ph,Me,CONH-3-pyridyl),(NH2,H,Ph,Me,NHCONHPh),(NH2,H,Ph,Me,NHCOCONHPh),(NH2,H,Ph,Et,CONHPh),(NH2,H,Ph,Et,CONH-3-pyridyl),(NH2,H,Ph,Et,NHCOPh),(NH2,H,Ph,Et,NHCO-2-furyl),(NH2,H,Ph,Et,NHCONHPh),(NH2,H,Ph,Et,NHCOCONHPh),(NH2,H,Ph,CH2OH,CONHPh),(NH2,H,Ph,CH2OH,CONH-3-pyridyl),(NH2,H,Ph,CH2OH,NHCONHPh),(NH2,H,Ph,CH2OH,NHCOCONHPh),(NH2,H,OH,Me,CONHPh),(NH2,H,OH,Me,CONH-3-pyridyl),(NH2,H,OH,Me,NHCONHPh),(NH2,H,OH,Me,NHCOCONHPh),(NH2,H,OH,Et,CONHPh),(NH2,H,OH,Et,CONH-3-pyridyl),(NH2,H,OH,Et,NHCOPh),(NH2,H,OH,Et,NHCO-2-furyl),(NH2,H,OH,Et,NHCONHPh),(NH2,H,OH,Et,NHCOCONHPh),(NH2,H,OH,CH2OH,CONHPh),(NH2,H,OH,CH2OH,CONH-3-pyridyl),(NH2,H,OH,CH2OH,NHCONHPh),(NH2,H,OH,CH2OH,NHCOCONHPh),(NH2,Me,H,Me,CONHPh),(NH2,Me,H,Me,CONH-3-pyridyl),(NH2,Me,H,Me,NHCONHPh),(NH2Me,H,Me,NHCOCONHPh),(NH2,Me,H,Et,CONHPh),(NH2,Me,H,Et,CONH-3-pyridyl),(NH2,Me,H,Et,NHCOPh),(NH2,Me,H,Et,NHCO-2-furyl),(NH2,Me,H,Et,NHCONHPh),(NH2,Me,H,Et,NHCOCONHPh),(NH2,Me,H,CH2OH,CONHPh),(NH2,Me,H,CH2OH,CONH-3-pyridyl),(NH2,Me,H,CH2OH,NHCONHPh),(NH2,Me,H,CH2OH,NHCOCONHPh),(NH2,Me,Me,Me,CONHPh),(NH2,Me,Me,Me,CONH-3-pyridyl),(NH2,Me,Me,Me,NHCONHPh),(NH2,Me,Me,Me,NHCOCONHPh),(NH2,Me,Me,Et,CONHPh),(NH2,Me,Me,Et,CONH-3-pyridyl),(NH2,Me,Me,Et,NHCOPh),(NH2,Me,Me,Et,NHCO-2-furyl),(NH2,Me,Me,Et,NHCONHPh),(NH2,Me,Me,Et,NHCOCONHPh),(NH2,Me,Me,CH2OH,CONHPh),(NH2,Me,Me,CH2OH,CONH-3-pyridyl),(NH2,Me,Me,CH2OH,NHCONHPh),(NH2,Me,Me,CH2OH,NHCOCONHPh),(NH2,Me,Ph,Me,CONHPh),(NH2,Me,Ph,Me,CONH-3-pyridyl),(NH2,Me,Ph,Me,NHCOPh),(NH2,Me,Ph,Me,NHCO-2-furyl),(NH2,Me,Ph,Me,NHCONHPh),(NH2,Me,Ph,Me,NHCOCONHPh),(NH2,Me,Ph,Et,CONHPh),(NH2,Me,Ph,Et,CONH-3-pyridyl),(NH2,Me,Ph,Et,NHCOPh),(NH2,Me,Ph,Et,NHCO-2-furyl),(NH2,Me,Ph,Et,NHCONHPh),(NH2,Me,Ph,Et,NHCOCONHPh),(NH2,Me,Ph,CH2OH,CONHPh),(NH2,Me,Ph,CH2OH,CONH-3-pyridyl),(NH2,Me,Ph,CH2OH,NHCONHPh),(NH2,Me,Ph,CH2OH,NHCOCONHPh),(NH2,Me,OH,Me,CONHPh),(NH2,Me,OH,Me,CONH-3-pyridyl),(NH2,Me,OH,Me,NHCONHPh),(NH2,Me,OH,Me,NHCOCONHPh),(NH2,Me,OH,Et,CONHPh),(NH2,Me,OH,Et,CONH-3-pyridyl),(NH2,Me,OH,Et,NHCOPh),(NH2,Me,OH,Et,NHCO-2-furyl),(NH2,Me,OH,Et,NHCONHPh),(NH2,Me,OH,Et,NHCOCONHPh),(NH2,Me,OH,CH2OH,CONHPh),(NH2,Me,OH,CH2OH,CONH-3-pyridyl),(NH2,Me,OH,CH2OH,NHCONHPh),(NH2,Me,OH,CH2OH,NHCOCONHPh),(NH2,Ph,H,Me,CONHPh),(NH2,Ph,H,Me,CONH-3-pyridyl),(NH2,Ph,H,Me,NHCONHPh),(NH2,Ph,H,Me,NHCOCONHPh),(NH2,Ph,H,Et,CONHPh),(NH2,Ph,H,Et,CONH-3-pyridyl),(NH2,Ph,H,Et,NHCOPh),(NH2,Ph,H,Et,NHCO-2-furyl),(NH2,Ph,H,Et,NHCONHPh),(NH2,Ph,H,Et,NHCOCONHPh),(NH2,Ph,H,CH2OH,CONHPh),(NH2,Ph,H,CH2OH,CONH-3-pyridyl),(NH2,Ph,H,(H2OH,NHCONHPh),(NH2,Ph,H,CH2OH,NHCOCONHPh),(NH2,Ph,Me,Me,CONHPh),(NH2,Ph,Me,Me,CONH-3-pyridyl),(NH2,Ph,Me,Me,NHCONHPh),(NH2,Ph,Me,Me,NHCOCONHPh),(NH2,Ph,Me,Et,CONHPh),(NH2,Ph,Me,Et,CONH-3-pyridyl),(NH2,Ph,Me,Et,NHCOPh),(NH2,Ph,Me,Et,NHCO-2-furyl),(NH2,Ph,Me,Et,NHCONHPh),(NH2,Ph,Me,Et,NHCOCONHPh),(NH2,Ph,Me,CH2OH,CONHPh),(NH2,Ph,Me,CH2OH,CONH-3-pyridyl),(NH2,Ph,Me,CH2OH,NHCONHPh),(NH2,Ph,Me,CH2OH,NHCOCONHPh),(NH2,Ph,Ph,Me,CONHPh),(NH2,Ph,Ph,Me,CONH-3-pyridyl),(NH2,Ph,Ph,Me,NHCOPh),(NH2,Ph,Ph,Me,NHCO-2-furyl),(NH2,Ph,Ph,Me,NHCONHPh),(NH2,Ph,Ph,Me,NHCOCONHPh),(NH2,Ph,Ph,Et,CONHPh),(NH2,Ph,Ph,CONH-3-pyridyl),(NH2,Ph,Ph,Et,NHCOPh),(NH2,Ph,Ph,Et,NHCO-2-furyl),(NH2,Ph,Ph,Et,NHCONHPh),(NH2,Ph,Ph,Et,NHCOCONHPh),(NH2,Ph,Ph,CH2OH,CONHPh),(NH2,Ph,Ph,CH2OH,CONH-3-pyridyl),(NH2,Ph,Ph,CH2OH,NHCOPh),(NH2,Ph,Ph,CH2OH,NHCO-2-furyl),(NH2,Ph,Ph,CH2OH,NHCONHPh),(NH2,Ph,Ph,CH2OH,NHCOCONHPh),(NH2,Ph,OH,Me,CONHPh),(NH2,Ph,OH,Me,CONH-3-pyridyl),(NH2,Ph,OH,Me,NHCONHPh),(NH2,Ph,OH,Me,NHCOCONHPh),(NH2,Ph,OH,Et,CONHPh),(NH2,Ph,OH,Et,CONH-3-pyridyl),(NH2,Ph,OH,Et,NHCOPh),(NH2,Ph,OH,Et,NHCO-2-furyl),(NH2,Ph,OH,Et,NHCONHPh),(NH2,Ph,OH,Et,NHCOCONHPh),(NH2,Ph,OH,CH2OH,CONHPh),(NH2,Ph,OH,CH2OH,CONH-3-pyridyl),(NH2,Ph,OH,CH2OH,NHCOPh),(NH2,Ph,OH,CH2OH,NHCO-2-furyl),(NH2,Ph,OH,CH2OH,NHCONHPh),(NH2,Ph,OH,CH2OH,NHCOCONHPh),-   (NHCH2CH(OH)CH2OH,H,H,Me,CONHPh),(NHCH2CH(OH)CH2OH,H,H,Me,CONH-3-pyridyl),(NHCH2CH(OH)CH2OH,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2OH,H,H,Me,NHCO-2-furyl),(NHCH2CH(OH)CH2OH,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2OH,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2OMe,H,H,Me,CONHPh),(NHCH2CH(OH)CH2OMe,H,H,Me,CONH-3-pyridyl),(NHCH2CH(OH)CH2OMe,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2OMe,H,H,Me,NHCO-2-furyl),(NHCH2CH(OH)CH2OMe,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2OMe,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2NH2,H,H,Me,CONHPh),(NHCH2CH(OH)CH2NH2,H,H,Me,CONH-3-pyridyl),(NHCH2CH(OH)CH2NH2,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2NH2,H,H,Me,NHCO-2-furyl),(NHCH2CH(OH)CH2NH2,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2NH2,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2NHMe,H,H,Me,CONHPh),(NHCH2CH(OH)CH2NHMe,H,H,Me,CONH-3-pyridyl),(NHCH2CH(OH)CH2NHMe,H,Me,NHCOPh),(NHCH2CH(OH)CH2NHMe,H,H,Me,NHCO-2-furyl),(NHCH2CH(OH)CH2NHMe,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2NHMe,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,CONHPh),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,CONH-3-pyridyl),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,NHCO-2-furyl),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2NHCOMe,H,H,Me,NHCOCONHPh),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,CONHPh),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,CONH-3-pyridyl),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,NHCOPh),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,NHCO-2-furyl),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,NHCONHPh),(NHCH2CH(OH)CH2N(Me)Me,H,H,Me,NHCOCONHPh),(NHC(O)C(O)NH2,H,H,Me,CONHPh),(NHC(O)C(O)NH2,H,H,Me,CONH-3-pyridyl),(NHC(O)C(O)NH2,H,Me,NHCOPh),(NHC(O)C(O)NH2,H,H,Me,NHCO-2-furyl),(NHC(O)C(O)NH2,H,H,Me,NHCONHPh),(NHC(O)C(O)NH2,H,H,Me,NHCOCONHPh),(NHC(O)C(O)NHMe,H,H,Me,CONHPh),(NHC(O)C(O)NHMe,H,H,Me,CONH-3-pyridyl),(NHC(O)C(O)NHMe,H,H,Me,NHCOPh),(NHC(O)C(O)NHMe,H,H,Me,NHCO-2-furyl),(NHC(O)C(O)NHMe,H,H,Me,NHCONHPh),(NHC(O)C(O)NHMe,H,H,Me,NHCOCONHPh),(NHC(O)C(O)N(Me)Me,H,H,Me,CONHPh),(NHC(O)C(O)N(Me)Me,H,H,Me,CONH-3-pyridyl),(NHC(O)C(O)N(Me)Me,H,H,Me,NHCOPh),(NHC(O)C(O)N(Me)Me,H,H,Me,NHCO-2-furyl),(NHC(O)C(O)N(Me)Me,H,H,Me,NHCONHPh),(NHC(O)C(O)N(Me)Me,H,H,Me,NHCOCONHPh),

In above structural formula (Ii) or (Ij), the combination of B, Linker,A, R⁵ (B, Linker, A, R⁵) are the following compounds.

TABLE 169 B Linker A R5 B1 Ph- L1

A1

R51 —CN B2 2-pyridyl- L2

A2

R52 —C≡CH B3 4-Me-Ph- L3

A3

R53 —C≡CMe B4 cHex- L4

A4

R54 —CF3 B5 cHex-CH2— L5

A5

R55 —CH2Cl R56 CHCl2

-   (B, Linker, A,    R⁵)=(B1,L1,A1,R51),(B1,L1,A1,R52),(B1,L1,A1,R53),(B1,L1,A1,R54),(B1,L1,A1,R55),(B1,L1,A1,R56),(B1,L1,A2,R51),(B1,L1,A2,R52),(B1,L1,A2,R53),(B1,L1,A2,R54),(B1,L1,A2,R55),(B1,L1,A2,R56),(B1,L1,A3,R51),(B1,L1,A3,R52),(B1,L1,A3,R53),(B1,L1,A3,R54),(B1,L1,A3,R55),(B1,L1,A3,R56),(B1,L1,A4,R51),(B1,L1,A4,R52),(B1,L1,A4,R53),(B1,L1,A4,R54),(B1,L1,A4,R55),(B1,L1,A4,R56),(B1,L1,A5,R51),(B1,L1,A5,R52),(B1,L1,A5,R53),(B1,L1,A5,R54),(B1,L1,A5,R55),(B1,L1,A5,R56),(B1,L2,A1,R51),(B1,L2,A    1,R52),(B1,L2,A    1,R53),(B1,L2,A1,R54),(B1,L2,A1,R55),(B1,L2,A1,R56),(B1,L2,A2,R51),(B1,L2,A2,R52),(B1,L2,A2,R53),(B1,L2,A2,R54),(B1,L2,A2,R55),(B1,L2,A2,R56),(B1,L2,A3,R51),(B1,L2,A3,R52),(B1,L2,A3,R53),(B1,L2,A3,R54),(B1,L2,A3,R55),(B1,L2,A3,R56),(B1,L2,A4,R51),(B1,L2,A4,R52),(B1,L2,A4,R53),(B1,L2,A4,R54),(B1,L2,A4,R55),(B1,L2,A4,R56),(B1,L2,A5,R51),(B1,L2,A5,R52),(B1,L2,A5,R53),(B1,L2,A5,R54),(B1,L2,A5,R55),(B1,L2,A5,R56),(B1,L3,A1,R51),(B1,L3,A1,R52),(B1,L3,A1,R53),(B1,L3,A1,R54),(B1,L3,A1,R55),(B1,L3,A1,R56),(B1,L3,A2,R51),(B1,L3,A2,R52),(B1,L3,A2,R53),(B1,L3,A2,R54),(B1,L3,A2,R55),(B1,L3,A2,R56),(B1,L3,A3,R51),(B1,L3,A3,R52),(B1,L3,A3,R53),(B1,L3,A3,R54),(B1,L3,A3,R55),(B1,L3,A3,R56),(B1,L3,A4,R51),(B1,L3,A4,R52),(B1,L3,A4,R53),(B1,L3,A4,R54),(B1,L3,A4,R55),(B1,L3,A4,R56),(B1,L3,A5,R51),(B1,L3,A5,R52),(B1,L3,A5,R53),(B1,L3,A5,R54),(B1,L3,A5,R55),(B1,L3,A5,R56),(B1,L4,A    1,R51),(B1,L4,A1,R52),(B1,L4,A1,R53),(B1,L4,A1,R54),(B1,L4,A1,R55),(B1,L4,A1,R56),(B1,L4,A2,R51),(B1,L4,A2,R52),(B1,L4,A2,R53),(B53),(B1,L4,A2,R54),(B1,L4,A2,R55),(B1,L4,A2,R56),(B1,L4,A3,R51),(B1,L4,A3,R52),(B1,L4,A3,R53),(B1,L4,A3,R54),(B1,L4,A3,R55),(B1,L4,A3,R56),(B1,L4,A4,R51),(B1,L4,A4,R52),(B1,L4,A4,R53),(B1,L4,A4,R54),(B1,L4,A4,R55),(B1,L4,A4,R56),(B1,L4,A5,R51),(B1,L4,A5,R52),(B1,L4,A5,R53),(B1,L4,A5,R54),(B1,L4,A5,R55),(B1,L4,A5,R56),(B1,L5,A1,R51),(B1,L5,A1,R52),(B1,L5,A1,R53),(B1,L5,A1,R54),(B1,L5,A1,R55),(B1,L5,A1,R56),(B1,L5,A2,R51),(B1,L5,A2,R52),(B1,L5,A2,R53),(B1,L5,A2,R54),(B1,L5,A2,R55),(B1,L5,A2,R56),(B1,L5,A3,R51),(B1,L5,A3,R52),(B1,L5A3,R53),(B1,L5,A3,R54),(B1,L5,A3,R55),(B1,L5,A3,R56),(B1,L5,A4,R51),(B1,,L5,A4,R52),(B1,L5,A4,R53),(B1,L5,A4,R54),(B1,L5,A4,R55),(B1,L5,A4,R56),(B1,L5,A5,R51),(B1,L5,A5,R52),(B1,L5,A5,R53),(B1,L5,A5,R54),(B1,L5,A5,R55),(B1,L5,A5,R56),(B2,L1,A1,R51),(B2,L1,A1,R52),(B2,L1,A1,R53),(B2,L1,A1,R54),(B2,L1,A1,R55),(B2,L1,A1,R56),(B2,L1,A2,R51),(B2,L1,A2,R52),(B2,L1,A2,R53),(B2,L1,A2,R54),(B2,L1,A2,R55),(B2,L1,A2,R56),(B2,L1,A3,R51),(B2,L1,A3,R52),(B2,L1,A3,R53),(B2,L1,A3,R54),(B2,L1,A3,R55),(B2,L1,A3,R56),(B2,L1,A4,R51),(B2,L1,A4,R52),(B2,L1,A4,R53),(B2,L1,A4,R54),(B2,L1,A4,R55),(B2,L1,A4,R56),(B2,L1,A5,R51),(B2,L1,A5,R52),(B2,L1,A5,R53),(B2,L1,A5,R54),(B2,L1,A5,R55),(B2,L1,A5,R56),(B2,L2,A1,R51),(B2,L2,A1,R52),(B2,L2,A1,R53),(B2,L2,A1,R54),(B2,L2,A1,R55),(B2,L2,A1,R56),(B2,L2,A2,R51),(B2,L2,A2,R52),(B2,L2,A2,R53),(B2,L2,A2,R54),(B2,L2,A2,R55),(B2,L2,A2,R56),(B2,L2,A3,R51),(B2,L2,A3,R52),(B2,L2,A3,R53),(B2,L2,A3,R54),(B2,L2,A3,R55),(B2,L2,A3,R56),(B2,L2,A4,R51),(B2,L2,A4,R52),(B2,L2,A4,R53),(B2,L2,A4,R54),(B2,L2,A4,R55),(B2,L2,A4,R56),(B2,L2,A5,R51),(B2,L2,A5,R52),(B2,L2,A5,R53),(B2,L2,A5,R54),(B2,L2,A5,R55),(B2,L2,A5,R56),(B2,L3,A1,R51),(B2,L3,A1,R52),(B2,L3,A1,R53),(B2,L3,A1,R54),(B2,L3,A1,R55),(B2,L3,R56),(B2,L3,A2,R51),(B2,L3,A2,R52),(B2,L3,A2,R53),(B2,L3,A2,R54),(B2,L3,A2,R55),(B2,L3,A2,R56),(B2,L3,A3,R51),(B2,L3,A3,R52),(B2,L3,A3,R53),(B2,L3,A3,R54),(B2,L3,A3R55),(B2,L3,A3,R56),(B2,L3,A4,R51),(B2,L3,A4,R52),(B2,L3,A4,R53),(B2,L3,A4,R54),(B2,L3,A4,R55),(B2,L3,A4,R56),(B2,L3,A5,R51),(B2,L3,A5,R52),(B2,L3,A5,R53),(B2,L3,A5,R54),(B2,L3,A5,R55),(B2,L3,A5,R56),(B2,L4,A1,R51),(B2,L4,A1,R52),(B2,L4,A1,R53),(B2,L4,A1,R54),(B2,L4,A1,R55),(B2,L4,A1,R56),(B2,L4,A2,R51),(B2,L4,A2,R52),(B2,L4,A2,R53),(B2,L4,A2,R54),(B2,L4,A2,R55),(B2,L4,A2,R56),(B2,L4,A3,R51),(B2,L4,A3,R52),(B2,L4,A3,R53),(B2,L4,A3,R54),(B2,L4,A3,R55),(B2,L4,A3,R56),(B2,L4,A4,R51),(B2,L4,A4,R52),(B2,L4,A4,R53),(B2,L4,A4,R54),(B2,L4,A4,R55),(B2,L4,A4,R56),(B2,L4,A5,R51),(B2,L4,A5,R52),(B2,L4,A5,R53),(B2,L4,A5,R54),(B2,L4,A5,R55),(B2,L4,A5,R56),(B2,L5,A1,R51),(B2,L5,A1,R52),(B2,L5,A1,R53),(B2,L5,A1,R54),(B2,L5,A1,R55),(B2,L5,A1,R56),(B2,L5,A2,R51),(B2,L5A2,R52),(B2,L5,A2,R53),(B2,L5,A2,R54),(B2,L5,A2,R55),(B2,L5,A2,R56),(B2,L5,A3,R51),(B2,L5,A3,R52),(B2,L5,A3,R53),(B2,L5,A3,R54),(B2,L5,A3,R55),(B2,L5,A3,R56),(B2,L5,A4,R51),(B2,L5,A4,R52),(B2,L5,A4,R53),(B2,L5,A4,R54),(B2,L5,A4,R55),(B2,L5,A4,R56),(B2,L5,A5,R51),(B2,L5,A5,R52),(B2,L5,A5,R53),(B2,L5,A5,R54),(B2,L5,A5,R55),(B2,L5,A5,R56),(B3,L1,A1,R51),(B3,L1,A1,R52),(B3,L1,A1,R53),(B3,L1,A1,R54),(B3,L1,A1,R55),(B3,L1,A1,R56),(B3,L1,A2,R51),(B3,L1,A2,R52),(B3,L1,A2,R53),(B3,L1,A2,R54),(B3,L1,A2,R55),(B3,L1,A2,R56),(B3,L1,A3,R51),(B3,L1,A3,R52),(B3,L1,A3,R53),(B3,L1,A3,R54),(B3,L1,A3,R55),(B3,L1,A3,R56),(B3,L1,A4,R51),(B3,L1,A4,R52),(B3,L1,A4,R53),(B3,L1,A4,R54),(B3,L1,A4,R55),(B3,L1,A4,R56),(B3,L1,A5,R51),(B3,L1,A5,R52),(B3,L1,A5,R53),(B3,L1,A5,R54),(B3,L1,A5,R55),(B3,L1,A5,R56),(B3,L2,A1,R51),(B3,L2,A1,R52),(B3,L2,A1,R53),(B3,L2,A1,R54),(B3,L2,A1,R55),(B3,L2,A1,R56),(B3,L2,A2,R51),(B3,L2,A2,R52),(B3,L2,A2,R53),(B3,L2,A2,R54),(B3,L2,A2,R55),(B3,L2,A2,R56),(B3,L2,A3,R51),(B3,L2,A3,R52),(B3,L2,A3,R53),(B3,L2,A3,R54),(B3,L2,A3,R55),(B3,L2,A3,R56),(B3,L2,A4,R51),(B3,L2,A4,R52),(B3,L2,A4,R53),(B3,L2,A4,R54),(B3,L2,A4,R55),(B3,L2,A4,R56),(B3,L2,A5,R51),(B3,L2,A5,R52),(B3,L2,A5,R53),(B3,L2,A5,R54),(B3,L2,A5,R55),(B3,L2,A5,R56),(B3,L3,A1,R51),(B3,L3,A1,R52),(B3,L3,A1,R53),(B3,L3,A1,R54),(B3,L3,A1,R55),(B3,L3,A1,R56),(B3,L3,A2,R51),(B3,L3,A2,R52),(B3,L3,A2,R53),(B3,L3,A2,R54),(B3,L3,A2,R55),(B3,L3,A2,R56),(B3,L3,A3,R51),(B3,1,3,A3,R52),(B3,L3,A3,R53),(B3,L3,A3,R54),(B3,L3,A3,R55),(B3,L3,A3,R56),(B3,L3,A4,R51),(B3,L3,A4,R52),(B3,L3,A4,R53),(B3,L3,A4,R54),(B3,L3,A4,R55),(B3,L3,A4,R56),(B3,L3,A5,R51),(B3,L3,A5,R52),(B3,L3,A5,R53),(B3,L3,A5,R54),(B3,L3,A5,R55),(B3,L3,A5,R56),(B3,L4,A1,R51),(B3,L4,A1    ,R52),(B3,L4,A1,R53),(B3,L4,A1,R54),(B3,L4,A1,R55),(B3,L4,A1,R56),(B3,L4,A2,R51),(B3,L4,A2,R52),(B3,L4,A2,R53),(B3,L4,A2,R54),(B3,L4,A2,R55),(B3,L4,A2,R56),(B3,L4,A3,R51),(B3,L4,A3,R52),(B3,L4,A3,R53),(B3,L4,A3,R54),(B3,L4,A3,R55),(B3,L4,A3,R56),(B3,L4,A4,R51),(B3,L4,A4,R52),(B3,L4,A4,R53),(B3,L4,A4,R54),(B3,L4,A4,R55),(B3,L4,A4,R56),(B3,L4,A5,R51),(B3,L4,A5,R52),(B3,L4,A5,R53),(B3,L4,A5,R54),(B3,L4,A5,R55),(B3,L4,A5,R56),(B3,L5,A1,R51),(B3,L5,A1,R52),(B3,L5,A1,R53),(B3,L5,A1,R54),(B3,L5,A1,R55),(B3,L5,A1,R56),(B3,L5,A2,R51),(B3,L5,A2,R52),(B3,L5,A2,R53),(B3,L5,A2,R54),(B3,L5,A2,R55),(B3,L5,A2,R56),(B3,L5,A3,R51),(B3,L5,A3,R52),(B3,L5,A3,R53),(B3,L5,A3,R54),(B3,L5,A3,R55),(B3,L5,A3,R56),(B3,L5,A4,R51),(B3,L5,A4,R52),(B3,L5,A4,R53),(B3,L5,A4,R54),(B3,L5,A4,R55),(B3,L5,A4,R56),(B3,L5,A5,R51),(B3,L5,A5,R52),(B3,L5,A5,R53),(B3,L5,A5,R54),(B3,L5,A5,R55),(B3,L5,A5,R56),(B4,L1,A1,R51),(B4,L1,A1,R52),(B4,L1,A1,R53),(B4,L1,A1,R54),(B4,L1,A1,R55),(B4,L1,A1,R56),(B4,L1,A2,R51),(B4,L1,A2,R52),(B4,L1,A2,R53),(B4,L1,A2,R54),(B4,L1,A2,R55),(B4,L1,A2,R56),(B4,L1,A3,R51),(B4,L1,A3,R52),(B4,L1,A3,R53),(B4,L1,A3,R54),(B4,L1,A3,R55),(B4,L1,A3,R56),(B4,L1,A4,R51),(B4,L1,A4,R52),(B4,L1,A4,R53),(B4,L1,A4,R54),(B4,L1,A4,R55),(B4,L1,A4,R56),(B4,L1,A5,R51),(B4,L1,A5,R52),(B4,L1,A5,R53),(B4,L1,A5,R54),(B4,L1,A5,R55),(B4,L1,A5,R56),(B4,L2,A1,R51),(B4,L2,A1,R52),(B4,L2,A1,R53),(B4,L2,A1,R54),(B4,L2,A    1,R55),(B4,L2,A1,R56),(B4,L2,A2,R51),(B4,L2,A2,R52),(B4,L2,A2,R53),(B4,L2,A2,R54),(B4,L2,A2,R55),(B4,L2,A2,R56),(B4,L2,A3,R51),(B4,L2,A3,R52),(B4,L2,A3,R53),(B4,L2,A3,R54),(B4,L2,A3,R55),(B4,L2,A3,R56),(B4,L2,A4,R51),(B4,L2,A4,R52),(B4,L2,A4,R53),(B4,L2,A4,R54),(B4,L2,A4,R55),(B4,L2,A4,R56),(B4,L2,A5,R51),(B4,L2,A5,R52),(B4,L2,A5,R53),(B4,L2,A5,R54),(B4,L2,A5,R55),(B4,L2,A5,R56),(B4,L3,A1,R51),(B4,L3,A1,R52),(B4,L3,A1,R53),(B4,L3,A1,R54),(B4,L3,A1,R55),(B4,L3,A1,R56),(B4,L3,A2,R51),(B4,L3,A2,R52),(B4,L3,A2,R53),(B4,L3,A2,R54),(B4,L3,A2,R55),(B4,L3,A2,R56),(B4,L3,A3,R51),(B4,L3,A3,R52),(B4,L3,A3,R53),(B4,L3,A3,R54),(B4,L,3,A3,R55),(B4,L3,A3,R56),(B4,L3,A4,R51),(B4,L3,A4,R52),(B4,L3,A4,R53),(B4,L3,A4,R54),(B4,L3,A4,R55),(B4,L3,A4,R56),(B4,L3,A5,R51),(B4,L3,A5,R52),(B4,L3,A5,R53),(B4,L3,A5,R54),(B4,L3,A5,R55),(B4,L3,A5,R56),(B4,L4,A1,R51),(B4,L4,A1,R52),(B4,L4,A1,R53),(B4,L4,A1,R54),(B4,L4,A1,R55),(B4,L4,A1,R56),(B4,L4,A2,R51),(B4,L4,A2,R52),(B4,L4,A2,R53),(B4,L4,A2,R54),(B4,L4,A2,R55),(B4,L4,A2,R56),(B4,L4,A3,R51),(B4,L4,A3,R52),(B4,L4,A3,R53),(B4,L4,A3,R54),(B4,L4,A3,R55),(B4,L4,A3,R56),(B4,L4,A4,R51),(B4,L4,A4,R52),(B4,L4,A4,R53),(B4,L4,A4,R54),(B4,L4,A4,R55),(B4,L4,A4,R56),(B4,L4,A5,R51),(B4,L4,A5,R52),(B4,L4,A5,R53),(B4,L4,A5,R54),(B4,L4,A5,R55),(B4,L4,A5,R56),(B4,L5,A1,R51),(B4,L5,A1,R52),(B4,L5,A1,R53),(B4,L5,A1,R54),(B4,L5,A1,R55),(B4,L5,A1,R56),(B4,L5,A2,R51),(B4,L5,A2,R52),(B4,L5,A2,R53),(B4,L5,A2,R54),(B4,L5,A2,R55),(B4,L5,A2,R56),(B4,L5,A3,R51),(B4,L5,A3,R52),(B4,L5,A3,R53),(B4,L5,A3,R54),(B4,L5,A3,R55),(B4,L5,A3,R56),(B4,L5,A4,R51),(B4,L5,A4,R52),(B4,L5,A4,R53),(B4,L5,A4,R54),(B4,L5,A4,R55),(B4,L5,A4,R56),(B4,L5,A5,R51),(B4,L5,A5,R52),(B4,L5,A5,R53),(B4,L5,A5,R54),(B4,L5,A5,R55),(B4,L5,A5,R56),(B5,L1,A1,R51),(B5,L1,A1,R52),(B5,L1,A1,R53),(B5,L1,A1,R54),(B5,L1,A    1,R55),(B5,L1,A1,R56),(B5,L1,A2,R51),(B5,L1,A2,R52),(B5,L1,A2,R53),(B5,L1,A2,R54),(B5,L1,A2,R55),(B5,L1,A2,R56),(B5,L1,A3,R51),(B5,L1,A3,R52),(B5,L1,A3,R53),(B5,L1,A3,R54),(B5,L1,A3,R55),(B5,L1,A3,R56),(B5,L1,A4,R51),(B5,L1,A4,R52),(B5,L1,A4,R53),(B5,L1,A4,R54),(B5,L1,A4,R55),(B5,L1,A4,R56),(B5,L1,A5,R51),(B5,L1,A5,R52),(B5,L1,A5,R53),(B5,L1,A5,R54),(B5,L1,A5,R55),(B5,L1,A5,R56),(B5,L2,A1,R51),(B5,L2,A1,R52),(B5,L2,A1,R53),(B5,L2,A1,R54),(B5,L2,A1,R55),(B5,L2,A1,R56),(B5,L2,A2,R51),(B5,L2,A2,R52),(B5,L2,A2,R53),(B5,L2,A2,R54),(B5,L2,A2,R55),(B5,L2,A2,R56),(B5,L2,A3,R51),(B5,L2,A3,R52),(B5,L2,A3,R53),(B5,L2,A3,R54),(B5,L2,A3,R55),(B5,L2,A3,R56),(B5,L2,A4,R51),(B5,L2,A4,R52),(B5,L2,A4,R53),(B5,L2,A4,R54),(B5,L2,A4,R55),(B5,L2,A4,R56),(B5,L2,A5,R51),(B5,L2,A5,R52),(B5,L2,A5,R53),(B5,L2,A5,R54),(B5,L2,A5,R55),(B5,L2,A5,R56),(B5,L3,A1,R51),(B5,L3,A1,R52),(B5,L3,A1,R53),(B5,L3,A1,R54),(B5,L3,A1,R55),(B5,L3,A1,R56),(B5,L3,A2,R51),(B5,L3,A2,R52),(B5,L3,A2,R53),(B5,L3,A2,R54),(B5,L3,A2,R55),(B5,L3,A2,R56),(B5,L3,A3,R51),(B5,L3,A3,R52),(B5,L3,A3,R53),(B5,L3,A3,R54),(B5,L3,A3,R55),(B5,L3,A3,R56),(B5,L3,A4,R51),(B5,L3,A4,R52),(B5,L3,A4,R53),(B5,L3,A4,R54),(B5,L3,A4,R55),(B5,L3,A4,R56),(B5,L3,A5,R51),(B5,L3,A5,R52),(B5,L3,A5,R53),(B5,L3,A5,R54),(B5,L3,A5,R55),(B5,L3,A5,R56),(B5,L4,A1,R51),(B5,L4,A1,R52),(B5,L4,A1,R53),(B5,L4,A1,R54),(B5,L4,A1,R55),(B5,L4,A1,R56),(B5,L4,A2,R51),(B5,L4,A2,R52),(B5,L4,A2,R53),(B5,L4,A2,R54),(B5,L4,A2,R55),(B5,L4,A2,R56),(B5,L4,A3,R51),(B5,L4,A3,R52),(B5,L4,A3,R53),(B5,L4,A3,R54),(B5,L4,A3,R55),(B5,L4,A3,R56),(B5,L4,A4,R51),(B5,L4,A4,R52),(B5,L4,A4,R53),(B5,L4,A4,R54),(B5,L4,A4,R55),(B5,L4,A4,R56),(B5,L4,A5,R51),(B5,L4,A5,R52),(B5,L4,A5,R53),(B5,L4,A5,R54),(B5,L4,A5,R55),(B5,L4,A5,R56),(B5,L5,A1,R51),(B5,L5,A1,R52),(B5,L5,A1,R53),(B5,L5,A1,R54),(B5,L5,A1,R55),(B5,L5,A1,R56),(B5,L5,A2,R51),(B5,L5,A2,R52),(B5,L5,A2,R53),(B5,L5,A2,R54),(B5,L5,A2,R55),(B5,L5,A2,R56),(B5,L5,A3,R51),(B5,L5,A3,R52),(B5,L5,A3,R53),(B5,L5,A3,R54),(B5,L5,A3,R55),(B5,L5,A3,R56),(B5,L5,A4,R51),(B5,L5,A4,R52),(B5,L5,A4,R53),(B5,L5,A4,R54),(B5,L5,A4,R55),(B5,L5,A4,R56),(B5,L5,A5,R51),(B5,L5,A5,R52),(B5,L5,A5,R53),(B5,L5,A5,R54),(B5,L5,A5,R55),(B5,L5,A5,R56).

Test Example 1 Lowering Effect on Brain β Amyloid in Rats

A test compound was suspended in 0.5% methylcellulose, the finalconcentration was adjusted to 2 mg/mL, and this was orally administeredto male Crg:SD rat (7 to 9 week old) at 10 mg/kg. In a vehicle controlgroup, only 0.5% methylcellulose was administered, and an administrationtest was performed at 3 to 8 animals per group. A brain was isolated 3hours after administration, a cerebral hemisphere was isolated, a weightthereof was measured, the hemisphere was rapidly frozen in liquidnitrogen, and stored at −80° C. until the day for extraction. The frozencerebral hemisphere was transferred to a homogenizer manufactured byTeflon (registered trade mark) under ice cooling, a 5-fold volume of aweight of an extraction buffer (containing 1% CHAPS({3-[(3-chloroamidopropyl)dimethylammonio]-1-propanesulfonate}), 20 mMTris-HCl (pH 8.0), 150 mM NaCl, Complete (Roche) protease inhibitor) wasadded, up and down movement was repeated, and this was homogenized tosolubilize for 2 minutes. The suspension was transferred to acentrifugation tube, allowed to stand on an ice for 3 hours or more and,thereafter centrifuged at 100,000×g and 4° C. for 20 minutes. Aftercentrifugation, the supernatant was transferred to an ELISA plate(product No. 27730, Immuno-Biological Laboratories) for measuring βamyloid 1-40. ELISA measurement was performed according to the attachedinstruction. The lowering effect was calculated as a ratio compared tothe brain b amyloid 1-40 level of vehicle control group.

TABLE 170 Compound No. % of vehicle control group 634 21.1 622 50.1

Compound No. 733, 359, 39, 212, 793, 204, 243, 482 and 1282 also loweredthe brain β amyloid 1-40 with approximately 60 to 90% reduction comparedto those of a vehicle control group.

Therefore, it is shown that Compound (I) lowers the brain β amyloid 1-40in rats.

Test Example 2 Lowering Effect on Brain β Amyloid in Mice

A test compound was suspended in 0.5% methylcellulose, the finalconcentration was adjusted to 10 mg/mL, and this was subcutaneouslyadministered to back of male Crlj:CD-1(ICR) mouse (7 to 8 week old) at100 mg/kg. In a vehicle control group, only 0.5% methylcellulose wasadministered. A test was performed at 4 to 8 animals per group. A brainwas isolated 3 hours after administration. The subsequent operationswere the same as in the above test in rat.

TABLE 171 Compound No. % of vehicle control group 1199 14.1 1043 15.01100 20.2  127 25.2  605 36.5  396 38.4 1244 50.1  651* 52.3(*3 hours after 30 mg/kg of subcutaneous administration)

Compounds 309, 165, 739, 1266, 900, 220, 964, 1262 and 1014 also loweredthe brain β amyloid 1-40 with approximately 60 to 90% reduction comparedto those of vehicle control group.

Therefore, it is shown that Compound (I) lowers the brain β amyloid 1-40in mice.

Formulation Example 1

A granule containing the following ingredients is prepared.

Ingredient Compound represented by formula (I)  10 mg Lactose 700 mgCorn starch 274 mg HPC-L  16 mg 1000 mg 

The compound represented by the formula (I) and lactose are passedthrough a 60 mesh sieve. Corn starch is passed through a 120 mesh sieve.These are mixed with a V-type mixer, to a mixed powder is added a HPC-L(lower viscosity hydroxypropylcellulose) aqueous solution, the materialsare kneaded, granulated (extrusion granulation, pore diameter 0.5 to 1mm), and dried. The resulting dry granule is passed through a sieveusing a vibration sieve (12/60 mesh) to obtain a granule.

Formulation Example 2

A granule for filling into a capsule containing the followingingredients is prepared.

Ingredient Compound represented by formula (I) 15 mg Lactose 90 mg Cornstarch 42 mg HPC-L  3 mg 150 mg 

The compound represented by the formula (I) and lactose are passedthrough a 60 mesh sieve. Corn starch is passed through a 120 mesh sieve.These are mixed, to a mixed powder is added a HPC-L solution, thematerials are kneaded, granulated., and dried. The resulting dry granuleis size-adjusted, 150 mg of which is filled into a No. 4 hard gelatincapsule.

Formulation Example 3

A tablet containing the Mowing ingredients is prepared.

Ingredient Compound represented by the formula (I) 10 mg Lactose 90 mgMicrocrystalline cellulose 30 mg CMC-Na 15 mg Magnesium stearate  5 mg150 mg 

The compound represented by the formula (I), lactose, microcrystallinecellulose, CMC-Na (carboxymethylcellulose sodium salt) are passedthrough a 60 mesh sieve, and mixed. Into a mixed powder is mixedmagnesium stearate to obtain a mixed powder for tabletting. The presentmixed powder is compressed to obtain 150 mg of a tablet.

Formulation Example 4

The following ingredients are warmed, mixed, and sterilized to obtain aninjectable.

Ingredient Compound represented by the formula (I) 3 mg Nonionicsurfactant 15 mg Purified water for injection 1 ml

INDUSTRIAL APPLICABILITY

The pharmaceutical composition of the present invention can be a usefulmedicament for treating disease induced by production, secretion and/ordeposition o β amyloid, especially Alzheimer's disease.

The invention claimed is:
 1. A method for treating Alzheimer's disease,comprising: administering a composition in an amount effective fortreating Alzheimer's disease to a subject in need thereof, wherein thecomposition contains a compound represented by the general formula (I):

wherein ring A is

R⁹ and R¹⁰ are each independently a hydrogen atom, halogen, hydroxy,cyano, nitro, mercapto, optionally substituted lower alkyl, optionallysubstituted lower alkoxy, optionally substituted lower alkenyl,optionally substituted lower alkynyl, optionally substituted acyl,optionally substituted acyloxy, carboxy, optionally substituted loweralkoxycarbonyl, optionally substituted lower alkoxycarbonyloxy,optionally substituted lower aryloxycarbonyloxy, optionally substitutedamino, optionally substituted carbamoyl, optionally substitutedcarbamoyloxy, optionally substituted lower alkylthio, optionallysubstituted arylthio, optionally substituted lower alkylsulfonyl,optionally substituted arylsulfonyl, optionally substituted lower alkylsulfinyl, optionally substituted arylsulfinyl, optionally substitutedlower alkylsulfonyloxy, optionally substituted arylsulfonyloxy,optionally substituted sulfamoyl, an optionally substituted carbocyclicgroup, optionally substituted carbocyclicoxy, an optionally substitutedheterocyclic group, or optionally substituted heterocyclicoxy; G is

wherein Q¹ and Q² are each independently a bond, optionally substitutedlower alkylene, or optionally substituted lower alkenylene; W¹ is O orS; R¹² is a hydrogen atom, lower alkyl, hydroxy lower alkyl, loweralkoxy lower alkyl, lower alkoxycarbonyl lower alkyl, carbocyclic loweralkyl, or acyl; ring B is an optionally substituted carbocyclic group oran optionally substituted heterocyclic group,

wherein Alk¹ is lower alkylene or lower alkenylene; R⁰ is a hydrogenatom, lower alkyl, or acyl; X is S, O, or NR¹; R¹ is a hydrogen atom orlower alkyl; each of R^(2a) and R^(2b) is a hydrogen atom, R^(3a),R^(3b), R^(4a), and R^(4b) are each independently a hydrogen atom,halogen, hydroxy, optionally substituted lower alkyl, optionallysubstituted lower alkenyl, optionally substituted acyl, carboxy,optionally substituted lower alkoxycarbonyl, optionally substitutedamino, optionally substituted carbamoyl, an optionally substitutedcarbocyclic group, or an optionally substituted heterocyclic group; n is2 and m is 0; each R^(3a), each R^(3b), each R^(4a), and each R^(4b) maybe independently different; R⁵ is optionally substituted lower alkyl;its pharmaceutically acceptable salt, or a solvate thereof as an activeingredient.
 2. The method for treating Alzheimer's disease according toclaim 1, wherein X is S.
 3. The method for treating Alzheimer's diseaseaccording to claim 1, wherein E is a bond.
 4. The method for treatingAlzheimer's disease according to claim 1, wherein ring B is aryloptionally substituted with one or more substituents selected from thegroup consisting of halogen, hydroxy, optionally substituted loweralkyl, optionally substituted lower alkoxy, optionally substituted acyl,optionally substituted amino, cyano, optionally substituted carbamoyl,an optionally substituted carbocyclic group, optionally substitutedcarbocyclicoxy, and an optionally substituted heterocyclic group orheteroaryl optionally substituted with one or more substituents selectedfrom the group consisting of halogen, hydroxy, optionally substitutedlower alkyl, optionally substituted lower alkoxy, optionally substitutedacyl, optionally substituted amino, cyano, optionally substitutedcarbamoyl, an optionally substituted carbocyclic group, optionallysubstituted carbocyclicoxy, and an optionally substituted heterocyclicgroup.
 5. The method for treating Alzheimer's disease according to claim1, wherein G is represented by the formula:


6. The method for treating Alzheimer's disease according to claim 1,wherein R⁵ is C1 to C3 alkyl.
 7. The method for treating Alzheimer'sdisease according to claim 1, wherein R⁵ is methyl.
 8. The method fortreating Alzheimer's disease according to claim 1, wherein R^(3a) andR^(3b) are each independently a hydrogen atom, halogen, hydroxy,optionally substituted lower alkyl, optionally substituted lower alkoxy,or optionally substituted aryl.
 9. The method for treating Alzheimer'sdisease according to claim 1, wherein all of R^(3a) and all of R^(3b)are hydrogen atoms.